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                                                         ABSTRACT 
 
DNA ligases (EC.6.5.1.1) are key enzymes that catalyze the formation of phosphodiester 
bonds at single-stranded or double-stranded breaks between adjacent 5’-PO4 and 3’-OH 
groups of DNA. These enzymes are essential guardians of genomic integrity and have 
recently been drawing a lot of attention as novel therapeutic targets in anti-bacterial and anti-
cancer therapies. 
A novel, non-electrophoretic assay method, based on the strength of interaction of the 
oligonucleotides with Q-sepharose (a strong anion exchanger), was developed to screen 
inhibitors of DNA ligases from natural product pools as well as chemical libraries. The 
binding affinities to Q-sepharose resin of a nicked DNA substrate (created from a 30-mer 
hairpin oligonucleotide and complementary 
32
P-labelled 6-mer oligonucleotide) and its 
sealed, ligated product (36-mer) were determined. Initial optimisation studies were performed 
with T4 DNA ligase, PBCV-1 DNA ligase and a catalytically active form of human DNA 
ligase I in the presence of doxorubicin (inhibitor of ATP-dependent ligases). These results 
when analysed in parallel between the conventional electrophoretic assay and the labelled 
nick-sealing assay showed that the newly developed assay is a reliable non-electrophoretic 
method in identifying potent DNA ligase inhibitors. The feasibility of the assay was tested in 
screening a collection of whole cell mass extracts, obtained from a natural product library 
from Basidiomycetes, in 96-well format. 
A novel single DNA ligase was identified, expressed and characterised from Trichomonas 
vaginalis (TV), a pathogenic protozoan parasite. Protein sequence analysis of TV DNA ligase 
indicates a strong sequence similarity to DNA ligase I homologues. The activity of 
recombinant TV DNA ligase I (TVlig) was investigated using protein expressed in E.coli 
cells. The TVlig gene product is 76 kDa and showed optimal ligation activity on a nicked 
DNA substrate at pH 7-8 in the presence of 1 mM ATP and (8- 20) mM MgCl2 at 30-38
o
C. 
The inhibition of the only DNA ligase present in T. vaginalis might suggest for a rational 
approach to stop replication and hence propagation of the parasite during infection. 
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CHAPTER 1:  INTRODUCTION 
 
In the 1960s, biologists were seeking to identify the enzymatic activity that was 
responsible for both rejoining breaks caused by ultraviolet radiation and completing 
the sealing of DNA that had moved as a result of recombination. Various groups, 
independently and simultaneously, identified and purified the enzymatic activity 
which formed phosphodiester bonds between DNA ends held by hydrogen-bond 
pairing in double-stranded configuration and named it as DNA ligase (Becker et al., 
1967; Gellert, 1967; Zimmerman et al., 1967).   
 
DNA ligases are ubiquitous cellular proteins that catalyse the formation of 
phosphodiester bonds between nucleotides at potentially damaging nicks or breaks in 
DNA (Figure 1.1; Weiss & Richardson, 1967; Modrich et al., 1973; Lehman, 1974; 
Shuman, 1996; Timson et al., 2000). They are essential for the accurate copying and 
maintenance of DNA by replication and repair. A nick can be described as a 
juxtaposed 3‟hydroxyl (3‟-OH) terminated DNA strand adjacent to a 5‟ phosphate 
(5‟-PO4) terminated DNA strand both annealed to a complementary templating DNA 
strand. Nicks or strand-breaks in DNA occur as a result of DNA replication within 
undamaged cells (Lehman, 1974).  
    
                             
POH5’ 3’
3’ 5’
5’ 3’
5’3’
DNA Damage
Nick
Ligation
5’ 3’
5’3’
DNA Ligase
 
                             Figure 1.1:  Repair of nick by DNA ligase 
DNA damage caused by damaging agents, such as ionising radiations, leaves a nick at DNA strand. 
DNA ligases catalyse the synthesis of phosphodiester bond at the site of these nicks and restore the 
continuity of the repaired DNA strand. 
 
DNA ligases catalyse the joining of Okazaki fragments, generated by discontinuous 
DNA synthesis on the lagging strand during such genome replication (Ogawa & 
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Okazaki, 1980). Ligases are also essential for the ligation step in variable (V) - 
diversity (D) – joining (J) recombination [V(D)J], a mechanism to generate antigen 
receptor diversity (Grawunder et al., 1998; Verkaik et al., 2002). They have also 
found widespread use as a tool for in vitro DNA manipulation, cloning techniques and 
ligase based diagnostic assays for mutation detection (Subryamanya et al., 1996; Cao, 
2001).  
DNA ligases belong to a family of covalent nucleotidyl transferases that includes 
RNA ligases and GTP-dependent mRNA capping enzymes (Shuman & Schwer, 
1995). The nucleotidyl transferase (NTases) is a superfamily of phosphotransferase 
enzymes are defined by a set of conserved sequence motifs and act through a lysyl-N-
NMP intermediate (Shuman & Lima, 2004).  
1.1 Classes of DNA ligases 
 
Despite the occurrence of DNA ligases in all organisms, they show a wide diversity of 
molecular sizes, amino acid sequences and properties (Doherty & Suh, 2000; Timson 
et al., 2000; Ellenberger & Tomkinson, 2008). They are grouped into two families 
according to their high-energy cofactor requirements for either ATP or NAD
+
. ATP-
dependent DNA ligases (EC 6.5.1.1) are more widely distributed in eukaryotic and 
archaeal cells but are also encoded by certain eukaryotic viruses, bacteriophage and 
eubacteria (Cheng & Shuman, 1997; Timson et al., 2000; Martin & MacNeil, 2002). 
NAD
+
-dependent DNA ligases (EC 6.5.1.2) are encoded predominantly by eubacteria 
(Wilkinson et al., 2001) but also by certain eukaryotic viruses, such as the 
entomopoxviruses (Sriskanda et al., 2001) and mimiviruses (Benarroch & Shuman, 
2006).  
 
The eukaryotic ATP-dependent DNA ligases vary greatly in distribution, size and 
their ability to ligate a range of nucleic acid substrates (Ellenberger & Tomkinson, 
2008). For example, DNA ligase I appears to be conserved in all eukaryotes, as an 
orthologue has been identified and characterised in a diverse range of organisms, from 
yeast and plants to mammals (Martin & MacNeill, 2002). Mammals, however, encode 
for four distinct ATP dependent DNA ligases (I, IIIα, IIIβ and IV; DNA ligase II is 
now classified as DNA ligase IIIα) whereas lower organisms such as Saccharomyces 
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cerevisiae encode for only two DNA ligases - Cdc9, a homologue of human DNA 
ligase I (HuLigI) and DNL4, a homologue of DNA ligase IV (Tomkinson & Mackay, 
1998; Tomkinson & Levin, 2005). Mammalian DNA ligases are large polypeptides 
(>900 amino acid residues) whereas the virus encoded ATP-dependent DNA ligases, 
for example from bacteriophage T7 (359 amino acid residues) and Paramecium 
bursaria Chlorella virus 1 (PBCV-1, 298 amino acid residues) are much smaller 
(Subramanya et al., 1996; Ho et al., 1997; Tomkinson & Levin, 2005). An ATP 
dependent DNA ligase I has also been identified in the parasitic protozoan 
Plasmodium falciparum (912 amino acid residues; Buguliskis et al., 2007) and 
Trichomonas vaginalis (679 amino acid residues; discussed in detail in Chapter 3). 
 
The presumption that bacteria encode only NAD
+
-dependent DNA ligases (referred to 
as LigA) was overturned by the demonstration of an ATP-dependent DNA ligase (268 
amino acid residues) in the respiratory pathogen Haemophilus influenzae (Cheng & 
Shuman, 1997). ATP-dependent DNA ligase homologues coexist with NAD
+
-
dependent enzymes in several other bacterial species, including major human 
pathogens such as Neisseria meningitidis, Vibrio cholerae and Mycobacterium 
tuberculosis (Wilkinson & Bowater, 2001; Gong et al., 2004). 
 
Previously it was suggested that archaeal ligases exclusively utilize ATP as their 
nucleotide substrate (Keppetipola & Shuman, 2005) but this assumption has been 
more recently contested by the observations that the cofactor requirement of archaeal 
DNA ligases is not solely limited to ATP. Table 1.1 lists diverse nucleotide substrate 
specificities of various archaeal DNA ligases encoded by selection of organisms. 
Haloferax volcanii (H. volcanii), a halophilic archaeon, is found to have both ATP 
and NAD
+
-dependent
 
DNA ligases (Zhao et al., 2006). Phylogenetic analysis 
suggested that the ligase was acquired by lateral gene transfer from eubacteria and 
may provide additional ligase activity under conditions of high genotoxic stress 
(Poidevin & MacNeill, 2006). Individually neither ATP nor NAD
+ 
enzyme is essential 
for cell viability, but the deletion of both ligases in H. volcanii is lethal, indicating that 
the enzymes share an essential function (Zhao et al., 2006). The recently identified 
DNA ligase from Sulfophobococcus zilligii is reported to utilise any of the three 
nucleotide substrates; ATP, ADP and GTP (Sun et al., 2008). The undifferentiated 
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nucleotide specificities of these archaeal ligases might be explained if they recognized 
only the ADP component common to all three nucleotides (Shuman, 2009). 
Table 1.1: Nucleotide substrate specificities of various archaeal ATP-
dependent DNA ligases 
               
Archaeon  Nucleotide specificity  
Acidithiolbacillus ferroxidans  ATP  
Aeropyrum permix  ATP, ADP  
Ferroplasma acidophilum  ATP, NAD
+
  
Pyrococcus horikoshii  ATP, ADP  
Staphylothermus marinus  ATP, ADP  
Thermplasma acidophilum  ATP, NAD
+
  
   
  (Information compiled from Keppetipola & Shuman, 2005; Ferrer et al., 2008; Shuman et al., 2009) 
 
1.2 Reaction Mechanism of Nucleotidyltransferase Superfamily 
 
The analysis of the biochemistry of the ligase reaction mechanism has revealed that 
all DNA ligases catalyse the synthesis of phosphodiester bonds in a very similar 
manner (Lee et al., 2000). The enzyme mechanism (Figure 1.2) involves three main 
steps (Lehman, 1974). The initial step involves the nucleophilic attack on the -
phosphate of ATP (or adenyl-phosphate of NAD
+
) by the active site lysine residue in 
motif I (Figure 1.3; Gumport & Lehman, 1971; Timson et al., 2000).  Pyrophosphate 
(PPi) is released and a covalent ligase-adenylate intermediate (EpA) is formed in 
which AMP is linked to the lysine via a phosphoamide bond (Figure 1.2, panel D; 
Gumport & Lehman, 1971; Lehman, 1974). In 2002, Cherepanov & Vries 
demonstrated that step 1 in the reaction catalysed by T4 DNA ligase uses 
dimagnesium ATP-Mg2 for transfer of the adenyl moiety to the ligase. In the second 
step, AMP is transferred to the 5‟-phosphate terminated nicked DNA strand via a 
pyrophosphate bond, forming a DNA-adenylate intermediate (AppDNA; Olivera et 
al., 1968; Yang & Chan, 1992).  The final step involves the ligase catalysed attack by 
the 3‟-OH group of the juxtaposed DNA strand on the adenylated strand of the 
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AppDNA resulting in the joining of the two polynucleotides and release of AMP 
(Shuman, 1996). One ATP molecule is utilised per nick-sealing event (Crut et al., 
2008). In NAD
+
-dependent DNA ligases the enzyme-AMP adenylate is formed by the 
breakdown of NAD
+
 and the release of NMN rather than PPi (Martin & MacNeill, 
2002).  
 
RNA ligases join 3‟-OH and 5‟-PO4 terminated RNA through the same series of 
catalytic steps as those employed by DNA ligases (Shuman & Lima, 2004). These 
steps involve the formation of a step 1 covalent ligase-adenylate and release of 
pyrophosphate followed by the formation of the step two RNA-adenylate intermediate 
and step three catalysis of strand joining and AMP release (Figure 1.2, panel B). The 
RNA ligases can be divided into two distinct families: RNA ligase 1 (Rnl1) and RNA 
ligase 2 (Rnl2). The Rnl1 family includes enzymes such as bacteriophage T4 RNA 
ligase 1 (the first RNA ligase to be identified; Silber et al., 1972), and the tRNA 
ligases of plants and fungi. The Rnl2 family includes enzymes such as T4 RNA ligase 
2 and the RNA editing ligases (RELs) found in the kinetoplast of the protozoa 
Typanosoma and Leishmania (Ho & Shuman, 2002). Rnl1s function in the repair of 
single strand RNA breaks in tRNA anticodon loops or breaks in mRNAs introduced 
by site-specific RNA endonucleases during the RNA-based antiviral response 
(Nandakumar et al., 2006). Rnl2s play an important role in sealing nicks in duplex 
RNA, particularly during mRNA editing by RELs (Nandakumar et al., 2006). Rnl1 
and Rnl2 have very little sequence similarity outside of the conserved nucleotidyl 
transferase core (Ho & Shuman, 2002; Pascal, 2008). 
 
RNA capping enzymes (previously termed RNA guanyltransferases) transfer GMP 
derived from GTP onto the 5‟-diphosphate terminus of triphosphatase processed 
mRNAs to form a G(5‟)ppp(5‟)RNA cap structure. This plays an important role in the 
processing, protection and transporting of mRNAs to the ribosome (Shuman & 
Schwer, 1995; Shuman & Lima, 2004). The capping mechanism involves three 
separate reactions, catalysed either by three separate enzymes or by modular 
combinations between the various components creating either a single enzyme or two 
enzymes depending on the organism (Hakansson & Wigley, 1998, Shuman & Lima, 
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2004). The first step entails the removal of the terminal 5‟-PO4 from mRNA 
(pppRNA) by an RNA triphosphatase. 
 
                            
Figure 1.2: The conserved reaction mechanism of covalent nucleotide 
transferase enzymes 
The reaction mechanism of DNA ligases (panel A), RNA ligases (panel B) and capping enzymes 
(panel C) is shown. Step one involves the nucleophilic attack by the active site lysine on the -
phosphate of the nucleotide substrate and the formation of a covalent enzyme adenylate linked by a 
phosphoamide bond. The chemical structure of the phosphoamide bond forming the covalent enzyme 
intermediate is shown in panel D. The abbreviated terms are described in the text (Adapted from 
Doherty, 1999; Doherty & Suh, 2000).  
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The second reaction, catalysed by RNA capping enzymes, involves the linkage of 
GMP to the 5‟ diphosphate terminated RNA via an intermediate step in which the 
GMP is covalently linked to the capping enzyme active site lysine (located in motif I 
which is also conserved in RNA and DNA ligases), through a phosphoamide bond. 
This step most resembles the catalytic mechanism of DNA and RNA ligases (Figure 
1.2, panel C; Shuman & Hurwitz, 1981; Hakansson & Wigley, 1998). The third step 
involves a final enzyme activity, RNA guanine-7-methyltransferase, which catalyses 
the methylation at N7 of the guanine base (Shuman & Hurwitz, 1981; Hakansson & 
Wigley, 1998).  
 
Accumulation of nicked-DNA adenylates (AppDNA) are observed during nick 
sealing by various ATP dependent bacterial DNA ligases, reflecting the dissociation 
of DNA ligase before step 3 (Gong et al., 2004; Zhu & Shuman, 2007). For most 
ligases the ligation reaction is functionally unidirectional, i.e. it proceeds forward 
from step 1 to 2 and 3; for example, when the ligase apoenzyme is incubated with a 
pre-adenylated nicked DNA substrate, the reaction is predisposed towards step 3 and 
phosphodiester formation (Odell & Shuman, 1999; Nandakumar et al., 2006; Crut et 
al., 2008). Although Modrich et al. (1972) and Sekiguchi & Shuman (1997) have 
shown that steps in the nick ligation pathway may be reversible when forced. Modrich 
et al. (1972) demonstrated this with the incubation of supercoiled closed circular 
DNA with excess E. coli DNA ligase in the presence of AMP. This yielded DNA 
molecules with single-strand breaks and covalently-closed circular DNA. Supercoiled 
DNA was also converted to slower migrating forms by Vaccinia virus DNA ligase. 
The AMP and magnesium-dependent relaxation reaction required excess amounts of 
ligase in relation to the input DNA substrate, ratios which are obviously not present in 
the cell under physiological conditions (Sekiguchi & Shuman, 1997).  
 
The adenylated form of DNA ligase is stable and enhances its nick sensing capability 
(Sriskanda & Shuman, 1998). Occupation of the nucleotide binding site by AMP, is 
crucial to nick recognition as the enzyme undergoes a conformational change which 
exposes the DNA binding surface of domain one (see section 1.3), allowing the 5‟-
PO4
 
of the nicked DNA to make direct contact with the adenylation site of the enzyme 
(Sekiguchi & Shuman, 1997; Odell et al., 2000).  Mutations in the ligase active site 
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that prevent the binding of ATP, particularly mutations of the active site lysine and 
arginine in motif I; have been found to eliminate the binding of the enzyme to nicked 
DNA (Sekiguchi & Shuman, 1997). This suggests that only the catalytically 
competent form (EpA) is capable of high affinity DNA binding, although enzymes 
with mutations in the active site lysine are able to turn-over and ligate DNA when 
incubated with a pre-adenylated DNA substrate (Sekiguchi & Shuman, 1997; 
Sriskanda & Shuman, 1998). 
 
1.3 The overall domain structure of DNA ligases  
 
Sequence alignments of a number of enzymes that catalyse nucleotidyl transfers 
including all DNA ligases (ATP and NAD
+
-dependent), RNA ligases (Rnl1 and Rnl2 
families) as well as RNA capping enzymes, which share homologous reaction 
chemistry, have shown the presence of several regions of amino acid homology with 
six motifs of conserved residues with consistent spacing (Shuman, 1996; Shuman & 
Lima, 2004). These conserved motifs were previously numbered I, III, IIIa, IV and V 
(ATP-dependent DNA ligase and mRNA capping enzymes contain an addition 
homologous motif, VI), until recently when Shuman and co-workers proposed the 
existence of another conserved motif (Ia), downstream of motif I and first suggested 
to be such a motif in 1997 (Figure 1.3, panel A; Odell, PhD thesis, 1997; Nair et al., 
2007; Shuman, 2009). These motifs make up the common tertiary structure of the 
catalytic core and nucleotide binding pocket of DNA ligases (Figure 1.3, panel A; 
Subramanya et al., 1996; Odell et al., 2000).  
 
The numbering of the motifs corresponds to the position within the primary sequence 
with motif I being the most proximal to the protein N-terminus and motif VI, to the C-
terminus. Mutations of the conserved residues that make up these motifs have been 
shown to be critical for activity in nucleotidyltransferase enzymes (Subramanya et al., 
1996). There is virtually no sequence similarity between ATP and NAD
+
-dependent 
DNA ligases except in this central DNA ligase catalytic core of motifs I through V 
(Timson et al., 2000; Martin & MacNeill, 2002) as NAD
+
-dependent ligases lack a 
recognisable counter-part of motif VI (Sriskanda et al., 2001). 
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Figure 1.3: Sequence alignment of conserved sequence motifs and domain 
organisation in nucleotidyl transferases. 
Sequence motifs (designated I, Ia, III, IIIa, IV, V and VI; highlighted in yellow, brown, green, cyan, 
red, magenta and blue respectively) conserved in DNA ligases, RNA ligases and RNA capping 
enzymes are shown. The alignment includes the ATP-dependent DNA ligases [encoded by: 
Paramecium bursaria Chlorella virus 1 (PBCV-1; NP_048900), Bacteriophage T7 (T7; P00969), 
human DNA ligase I (HuLig1; NP_000225), S. Solfataricus (Ssolig; AAK40535), Pyrococcus furiosus 
(Pfulig; NP_579364), Trichomonas vaginalis DNA ligase I (TV lig; XP_001581589)], NAD
+
-
dependent DNA ligases [encoded by: E. coli (EcoLigA; P15042), Enterococcus faecalis (EfaLigA; 
NP_814472), Thermus filiformis (TfiLigA; Q9ZHI0), Mycobacterium tuberculosis (MtuLigA; 
NP_217530), Haemophilus influenzae (HinLigA; NP_439257), Bacillus stearothermophilus (BstLigA; 
NP_622271)], ATP-dependent RNA ligases [encoded by T4 (T4 Rnl2; NP_049790.), Trypanosoma 
brucei (TbREL1; XP_001219001), T4 Rnl1 (NP_049839), Pyrococcus abyssi (Pab Rnl3; CAB49026)] 
and GTP-dependent RNA capping enzymes from PBCV-1 (NP_048451). Panel B shows domain 
organisation of Bacteriophage T7 DNA ligase. The larger adenylation domain (AdD) is shown in grey 
and the smaller OB-fold domain in green. ATP located within the active site is coloured according to 
element.  
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The smaller, structurally less complex DNA ligases, those encoded by viruses and 
bacteriophages, have a minimal two-domain structure. This is highlighted by the 
atomic structures of the ATP-dependent DNA ligases from bacteriophage T7 (359 
residues; Figure 1.3, panel B; Subramanya et al., 1996) and PBCV-1 DNA ligase (298 
residues; Odell et al., 2000; Odell et al., 2003). A large N-terminal nucleotide binding 
domain (adenylation domain; AdD), which binds ATP, and a smaller C-terminal 
oligonucleotide binding domain (OB-fold) are structurally analogous to the catalytic 
core of complex multidomain DNA ligases found in bacteria and higher eukaryotes 
(Figure 1.4; Martin & MacNeill, 2002).  
 
The adenylation domain consists of two, twisted anti-parallel -sheets and six -
helices (Figure 1.3, panel B; shown in grey). The adenylate binding pocket composed 
of the six peptide motifs I, Ia, III, IIIa, IV and V lies in the adenylation domain   
(Subramanya et al., 1996; Nair et al., 2007). The active site lysine residue to which 
AMP becomes covalently linked is located within conserved motif I (KxDGxR) 
(Cong & Shuman, 1995; Odell et al., 2000). The OB-fold domain, consisting of a 
single five-stranded anti-parallel β barrel and an α helix, assists in the formation of the 
ligase-AMP intermediate during step 1 of ligation reaction (Figure 1.3, panel B; 
shown in green; Sriskanda & Shuman, 1998). The OB-fold domain binds across the 
minor groove of double-stranded DNA and interacts with the DNA strand adjacent to 
the 5‟ phosphate end of the nick (Nair et al., 2007). In ATP-dependent ligases, the 
OB-fold domain closes over the adenylation domain during step I of the ligation 
reaction to contribute the residues of conserved residues of motif VI required for 
AMP transfer to the active site lysine (Odell et al., 2000; Pascal et al., 2006). RNA 
capping enzymes use a similar mechanism and two domain structure to form a 
capping enzyme-GMP intermediate, before transferring GMP to the 5‟ end of mRNA 
(Pascal, 2008).  
 
After formation of the ligase-AMP reaction intermediate, the OB fold domain 
functions as a DNA-binding component during steps 2 and 3. For these steps the OB 
fold turns to orient DNA-binding residues for interaction with the DNA substrate and 
the motif VI residues are exposed on the protein surface away from the active site 
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(Nair et al., 2007; Pascal, 2008). This conformational flexibility of the ligase is 
accommodated by an extended polypeptide linker, containing motif V, which serves 
as a bridging segment joining the adenylation and the OB fold domains and also 
assists in loading the enzyme onto DNA (Nair et al., 2007). 
 
AdD OBIa Zn HhH
DBD AdD OB
AdD OB
AdD C-term
C-termAdD
Viral DNA ligase
NAD+ -dependent DNA ligase
RNA ligase 1 family
RNA ligase 2 family
Representative Eukaryotic
DNA ligase I
 
          Figure 1.4: Domain architecture of DNA and RNA ligases 
The adenylation domain, consisting of the conserved motifs (I, Ia, III, IIIa, IV and V) which catalyse 
the three step end-joining reaction, is conserved in all polynucleotide ligases. The AdD and OB fold 
domains represent the catalytic core of ATP and NAD
+
-dependent DNA ligases. Viral DNA ligases are 
much smaller than cellular DNA ligases and are devoid of any additional N or C-terminal domains. 
Accessory domains extending from the adenylation domain promote the ligation reaction or provide 
special substrate binding properties for specific ligases. RNA ligase 1 (Rnl1) and RNA ligase 2 (Rnl2) 
have a conserved adenylation domain and unique C-terminal domain which is distinct in two families 
and is unrelated to the C-terminal OB-fold domains of DNA ligases and RNA capping enzymes. 
Abbreviations: DNA binding domain (DBD), OB fold (OB) domain, Helix-hairpin-helix (HhH), 
Domain Ia (Ia), Zinc-binding domain (Zn) and C-terminal domains (C-term) (Information taken from 
Nandakumar et al., 2007; Ellenberger & Tomkinson, 2008). 
 
 
In addition to the nucleotide binding and OB-fold domains described above ligases of 
multicellular organisms, such as human DNA ligase I (HuLigI), have a dedicated N-
terminal DNA-binding domain (DBD; Pascal et al., 2004). The DBD domain makes 
protein-protein interactions with the adenylation and the OB-fold domain and allows 
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ligase I to encircle its DNA substrate and hence contributes a substantial DNA-
binding affinity of the enzyme. This domain also serves to distort the DNA structure, 
widening the minor groove that exposes the ligatable ends of the DNA substrate to 
conserved residues of the catalytic core (Tomkinson et al., 2006; Pascal, 2008).  
Pascal et al. (2004) also identified two divalent metal binding sites in the active site of 
the nucleotide-binding domain. The OB-domain in HuLigI also appear to aid substrate 
selection and hence prevent untimely ligation of Okazaki fragments before the 
removal of the RNA primer thereby adding to the fidelity of the DNA ligation event 
(Pascal et al., 2004).  
 
NAD
+
-dependent bacterial DNA ligases have a highly conserved adenylation domain 
and OB-domain but lack the N-terminal DBD found in mammalian DNA ligases. This 
DBD is substituted for by a C-terminal, helix-hairpin-helix (HhH) domain (Figure 
1.4; Lee et al., 2000). The HhH domain binds DNA in the minor groove and serves as 
a functional mimic of the mammalian DBD (Lee et al., 2000). Domain Ia is unique to 
NAD
+
-dependent DNA ligases. It is required for the formation of the ligase-AMP 
intermediate during step I of the ligation reaction and its deletion leads to a loss in the 
adenylation capability of the enzyme (Sriskanda et al., 2001; Gajiwala & Pinko, 
2004). The Zn domain appears to provide structural support to the ligase architecture 
in bridging the OB and HhH domains (Nandakumar et al., 2007).   
 
RNA ligases (Rn1 and Rnl2) use only the AdD domain to catalyse the first step of 
their reaction chemistry, but have a unique C-terminal domain, distinct in the two 
ligase families, required for AMP-RNA formation for the step 2 reaction (Figure 1.4; 
Ho et al., 2004). 
1.4 Structure of DNA ligases 
 
The progress in structural studies of nucleotidyl transferase enzymes has added to our 
understanding of the mechanism of action of these enzymes. The structures of 
nucleotide bound DNA and RNA ligases (Odell et al., 2000; Nandakumar et al., 
2006; Nishida et al., 2006; Pascal et al., 2006) and nucleic acid bound DNA and RNA 
ligases (Pascal et al., 2004; Nair et al., 2007; Nandakumar et al., 2007) have provided 
molecular insights into different steps of the reactions catalysed by these enzymes.  
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1.4.1 ATP-dependent DNA ligases 
 
The crystal structure of several ATP- dependent DNA ligases has been solved. These 
include: bacteriophage T7 DNA ligase in complex with ATP (Figure 1.3, panel B; 
Subramanya et al., 1996), enzyme-AMP covalent complexes of PBCV-1 DNA ligase 
(Odell et al., 2000; Odell et al., 2003), N-terminally truncated HuLigI complexed 
with an AMP-DNA reaction intermediate (Pascal et al., 2004), Sulfolobus solfataricus 
DNA ligase in complex with heterotrimeric Proliferating Cell Nuclear Antigen 
(PCNA; Pascal et al., 2006) and PBCV-1 DNA ligase-AMP intermediate bound to 
phosphorylated DNA substrate (Nair et al., 2007). These studies suggest that all DNA 
ligases except the simplest viral ligases completely encircle their DNA substrates 
(Ellenberger & Tomkinson, 2008).  
 
The crystal structure of human DNA ligase I (HuLigI; 232-919 amino acid residues; 
the first structure of a DNA ligase complexed to nucleic acid substrate), revealed the 
function of a novel N-terminal α-helical extension as a DNA binding domain (DBD, 
Figure 1.5, panel B; Pascal et al., 2004). The AdD and OB domains interact to form a 
continuous protein surface that engages the minor groove of DNA (Pascal et al., 
2004). This interaction of enzyme with DNA alters the substrate conformation 
resulting in adoption of an RNA-like A form helix, partially unwinding the DNA 
duplex and positions the DNA ends in the active site for the joining reaction (Pascal, 
2008). The HuLigI-DNA structure revealed that a dramatic conformational change 
between AdD and OB domain is necessary to proceed the nick joining activity of the 
enzyme.  The DBD interacts with AdD and OB domains establishing a ligase protein 
clamp which fully encircles the DNA substrate (Figure 1.7, panel A; Pascal et al., 
2004). 
 
Recent studies have shown that the DBD of HuLigI also interacts with PCNA and the 
heterotrimeric cell cycle checkpoint clamp, hRad9-hRad1-hHus1 (9-1-1), where it 
preferentially binds to the hRad1 subunit (Song et al., 2009). This was previously 
reported in DNA ligases from P. furiosus and S. solfataricus using DBD residues for 
interaction with PCNA sliding clamps (Pascal et al., 2006; Pascal, 2008). The DBD-
PCNA interactions stimulate ligation activity in these organisms (Pascal, 2008). 
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Figure 1.5: Structural configuration of viral, bacterial and mammalian 
DNA ligases bound to DNA 
The DNA ligases from PBCV-1, Escherichia coli (LigA) and human ligase I (HuLigI) adopt a similar 
ring shaped structure in complex with a nicked DNA substrate. A conserved catalytic core consisting of 
AdB and OB fold domains contacts the DNA substrate during step 2 and 3 of end joining reaction. 
PBCV-1 has a latch like structure in the OB fold domain, E. coli LigA has a C-terminal helix-hairpin-
helix (HhH) domain and HuLigI has an N-terminal DNA binding (DBD) domain all of which interact 
with DNA to complete the ring-shaped structure in conjunction with the catalytic core. (Lee et al., 
2000; Pascal et al., 2004; Nair et al., 2007). 
 
The structure of PBCV-1 DNA ligase in complex with nicked DNA reflects the 
conformation of the enzyme prior to step two catalysis, as it shows the protein 
engaged at the nick before AMP is transferred to the 5‟-PO4 (i.e. before the AppDNA 
intermediate is formed; Nair et al., 2007). The enzyme forms a „C-shaped‟ protein 
clamp around the nicked DNA substrate with protein contacts in the AdD, OB-fold 
domain and a 30 residue lysine-rich surface loop, „latch‟ region (Figure 1.5, panel A; 
Figure 1.6; Nandakumar et al., 2007). Previous structures of the PBCV-1 enzyme-
adenylate reveal that in this enzyme conformation the OB-fold domain is positioned 
away from the AdD to expose the AMP-binding pocket (Figure 1.7, panel A ; Odell et 
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al., 2003). In order to close the clamp around the nicked DNA substrate, „kissing‟ 
contacts are formed between the N-terminal AdD and C-terminal „latch‟ region  
(Figure 1.7, panel B) in the OB-fold domain.  
 
The importance of the β-hairpin loop region was originally intuited from previous 
PBCV-1 DNA ligase biochemical analyses. The latch was disordered in the absence 
of DNA and only becomes ordered upon binding to DNA (Figure 1.7, panels A & B, 
shown in red; Odell et al., 2000; Odell et al., 2003). Replacement of the latch module 
with a smaller flexible loop (Gly-Ser-Gly-Ser-Gly) resulted in a 10-fold decrease in 
the specific activity and nick sealing when compared to the wild type enzyme (Odell 
et al., 2003; Nair et al., 2007). The peptide segment (residues 202-231) which 
encompasses the disordered loop region was found to be proteolytically sensitive after 
limited digestion with trypsin and chymotrypsin; although the latch was resistant to 
proteolysis in the presence of DNA (Odell & Shuman, 1999). In the new structure of 
the PBCV-1 ligase, upon binding to DNA, following a 63 Å movement of the OB-
fold domain, the now-ordered latch encircles the DNA (Figure 1.6, panel A). 
Structural comparison of HuLigI and PBCV-1 DNA ligase reveals that the AdD and 
OB domains adopt similar conformations while the α-helical DBD and β-hairpin latch 
occupy almost the same angular position when docked on the nicked DNA substrate 
(Shuman, 2009).  
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Figure 1.6: Fold structure of PBCV-1 DNA ligase upon DNA binding  
Ribbon diagram shows the DNA clamp formed by PBCV-1 DNA ligase as it encircles the nicked DNA 
substrate. The latch (red) encircles and clamps the DNA substrate. The arrow represents the domain 
shift by the OB-fold domain in order to position the now structured C-terminal „latch‟ region for DNA 
stabilisation and interdomain contacts with the AdD (PDB 2QT). The adenylation domain is shown in 
grey, the OB-fold domain in green and the latch region in red (adapted from Nair et al., 2007). The 
image was prepared with PyMol (DeLano, 2002). 
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Figure 1.7: Conformational changes occurring in the structure of PBCV-1 
DNA ligase upon DNA binding 
Ribbon diagrams showing the DNA ligase, panel A: without DNA (PDB: 1P8L), panel B: with the 
addition of nicked DNA substrate (DNA not shown) (PDB: 2Q2T). Upon addition of DNA, the 
disordered latch (red) becomes ordered and encircles and clamps the DNA substrate (Odell et al., 2000; 
Nair et al., 2007). The images were prepared with PyMol (DeLano, 2002). 
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1.4.2 NAD+-dependent DNA ligases 
 
The crystal structures of full-length adenylated Thermus filiformis DNA ligase (Lee et 
al., 2000), Enterococcus faecalis ligase (Gajiwala & Pinko, 2004), adenylation 
domain of the NAD
+
-dependent Mycobacterium tuberculosis DNA ligase (Srivastava 
et al., 2005) and E. coli ligase in complex with DNA (Nandakumar et al., 2007) have 
been determined. 
 
The structure of E. coli LigA (EcoLigA) in complex with an AMP-DNA reaction 
intermediate revealed that the topology and connectivity of the circumferential clamp 
formed by LigA is distinct from the arrangement adopted by HuLigI (Figure 1.8, 
panels A & B; Pascal et al., 2004; Nandakumar et al., 2007).  
 
EcoLigA encircles the nicked DNA as a „C-shaped protein clamp‟ with multiple 
residues in the AdD, OB and HhH domains contacting the DNA and a 19 bp 
„footprint‟ over the centrally placed nick (Nandakumar et al., 2007). The HhH was 
found to interact in the minor groove of both DNA strands close to the nick. The zinc 
finger motif and domain Ia made no physical DNA contacts. Domain Ia is known to 
play a role in ligase adenylation and the zinc finger module was found to stabilise the 
OB and HhH domains and it remains in a fixed position in relation to the OB-fold 
domain (Nandakumar et al., 2007). The HhH domain undergoes a large shift relative 
to the OB-fold domain in order to facilitate the formation of contacts with the DNA 
backbone (Nandakumar et al., 2007).  
 
The HuLigI DBD and EcoLigA HhH domain have different protein folds, but occupy 
similar positions on the DNA substrate (see Figure 1.8, panels A & B). They appear to 
play analogous roles contacting and stabilising the DNA in co-ordination with the 
conserved AdD and OB-fold domains (Tomkinson et al., 2006; Nandakumar et al., 
2007). HuLigI closes the protein clamp around the nicked DNA substrate via „kissing‟ 
contacts between the OB-fold domain and DBD. EcoLigA closes the clamp via 
kissing contacts between the AdD and HhH domains in the major groove of the DNA, 
opposite the nick. 
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Figure 1.8: Comparison of HuLigI ligase I and E. coli LigA fold structure 
Ribbon diagrams comparing the DNA clamp of: HuLigI (PDB 1X9N) and EcoLigA (PDB 2OWO). 
The adenylation domains of the two proteins were aligned. The arrows indicate the movement of the 
relevant domains encircling the DNA and closing the circumferential protein clamp. In both structures 
the AdD is coloured in grey and the OB-fold domain in green. In HuLigI the DBD is highlighted in red. 
In EcoLigA, domain Ia is shown in magenta, the zinc-finger domain in yellow, HhH in red and the C-
terminal BRCT domain in blue (adapted from Nandakumar et al., 2007).  
 
1.5 Mammalian DNA ligases 
 
Mammalian cells have LIG1, LIG3 and LIG4 genes encoding for four distinct DNA 
ligases (I, IIIα, IIIβ and IV; Montecucco et al., 1992; Tomkinson & Mackay, 1998; 
Tomkinson et al., 2006). Homologues of LIG1 and LIG4 genes are reportedly present 
in all eukaryotes but LIG3 genes are restricted to vertebrates (Tomkinson & Mackay, 
1998). The catalytic core of mammalian DNA ligases (comprising of AdD and OB-
fold domains) is embellished with additional N- and C- terminal domains, which are 
essential for biological activity and protein-protein interactions (Timson et al., 2000, 
Pascal et al., 2006; Tomkinson et al., 2006).   
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1.5.1 DNA ligase I 
 
DNA ligase I is the main replicative ligase of eukaryotes where its function is to join 
Okazaki fragments during lagging strand DNA synthesis (Ogawa & Okazaki, 1980; 
Martin & MacNeil 2002). It also plays a role in the base excision repair pathway 
(BER; described in depth in section 1.7.1.3) where it seals single-strand nicks after 
repair of DNA damage (Martin & MacNeil, 2002; Almeida & Sobol, 2007). The 
human cell line 46BR.1G1, which is defective in DNA ligase I function, exhibits 
abnormal joining of Okazaki fragments during S phase of the cell cycle, a defect that 
can be complemented by addition of exogenous DNA ligase I protein (Doherty & 
Suh, 2000). This cell line is also hypersensitive to simple DNA-alkylating agents (e.g. 
methyl methanesulphonate) because of a defect in the long-patch sub-pathway of base 
excision repair (Levin et al., 2000).  
 
DNA ligase I is the product of the LIG1 gene, is composed of a carboxyl-terminal 
catalytic core, an N-terminal DNA binding domain and a PCNA binding motif 
(Figure 1.9; Tomkinson et al., 1990; Pascal et al., 2004). The recruitment of HuLigI 
to the site of DNA damage is dependent on its interaction with PCNA (Levin et al., 
1997; Tomkinson & Mackey, 1998). Human PCNA (HuPCNA) has been shown to 
interact with and stimulate the activity of HuLigI, although the specific mechanism of 
stimulation is unknown (Levin et al., 1997; Pascal et al., 2006). PCNA is a 
homotrimer that non-specifically binds to and encircles DNA at the site of a nick. It is 
termed a member of the DNA „sliding clamp family‟ – a group of enzymes that act as 
a scaffold for the assembly of DNA processing factors (Tom et al., 2001; Dionne et 
al., 2003). It associates with, and facilitates the interaction of more than 25 cellular 
proteins involved in DNA synthesis and repair (Pascal et al., 2006). PCNA-interacting 
proteins contain a consensus sequence called the PCNA-interacting protein box (PIP).  
The conserved motif QXXhXXaa is located in this sequence; where X represents any 
amino acid, h represents hydrophobic residues (e.g. Leu, Ile, or Met), and „aa‟ 
represents aromatic residues (e.g. Phe, Tyr, or Trp; Vivona & Kelman, 2003).  HuLigI 
contacts PCNA, via the PIP motif, at the PCNA inter-domain connector loop (IDCL; 
Pascal et al., 2006). Recent structural studies involving the yeast DNA ligase I 
homologue, Cdc9, have revealed another site of interaction for the ligase PIP motif 
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within the C-terminal domain of PCNA (Vijayakumar et al., 2007). Vijayakumar et 
al. (2007) also showed that the nick-joining ability of Cdc9 was inhibited by 
replication factor C (RFC), the protein responsible for loading PCNA onto DNA 
(Dionne et al., 2003). They found that nick joining activity was recovered when 
PCNA was loaded onto DNA by RFC and the RFC/PCNA complex had dissociated 
following loading. As neither PCNA nor DNA ligase I has specific nick-sensing 
ability, it is hypothesised that RFC holds the PCNA at the nick generated by the 
action of DNA polymerase and Flap endonuclease-1(FEN-1; FEN-1 is the structure 
specific nuclease involved in cleavage of over-lapping nucleotides – „flaps‟ that occur 
during DNA replication and repair). 
 
HuLigI also interacts with hRad9-hRad1-hHus1 (9-1-1), a heterotrimeric DNA sliding 
clamp, involved in cell cycle checkpoints and known to be a sensor of DNA damage  
(Wang et al., 2006; Song et al., 2009). The 9-1-1 clamp complex is loaded onto DNA 
by hRad17-RFC in response to replication blockage and DNA damage to initiate a 
signalling cascade (Wang et al., 2006). Recent studies have shown interactions 
between the DBD of HuLigI with both PCNA and 9-1-1 clamps (Pascal et al., 2006; 
Song et al., 2009). The interactions between HuLigI and PCNA linked to DNA 
initially occur via the HuLigI PIP box, thereby facilitating a subsequent interaction 
between the HuLigI DBD and PCNA (Song et al., 2009). 
 
HuLigI also encodes an N-terminal nuclear localisation signal (NLS; Figure 1.9). 
NLS‟s contain lysine and/or arginine clusters immediately preceded by a proline 
(Dingwall & Laskey, 1991). Localisation of the enzyme to the nucleus allows it to be 
targeted to DNA replication and repair protein complexes (Montecucco et al., 1995).  
 
Recently, Vijayakumar et al. (2009) reported that phosphorylation of the N-terminal 
region of HuLigI in post-translational modifications is critical for its
 
participation in 
different DNA transactions. Their group expressed a mutant version of HuLigI in the 
46BR.1G1 (HuLigI-deficient) cell line, in which four serine residues (Ser51, 66, 76, 
and 91), phosphorylated
 
in vivo, were replaced with either alanine or aspartic acid. 
The cell lines expressing these phosphorylation site mutants exhibited a dramatic 
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reduction in proliferation and DNA
 
synthesis and were also hypersensitive to DNA 
damage (Vijayakumar et al., 2009). 
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Figure 1.9: Domain structures of mammalian DNA ligases  
Schematic representation of human DNA ligase I, IIIα, IIIβ and IV with some regions of the proteins 
and approximate binding sites shown for some of their main, known partners. The DNA binding 
domain (DBD; red), catalytic core (composed of adenylation; grey and OB-fold domain; green) are 
conserved in ligases (I-IV). The positions of the active site lysine residues (K568, K508, K421, K508, 
K421 and K213) within the adenylation domain that form the covalent bond with AMP are shown. 
Abbreviations: PCNA - Proliferating cell nuclear antigen, NLS - nuclear localisation signals, BRCT - 
Breast and ovarian cancer susceptibility protein 1 C-terminal, ZnF - Zinc finger, MLS - mitochondrial 
leader sequence. 
 
1.5.2 DNA ligase III 
 
DNA ligase III is unique to vertebrates and is therefore absent in lower eukaryotes 
(Martin & MacNeill, 2002). The mammalian LIG3 gene encodes for three different 
DNA ligase polypeptides (Figure 1.9). The nuclear and mitochondrial versions of 
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DNA ligase IIIα are synthesised in somatic cells by the use of different in-frame 
alternative translational initiation sites from DNA ligase IIIα mRNA (Lakshmipathy 
& Campbell, 1999; Perez-Jannotti et al., 2001). DNA ligase IIIβ is generated by a 
germ-cell specific alternative splicing mechanism, in which the terminal 3‟-coding 
exon in DNA ligase IIIα mRNA is replaced by a different exon (Perez-Jannotti et al., 
2001). The two isoforms of DNA ligase III differ at their C-termini. DNA ligase IIIα 
contains a breast and ovarian cancer susceptibility protein (BRCT) motif (Figure1.8; 
Timson et al., 2000). The BRCT domain, an autonomously folding protein module of 
about 95 amino acids was first identified in the carboxy-terminal region of the 
BRCA1 tumour suppressor protein but which has since been found in a range of 
proteins implicated in DNA replication, DNA repair and checkpoint functions (Moore 
et al., 2000).  In DNA ligase IIIβ, this motif is replaced by a short sequence which 
acts as a nuclear localization signal (Lakshmipathy & Campbell, 1999).  
 
The BRCT domain of HuLigIIIα facilitates the enzyme‟s interaction with XRCC1, a 
multi-domain protein that functions as a „molecular scaffold‟, stabilising DNA and 
interacting with other proteins involved in the base excision repair pathway (BER) 
such as DNA polymerase β (polβ) and poly(ADP-ribose) polymerase (PARP; 
Caldecott et al., 1994; Doherty & Suh, 2000; Thompson & West, 2000).  DNA ligase 
III also contains an N-terminally located zinc finger domain, containing four cysteine 
residues that are homologous to the zinc finger domain of PARP (Mackey et al., 
1999). The LigIII zinc finger is known to interact with, and mediate the binding of the 
HuLigIII-XRCC1 complex with DNA (Mackey et al., 1999; Tomkinson et al., 2006).  
 
Cotner-Gohara et al. (2008) showed that the ZnF alone fails to bind tightly to nicked 
DNA and instead functions in cooperative manner with the DBD to form a DNA-
binding module that interacts specifically with nicked DNA. The catalytic core of 
DNA ligase III also binds selectively to nicked DNA but nick joining activity is 
greatly accelerated by the ZnF-DBD module in full-length DNA ligase III, suggesting 
that the ZnF-DBD and catalytic core function as two separate DNA-binding modules 
during catalysis. The jack knife model proposed by Cotner-Gohara et al. (2008) 
suggests that the two DNA binding modules of DNA ligase III contact the DNA 
substrate at different times during the end-joining reaction. The ZnF-DBD domain 
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binds to the nick first and then subsequently disengages from the nick to allow access 
by the catalytic core for catalysis (Ellenberger & Tomkinson, 2008). 
 
1.5.3 DNA ligase IV 
 
DNA ligase IV (911 amino acids), encoded by LIG4, is characterized by a carboxy–
terminal extension comprising two BRCT domains (Figure 1.9), and the region 
between them that binds the 38 kDa XRCC4 protein (Grawunder et al., 1998; Sibanda 
et al., 2001). This interaction has been found to increase the stability of DNA binding 
by ligase IV and stimulate double-strand DNA break repair (Critchlow et al., 1997; 
Grawunder et al., 1998). Cells that lack XRCC4 or DNA ligase IV are hypersensitive 
to ionising radiation and are deficient in V(D)J recombination [variable (V)-
diversity(D)-joining(J) - a site specific recombination process; Li et al., 1995; Gao et 
al., 1998]. The DNA ligase IV/XRCC4 complex is required for repairing DNA 
double- strand breaks by the non-homologous end joining pathway (NHEJ) pathway 
(described in detail in section 1.8.1.1; Martin & MacNeill, 2002). Biochemical and 
genetic analyses have revealed that DNA ligase IV is the primary ligase utilised for 
end joining as neither DNA ligase I nor III are able to complement for DNA ligase IV 
in cells deficient in the enzyme (Baumann & West, 1998).  
 
1.6 PBCV-1 DNA ligase 
 
PBCV-1 DNA ligase is the smallest (298 amino acid) eukaryotic ATP-dependent 
ligase that has been characterised to date (Ho et al., 1997). Other eukaryotic DNA 
ligases such as human ligases I, III and IV are 919, 922 and 844 amino acid 
polypeptides respectively (Martin & MacNeil, 2002). PBCV-1 is a lytic protovirus of 
the family Phycodnaviridae (large polyhedral, plaque-forming viruses) of the genus 
Chlorovirus. It infects the Chlorella algae which are endosymbionts of the protozoan 
organism Paramecium bursaria (Yamada et al., 2006). The PBCV-1 genome is a 
linear, double-strand DNA molecule with inverted terminal repeats and covalently 
closed hairpin telomeres. The sequence of the 330-kbp PBCV-1 genome encodes 380 
polypeptides (Ho et al., 1997; Yamada et al., 2006 ). Many proteins encoded by 
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PBCV-1 are the smallest or among the smallest proteins in their class these include 
the PBCV-1 DNA ligase, RNA capping enzyme (guanylyltransferase) and 
topoisomerase (Ho et al., 1997; Shuman & Lima, 2004).  
 
Topoisomerases manipulate the topological state of cellular DNA by controlling the 
superhelicity and DNA strand interlocking. They are involved in the relaxation of 
supercoiled DNA by the cleavage of one strand and rotating it around the intact strand   
(type I) or by passing an intact DNA duplex through a DNA strand break in the same 
or a neighbouring DNA duplex (type II; Lavrukhin et al., 2000). The 120 kDa, type II 
topoisomerase encoded by PBCV-1, cleaves double-stranded DNA thirty times faster 
than human toposiomerase II (Lavrukhin et al., 2000). As with the PBCV-1 DNA 
ligase, it is used as a model enzyme to study the mechanism, biochemistry and 
structure-function analysis of topoisomerase activity (Lavrukhin et al., 2000). 
 
The PBCV-1 DNA ligase consists only of the conserved catalytic core without the 
flanking N and C terminal domains found in the larger cellular, eukaryotic DNA 
ligases (Figure 1.10, panel A; Ho et al., 1997). The structure of the 34 kDa PBCV-1 
DNA ligase-adenylate has been determined and reflects the same two-domain 
arrangement (a 188 amino acid N-terminal adenylation domain and a 110 residue OB-
fold domain) and structural features of the larger 41 kDa T7 DNA ligase (Subramanya 
et al., 1996; Odell et al 2000). This can be seen in superimposition of the active sites 
of the two enzymes where critically conserved residues in the key motifs I and III and 
their contacts with the ribose sugar of adenine ring align almost identically (Figure 
1.10, panel B; Odell et al., 2000). 
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Figure 1.10: PBCV-1 DNA ligase amino acid sequence and 
superimposition of conserved motifs in PBCV-1 and T7 bacteriophage 
 
The PBCV-1 DNA ligase consists only of the conserved catalytic core without the flanking N and C 
terminal domains. Panel A :Nucleotidyltransferase motifs comprising AdD [I (green), Ia (brown), III 
(yellow), IIIa (cyan), IV (purple), V (blue)] and OB-fold domain [VI (red)] are highlighted. Panel B: 
Superimposition of key residues of  the active site in motifs I and III and their contacts with the ribose 
sugar of AMP in PBCV-1 (shown in green) and ATP in T7 bacteriophage ligase (shown in purple)  
(Odell et al., 2003). 
  
 
 PBCV-1 DNA ligase is regarded by some as the catalytic core present in all ligases 
such that anything that applies to the catalytic core of this enzyme will apply to the 
larger ligases (Odell et al., 2003). This „minimal‟ enzyme is a fully functional ligase 
as it is able to sustain mitotic growth, excision repair and non-homologous end joining 
(NHEJ) in S. cerevisiae strains deleted for the endogenous ligases, the Cdc9 (the LigI 
homologue, essential for cell growth) and LIG4 (a DNA ligase IV homologue, not 
essential for cell growth). It is also able to repair yeast DNA damage induced by UV 
irradiation or treatment with methyl methane sulphonate (MMS; Sriskanda et al., 
1999).  
 
In recent years, PBCV-1 ligase has emerged as an excellent model for structural and 
functional studies of eukaryotic ligases. PBCV-1 DNA ligase is the only DNA ligase 
with structures analysed for DNA bound and unligated states, providing instructive 
insights into the conserved mechanism of DNA ligation and conformational changes 
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that occur upon DNA binding (Figure 1.7; Odell et al., 2000; Odell et al., 2003; Nair 
et al, 2007). The fact that the recombinant PBCV-1 ligase is purified in high yield as 
ligase-adenylate offered an opportunity to solve the structure of the covalent reaction 
intermediates (Ho et al., 1997; Odell et al., 2000; Odell et al., 2003). 
 
1.7 DNA repair proteins as therapeutic targets 
 
The genetic connections between DNA repair and human cancers have increased 
interest in the proteins that recognise and rectify specific sites of DNA damage 
(Madhusudan & Hickson, 2005; Damia & D‟Incalci, 2007). An increase in the 
activity of proteins involved in DNA damage repair pathways is observed in early 
precursor lesions of human breast, colon, lung and urinary bladder tumours (Martin et 
al., 2008). It is characterised by the phosphorylation of many DNA damage response 
proteins hence suggesting that activation of DNA damage response machinery is a 
consequence of oncogenic activity (Barktova et al., 2005). The activation of DNA 
repair pathways in tumourigenesis suggests their function in protecting cells against 
deleterious genetic changes that contribute to cancer formation (Lord et al., 2006).  
 
Ionising radiation and chemotherapeutic drugs, currently used in the treatment of 
cancer, directly or indirectly damage DNA. Mammalian cells have highly conserved 
DNA damage sensor mechanisms that result in the activation of a number of signal 
transduction pathways leading to cell cycle arrest and thus allowing repair or the 
induction of apoptosis to eliminate heavily damaged cells (Hoeijmakers, 2001; 
Martin, 2001). Activation of repair pathways can lead to the survival of tumour cells 
and have a negative impact on the treatment efficacy, leading to resistance to 
therapies.  The causes of resistance to DNA damaging agents can be associated with 
increased cellular repair activities while defects in DNA repair pathways results in 
hypersensitivity to these agents (Tentori & Graziani, 2005; Damia & D‟Incalci, 2007).  
Therefore, effectiveness of the existing therapies, ionising radiation and cytotoxic 
drugs, may be improved in combination with the pharmacological inhibition of DNA 
repair pathways or DNA damage signalling pathways.  
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1.7.1 Overview of DNA repair pathways 
 
DNA lesions can involve a single-strand of DNA (single-strand breaks) or both 
strands (double-strand breaks or DSBs). Single-strand breaks are repaired by the base 
excision repair (BER) pathway and nucleotide excision repair (NER) pathway 
whereas double-strand breaks are repaired by the non-homologous end joining 
(NHEJ) and homologous recombination (HR) pathways (Takata et al., 1998; Costa et 
al., 2003; Almeida & Sobol, 2007). 
 
DSBs in DNA can arise on genome exposure to a variety of DNA-damaging
 
agents, 
such as ionizing radiation (IR), ultra-violet light, reactive
 
chemicals and reactive 
oxygen species (Lord et al., 2006; Tomimatsu et al., 2007). DSBs also occur from 
closely spaced single-strand breaks, during replication of single-strand breaks or in 
normal endogenous processes that demand that genome sequences be rearranged such 
as generation of genetic diversity in meiosis and V(D)J recombination during 
development of the immune system (Grawunder et al., 1998; Hoeijmakers, 2001; 
Verkaik et al., 2002). Cells respond to DSBs by activating a complex DNA-damage-
response pathway that includes cell-cycle arrest, the transcriptional and post-
transcriptional activation of a subset of genes (including those associated with DNA 
repair) or may stimulate apoptosis if the damage is too significant (Lord et al., 2006; 
Wyman & Kannar, 2006).  
 
The cellular response to DSBs is activated by ataxia-telangiectasia mutated (ATM) 
kinase, a phosphatidylinositol 3-kinase-related kinase (PIKK) defective in ataxia 
telangiectasia (AT - an autosomal recessive disorder; Hoeijmakers, 2001; Tomimatsu 
et al., 2007). ATM is activated when it is recruited to sites of DSB damage by the 
MRE11-RAD50-NBS1 (MRN) complex (Wyman & Kannar, 2006). Following ATM 
activation, several DNA-repair and cell cycle checkpoint proteins, including P53, the 
kinases CHK1 and CHK2, are activated leading to cell cycle arrest and DNA repair 
(Tomimatsu et al., 2007). During cell cycle arrest, DSBs are repaired by NHEJ and 
HR (Wyman et al., 2004; Hefferin & Tomkinson, 2005). 
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HR dominates in late S and the G2 phase of the cell cycle and repairs breaks by 
copying genetic information from either homologous chromosomes or sister 
chromatids (Wyman et. al., 2004; Lord et al., 2006). NHEJ is a homology 
independent process for DSB repairs in the G0, G1 and early S phases of the cell 
cycle (Jayaram et al., 2008). 
 
1.7.1.1 Non-homologous end joining pathway (NHEJ) 
 
Eukaryotic NHEJ is a multi-step reaction catalysed by a core set of conserved 
proteins, comprising the Ku70-Ku80 heterodimer (Ku) and a complex of DNA ligase 
IV, XRCC4 and XLF/Cernunnos  (Figure 1.11, panel A; Hefferin & Tomkinson, 
2005; Lord et al., 2006). Ku has high affinity for DNA ends and binds as a ring to 
double- strand break ends, where it can translocate along the duplex (Wyman & 
Kannar, 2006). The crystal structure of Ku complexed with DNA revealed that the 
heterodimer has a toroidal shape with a central hole to accommodate duplex DNA 
(Hefferin & Tomkinson, 2005). The DNA-binding subunits of Ku70 and Ku80 bind to 
the ends of DSB and then recruit DNA-dependent protein kinase (DNA-PKcs; a 
member of the PIKKs family). Assembled together on a DNA end, Ku and DNA-
PKcs constitute the DNA-dependent kinase (DNA-PK). Activated DNA-PK 
holoenzyme recruits other DNA-repair proteins including Artemis, XRCC4, DNA 
ligase IV along with XLF/Cernunnos and DNA polymerase µ to site of DNA damage 
to carry out the DNA end joining (Wyman & Kannar, 2006; Tomimatsu et al., 2007). 
The Artemis protein, an endonuclease, is essential for processing damaged DNA ends 
such as heterologous loop and stem-loop DNA structures containing single-stranded 
DNA adjacent to double-stranded DNA (Wyman & Kannar, 2006).  A DNA ligase IV 
monomer forms a stable complex with a XRCC4 dimer that appears to stabilise, 
activate and target the ligase to the double-strand break and this complex carries out 
the final ligation step (Jayaram et al., 2008). XRCC4 possess DNA binding affinity 
and the residues involved in the interaction between XRCC4 and DNA ligase IV are 
highly conserved across eukaryotic species from human to yeasts (Hefferin & 
Tomkinson, 2005). Recently, an XRCC4-like protein, XLF (also known as 
Cernunnos), has been identified as an interaction partner of the DNA ligase 
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IV/XRCC4 complex, the function of which is not known in NHEJ (Lord et al., 2006; 
Jayaram et al., 2008). 
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Figure 1.11: NHEJ and HR pathway for double-strand DNA repair 
Double-strand breaks in DNA are repaired by non-homologous end joining pathway (NHEJ) or 
Homologous recombination (HR) pathway. Panel A: NHEJ mechanism of DSB repair. Induction of a 
double-strand break results in the recruitment of the Ku heterodimer to the lesion site to bind the free 
DNA. This is followed by the recruitment of the catalytic subunit of DNA protein kinase (DNA-PKcs). 
Assembly of DNA-PK results in the recruitment of the DNA ligase IV/XRCC4/XLF complex. After 
gap filling by DNA polymerase µ, DNA ligase IV seals the nick (Jayaram et al., 2008). Panel B: DNA 
double-strand break repair through homologous recombination. The close pairs of parallel lines 
represent the two strands of duplex DNA, while the lighter coloured pair is the sister chromatid of the 
darker coloured pair. Upon double-strand damage, the ends are nucleolytically processed to result in 3‟ 
single-stranded tails. Processed broken DNA forms a joint molecule with the intact homologous repair 
template DNA using strand invasion and strand exchange activities of Rad51 protein. The damage 
isrepaired by resynthesis of DNA (Filippo et al., 2008). 
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1.7.1.2 Homologous Recombination (HR) 
 
Homologous recombination consists of processing of double-strand breaks (DSB) to 
give single-strand tails, formation of a recombinase filament on the resultant single-
stranded DNA (ssDNA), strand invasion into a homologous sequence followed by 
DNA polymerase extension and ligation (Wyman et al., 2004; Wyman & Kannar, 
2006). 
 
DNA breaks are first converted to 3‟ ssDNA tails by nuclease activities of the MRN 
complex consisting of Mre11, Rad50 and NBS1 (Nijmegen breakage syndrome 1) 
proteins (Figure 1.11, panel B; Wyman et al., 2004; Filippo et al., 2008). The single-
stranded DNA is bound by replication protein A (RPA), which is later displaced by 
Rad51 (Wyman et al., 2004). The heterotrimeric RPA is an abundant nuclear protein 
that binds to and removes secondary structures in the ssDNA. Rad51 is a eukaryotic 
recombinase protein that mediates the pairing and shuffling of DNA sequences during 
HR (Wyman & Kannar, 2006). The Rad51-ssDNA nucleoprotein filament assembly, 
referred to as the presynaptic filament, is a slow process and prone to interference by 
the ssDNA binding protein RPA. It requires the involvement of recombination 
mediator proteins, such as Breast Cancer Type 2 susceptibility protein (BRCA2), for 
enhancement (Filippo et al., 2008). BRCA2 physically interacts with Rad51 and 
overcome the inhibitory effect of RPA on the assembly of the presynaptic filament. 
Cells deficient in BRCA2 are sensitive to DNA-damaging agents and mutations in the 
BRCA2 gene are known to predispose the affected individuals to breast, ovarian, and 
other cancers (Lord et al., 2006). The Rad51 nucleoprotein filament mediates 
homology recognition, strand invasion and strand exchange during the repair process 
(Wyman & Kannar, 2006; Filippo et al., 2008). 
 
DNA polymerase uses the joint molecule between the broken DNA and the intact 
homologous template as a substrate to reincorporate missing nucleotides. The gaps are 
ligated at the end of the newly synthesised sequence and the process is completed by 
resolvases, which remove the links between sister chromatids (Wyman et al., 2004).  
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In addition to HR and NHEJ, a non-conservative backup pathway called Micro 
homologous end joining (MHEJ) exists for double-strand break repair, which relies on 
micro homologies at repair junctions (Wang et al., 2003).  This was identified in 
NHEJ deficient cells where DNA substrates with non-matched ends were joined at 
much lower frequency than compatible-ended substrates (Wang et al., 2003). This 
type of mechanism is also found to be involved in chromosomal translocations and is 
independent of the core proteins involved in NHEJ (Tsuji et al., 2004).  Recent 
studies have shown that MHEJ and NHEJ are two distinct pathways. NHEJ relies on 
the Ku heterodimer and the DNA ligase IV/XRCC4 complex but MHEJ requires 
DNA ligase I or III depending on the length of micro homology sequences (Liang et 
al., 2008). 
 
1.7.1.3 Base Excision Repair (BER) 
 
Base excision repair (BER) is the predominant DNA damage repair pathway for the 
processing of small base lesions that do not distort the DNA helix (Krokan et al., 
2000; Hoeijmakers, 2001). These include alterations of DNA bases by deamination of 
cytosine to uracil, errors in DNA replication (misincorporation of dUTP or 8-oxo-
dGTP) and from by-products of normal cellular metabolism such as reactive oxygen 
species (Izumi et al., 2003). The reactive oxygen species include superoxide anions, 
hydroxyl radicals and hydrogen peroxide, derived from oxidative respiration and 
products of lipid peroxidation (Izumi et al., 2003; Almeida & Sobol, 2007).  
 
BER is normally initiated by a lesion-specific DNA glycosylase which recognises and 
removes the aberrant DNA base to leave an apurinic or apyrimidinc site (AP site; 
Figure 1.12; Krokan et al., 2000; Fortini & Dogliotti, 2007). Once the AP sites in 
DNA are created by this excision, AP endonucleases (APE) cleave the phosphodiester 
bond immediately 5‟ to the lesion leaving behind a strand break with a normal 3‟-
hydroxyl group terminated deoxyribonucleotide strand and a 5‟deoxyribose-
phosphate terminated strand (5‟dRP; Almeida & Sobol, 2007).  
 
AP sites generated during BER are processed by two sub-pathways: short-patch BER 
or long-patch BER (Sattler et al., 2003; Almeida & Sobol, 2007). Short-patch BER 
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involves replacement of a single nucleotide whereas in long-patch BER, 2-13 
nucleotides are replaced (Hoeijmakers, 2001). 
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Figure 1.12: General model of the short-patch (left) and long-patch (right) 
DNA repair pathways.  
BER is initiated by glycosylase activity followed by strand excision by APE. In short-patch BER DNA 
polymerase β incorporates the nucleotide and the resulting nick is sealed by a complex of XRCC1 and 
DNA ligase IIIα. Long-patch pathway results in the replacement of 2-13 nucleotides including the 
damaged base. In this type of sub-pathway, the 5‟ dRP moiety is removed as part of a flap of DNA by 
FEN1 and re-ligation is completed by DNA ligase I. 
 
 
In short patch BER, the 5‟-terminal dRP resulting from AP endonuclease incision is 
removed by intrinsic AP lyase activity of DNA polymerase β (pol β) leaving a single 
nucleotide gap (Krokan et al., 2000). The gap is filled by pol β and the nick is usually 
sealed by a DNA ligase III/XRCC1 heterodimer to complete the repair (Caldecott et 
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al., 1996). X-ray Cross Complementation protein 1 (XRCC1), discovered by its 
ability to complement a hypersensitivity phenotype towards DNA damaging agents, 
acts as a scaffold protein in BER. It coordinates and facilitates single-strand repair by 
forming a tight complex with DNA ligase III and interacts with other DNA repair 
proteins including pol β (Caldecott et al., 1996).  
 
In long patch BER, the repair size is usually 2-13 nucleotides in length. This pathway 
(Figure 1.12) utilizes AP endonuclease for the 5‟-incision but a flap endonuclease 
(FEN1) is required to remove the 5‟-terminal dRP moiety along with at least one 
adjacent nucleotide to leave a gap of two or more nucleotides (Almeida & Sobol, 
2007; Fortini & Dogliotti, 2007). This pathway is responsible for repairing damage 
caused by γ irradiation as these lesions are resistant to dRP elimination by DNA 
polymerase β and requires FEN1 for processing (Sattler et al., 2003). Repair of such 
sites requires PCNA, a toroidal homotrimeric DNA binding protein that encircles 
template DNA, to form a holoenzyme complex with DNA polymerase δ or Ɛ in 
conjunction with replication factor C (RF-C) and PCNA loading factor (Izumi et al., 
2003). PCNA encircles duplex DNA in its central cavity and provides a platform for 
the attachment of the polymerase (Fortini & Dogliotti, 2007). DNA synthesis and 
strand displacement by pol β is stimulated by the combined presence of FEN1 and 
poly(ADP-ribose)polymerase 1 (PARP1; Krokan et al., 2000; Hoeijmakers, 2001). 
PARP1 recognises the single-strand breaks in the sugar-phosphate backbone of DNA 
via an N-terminal zinc finger domain, translating the occurrence of DNA breaks into a 
DNA repair response by covalently transferring ADP-ribose moieties to a variety of 
nuclear proteins including PARP itself that are then activated or recruited to the site of 
damage (Tentori & Graziani, 2005). Long-patch repair pathway uses DNA ligase I as 
an end step to seal the nick (Sattler et al., 2003).  
 
1.7.1.4 Nucleotide excision repair (NER) 
 
Nucleotide excision repair pathway, a multiprotein repair system, acts on lesions 
produced by UV irradiation [e.g. cyclobutane pyrimidine dimers (CPDs) and 6-4 
photoproducts (6-4 PPs)] and DNA adducts induced by chemicals like aflatoxinB1 
and N-acetoxy-2-acetylaminofluorene (NA-AAF) that lead to helical distortion of the 
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DNA duplex, interfere with base pairing and obstruct transcription (Hoeijmakers, 
2001; Fousteri & Mullenders, 2008). This process requires the combined action of a 
number of proteins that carry out damage recognition, local opening of the DNA 
duplex around the lesion, dual incision in the damaged DNA strand, gap repair 
synthesis and strand ligation (Figure 1.13).  
 
There are two distinct NER sub pathways which differ only in the step involving 
recognition of the DNA lesion: transcription-coupled (TC-NER) repair, for the repair 
of actively transcribed genes and global genome (GG-NER) repair, for the removal of 
damage over the entire genome (Fousteri & Mullenders, 2008; Shuk et al., 2008). 
Initial damage sensing is performed by the heterotrimeric complex XPC-HR23B in 
GG-NER and by RNA polymerase II complex (RNAPIIo) in TC-NER. The six core 
factors that have been implicated in the damage recognition and dual incision steps of 
GG-NER are the XPC-hHR23B complex, transcription factor IIH (TFIIH; a nine 
subunit complex that functions in both NER and transcription initiation), XPA 
(xeroderma pigmentosum complementation group A; a zinc metalloprotein that acts 
as a limiting factor in NER damage recognition), replication protein A (RPA; a 
heterotrimeric protein, that binds to single-stranded DNA and is involved in DNA 
replication and DNA damage checkpoints), XPG and XPF-ERCC1 (Hoeijmakers, 
2001; Costa et al., 2003; Shuk et al., 2008). 
 
 After lesion recognition, all subsequent steps leading to assembly of a functional 
NER complex require the same NER core factors in GG-NER and TC-NER. Once 
XPA is bound to the lesions, it recruits the DNA repair transcription complex TFIIH 
and opening of the DNA helix is initiated by the XPD and XPB helicases (subunits of 
TFIIH; Hoeijmakers, 2001; Costa et al., 2003; Fousteri & Mullenders, 2008). Once 
the DNA has been unwound, XPG and XPF-ERCC1 are sequentially employed to 
make the 3‟ and 5‟ incisions, respectively, on each side of the lesion. Following 
incision, the damaged oligomer of approximately 24 to 32 nucleotides is excised 
(Shuk et al., 2008). PCNA assists DNA polymerase to fill the excision gap and the 
nick is sealed by DNA ligase I to complete the pathway (Hoeijmakers, 2001). Recent 
studies suggest to the XRCC1-Ligase III complex as the principal ligase involved in 
the ligation step of NER throughout the cell cycle in addition to DNA ligase I that is 
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mainly engaged in NER during S phase (Fousteri & Mullenders, 2008; Shuk et al., 
2008). 
XPA
RPA
TFIIH
Local unwinding
XPG
XPF-ERCC1
PCNA/RFC
Strand dual incision
Excised strand
Repair synthesis
Ligation
DNA ligase I
 
Figure 1.13: Simplified model of steps in Nucleotide excision repair (NER) 
after DNA lesion recognition.   
NER is initiated with DNA damage recognition followed by the local unwinding of the DNA. Dual 
incision removes the damaged DNA fragment around the lesion; the single-strand gap is filled by DNA 
polymerase , PCNA and RFC. The nick is sealed by DNA ligase I. Abbreviations: XPA- xeroderma 
pigmentosum complementation group A; RPA- Replication protein A; TFIIH - Transcription factor 
IIH; XPG and XPF-xeroderma pigmentosum complementation group G and F respectively; PCNA- 
Proliferating cell nuclear antigen; RFC- Replication factor C. 
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1.7.2 Inhibition of DNA repair proteins 
 
Cell lines derived from patients with inherited DNA repair disorders are generally 
very sensitive to certain DNA damaging agents (alkylating agents, ionising radiations 
etc.). Various molecular genetics approaches are used to study phenotypic effects of 
disabling DNA repair function in mammalian systems. These include mice knock out 
studies, anti-sense and/or RNA interference approaches that abolish expression of 
gene of interest. Such studies have indicated that down regulation of DNA repair 
proteins sensitises cells to a specific set of damaging agents, thereby leading to the 
development of several potential drug targets and small molecule inhibitors of DNA 
repair.  
1.7.2.1 Poly(ADP-ribose) polymerase 1 (PARP1) 
 
Poly(ADP-ribose) polymerases (PARPs) constitutes a family of cell signalling 
enzymes which catalyses poly(ADP-ribosylation) of DNA-binding proteins. 
Poly(ADP-ribose) polymerase 1 (PARP1), encoded by the ADPRT (ADP-ribosyl 
transferase) gene, has emerged as a critical regulatory component of the immediate 
cellular response to DNA damage (Tentori et al., 2005). PARP1 interacts with DNA 
ligase III, XRCC1, DNA polymerase and other components of single-strand break 
repair (Fortini & Dodliotti, 2007). On activation, PARP1 transfers ADP-ribose unit 
from NAD
+ 
to nuclear target proteins and itself forming long and branched polymers 
of poly (ADP-ribose) (PAR; Martin, 2001; Tentori et al., 2005). Negatively charged 
polymers of ADP-ribose (PAR) attached to PARP1 itself and histones lead to 
chromatin relaxation, facilitating the access of base excision repair proteins and 
activating these repair enzymes. When DNA is moderately damaged, PARP1 is 
activated and participates in the DNA repair process and the cell survives. However in 
the presence of extreme DNA damage, PARP1 is over activated and induces depletion 
of cellular NAD
+
 and ATP levels leading to cell dysfunction or necrosis (Madhusudan 
& Hickson, 2005; Tentori et al., 2005). 
Preclinical studies have confirmed the chemo-sensitising and radio-sensitising effects 
of PARP inhibitors. PARP inhibitor - AG014699 (Phase II clinical trial study) is used 
to potentiate cytotoxic effects of the antitumor drug, Temozolomide, (TMZ; Tentori et 
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al., 2005; Albert et al., 2007). TMZ interacts with DNA and generates a wide 
spectrum of base adducts such a N7-methylguanine (N7-MeG) and N3-methyladenine 
(N3-MeA). N3-MeA and N7-MeG adducts are repaired by BER, which substitutes a 
single modified nucleotide (Figure 1.14). The enhancement of antitumor activity 
derives from the impairment of the co-ordinating function of PARP1 and the resulting 
nicks are left unrepaired due to the interruption of the BER process (Tentori et al., 
2005).  
Cells with germline mutations in BRCA1 and BRCA2 genes have a strong tendency 
to transform to cancerous cells (Turner et al., 2005). These cells are defective in 
homologous recombination (HR), which relies on BRCA2 to localise Rad51 to sites 
of DSBs and mediate DNA repair (Lord et al., 2006). PARP inhibitors are lethal with 
BRCA2 deficiency as inhibition of PARP probably leads to persistence of DNA 
lesions that would normally be repaired by BRCA2 mediated HR (Turner et al., 
2005). 
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Figure 1.14: Molecular mechanisms underlying cytotoxicity induced by 
Temozolomode, as single agent or combined with PARP inhibitor 
Temozolomode (TMZ) generates a variety of DNA adducts such as N7-methylguanine (N7-MeG) or 
N3-methyladenine (N3-MeA) which are both removed by base excision repair (BER). Inhibition of 
PARP prevents recruitment of BER components involved in the repair process of N-methylpurines; this 
results in generation of strand breaks and induction of apoptosis. 
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1.7.2.2 Base excision repair (BER) proteins 
 
BER is able to recognise and repair the DNA damage caused by alkylating agents 
(Krokan et al., 2000; Izumi et al., 2003). The inhibition of BER sensitises cells to the 
cytotoxic effects of different alkylating agents. Methoxyamine (MX) is a small 
molecule inhibitor that binds to the AP sites and prevents their processing by APE1, 
leading to the accumulation of abasic sites (Figure 1.15; Damia & D‟Incalci, 2007; 
Martin et al., 2008). Another small molecule inhibitor, E330 is able to inhibit the 
redox activity of APE1 and has been shown to increases the cytotoxic activitiy of 
alkylating agents in an ovarian cancer cell line (Madhusudan & Middleton, 2005).  A 
synthetic compound palmoic acid inhibits the polymerase and lyase activities of polβ 
that is required to synthesise new DNA strand after the removal of damaged base 
(Damia & D‟Incalci, 2007).  
 
1.7.2.3 Double-strand break repair proteins  
 
Inhibitors of ataxia-telangiectasia mutated (ATM) kinase and DNA dependent protein 
kinase (DNA-PKcs) are being developed as potential therapeutics for the treatment of 
cancer (Lord et al., 2006; Salles et al., 2006). A small molecule ATM inhibitor, 
KU55933, sensitises cells to ionising radiation, etoposide and doxorubicin (Figure 
1.14; Lord et al., 2006). Several small molecule inhibitors of DNA-PKcs including 
Vanillin and Salvicine have also been developed (Salles et al., 2006). Figure 1.15 
highlights the extent to which the DNA repair pathways inhibitors are being 
developed. 
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Figure 1.15: Schematic representation of the main DNA repair pathway 
and their inhibition under investigation 
Abbreviations – DR: Direct repair; MGMT: O6-alkylguanine-DNA-alkyltransferase; BER: Base 
excision repair; APE1: apurinic endonuclease; PARP: poly(ADP-ribose)polymerase; NER: nucleotide 
excision repair; GGR: global genome repair; TCR: transcription coupled repair; DSBR: double-strand 
break repair; HR: homologous recombination; NHEJ: non-homologous end joining. Triangled 
pathways are the ones for which an inhibiting strategy has been pursued. The yellow highlighted 
proteins are the targets to which inhibitors (red boxes) are used for preclinical studies. 
 
 
1.7.3 DNA ligases as drug targets 
 
The inhibition of various DNA binding proteins, such as DNA gyrase (type II 
topoisomerase; an enzyme that unwinds double stranded DNA), is widely reported in 
literature (Bernard et al., 1993; Chen et al., 1996). Its inhibition by quinolones and 
aminocoumarins induces cell death by stimulating DNA damage and blocking 
replication processes (Chen et al., 1996). Despite the predominant strategy in 
chemotherapy being focussed on substances that interfere with DNA metabolism, 
DNA ligases have received little attention as possible targets for anti-tumour agents. 
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After the lesions have been removed and gaps are filled with DNA polymerases by 
the DNA damage repair pathway, a DNA ligase finally seals the nicks into 
phosphodiester bonds, restoring the DNA fidelity (Timson et al., 2000; Tomkinson et 
al., 2006). Since DNA ligases in bacteria and eukaryotes use different cofactors, its 
binding site has been targeted by some groups to identify competitive inhibitors which 
can distinguish between the two kinds of DNA ligases based on the structural 
differences in the co-factor binding site (Gajiwala & Pinko, 2004; Srivastava et al., 
2005). 
 
The presence of a distinctive N-terminal Ia domain in NAD
+
-dependent DNA ligases 
(LigA) has made them an attractive target for the development of broad-spectrum 
antibacterial drugs. Brotz-Oesterhelt et al. (2003) have demonstrated remarkable 
specificity of Pyridochromanones for E. coli LigA compared to the ATP dependent 
HuLigI. Increased drug resistance in pathogenic bacteria such as Mycobacterium 
tuberculosis have lead researchers to seek to identify various small molecule 
inhibitors of LigA either by high-throughput screening of chemical libraries or virtual 
screening by computational docking of ligands into the LigA crystal structures 
(Srivastava et al., 2005; Dwivedi et al., 2008).   
  
The unravelling of the crystal structure of HuLigI and the advances in the 
understanding of the molecular mechanisms involved in DNA damage repair 
pathways have made available potentially new targets suitable for new anti-cancer 
therapies or to enhance the anti-tumour activity of current DNA-damaging agents. 
The majority of the DNA ligase activity in proliferating cells is attributable to DNA 
ligase I as compared to other DNA ligases, which represent the majority of the ligase 
activity in resting cells (Signoret & David, 1986). Montecucco et al. (1992) observed 
a significant increase in the level of DNA ligase I after induction of cell proliferation 
from a resting state in HL-60 and NIH-3T3 cells whereas gene expression of the 
enzyme decreased in these cell lines after differentiation. 
 
In 2001, Sun et al. studied the level of HuLigI in human malignant and benign tissues 
obtained from cancer patients, and peripheral blood lymphocytes obtained from 
healthy donors. The comparison was made between 29 different human tumour 
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specimens ranging from breast to neuroblastoma tissue and 3 benign tissues (2 breast 
and 1 lung). The studies concluded that the level of DNA ligase I in malignant 
tumours was considerably higher than in benign normal tissue and peripheral blood 
lymphocytes (Sun et al., 2001). This study provided strong evidence that the level of 
DNA ligase I is considerably up-regulated in human tumour cells in comparison with 
normal tissues and that the activity of this enzyme may be essential for the survival of 
tumour cells.  
 
Sun et al. (2002) studied the modulation of DNA ligase I expression by anticancer 
drugs that damage DNA directly or indirectly. Their studies showed that gemicitabine 
(a pyrmidine antimetabolite) increased the level of DNA ligase I in various human 
tumour cells either without affecting or with a concomitant decrease in levels of other 
DNA ligases (III and IV). Their study concluded that gemicitabine treatment arrests 
DNA replication through incorporation of gemicitabine triphosphate into replicating 
DNA and that this triggers an increase in DNA ligase I levels in cancer cells They 
observed the same effect in MiaPaCa cells treated with other anticancer agents 
(hydroxyurea and ara-C), which share a common mechanism of action with 
gemacitabine.  
 
Recently, Chen et al. (2008) have conducted a virtual screen for small molecules that 
could dock into the N-terminal DNA binding domain (DBD) of HuLigI. They 
identified three compounds (L189, L67 and L82) inhibiting the second and third steps 
of the ligation reaction. L67 and L189 act as competitive inhibitors, preventing the 
interactions of the DBD of human ligase I with nicked DNA whereas L82 is an non-
competitive inhibitor, analogous to campothecin (DNA topoisomerase I inhibitor). 
Campothecin binds to topoisomerase I and DNA (the covalent complex) resulting in a 
ternary complex. This prevents DNA re-ligation and therefore causes DNA damage 
(Bodley & Shapiro, 1995).   
 
Other anti-tumour drugs like Doxorubicin are potent inhibitors of DNA ligases having 
an IC50 (μM) of 1.3-0.3 for E. coli. 2-0.4 for T4 ligase and 1.8-0.4 for HuLigI 
(Ciarrocchi et al., 1999). 
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Tan et al. (1996) identified HuLigI inhibitors from a natural product library derived 
from plant extracts. They isolated certain inhibitors, such as ursolic and oleanolic 
acids, which disrupted the activity of enzyme by interfering with the initial 
adenylation step of the ligation reaction. The isolated molecules did not disrupt the 
DNA relaxation of supercoiled plasmid indicating that, although the same enzyme 
active site may be involved in both enzyme adenylation and DNA relaxation, 
inhibitors may exert allosteric effects by inducing conformational changes that disrupt 
only one of these activities (Tan et al., 1996). 
 
Whilst the inhibitory effect of several classes of natural-product, anti-leukaemic 
drugs, including anthracyclines, the Catharanthus (Vinca) alkaloids and 
podophyllotoxin against purified DNA ligase from both normal and leukaemic 
lymphocytes has already been described in the literature (Yang et al., 1992; Tan et al., 
1996; Ciarrocchi et al., 1999; Chen et al., 2008), ligase inhibition has not been seen as 
the primary reason for the efficacy of these drugs.  
The recent identification of a single replicative DNA ligase from parasitic protozoans 
- Plasmodium falciparum (P. falciparum; Buguliskis et al., 2007) and Trichomonas 
vaginalis (T. vaginalis; discussed in detail in Chapter 3) suggests that these organisms 
are reliant on a single ligase for all DNA repair and replicative activities.  This may be 
a potential drug target if a suitable compound could be found that would selectively 
inhibit the parasite enzyme and not those of the host. 
 
 
 
 
 
 
 
 
46 
 
1.9 Aims 
 
The work described herein had three aims: 
(i) To develop a high-throughput, non-electrophoretic ligase inhibitor screen 
that could be used to identify molecules that can selectively target DNA 
ligase enzymes.  
 
(ii) To identify and produce ligase enzymes, for use in the above assay, 
whose inhibition could potentially have medical benefit.  This would 
include the human replicative DNA ligase I as a potential cancer 
therapeutic and the single DNA ligase enzyme from a parasitic 
protozoan. 
 
(iii) To validate the Trichomonas vaginalis DNA ligase as a drug target the 
enzyme required to be cloned, purified and characterised, prior to being 
put through into the inhibitor screen. 
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CHAPTER 2: GENERAL MATERIALS AND METHODS 
 
Standard molecular biology techniques and protocols used in this thesis, based on 
those described by Sambrook and Russell (2001), are summarised below. All 
chemicals were supplied by Sigma and were of analytic grade unless otherwise 
indicated.   
2.1 DNA Isolation and Manipulation 
2.1.1 Preparation of competent cells and transformation of DNA 
 
Competent E. coli cells (DH5α and BL21 DE3) were prepared using a modified 
calcium chloride method (Dagert & Ehrlich, 1979). The cells were streaked onto 
Luria Agar (LA: 1% (w/v) bactotryptone, 1% (w/v) NaCl, 0.5% (w/v) yeast extract, 
0.2% (w/v) bactoagar) and incubated overnight at 37
o
C. A single colony was 
inoculated into Luria Broth (LB: 1% bactotryptone (w/v), 0.5% NaCl (w/v), 0.5% 
yeast extract (w/v), pH 7.4), and grown overnight at 37
o
C with shaking. The overnight 
E. coli culture was diluted 1 in 100 into fresh LB and grown at 37
o
C with shaking 
until early log phase (Optical Density at 595 nm of 0.4-0.5) was reached. The cells 
were harvested by centrifugation at 16,000 x g for 5 minutes at 4
o
C (all subsequent 
steps were performed at 4
o
C). The cells were re-suspended in one culture volume of 
sterile, ice-cold 0.1 M MgCl2 and incubated for one minute before pelleting at 16,000 
x g for 5 minutes. The cells were re-suspended in one half of the culture volume in 
sterile, ice-cold 0.1 M CaCl2 and incubated on ice for 30 minutes. The cells were 
again harvested at 16,000 x g, re-suspended in one tenth of the culture volume of 
sterile, ice-cold, 0.1 M CaCl2 and 30% glycerol then stored in 100 μl aliquots at -
80
o
C. 
 
Plasmid DNA or ligation reactions were added to 100 μl of competent cells and 
incubated on ice for 20 minutes. The cells were heat-shocked at 42
o
C for 90 seconds 
and returned to ice for 5 minutes. LB was added (0.5 ml) and the cells were incubated 
at 37
o
C for at least one hour and subsequently plated onto LA plates containing the 
appropriate antibiotic (filter sterilised; 0.2 μm filter). 
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2.1.2 Small-scale preparation of plasmid DNA (Qiagen modified 
alkaline lysis) 
 
Plasmid DNA was prepared using a modified alkaline lysis method (Birnboim & 
Doly, 1979) designed by Qiagen (USA). E. coli DH5α cells transformed with the 
plasmid of interest were grown overnight at 37
o
C, with shaking, in 5 ml LB 
containing the appropriate antibiotic. The cells were harvested by centrifugation and 
the bacterial pellet was resuspended in 250 μl buffer P1 (50 mM Tris-HCl pH 8.0 and 
10 mM EDTA) supplemented with RNase A 100 μg/ml. Buffer P2 (250 μl; 200 mM 
NaOH and 1% SDS, w/v) was added followed by buffer N3 (350 μl; the composition 
of the buffer is proprietary of Qiagen), the tubes were gently inverted to mix and 
centrifuged in a micro centrifuge for 10 minutes at 16,000 x g. The supernatant was 
applied to a QIAprep spin column (blue column) and centrifuged at 16,000 x g for 60 
seconds. The columns were washed by application of 0.75 ml buffer PE (the 
composition of the buffer is proprietary of Qiagen) and centrifugation at 16,000 x g 
for 60 seconds followed by another 60 second centrifugation to remove any residual 
wash buffer. The column was placed in a clean 1.5 ml eppendorf tube and 30-50 μl of 
sterile distilled water was added to the centre of the column. The column was 
incubated at room temperature for one minute before elution of the DNA by 
centrifugation at maximum speed for 60 seconds. 
 
 2.1.3 Resolving of DNA by agarose gel electrophoresis (AGE) 
 
Molecular biology grade agarose was melted in 1 x Tris-Borate-EDTA buffer (89 mM 
Tris, 89 mM boric acid and 2.0 mM EDTA) or 1 x Tris-acetate-EDTA buffer (40 mM 
Tris, 1.14% (v/v) glacial acetic acid and 1 mM EDTA) to a final concentration of 
0.7% or 1% w/v agarose. The solution was cooled until it could be hand-held and 
ethidium bromide was added to a final concentration of 0.5 μg/ml. The solution was 
poured into a sealed gel platform and allowed to set. DNA loading buffer (6x loading 
buffer: 0.25% bromophenol blue, 30% v/v glycerol) was added to the DNA in a 1:5 
ratio. A commercial DNA molecular weight ladder was loaded into the first lane of all 
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gels. The agarose gels were run at 100-110 V for one hour in 1 x TBE or 1 x TAE 
buffer and the DNA was visualised by UV light at 254 nm (long wave length UV 
light, 320 nm, was used when purifying DNA from agarose gels). DNA fragments 
smaller than 300 bp were resolved on 2% agarose gels. 
2.1.4 Purification of DNA  
2.1.4.1 QIAQUICK gel extraction 
 
DNA fragments were resolved by 2% AGE and gel purified using the Qiagen gel 
purification kit. The DNA fragment was excised from the gel, three volumes of Buffer 
QG (the composition of the buffer is proprietary of Qiagen; contains guanidine 
thiocyanate) was added (three volumes of buffer: 1 volume of gel) followed by 
incubation at 50
o
C until the gel slice had dissolved. One gel volume of isopropanol 
was added and the sample was mixed. 800 μl of the sample was applied to the 
QIAquick DNA affinity column (purple column) and this was centrifuged at 16,000 x 
g for 60 seconds. The flow through was discarded and the column washed with 750 μl 
of Buffer PE before centrifugation at 16,000 x g for 60 seconds. The flow through 
was again discarded and the column centrifuged at 16,000 x g for 60 seconds to 
remove any residual buffer. The column was placed in a clean 1.5 ml eppendorf tube 
and 30-50 μl of sterile distilled water was added to the centre of the column. The 
column was incubated at room temperature for one minute before elution of the DNA 
by centrifugation at maximum speed for 60 seconds. 
2.1.4.2 QIAQUICK DNA purification following PCR or restriction digest 
 
DNA from PCR (2.1.9) or restriction digest reactions (2.1.7) was purified using the 
QIAquick DNA purification protocol (Qiagen). Five volumes of Buffer PBI (the 
composition of the buffer is proprietary of Qiagen; contains guanidium chloride and 
propan-2-ol) was added, the sample was mixed and applied to the QIAquick column 
before centrifugation at 16,000 x g for 60 seconds. The flow through was discarded 
and the column washed with 750 μl of Buffer PE before centrifugation at 16,000 x g 
for 60 seconds. The DNA sample was processed as before (2.1.4.1) and eluted with 30 
μl sterile distilled water. 
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2.1.5 Genomic DNA extraction 
 
72-hours old Trichomonas vaginalis culture (an isolate from UCLH called UCLHI 
was obtained from Dr. Pamela Greenwell‟s laboratory who received these from 
Professor Akers from the London School of Hygiene and Tropical Medicine) was 
spun at 5000 x g for 15 minutes. The supernatant was discarded and the pellet 
resuspended in 1 ml lysis buffer (10 mM Tris-HCl pH 7.4, 5 mM EDTA, 10% SDS 
and 10 µg/ml proteinase K) preheated to 60
o
C and then incubated at this temperature 
for 30 minutes (Rosl, 1992). The lysed material was then incubated with 1 ml of 
phenol: chloroform (1:1 v/v), inverted to mix and centrifuged in a microcentrifuge for 
10 minutes at 16,000 x g. The top layer was retained, placed in a clean eppendorf tube 
and an equal volume of phenol: chloroform was added and processed as before. The 
top layer was again retained; three volumes of ice-cold 95% ethanol and a 1 in 10 
volume of 3 M sodium acetate were added, thoroughly mixed and stored at -20
o
C 
overnight. The re-suspended cells were thawed and centrifuged at 16,000 x g for 10 
minutes. The supernatant was discarded and the DNA was washed with 100 μl 70% 
ethanol without mixing, the pellet and wash were then centrifuged at 16,000 x g for 5 
minutes. The supernatant was discarded and the DNA pellet washed with 100 μl 95% 
ethanol and without mixing, these were centrifuged at 16,000 x g for 10 minutes. The 
supernatant was discarded and the pellet air-dried at 37
o
C for 30 minutes before being 
dissolved in 20μl sterile distilled water. 
2.1.6 cDNA Preparation 
2.1.6.1 SV Total RNA isolation 
 
HT-29 cells (metastatic colorectal cancer cell line) or MDA MB435 cells (breast 
carcinoma cell line), used to isolate total RNA using the SV RNA isolation kit 
(Promega), were a kind gift from Dr. M. Dwek‟s laboratory, University of 
Westminster. 175 µl of SV RNA lysis buffer (4 M guanidine thiocyanate, 10 mM Tris 
pH 7.5 and 0.97% β-mercaptoethanol) was added to 30 mg of frozen cells and mixed 
by inversion (Chirgwin et al., 1979). 350 µl of SV RNA dilution buffer (blue buffer, 
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the composition of the buffer is proprietary of Promega) was added to the sample 
which was then placed in a water bath at 70
o
C for 3 minutes, followed by 
centrifugation at 16,000 x g for 10 minutes. The clear lysate was transferred to a clean 
1.5 ml eppendorf tube and mixed with 200 µl of 95% ethanol. The mixture was 
transferred to an RNA-affinity, spin column and centrifuged at 16,000 x g for 60 
seconds. The flow through was discarded and column was washed with 600 µl of SV 
RNA wash solution (60 mM potassium acetate, 10 mM Tris pH 7.5 and 60% ethanol) 
before centrifugation at 16,000 x g for 60 seconds. The flow through was again 
discarded. The column was incubated for 15 min with 50 µl of DNase solution 
(yellow buffer, containing DNase I) at room temperature. The DNase I reaction was 
stopped by adding 200 µl of DNase stop solution and the column was centrifuged for 
60 seconds at maximum speed. The column was washed twice with 250 µl of RNA 
wash solution before centrifugation at 16,000x g for 60 seconds. The column was 
placed in a clean 1.5 ml eppendorf tube and 50-70 μl of nuclease free water (supplied 
by Promega) was added to the centre of the column to elute the RNA by 
centrifugation at maximum speed for 60 seconds. The eluted RNA was stored at -
80
o
C. 
2.1.6.2 PolyATtract® mRNA Isolation following total RNA isolation 
 
The mRNA was extracted from the total RNA using the Poly A Tract
® 
mRNA 
Isolation system (Promega). 500 µl of nuclease free water was added to 50 µl of 
previously isolated total RNA and incubated at 65
o
C for 10 minutes. The sample was 
mixed gently with 3 μl of biotinylated-oligo(dT) probe and 13 μl of 20 X SSC 
(containing 87.7 gm NaCl and 44.1 gm sodium citrate) for annealing to the 3´ poly(A) 
region of the mRNA in a total RNA sample (Moyer & Henderson, 1983).   
 
Streptavidin Paramagnetic Particles (SA-PMPs) were mixed gently by inversion, until 
the particles were completely dispersed. The SA-PMPs were captured by placing the 
tube in the supplied proprietary magnetic stand and the supernatant was carefully 
removed. The SA-PMPs were washed three times with 0.5 X SSC buffer (300 µl per 
wash); every wash followed by capturing the SA-PMPs using the magnetic stand, and 
removing the supernatant. The washed SA-PMPs were resuspended in 100 µl of 0.5 X 
SSC, mixed with the contents of the biotinylated-oligo(dT) annealing reaction and 
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incubated for 10 minutes at room temperature. The SA-PMPs were captured and 
washed four times with 0.1 X SSC (300 µl per wash) as before. The final SA-PMP 
pellet was resuspended in 100 µl of RNase-free water, magnetically re-captured and 
the eluted mRNA was transferred to a sterile 0.5 ml eppendorf tube. 
2.1.6.3 The Universal RiboClone® cDNA synthesis following mRNA isolation 
 
A reverse transcriptase (RT) reaction was performed with the previously isolated 
mRNA for cDNA synthesis using universal riboclone
®
 cDNA synthesis (Promega). A 
sample was prepared by mixing 13 µl of isolated mRNA (~2 µg) with 2 µl of oligo 
(dT) primer or gene specific primers or random primers (0.5 mg/ml each) and heated 
at 70
o
C for 5 minutes, followed by cooling on ice (Okayama & Berg, 1979). First 
strand synthesis was initiated by adding 5 µl of first strand 5 X buffer (contains 5 mM 
each of dATP, dCTP, dGTP and dTTP) and 1 µl of RNasin ribonuclease inhibitor to 
the sample, incubated at 42
o
C for 5 minutes and followed by the addition of 2.5 µl 
sodium pyrophosphate (40 mM) and 1.5 µl of AMV reverse transcriptase. The 
reaction was incubated at 42
o
C for 60 minutes and cooled on ice. 
 
Second strand synthesis was initiated by mixing 40 µl of second strand 2.5 X buffer, 3 
µl of DNA polymerase I and 0.5 µl of RNase H to 20 µl of previously synthesised 
first strand reaction and incubated at 14
o
C for 2 hours. The sample was heated to 70
o
C 
for 10 minutes before adding 0.5 µl of T4 DNA ligase. The reaction sample was again 
incubated at 37
o
C for 10 minutes and the reaction was stopped by adding 10 µl of 200 
mM EDTA. cDNA was extracted from the solution by adding an equal volume of 
phenol:chloroform:isoamyl alcohol (in a ratio 25:24:1), mixed thoroughly, and 
centrifuged at 16,000 x g in a microcentrifuge for 2 minutes at room temperature. The 
aqueous phase was transferred to a fresh 1.5 ml eppendorf tube, mixed with 0.5 
volumes of 7.5 M ammonium acetate and 2 volumes of cold (-20°C) 100% ethanol 
and stored  at -70°C for 30 minutes followed by centrifugation at 16,000 x g for 5 
minutes. The supernatant was removed and pellet was mixed with 500 µl of cold (-
20°C) 70% ethanol and centrifuged at 16,000 x g for 2 minutes. The supernatant was 
discarded and the pellet air-dried at 37
o
C for 30 minutes before being dissolved in   
20 μl sterile distilled water. 
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2.1.7 Restriction of plasmid DNA 
 
Plasmid DNA was prepared (as per section 2.1.2) and restricted with restriction 
endonucleases (New England Biolabs, USA) for 2 hours (single digest - one 
restriction endonuclease) or 4 hours (double digest - two restriction endonucleases). 
Plasmid DNA (300 ng, estimated by agarose gel electrophoresis) was incubated with 
the appropriate restriction buffer (New England Biolabs, to a final concentration of 1 
X) and 10 U of each restriction endonuclease, sterile distilled water was added to 
correct the final volume and the reaction was incubated at 37
o
C for the appropriate 
time. When restricting plasmid DNA that was to be used for the insertion of DNA 
fragments, Calf intestine phosphatase (CIP; New England Biolabs) was added (1 U) 
thirty minutes prior to the end of the digest reaction to prevent re-circularisation of the 
plasmid vector. The restriction digest was resolved by 1% or 0.7% agarose gel 
electrophoresis as described in section 2.1.3. Following restriction digest, the plasmid 
DNA or the gene of interest was purified via gel extraction (2.1.4.1) or via the 
QIAquick DNA purification protocol (2.1.4.2). 
 
2.1.8 Ligation of DNA fragments 
 
Prior to ligation, DNA fragments generated by restriction digest were purified as 
above (2.1.4). The DNA fragments were ligated into the plasmid of interest using T4 
DNA ligase (New England Biolabs). DNA fragments (500 ng; estimated by agarose 
gel electrophoresis) were incubated in ligase buffer (50 mM Tris-HCl, 10 mM MgCl2, 
10 mM dithiothreitol (DTT), 1.0 mM ATP, pH 7.5) with restricted plasmid DNA (200 
ng; in an insert to vector ratio of 2.5:1), 0.175 U T4 DNA ligase (0.25 U/ μg of DNA) 
and sterile distilled water was added to correct the final volume. The ligation reactions 
were incubated over night at 4
o
C (Olivera & Lehman, 1967) and the products were 
transformed into competent E. coli DH5α cells. 
2.1.8.1 Ligation of PCR products into pGEM-T 
 
PCR products were inserted into pGEM-T following the standard protocol (Promega). 
The PCR product (100 ng; estimated by agarose gel electrophoresis) was incubated 
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overnight at 4
o
C with ligation buffer (2 X; 60 mM Tris-HCl pH 7.8, 20 mM MgCl2, 
20 mM DTT, 2 mM ATP, 10% polyethylene glycol), pGEM-T vector (50 ng), 3 U T4 
DNA ligase and sterile distilled water to the correct final volume. The ligation 
reaction was transformed into E. coli JM109 cells (Promega) competent cells and 
plated onto LA containing the appropriate antibiotic as well as 0.5 mM isopropyl-β-
D-thiogalactopyranoside (IPTG) and 80 μg/ml of 5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside (X-gal; dissolved in 2 ml N, N-dimethyl formamide). Colonies 
were selected by blue/white colony screening to distinguish recombinant (white) 
colonies from non-recombinant ones (blue). White colonies were selected for DNA 
isolation as previously described (2.1.2) and the DNA insert was released by digestion 
with Nde I and Xho I as previously described (2.1.7). Control reactions to assess the 
formation of background blue colonies were also carried out. A positive control 
ligation reaction was prepared with 50 ng of the control plasmid, pGEM-luc vector 
DNA (Promega). The control plasmid contains multiple stop codons in all six reading 
frames, thus a low background of blue colonies should be obtained. A negative 
control reaction was also performed with 50 ng of pGEM-T plasmid only. 
 
2.1.9 Polymerase Chain Reaction (PCR) 
 
PCR was applied for the exponential in vitro amplification of particular DNA 
sequences by using sequence-specific synthetic oligonucleotide primers obtained from 
Invitrogen. A reaction mixture containing PCR master mix (2x Promega: 50 U/ml Taq 
DNA polymerase in Promega proprietary reaction buffer, 400 μm dATP, 400 μm 
dGTP, 400 μm dCTP, 400 μm dTTP and 3 mM MgCl2), template DNA (3 ng), 
forward and reverse primers (0.5 µM each) was prepared (Bartlett & Stirling, 2003). 
The PCR solution was overlaid with 200 μl of mineral oil and cycled in a 
thermocycler (Perkin-Elmer) as follows: an initial denaturation step of one cycle at 
95
o
C for one minute followed by 30 cycles of: denaturation, 94
o
C for one minute, 
primer annealling, 55
o
C-65
o
C for one minute (varied with the annealing temperature 
of the specific primers used in amplification reaction), polymerase extension 72
o
C for 
one minute and a final 7 minute extension at 72
o
C. The reactions were cooled to 4
o
C 
for overnight storage or to room temperature and gel purified as described in section 
2.1.4.  
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2.1.10 Radiolabelling of DNA substrate 
 
A labelling reaction was prepared as described by Shuman & Ru (1995), containing 
50 pmole of radioactive label (
32
P; GE Healthcare), 1 mM ATP (1800 pmole), 1300 
pmole DNA substrate (18-mer; figure 3.15, panel B), kinase buffer (60 mM Tris-HCl 
pH 8.0, 10 mM MgCl2, 10 mM DTT) and 10 U T4 polynucleotide kinase (New 
England Biolabs). The reaction was incubated at 37
o
C for one hour and terminated by 
heating to 60
o
C for 10 minutes. A small amount of 10% glycerol was added to the 
DNA solution and the radiolabelled DNA was separated from unincorporated label by 
20% native polyacrylamide gel electrophoresis in 1 X TBE at 400 V for one hour. No 
DNA loading buffer (composition 2.1.3) was added to the DNA as the dye and 
unincorporated label bind irreversibly and can contaminate the labelled DNA sample, 
instead, DNA was mixed with 1 mM EDTA and 5 μl formamide. The density of the 
glycerol is sufficient to carry the DNA into the well. The labelled 18-mer was located 
by autoradiography of the wet gel. The developed autoradiograph was placed 
underneath the glass plate to allow the DNA to be excised from the gel in an 
acrylamide slice. The DNA/acrylamide slice was then incubated overnight, with 
rocking at 4
o
C in distilled water containing 150 mM NaCl. The supernatant 
containing the DNA was then centrifuged at 16,000 x g. Three volumes of ice cold 
100% ethanol were added and the DNA was incubated at -20
o
C for two hours. 
Following this, the pellet was washed with ice cold 70% ethanol and the fractions 
were monitored for radioactive activity. The pellet was air-dried and dissolved in 100 
μl sterile distilled water. A 1/100 dilution (1 μl label dilution in 99 μl distilled water) 
of the radioactive label was prepared at stored at -20
o
C to determine the rate of decay 
of the radioactivity and to allow comparison with the incorporated material to guage 
the quantity of label incorporated. 
The amount of labelled substrate was measured using a Beckman coulter LS6500, 
multipurpose scintillation counter. 1 μl of the 1/100 dilution of the radioactive label 
was counted to determine the counts per pmole of label. 1 μl of the excised labelled 
DNA was counted and the amount of labelled substrate was determined using the 
following equation: 
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Count of 1μl of eluted substrate x substrate volume x 100/2.7* 
 
Counts per pmol of label 
 
 *(100/2.7 is the proportion of the label of the total amount of ATP used in the kinase reaction) 
 
 
2.1.11 Annealing of DNA substrates 
In order to determine the ratio for annealing, the A260 of each DNA substrate was 
determined and the concentration calculated according to the following formula: 
C = A260 x fc 
C = concentration of DNA 
A260 = absorbance of DNA at 260 nm 
f = dilution factor 
c = concentration (standard)/ absorption (standard) dsDNA = 0.05 μg/ml 
      ssDNA = 0.03 μg/ml 
 
The DNA substrates were added in the appropriate ratio (4:1 unmodified: modified 
for radioactively labelled substrates) to ensure that every labelled substrate was part of 
a productive nick and could therefore be utilised in a ligation reaction. Each substrate 
was heated at 65
o
C for five minutes in the presence of annealing buffer (50 mM Tris 
pH 7.5, 200 mM NaCl, 5.0 mM DTT, pH 7.5). The hairpin substrate was snap-cooled 
on ice before addition of the downstream 5‟phosphate labelled oligonucleotide. The 
reaction was slowly cooled to room temperature and incubated on ice. The annealed 
DNA was then either immediately used or stored at -20
o
C until required. 
 
2.1.12 Ligation Assay using Radiolabelled DNA substrate 
 
The standard DNA ligation assays were performed by incubating DNA ligase with the 
32
P-labelled DNA substrate (1 pmole) for 2 min at 37
o
C in ligation buffer, containing 
50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 5 mM DTT and 1 mM ATP in a total 
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volume of 20 µl. The reaction was terminated by the addition of 20 µl of loading 
buffer [98% (v/v) formamide, 10 mM EDTA, 0.01% (w/v) bromophenol blue]. 
Reaction samples were heated at 95
o
C for 5 minutes and electrophoresed through 20% 
polyacrylamide 7 M urea gel in 1 X Tris-borate-EDTA buffer. The gel was run at 
300-400 V for 2-3 hours and exposed to X-ray film or analysed with a 
Phosphorimager (GE Healthcare) and the intensity of the bands analysed with an 
Imagequant 5.2 (Typhoon scanner, GE Healthcare). 
2.2 Protein Purification 
2.2.1 Protein expression 
 
E. coli BL21 (DE3) cells were transformed with the plasmid of interest as before and 
inoculated into LB containing the appropriate antibiotic. The culture was incubated 
overnight at 37
o
C with shaking. 500 ml LB was inoculated with a 1 in 100 dilution of 
the overnight culture; adjusted to 200 µg/µl antibiotic and incubated at 37
o
C with 
shaking. When the optical absorbance at a wavelength of 595 nm (A595) reached 0.4-
0.5, the cultures were adjusted to 0.4 mM IPTG and incubated for a further 2 hours at 
37
o
C. The cells were harvested by centrifugation with a Sorvall Super T21 centrifuge 
(SL250T rotor) at 10,000 x g for 10 minutes at 4
o
C. The supernatant was discarded 
and the bacterial cell pellet re-suspended in Buffer A (25 ml/l of culture; 50 mM Tris-
HCl pH 7.0, 300 mM NaCl and 10% glycerol) and stored at -80
o
C. 
 
2.2.2 Cell lysis and protein solubilisation 
 
All steps were performed at 4
o
C. The re-suspended bacterial cell pellets were thawed 
on ice, adjusted to 2.0 μg/ml lysozyme and 2.0 mM phenylmethylsulphonyl fluoride 
(PMSF) and incubated for 30 minutes. Triton X-100 was added to 0.1% (v/v) and the 
cells were incubated for a further 30 minutes. The lysate was sonicated with six, 30 
second bursts at 40% power (Status 200, MS73 probe) to reduce viscosity followed by 
ultracentrifugation to remove cellular material in a Sorvall Discovery 90SE centrifuge 
and T865 rotor at 30,000 x g for one hour. The insoluble pellet fraction was 
resuspended in buffer A and retained for sodium dodecyl sulphate polyacrylamide gel 
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electrophoresis (SDS-PAGE) analysis and the enzyme in the soluble supernatant 
fraction was purified. 
2.2.3 Protein purification using Ni-NTA agarose resin 
 
The pre-charged nickel-nitrilotriacetic acid (Ni-NTA) agarose resin was prepared as 
per the manufacturer‟s instructions (Ni-NTA coupled to Sepharose CL-6B; 
QIAexpressionist Handbook, Qiagen, 2003). A 5.0 cm column was poured, the 
storage buffer was removed and the column washed with 5 column volumes of 
distilled water followed by 5 volumes of binding buffer (50 mM Tris-HCl pH 7.0 or 
pH 7.5, 300 mM NaCl and 10 mM imidazole). The soluble protein fraction was 
loaded onto the column and the flow through retained. The column was washed with 
5 volumes of wash buffer (50 mM Tris-HCl pH 7.0 or pH 7.5, 300 mM NaCl and 30 
mM imidazole); 5.0 ml fractions were collected. After optimising protein elution 
along an imidazole gradient (50 mM Tris-HCl pH 7.0 or pH 7.5, 300 mM NaCl and 
100 – 500 mM imidazole), subsequent protein preparations were eluted with elution 
buffer (50 mM Tris-HCl pH 7.0 or pH 7.5, 300 mM NaCl and 300 mM imidazole).  
After use, ionically-bound proteins were removed by washing the column with one 
volume of 2.0 M NaCl. Precipitated proteins, hydrophobically bound proteins and 
lipoproteins were removed by washing the column with three volumes of 0.5 M 
NaOH. The column was then washed with three column volumes of the elution buffer 
followed by three column volumes of binding buffer and re-used a maximum of three 
times. Following elution from Ni-NTA agarose, the protein was adjusted to 5.0 mM 
DTT and subjected to ion-exchange chromatography. 
 
2.2.4 Western blotting of proteins 
 
The transfer of proteins onto nitrocellulose was performed using the method described 
by Towbin et al. (1979) with a Bio-Rad western apparatus. The transfer was 
performed at 4
o
C for one hour (100 V) using a freshly prepared transfer buffer (25 
mM Tris, 192 mM glycine and 20% methanol). Proteins transferred onto the 
nitrocellulose membrane were visualised using Ponceau S stain (0.5% Ponceau S w/v 
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and 1% glacial acetic acid v/v). The membrane was de-stained by multiple washes in 
sterile distilled water. Following transfer of proteins and staining, the nitrocellulose 
membrane was washed with Tris-buffered saline (TBS)/Tween (TBS: 50 mM Tris pH 
7.5, 150 mM NaCl, 0.1% (v/v) Tween 20) and blocked overnight, at 4
o
C with 2% 
bovine serum albumin (BSA) (dissolved in TBS/Tween). The membrane was 
incubated with 5 μg/ml biotinylated anti-His antibody (Sigma, Germany) for one hour 
at room temperature. Following this, the membrane was washed three times for five 
minutes with TBS/Tween to remove any unbound antibody and then incubated with 2 
μg/ml horse radish peroxide (HRP) conjugated streptavidin (Pierce) for one hour. The 
detection of His-tagged proteins was performed by adding diaminobenzidine (DAB) 
in TBS/H2O2 using the method derived by Krajewski et al. (1995). The nitrocellulose 
membrane was again washed three times for five minutes in TBS/Tween. 
2.2.5 Glycerol gradient sedimentation 
 
An aliquot (70 μg) of the purified, wild type TV DNA ligase was mixed with catalase 
(50 μg), bovine serum albumin (BSA; 50 μg), and cytochrome c (50 μg). The mixture 
was applied to a 5 ml, 15-30% glycerol gradient containing 50 mM Tris–HCl pH 7.0, 
500 mM NaCl, 2 mM DTT, 1 mM EDTA, and 0.01% Triton X-100 (Tanese, 1997). 
The gradient was centrifuged in a Sorvall SW55 rotor at 368,000 x g for 17 hours at 
4°C. Fractions (~0.2 ml) were collected from the bottom of the tube. The polypeptide 
compositions of the gradient fractions were analyzed by SDS-PAGE.  
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CHAPTER 3: CHARACTERISATION OF T. vaginalis DNA 
LIGASE 
3.1 Introduction 
3.1.1 Trichomonas vaginalis 
The protozoans, meaning “first animal,” are an enigmatic group of single-celled 
eukaryotes forming the earliest-diverging lineages in eukaryotes. Although 
unicellular, they have a nucleus and membrane-bound organelles, making them 
functionally complex despite their small size (Honigberg, 1963). There are over 
50,000 species of protozoa, of which ~10,000 are parasitic species. Examples of 
parasitic protozoa include Trypanosoma (causes Chagas disease and sleeping 
sickness); Leishmania (causes leishmaniasis); Plasmodium falciparum (causes 
malaria); Entamoeba histolytica (causes amoebic dysentery) and Trichomonas 
vaginalis (causes trichomoniasis; Sood & Kapil, 2008). 
Trichomonas vaginalis (T. vaginalis), a flagellated pear-shaped parasitic protozoan 
(Figure 3.1), is the etiological agent of trichomoniasis; a sexually transmitted disease 
(STD) of global concern leading to an estimated 180 million cases per annum (Petrin 
et al., 1998). This disease is also linked to cervical cancer, atypical pelvic 
inflammatory disease infertility and predisposition to human immunodeficiency virus 
(HIV) infection (Petrin et al. 1998; Sood & Kapil, 2008). T. vaginalis is one of the 
most primitive eukaryotes. It lacks mitochondria in its cytoplasm but possesses a 
hydrogen-producing organelle called the hydrogenosome; of analogous function to
 
the 
mitochondria of more advanced eukaryotes (Cudmore et al., 2004). 
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Figure 3.1: Microscopic image of T. vaginalis trophozite and its interior 
components 
Panel A shows microscope image of T. vaginalis trophozite as seen in broth culture. The axostyle, 
undulating membrane and flagella are clearly visible. Panel B shows the picture of the interior 
components showing the position of hydrogenosomes and flagella (Petrin et al., 1998; 
http://www.tigr.org/tdb/e2k1/tvg).   
 
Trichomoniasis is treated with the antimicrobial agent 5-nitroimidazole, most usually 
metronidazole. Metronidazole is administered in an inactive form and diffuses into the 
hydrogenosome where it is modified to become cytotoxic by reduction via 
ferrredoxin-mediated electron transport (Schwebke & Burgess, 2004; Sood & Kapil, 
2008).  
 
Two hydrogenosomal proteins, pyruvate ferredoxin oxidoreductase and ferredoxin 
play a critical role in the reductive activation of metronidazole via the transfer of a 
single electron from ferredoxin to the nitro group of the drug, resulting in the 
formation of a free radical. The nitro radical is hypothesised to bind transiently to 
DNA, causing disruption and breakage of DNA strands and ultimately leading to cell 
death (Schwebke & Burgess, 2004).   
 
However, strains of T. vaginalis resistant to metronidazole (at least 5% of clinical 
cases) are on the rise, emphasising the need for research into alternative antibiotics 
and drug targets (Sood & Kapil, 2008). In metronidazole resistant strains, the 
expression levels of pyruvate ferrodoxin reductase and ferrodoxin are reduced 
dramatically, eliminating the ability of the parasite to activate metronidazole 
(Cudmore et al., 2004).  
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3.1.2 DNA damage and repair in parasitic protozoans 
 
DNA repair processes are vital to all living organisms. Failure to remove and replace 
damaged bases and nucleotides results in accumulation of multiple lesions which 
might lead to total genome degradation and loss of vital genetic information. DNA 
lesions take many forms, including single-strand and double-strand breaks, in addition 
to inter- and intra-strand crosslinks and modified bases (Hoeijmakers, 2001). Various 
pathways that operate in a manner to minimise information loss during DNA lesions 
are conserved throughout eukaryotes, and many eukaryotic enzymes have 
homologues in prokaryotes (Wang et al., 2003).  
 
Depending upon the type of DNA damage involved, cells employ a specific 
mechanism to fix the damage. When a single-strand break arises in the genome, the 
Base excision repair (BER) and Nucleotide excision repair (NER) pathways are 
involved (Sattler et al., 2003). When double-strand break arises, non-homologous end 
joining (NHEJ) appears to be the major pathway of repair (Wyman & Kannar, 2006).  
 
Various reports suggest that parasitic protozoa such as Plasmodium falciparum (P. 
falciparum), utilise long-patch BER for single-strand break repairs but interestingly, a 
NHEJ mechanism for double-strand break repair has not been described in any 
protozoal parasites to date (Haltiwanger et al., 2000; Burton et al., 2007). Conway et 
al. (2002a) observed that deletion of genes encoding Ku70/ Ku80 proteins (major 
proteins of NHEJ pathway) had no detectable effect on DNA damage repair in the 
closely related parasitic protozoan, Trypanosoma brucei.   
 
The recent publication of the T. vaginalis (hereafter referred to as TV) genome 
sequence has helped broaden the current understanding of the cellular and molecular 
pathways of the parasite (Carlton et al., 2007). However, still very little is known 
about the mechanisms that TV employs to maintain genomic integrity and stability 
during replication and repair. DNA replication is essential for parasitic proliferation 
and a DNA ligation capability is clearly important for DNA damage repair but to our 
current knowledge, no reports have been published on these enzymes in 
Trichomonads. To date there is only a single report (published contemporaneously 
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with this study) of a DNA ligase identified from a member of the parasitic protozoan 
family that from P. falciparum (Buguliskis et al., 2007).  
 
In this study, we report the identification, recombinant expression, purification and 
biochemical characterization of a DNA ligase I from TV. TV DNA ligase (hereafter 
referred to as TVlig) is a 679 amino acid polypeptide with a predicted molecular 
weight of 76430 Da. The presence of only one ligase in TV genome suggests this as a 
uniquely focal point for therapeutic intervention in this organism, disruption of which 
will stop replication and hence propagation of the parasite during infection. 
3.2 Material and methods 
3.2.1 Cloning of TVlig 
 
Genomic DNA was extracted from TV culture, obtained from Dr. Pamela 
Greenwell‟s laboratory (University of Westminster, London), as described in Chapter 
2 (section 2.1.5). The coding region of TVlig was amplified by polymerase chain 
reaction (PCR) as described in Chapter 2 (section 2.1.9), except the PCR master mix 
containing Taq polymerase was replaced with Phusion master mix (Finnzymes, UK) 
containing Pfu DNA polymerase. 
Two oligonucleotide primers that flanked the open reading frame of the TVlig were 
designed with Bam HI restriction enzyme sites on either side (5'-
GATCGGATCCGATGACTCAACAGGGAATTGC and 5‟-
GATCGGATCCTTATTTCTCAAATTGTTGATGATAGAG) (Accession number: 
XP_001581589; Invitrogen). Amplification was performed for 30 cycles, consisting 
of 1 minute at 94
o
C, 2 minutes at 55
o
C and 3 minutes at 72
o
C followed by final 
extension at 72
o
C for 7 minutes. 
The products were resolved on 0.7% agarose gel (as described in Chapter 2; section 
2.1.3) and the 2050 bp product was purified from the gel using the Qiagen DNA 
purification kit (as described in Chapter 2; section 2.1.4.1) and eluted in 30 µl-
distilled water.  
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3.2.2 Subcloning in pGEM-T vector 
 
The primers obtained from Invitrogen were not phosphorylated, so the purified PCR 
product was phosphorylated with T4 polynucleotide kinase (New England Biolabs; 
NEB) prior to an A-tailing reaction required to ligate the insert with the T-overhangs 
of the p-GEMT vector. 20 µl of PCR product was mixed with 1 X T4 kinase buffer 
(the composition of the buffer is proprietary of NEB), 1mM ATP solution and 0.02 U 
T4 kinase enzyme. The reaction mixture was incubated at 37
o
C for 30 minutes and the 
enzyme was heat inactivated at 65
o
C for 2 minutes. Taq polymerase (NEB) was used 
to add an A-tail (single A nucleotides to the 3‟ terminus of the PCR product) to the 
phosphorylated product. The reaction mixture (5 units of Taq polymerase, 0.2 mM 
dATP, 1 X Taq polymerase buffer and 10 µl of phosphorylated PCR product) was 
incubated at 72
o
C for 30 minutes and was purified using a Qiagen PCR purification 
kit (described in section 2.1.4.2).  
 
A ligation reaction was set up between the pGEM-T vector and the purified, A-tailed 
PCR product and transformed into E. coli JM109 cells (Chapter 2; 2.1.1 & 2.1.8) 
Plasmid DNA was extracted using a Qiagen plasmid mini-prep kit (Chapter 2; 2.1.2) 
from overnight cultures of transformed cells grown in liquid LB culture, containing 
100 µg/ml ampicillin, inoculated with a single white colony. The plasmid was 
digested with Bam HI and analysed on a 0.7% agarose gel. The released insert was 
extracted from the gel and then purified by using a Qiagen gel purification kit (as per 
Chapter 2; 2.1.4.2). The purified DNA fragment was ligated into Bam HI digested, 
CIP treated pET-16b vector (Chapter 2; 2.1.8). The ligated mixture was transformed 
into E. coli DH5α cells and plated onto LB-Ampicillin plates. Plasmid DNA was 
extracted using a Qiagen plasmid mini-prep kit from overnight cultures, inoculated 
with a single, transformed bacterial colony. The resulting clones were screened for the 
orientation of the Bam HI insert by using the plasmid as a template in a PCR reaction 
and T7 forward primer and reverse primer (3‟) of the gene under the same conditions 
as described earlier. The identities of the constructs were confirmed by sequencing the 
plasmid at the Advanced Biotechnology Centre (ABC; Imperial College, London). 
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3.2.3 Over-expression and Purification of TVlig 
 
An overnight culture of E. coli BL21(DE3) competent cells transformed with the 
plasmid pET-16b/TVlig was added to fresh LB medium supplemented with 100 
µg/ml ampicillin. The protein was expressed as previously described (Chapter 2; 
2.2.1) and the pellet was re-suspended in buffer A containing 50 mM Tris-HCl pH 
7.0, 300 mM NaCl and 10% glycerol. The re-suspended pellet was lysed as described 
earlier (Chapter 2; section 2.2.2) followed by centrifugation at 36,000 x g for 1 hour at 
4
o
C. The lysate was applied to Ni-NTA nickel-chelate resin (Qiagen) the protein was 
eluted with buffer A containing 300 mM imidazole (Chapter 2; 2.2.3). The elution 
profile was monitored via SDS-PAGE. The peak fraction of TVlig, determined by 
SDS-PAGE, was dialysed against buffer B containing 50 mM Tris-HCl pH 7.0, 10% 
glycerol, 5 mM DTT and 25 mM NaCl. The dialysed fraction was applied to S-
Sepharose and Blue-Sepharose (GE Healthcare) resins, equilibrated with buffer B 
containing 25 mM NaCl. The columns were washed with buffer B containing 15 mM 
NaCl and the protein was step eluted with buffer B containing 0.75, 0.1, 0.2, 0.3, 0.5 
and 1.0 M NaCl. The elution profile was monitored via 12% SDS-PAGE. The best 
protein recovery was obtained from S-Sepharose in the 0.2 M NaCl fractions. The 
peak fraction was dialysed against buffer B containing 100 mM NaCl. The purified 
protein was aliquoted in small volumes and stored at -80
o
C until required. 
 
3.2.4 Hind III DNA ligation assays with TVlig 
 
The purified, recombinant TVlig  was used to ligate Hind III digested  DNA in 50 
mM Tris-HCl pH 7.5, 10 mM MgCl2, 10 mM dithiothreitol, 1 mM ATP, 25 μg/ml 
bovine serum albumin, 5% Polyethylene glycol (PEG) 8000 at 16
o
C for 1 hour.. The 
concentration of PEG 8000 required for optimal ligation by the recombinant ligase 
was measured by adding 0% and 5% PEG 8000 to the reaction mixture. The ligated 
mix was resolved on 0.8% agarose gel, stained with ethidium bromide and viewed 
under UV illumination.  
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3.2.5 DNA ligation assays using 32P labelled substrate 
 
The 18-mer oligonucleotide (Figure 3.15; panel B) obtained from Invitrogen was 
labelled with 
32P at 5‟-end and the amount of labelled oligonucleotide was assessed as 
per section 2.1.10. 
 
The nicked duplex DNA substrate (Figure 3.15; panel C) formed by mixing the 18-
mer strand labelled with 
32P at its 5‟ end with the complementary 42-mer strand at a 
molar ratio of 1:4 (18-mer : 42-mer) in 0.2 M NaCl (section 2.1.11). The standard 
DNA ligation assays were performed by incubating TVlig (0.1 pmole) with the 
32
P-
labelled DNA substrate (1 pmole) for 2 minutes at 37
o
C in buffer C containing 50 
mM Tris-HCl pH 7.5, 10 mM MgCl2, 5 mM dithiothreitol (DTT) and 1 mM ATP 
(section 2.1.12). The effect of pH on the extent of ligation was examined by 
performing assays in reaction buffer C as indicated above except that it contained 
Tris-HCl (pH 7-8.5) or Sodium citrate (pH 4-6.5) or MOPS [3-(N-morpholino) 
propanesulfonic acid (pH 6-7.5)] as the buffering agent. Reactions were also 
performed with a variety of divalent metals and nucleotides at the described 
concentrations in the reaction buffer C.  
 
3.2.6 DNA ligase-DNA binding gel shift assay 
 
DNA binding activity of TVlig was tested by a protein-DNA complex gel shift assay. 
TVlig-DNA binding assay was performed by incubating up to 2.5 pmole of TVlig 
with 1 pmole of nicked DNA substrate in 50 mM Tris-HCl pH 7.5 and 5 mM 
dithiothreitol (DTT) at 22
o
C for 10 minutes. Glycerol (5% v/v final) was added to the 
samples before electrophoresing them through a non-denaturing 10% polyacrylamide 
gel in TBE buffer at 100 V for 2.5 hours at 4
o
C. The wet gel was wrapped in cling 
film and exposed to a phosphorimager plate at -80
o
C. The gel image was analysed 
with Imagequant (5.2) after scanning with a Typhoon phosphorimager (GE 
Healthcare). 
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3.2.7 Construction of active site mutant (K338A) of TVlig 
 
A PCR-based method was used to substitute the lysine (K) in the active site of motif I 
(Figure 1.3) with alanine (A). Two oligonucleotide primers that overlap the lysine 
residue in the active site motif I of TVlig were designed and synthesised (Invitrogen) - 
see table 3.1.  
 
PCR was performed in two steps in order to generate two halves of the TVlig gene 
with each half carrying an alteration in the codon for the predicted active site lysine, 
residue 338 (Figure 3.2).  For each reaction, 25 μl reaction samples were prepared 
using 2 X Taq master mix (final concentration 1 X, Promega), 0.5 μM primers (Table 
3.1) and 3 ng of pET-16b plasmid encoding the wild type (WT) TVlig. 
Table 3.1: Primers used to make mutations in active site of TVlig 
 
Primers PCR 1 PCR 2 
Forward 
primers 
GATCGGATCCGATGACTCAACAGGGAA
TTGC 
GAAGAATCACAGGCGAATACG
CTTACGATGGCGAAAGAGC 
Reverse Primers GCTCTTTCGCCATCGTAAGCGTATTCGC
CTGTGATTCTTC 
GATCGGATCCTTATTTCTCAAA
TTGTTGATGATAGAG 
 
Underlined nucleotides represent Bam HI restriction sites and nucleotides in red show the mutated 
position encoding for alanine. 
 
Amplification was performed for 30 cycles, consisting of 1 minute at 94
o
C, 2 minutes 
at 55
o
C and 1 minute at 72
o
C followed by final extension at 72
o
C for 7 minutes. The 
products were resolved on a 0.7% agarose gel and the ~1 Kb products were purified  
from the gel using the Qiagen DNA purification kit and eluted in 30 µl distilled water. 
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Wild type (WT) TV DNA ligase
Reaction 1 with 5’ WT ligase
primer and 3’ mutant primer
Reaction 2 with 5’ mutant
primer and 3’ WT ligase primer
Product A (1-1030 bp) Product B (995-2040 bp)
Final PCR using two mutated 
fragments as template
Full length active site mutant K338A TV DNA ligase
PCR using WT TV DNA ligase
as template
 
Figure 3.2:  PCR based method to introduce active site mutation in TV 
DNA ligase.  
 
The eluted DNA from the first two PCR reactions were mixed in the ratio 1:1 and 
used as a template for the final PCR amplification of full-length active site, K338A 
mutant of TVlig. In this reaction 25 μl samples were prepared using 2 X Taq master 
mix (final concentration 1 X, Promega), 0.5 μM forward and reverse primers for wild 
type TVlig and 3 ng of the DNA fragment mix (products A and B, Figure 3.2) 
obtained in the above PCR reactions using conditions as described above in section 
3.2.3. 
 
The full-length TVlig encoding product was resolved on a 0.7% agarose gel and 
purified from the gel using the Qiagen DNA purification kit and eluted from the DNA 
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affinity resin in 30 µl of sterile distilled water. The purified PCR product was digested 
with Bam HI restriction enzyme (New England Biolabs) for 1 hour at 37
o 
C and then 
ligated with Bam HI digested CIP-treated pET-16b vector for 16 hours at 4
o
C. The 
ligated mixture was transformed into E. coli DH5α cells (Invitrogen) and plated onto 
LB-Amp (50 µg/ml) plates. Plasmid DNA was extracted using a Qiagen plasmid 
mini-prep kit from overnight cultures, inoculated with randomly chosen single, 
transformed bacterial colonies. The identities of the constructs containing mutants 
were confirmed by sequencing the plasmid at the Advanced Biotechnology Centre 
(ABC), London. 
 
The confirmed mutants were transformed into E. coli BL21 (DE3) competent cells 
and protein was expressed and purified under similar conditions to those described in 
section 3.2.3. The purified protein was recovered from S-sepharose by elution with 
0.2 M NaCl. This peak fraction was then dialysed against buffer B containing 0.1 M 
NaCl. The purified protein was aliquoted in small volumes and stored at -80
o
C until 
required. 
3.2.8 Surface Plasmon Resonance (SPR) analysis 
 
All surface plasmon resonance (SPR) analysis was performed on the Biacore 2000 
automated system (Biacore AB; Uppsala, Sweden). Prior to substrate immobilisation 
the Biacore system was desorbed with BIAdesorb solutions 1, 0.5% (w/v) SDS in 
distilled water) and 2 (50 mM glycine-NaOH pH 9.5; Biacore AB; Uppsala, Sweden) 
and sanitised with BIAdisinfectant solution (1.0% sodium hyperchlorite (v/v) in 
distilled water; Biacore AB; Uppsala, Sweden). The system was then primed with 
degassed and filtered (with a 0.22 μm filter) Biacore buffer 1: 50 mM Tris pH 7.5, 50 
mM NaCl, 5.0 mM DTT, 5.0 mM EDTA pH 7.5 and 0.005% Surfactant p20 (Biacore 
AB; Uppsala, Sweden). The chip was docked and the priming protocol was repeated, 
the chip was then treated with 3 – 4 one minute pulses of 1.0 M NaCl in 50 mM 
NaOH to pre-condition the surface and normalised with BIAnormalising solution 
(70% glycerol v/v in distilled water; Biacore AB; Uppsala, Sweden). All experiments 
were performed at 20
o
C. HPLC-purified and desalted DNA substrates were obtained 
from Sigma-Aldrich (Poole) and used without any further purification. The 
biotinylated 21 bp (21-mer) oligonucleotide formed the bottom strand and was 
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annealed to various oligonucleotides (details given in Table 3.2 and Figure 3.24) to 
form double-stranded DNA substrates: 1. Gap – 10-mer and 5‟ phosphorylated 10-
mer oligonucleotide with templating 21-mer strand in a 1:2:3 ratio; 2. Nick – 10-mer 
and 5‟ phosphorylated 11-mer oligonucleotide with templating 21-mer strand (1:2:3 
ratio) and 3. Duplex – 21-mer oligonucleotide with templating 21-mer strand (1:1 
ratio). The experiments were performed with help from C. Brooke, University of 
Westminster. 
 
Table 3.2: Sequence information of DNA substrates immobilised for 
Biacore analysis 
                                        
Oligonucleotide Sequence
5‟ phosphorylated 
10-mer
5‟ACTATCGGAA
10-mer 5‟ATTGCGACC
5‟ phosphorylated 
11-mer
5‟CACTATCGGAA
21-mer 5‟ATTGCGACCCCACTATCGGAA
Biotinylated 
21-mer
5‟TTCCGATAGTGGGGTCGCAAT
 
 
The DNA substrates were annealed as described in Chapter 2 (2.1.11) in annealing 
buffer containing 5.0 mM EDTA. The cooled biotinylated substrates were diluted 
appropriately in Biacore buffer 1 (50 mM Tris pH 7.5, 50 mM NaCl, 5.0 mM DTT, 
5.0 mM EDTA pH 7.5 and 0.005% Surfactant p20) and immobilised in one of four 
flow cells of a streptavidin (SA) – coated sensor chip (Biacore AB; Uppsala, Sweden) 
in a Biacore 2000 (Biacore AB; Uppsala, Sweden). Immobilised DNA surfaces were 
equilibrated with 20 µl/min Biacore buffer 1. The gapped DNA substrate was 
immobilised in cell 4, the double-stranded (ds) duplex DNA substrate was 
immobilised in cell 3 and the nicked DNA substrate was immobilised in cell 2 (Figure 
3.24). Approximately 200 Resonance Units (RU) of each DNA substrate was 
immobilised in cells 2, 3 and 4. 
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Prior to injection, the concentration of each protein was determined by Bradford 
protein assay. The units of protein concentration were converted to μM using the 
following formula: 
 
 
The proteins were diluted to the appropriate concentration (as indicated in results 
section) with Biacore buffer 1 or 2 (50 mM Tris pH 7.5, 150 mM NaCl, 5.0 mM DTT, 
5.0 mM EDTA and 0.005% Surfactant p20) and injected into the system at 30 µl/min 
for three minutes. Each injection flowed over all four cells and the raw data was 
corrected by subtraction of cell 1 (control cell without DNA substrate). All DNA 
binding analysis was performed with the enzymes diluted to 50 – 60 mM NaCl unless 
otherwise specified. 
 
3.3 Results 
 
3.3.1 Identification of the putative TVlig gene 
 
TV has a genome of ~160 Mb which is suggested to encode for ~60,000 candidate 
proteins (Carlton et al., 2007). Annotation of the genome identified a homologue of 
an ATP dependent DNA ligase, accession number XP_001581589. In all other single 
cell eukaryotic organisms, for example Neurospora and Schizosaccharomyces, two 
ligase activities can be identified by a simple BLAST analysis. We attempted to 
identify other ligase sequences by searching the TV genome database using BLAST 
(NCBI/TIGR) with a number of ATP-dependent ligase proteins including the fission 
yeast (Schizosaccharomyces pombe) ligase I and IV sequences, small viral DNA 
ligase sequences (PBCV-1) and with an archael ATP-dependent ligase (Sulfolobus 
solfataricus; detailed sequence alignment attached in appendix 7.2.1). Not one of 
these searches identified a second ligase open reading frame (ORF). The only ORF in 
TV predicted to be a functional DNA ligase was 85859.m00330. Furthermore 
searching the TV database with this ORF also failed to identify any other ligase-
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related sequences. The putative TVlig ORF encodes for a 679 amino acid polypeptide 
with a calculated molecular weight of 76,430 Da and an isoelectric point of 7.8 
(http://www.expasy.org/cgi-bin/pi_tool; Gasteiger et al., 2005).   
 
BLAST analysis of the TVlig at the NCBI database showed that the putative 
polypeptide sequence had 51 and 53% similarity to human DNA ligase I (HuLigI) and 
Saccharomyces cerevisiae cdc9 (an orthologue of human DNA ligase I in the budding 
yeast) respectively. Table 3.3 shows the percentage homology of putative TVlig with 
an array of ATP dependent DNA ligases used in BLAST searches to identify any 
potential ligase ORFs in the TV genome. The homology shown by TVlig with DNA 
ligase III and IV is only limited to the catalytic core region, which is conserved in 
ligases throughout the eukarya and archaea. The amino acid sequence alignment of 
the putative TVlig with DNA ligase I enzymes encoded by a higher and lower 
eukaryote, H. sapiens and S. cerevisae respectively, is shown in figure 3.3. 
 
Our analysis suggests that the polypeptide is indeed a true homologue of the human 
replicative DNA ligase I and does not contain additional domains such as Zinc finger  
motif and BRCT domains present in DNA ligase III and IV respectively (detailed 
alignment studies are attached in the appendix 7.2.2). DNA ligases III and IV form 
stable complexes with accessory proteins (XRCC1 and XRCC4) to catalyse the 
ligation reaction (Ellenberger & Tomkinson, 2008). BLAST searches revealed that 
TV genome is devoid of any homologues of such accessory proteins. Further 
suggesting that the TVlig polypeptide is the homologue of the human/yeast replicative 
enzyme and that the repair pathways associated with these other ligases are absent in 
TV. 
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Table 3.3: Percentage homology of TVlig with known ATP dependent 
ligases 
DNA ligases Percentage 
identity
Percentage 
similarity
Accession number
DNA LIGASE  I
39 57 XP_001349768.1
Plasmodium falciparum DNA 
ligase I (PfLigI)
Sulfolobus solfataricus
DNA ligase 35 54 NC_002754.1 
Arabidopsis thaliana DNA ligase 
I 36 56 NP_172293.2
Saccharomyces cerevisiae DNA 
ligase I (cdc9) 31 53 NP_010117.1
Drosophila melanogaster DNA 
ligase I 32 54 NP_611843.2
Human DNA ligase I
(HuLigI) 31 51 NP_000225.1
DNA LIGASE IV
27 46 NP_001091738.1
Human DNA ligase IV
(HuLigIV)
Drosophila melanogaster DNA 
ligase IV 27 45 NP_572907.1
Saccharomyces cerevisiae DNA 
ligase IV (DnL4) 30 49 NP_014647.1
DNA LIGASE III
32 50 NP_039269.2
Human DNA ligase III (α)
(HuLigIII)
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Figure 3.3: Amino acid sequence alignment of DNA ligase I from T. 
vaginalis, H. sapiens and S. cerevisiae.   
Amino acid sequence of TVlig (T. vaginalis; obtained from the TIGR database; 85859.m00330), was 
aligned with the amino acid sequence of HuLigI (H. sapiens; obtained from NCBI; NP_000225.1) and 
cdc9 of Sacharomyces cerevisiae (an orthologue of human DNA ligase I; NP_010117.1). Conserved 
residues are shaded with green and identical residues with yellow. Positions of conserved motifs 
(labelled I – VI) are shown with a black bar underneath. The alignment was generated by ClustalW 
(Chenna et al., 2003). 
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All three domains of life, Eukaryota, Archaea and Bacteria (prokaryotes) possess 
sliding clamps to enhance the processivity of their replicative DNA polymerases 
(Stoimenov & Helleday, 2009). In prokaryotes, this activity is brought about by the 
actions of the β clamps, whereas in eukaryotes and archaeal organisms the analogous 
functions are provided by the PCNA (Warbrick, 2000). In addition to enhancing 
processivity of the polymerase, PCNA has been observed to act as a scaffold for the 
assembly of accessory processing factors such as DNA ligase I and the flap 
endonuclease, FEN1 (Vivona & Kelman, 2003; Stoimenov & Helleday, 2009). Most 
of the PCNA-interacting proteins, including DNA ligase I, contain a conserved PCNA 
Interacting Peptide (PIP) box whose sequence consensus is QXXhXXF(F/Y), where h 
is either M/L/I, to interact with the Inter domain connector loop (IDCL) and other 
residues located at the C-terminus of PCNA (Warbrick, 2000; Stoimenov & Helleday, 
2009). Inactivation of the PIP motif in HuLigI reduces its stable binding with PCNA 
in vitro and abolishes its targeting to replication foci (Pascal et al., 2006). Closer 
examination of the TVlig sequence revealed the presence of a potential PIP motif 
located at its N-terminus whose sequence (
3
QQGIAKFF
10
) exactly fits the consensus 
and whose location is consistent with that found in other replicative ligases (Figure 
3.4; panel A).  
 
NLS, usually a stretch of basic amino acids- lysine and arginine, is also suggested in 
the N-terminal region of TVlig. The sequence of ligase NLSs shows considerable 
conservation in higher eukaryotes such as human (
119
PKRRTARKQLPKR
131
), Mus 
musculus (
116
PKRRTARKQLPKR
128
) and Xenopus
 
laevis 
(
185
PKRKTARKQLPKR
197
). Although no sequence homology is reported in lower 
eukaryotes such as Plasmodium falciparum and Saccharomyces cerevisiae, the TV 
sequence in this region (
142
KTDKKVVKEKLKK
153
) is consistent with the NLS of 
higher eukaryotes (Figure 3.4; panel B; Cardoso et al., 1997). Identification of a PIP 
box and NLS signal in TVlig sequence further supports the view that the identified 
ORF encodes for a DNA ligase I. 
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Figure 3.4: Amino acid sequence alignment of PIP motif and NLS of DNA 
ligase I from T. vaginalis, H. sapiens, S.cerevisiae and P. falciparum 
The presence of potential PIP (PCNA interacting polypeptide) motif and NLS (Nuclear localisation 
signal) is suggested at the N-terminal of TVlig. Panel A shows the alignment of PIP motif and panel B 
shows the alignment of  NLS located at N-termini of TVlig (T.vaginalis; 85859.m00330), human DNA 
ligase I (H.sapiens; NP_000225), cdc9 of Saccharomyces cerevisiae (S.cerevisae; NP_010117.1) and 
Plasmodium falciparum DNA ligase I (P.falciparum; AAL59668). The PIP motif is absent in 
Plasmodium falciparum DNA ligase I. The alignment was performed with ClustalW (Chenna et al., 
2003). The search results were evaluated and the sequences were manually realigned. 
 
 
Biochemical analyses, especially targeted mutagenesis in a variety of ligases and 
capping enzymes, has enhanced our understanding of the role of critical residues in 
each conserved motif. The residues within the catalytic core of PBCV-1 DNA ligase, 
the smallest known ATP dependent DNA ligase, have been mutated to assess their 
role in the catalytic mechanism of DNA binding and repair (Odell et al., 2000; 
Sriskanda & Shuman, 2002a & 2002b; Nair et al., 2007). The role of essential amino 
acid residues residing within the catalytic core of TVlig was analysed by comparing 
with that of PBCV-1 DNA ligase and other ATP dependent DNA ligases (Figure 3.5, 
panel A).  
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The catalytic core of TVlig is composed of an adenylation domain (AdD) and 
oligomer binding (OB) domain (Figure 3.5, panel B). Within the AdD
 
is an adenylate-
binding pocket composed of six motifs (I, Ia,
 
III, IIIa, IV and V; Figure 3.5, panel A; 
Figure 3.30; panel B)
 
that define the polynucleotide ligase/mRNA capping enzyme 
superfamily
 
of covalent nucleotidyltransferases (Shuman & Lima, 2004; Tomkinson 
et al., 2006). The motif I (KYDGER) includes
 
the lysine (Lys338) to which it is 
probable that AMP becomes covalently linked
 
in the first step of the ligase reaction 
and an arginine (Arg343) which will contact the 3‟OH of the nucleotide ribose sugar 
and are thus critical in step one catalysis. Motifs Ia, III, IIIa,
 
IV and V contain 
conserved amino acids that contact AMP and
 
play essential roles in one or more steps 
of the ligation pathway (Doherty & Suh, 2000; Shuman, 2006). Motif IIIa normally 
contains a conserved aromatic base, here we find a phenylanine, Phe438 (Phe98 in 
PBCV-1 DNA ligase) that acts to sandwich the purine base of the ATP nucleotide 
with a conserved hydrophobic side chain from motif IV, here Met492 (Met164 in 
PBCV-1 DNA ligase). The significance of this aromatic/purine/hydrophobic 
arrangement to support the nucleotide base is observed in the structure of adenylated 
ATP dependent DNA ligases such as T7 (Subramanya et al., 1996) and PBCV-1 
DNA ligase (Odell et al., 2000), NAD
+
-dependent ligases such as Thermus filiformis 
(Tfi; Luo & Baranay, 1996) and RNA capping enzymes e.g. PBCV-1 mRNA capping 
enzyme (Hakansson & Wigley, 1998).  
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Figure 3.5: Sequence alignment of conserved motifs and domain 
organisation in predicted TVlig structure 
Panel A shows a ClustalW alignment analysis (Chenna et al., 2003) of sequence motifs conserved in 
characterised and putative ATP-dependent DNA ligases from Trichomonas vaginalis (Put. TV), 
Paramecium Bursaria Chlorella Virus -1 (PBCV-1) DNA ligase, Human DNA Ligase I (HuI), 
Bacteriophage T7 DNA ligase (T7), Vaccinia virus DNA ligase (Vac) and Saccharomyces cerevisiae 
DNA ligase (Sac). The spacings between the motifs are indicated. Panel B shows domain organisation 
in predicted TVlig structure. Abbreviations: PIP - PCNA interacting polypeptide; NLS - Nuclear 
localisation signal; AdD - Adenylation domain; OB - Oligomer binding domain; DBD - DNA binding 
domain. 
 
 
Motifs III and IV include conserved glutamate residues (here, Glu389 and Glu488) 
involved in metal binding, vital for catalysing conformational changes which drive 
forward steps one and three of the ligation reaction (Odell et al., 2000). A pair of 
conserved lysines (here, Lys512 and Lys513) that form contacts with the ribose sugar 
hydroxyl group of AMP are located in motif V (Sriskanda & Shuman, 2002b). These 
residues are also involved in stabilising the β and α-phosphate of ATP in a mechanism 
analogous to the stabilisation of GTP by capping enzymes (Sriskanda & Shuman, 
2002b). Located near the C-terminus of the OB domain is motif VI containing an 
acidic residue (here, Asp657), essential for forming contacts with the β-phosphate of 
ATP during step I of the reaction and thus required to form ligase-adenylate 
intermediate (Nair et al, 2007).
 
Two positively charged residues (here, Arg655 and 
Lys658) located in motif VI also serve to orientate the β and α-phosphate of ATP 
81 
 
during the adenylation reaction in step 1 of catalysis in a mechanism analogous to the 
mRNA capping enzymes (Doherty & Suh, 2000). 
   
 
In a manner similar to the domain organisation present in HuLigI, an additional DNA 
binding domain (DBD) and an N-terminal PCNA binding domain are present in TVlig 
(Figure 3.5, panel B; Figure 3.6). The DBD is present in all three mammalian DNA 
ligases (DNA ligase I, III and IV) and its deletion abolishes DNA binding and repair 
in HuLigI (Pascal et al., 2004). 
 
 
 
HuLigI CWKPGQKVPYLAVARTFEKIEEVSARLRMVETLSNLLRSVVALSPPDLLPVLYLSLNHLG
TVLig AWNRGDPIPFTFITKMVDELEPLTGKLEINDLLCKYFLAILMTTPKDIVPFVFLCLGQLR
.*: *: :*:  ::: .:::* ::.:*.: : *.: : :::  :* *::*.::*.*.:* 
HuLigI PPQQGLELGVGDGVLLKAVAQATGRQLESVRAEAAEKGDVGLVAENSRSTQRLMLPPP--
TVLig PNHEGVKINIGQESIISALGDKK-----VVKEKLKKEGDLSKVAQQIRSTQKSMTSMFGK
* ::*:::.:*:  ::.*:.: .      *: :  ::**:. **:: ****: * .  
HuLigI ---PLTASGVFSKFRDIARLTGSASTAKKIDIIKGLFVACRHSEARFIARSLSGRLRLGL
TVLig VNEAYTITGVYKEFLKMAGFQGANSDRNRTQTIQKLLTNCKPEEVKCIVRMLECKLRVGA
. * :**:.:* .:* : *: *  :: : *: *:. *: .*.: *.* *. :**:* 
HuLigI AEQSVLAALSQAVSLTPPGQEFPPAMVDAGKGKTAEARKTWLEEQGMILKQTFCEVPDLD
TVLig AHESFLFALGMAFRRR----EYIMGMIKN------NPDEEDLKDHGHLFREIYYRYPIID
*.:*.* **. *.       *:  .*:.       :. :  *:::* :::: : . * :*
HuLigI RIIPVLLEHGLERLPEHCKL--
TVLig EILVEFLRGSFKGAEKNINIKV
.*:  :*. .::   :: ::  
AdD
contact
DNA 
contact
OBD 
contact
DNA 
contact
AdD
contact
DNA 
contact
 
Figure 3.6: Amino acid sequence alignment of DNA binding domains of 
HuLigI and TV DNA ligase 
The alignment of amino acid sequences of DNA binding domain (DBD) of HuLigI and TVlig is 
shown. The DBD contacts and stabilises the DNA substrate in co-ordination with the conserved 
adenylation domain (AdD) and oligomer binding domain (OBD).  The positions of protein interactions 
with AdD, OBD and DNA substrate are highlighted in red. The alignment was performed with 
ClustalW (Chenna et al., 2003). The `*` indicates identical residues between the two ligases while 
conserved and semi-conserved substitutions are marked as `:` and `. ` respectively (Pascal et al., 2004). 
 
The DBD of HuLigI closes the protein clamp around the nicked DNA substrate via 
contacts between the N-terminal DBD and the C-terminal OB-fold domain. The 
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crystal structure of HuLigI bound to adenylated DNA highlighted the peptide regions 
of DBD involved in making these interactions (Figure 3.6; Pascal et al., 2004). Recent 
studies suggest that the DBD of HuLigI also interacts with PCNA and the 
heterotrimeric cell cycle checkpoint clamp, hRad9-hRad1-hHus1 (9-1-1; Song et al., 
2009). This was previously reported in archaeal DNA ligases from P. furiosus and S. 
solfataricus using DBD residues for interaction with PCNA sliding clamps (Pascal et 
al., 2006; Pascal, 2008). The DBD-PCNA interactions stimulate ligation activity in 
these organisms. The protein sequence of the potential DBD of putative TVlig, when 
aligned with HuLigI using ClustalW, suggest the presence of peptide regions involved 
in making contacts with DNA, AdD and OB domain (Figure 3.6; Chenna et al., 
2003). 
 
Trichomonas vaginalis represents one of the earliest branching lineages among the 
eukaryotes and has acquired many prokaryotic genes through lateral gene transfer 
(LGT; Carlton et al., 2007). Based on known DNA ligase sequences, a phylogenetic 
tree was constructed (organisms were randomly chosen from different origins) with 
the neighbour-joining method using Phylip (Figure 3.7; Felsenstein, 1993). 
Phylogenetic analysis suggests that TVlig is aligned more closely with lower 
unicellular eukaryotes such as S. pombe than higher eukaryotic species such as H. 
sapiens. Higher eukaryotes are known to have at least two DNA ligases, three in 
mammals, which play a role in DNA repair, replication and recombination however 
the number of ligases in lower eukaryotes appears somewhat variable. The TV 
polypeptide shares its highest indentity (39%, Table 3.3) with the recently identified 
DNA ligase I from P. falciparum and viral DNA ligases such as PBCV-1 DNA ligase. 
In these organisms there is a single copy of DNA ligase, which may not be surprising 
for viruses but it is certainly interesting that the only other fully sequenced parasitic 
organism (a single-celled eukaryote) also appears to have only a single ligase.  When 
we searched the P. falciparum database, with the same sequences used to trawl the 
TV database to find ligases, again only a single ligase was evident.  The evidence, 
therefore suggests, that either these parasitic organisms are overly sensitive to double-
strand breaks (DSB) in DNA or have evolved to repair DSB with DNA ligase I. 
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Figure 3.7: Phylogenetic analysis of ATP dependent DNA ligases.  
Phylogenetic tree showing the evolutionary relationship of some randomly chosen ATP-dependent 
DNA ligases was constructed using Phylip (Felsenstein, 1993) from sequence alignment data generated 
using ClustalW (Chenna et al., 2003). DNA sequences of ATP-dependent DNA ligases  were obtained 
from NCBI. The full names of the hosts of DNA sequences are: Schizosaccharomyces japonicas - 
XP_002171493, Coprinopsis cinerea - BAC76762, Saccharomyces cerevisiae - NP_010117.1, 
Schizosaccharomyces pombe - NP_593318.2,  Homo sapiens - NP_000225.1, Mus musculus - 
NP_001076657.1, Rattus rattus - NP_001019439.1, Anopheles gambiae - XP_319999.2, Arabidopsis 
thaliana - NP_175351.1, Caenorhabditis elegans - NP_741625.2, Drosophila melanogaster - 
NP_611843.2, Sulfolobus solfataricus - AAK40535, Paramecium bursaria Chlorella virus-1 - 
NP_048900, Bacteriophage T7 - NP_041963, Pyrococcus furiosus - NP_579364, Plasmodium 
falciparum - AAL59668, Plasmodium knowlesi - XP_00226193. 
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3.3.2 Cloning of the putative TVlig 
 
Following identification of the open reading frame (ORF) of a putative DNA ligase 
from the TV genome, primers complementary to the 5‟ and 3‟ ends of the nucleotide 
sequence of the polypeptide were designed (sequences given in section 3.2.1). 
Genomic DNA was extracted from a 72-hour TV culture by the phenol-chloroform 
method (as described in section 2.1.5) and used as a template for amplification of the 
putative ligase gene by PCR. The amplification was performed using Pfu polymerase, 
a proof reading enzyme, to exclude (or at least minimise) the introduction of 
mutations in the course of the reaction. A product was obtained by the PCR reaction 
that was consistent with the expected size for the TV ORF of 2040 bp when analysed 
by electrophoresis (Figure 3.8) and gel purified.  
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Figure 3.8: PCR product of TVlig resolved on a 0.7% agarose gel 
Genomic DNA was extracted from a TV culture by the phenol-chloroform method and used as a 
template in PCR amplification.  The PCR consisted of 30 cycles of 1 minute denaturation at 94
o
C, 2 
minute annealing at 55
o
C and 3 minute extension at 72
o
C with TVlig specific primers. DNA products 
were resolved on a 0.7% agarose gel run in 0.5 X TBE buffer visualised by staining with ethidium 
bromide (0.5 µg/ml for 20 minutes). Lane 1 shows 1 Kb ladder molecular weight markers (Promega) 
and Lanes 2 and 3 shows separately amplified 5 µl aliquots of PCR reactions. A black arrow indicates 
the position of the putative TVlig product. 
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The gel-purified, A-tailed PCR product was inserted into pGEM-T and the putative 
positive (white) clones were screened by restriction digest of mini-prepped plasmid 
DNA to observe any insert release by agarose gel electrophoresis (Figure 3.9, panel 
A). A number of positive clones were obtained from which larger scale ultra-pure 
plasmid mini preps were made and sent for sequencing. Once sequenced we were able 
to verify that the strain of TV we had obtained in the UK had exactly the same 
sequence as the US strain used to generate the genomic DNA sequence. This is 
somewhat surprising to us that there was not even a silent base pair change and either 
suggests that the two sources of TV were very similar or that the gene is strongly 
conserved. 
 
To characterise the putative TVlig, a fully sequenced ligase gene was sub-cloned into 
the expression plasmid pET-16b (Novagen). Figure 3.9, panel B; shows the insert 
release after the restriction digest of one of these plasmids. The sequence of the final 
clone again exactly matched that of the open reading frame published by TIGR. 
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Figure 3.9: Restriction digest confirmation of TVlig clone in pGEM-T and 
pET-16b. 
The A-tailed PCR product was ligated into pGEM-T. E. coli DH5α cells transformed with the ligation 
mixture apparently containing plasmid with an insert (white colonies) were selected and the gene was 
released from the vector by restriction with Bam HI.  
Panel A: molecular weight markers are resolved in lane 1; Lane 2: Uncut plasmid; Lane 3: Plasmid 
digested with Bam HI. The TVlig was then sub-cloned into pET-16b and the success of the insertion 
confirmed by restriction with Bam HI as shown in panel B. Lane 1: molecular weight marker; Lane 2:  
Bam HI digested plasmid.  
 
3.3.3 Over-expression and Purification of TVlig 
 
The recombinant pET-16b vector carrying the TVlig gene was transformed into E. 
coli BL21(DE3) cells for inducible control of the expression of the protein. Following 
induction with IPTG, cells harbouring the recombinant plasmid produced a prominent 
~75 kDa polypeptide (Figure 3.10). The size of this species is consistent with the 76 
kDa estimated for the TVlig on the basis of the amino acid sequence. It is however 
somewhat smaller than might be expected from the addition of the ten histidine tag 
(~3 kDa) at the amino terminus of the protein. Anomalous electrophoretic mobility of 
DNA ligases has been reported earlier, for example, PBCV-1 DNA ligase (predicted 
size of 34 kDa)
 
migrates slowly and corresponds to ~40 kDa polypeptide on SDS-
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PAGE (Odell & Shuman, 1999). Takano et al. (1988) suggest that nearly a 10-kDa 
difference in apparent size between the deduced mass and the relative SDS-PAGE-
determined mass is within the error attributable to anomalous migration of proteins on 
SDS-PAGE. 
 
When the lysate of the induced cells was centrifuged, this protein remained soluble. 
The recombinant His-tagged protein was purified from the soluble extract by Ni-NTA 
affinity chromatography. The Ni-NTA column was washed with 25 mM imidazole to 
remove loosely bound contaminating proteins. Histidine-tagged proteins were eluted 
with buffer A containing 300 mM imidazole (as described in section 3.2.3; Figure 
3.10; panel A). The peak fraction, determined by inspection of the Coomassie stained 
gel, was then dialysed against 25 mM NaCl and applied separately to Blue-sepharose 
(cation exchange resin) and S-sepharose (cation exchange resin with sulphonyl 
exchange group; -SO3¯) resins. Blue-sepharose is a strong cationic ion exchanger with 
cibacron blue (a triazine dye) covalently attached to the sepharose matrix by the 
triazine coupling method. Cibacron blue binds most enzymes requiring adenyl-
containing cofactors (e.g. NAD
+
;
 
Lascu
 
et al., 1984). It acts as a strong cationic ion 
exchanger because of its negative charge and binds other proteins at pH-values below 
their isoelectric points (Lascu
 
et al., 1984). 
 
The salt gradient applied to Blue-sepharose helped remove some of the higher and 
lower contaminating protein bands but a lot of the TVlig protein was lost during the 
process (estimated by SDS-PAGE analysis; Figure 3.10; panel B). Column 
chromatography on S-sepharose and elution along a NaCl gradient, yielded an 
apparently homogenous protein preparation (Figure 3.10; panel C), with better 
recovery as compared to Blue-sepharose and was used as the final purification step.  
Approximately 5 mg of TVlig was obtained per 1 litre of culture as estimated by a 
Bradford protein assay (calibration curve attached in the appendix 7.4). The size of 
the polypeptide was estimated by comparing with marker proteins on Coomassie 
stained SDS gel (when present in small amounts; Figure 3.10; panel C; lane 3 or 5). 
The over expressed protein is bigger than the 75 kDa marker protein consistent with 
its estimated size (78 kDa). We therefore analysed by western blot to confirm that it 
was indeed a his-tagged protein that must have come from our pET-16b plasmid. 
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Figure 3.10: Elution profile of TVlig from Ni-NTA, Blue-Sepharose and S-
Sepharose 
TVlig was expressed in BL21(DE3) cells by induction with 0.4 mM IPTG for two hours at 37
o
C. The 
lysed, soluble extract was applied to Ni-NTA resin and eluted with buffer A (50 mM Tris-HCl pH 7.0, 
300 mM NaCl and 10% glycerol) containing 300 mM imidazole. The polypeptide composition was 
analysed by SDS-PAGE (12% resolving gel) stained with Coomassie Brilliant Blue. 
Panel A: Bio-Rad Precision Plus All Blue pre-stained molecular weight marker was resolved in lane 1 
(molecular weight of marker proteins are shown to the left of the gel); Lane 2: pellet fraction; Lane 3: 
flow through; Lane 4: wash fractions (25 mM imidazole in buffer A); Lane 5: elution fractions (300 
mM imidazole in buffer A). The protein peaks eluted from Ni-NTA resin were diluted to 25 mM NaCl 
and applied separately to Blue-sepharose and S-sepharose resins and eluted along an NaCl gradient 
(NaCl in buffer A: 50 mM Tris-HCl pH 7.0, 5.0 mM DTT, 10% glycerol). The elution profile from 
Blue-sepharose and S-sepharose columns are analysed in panels B & C respectively.  
Panel B - Lane 1: Bio-Rad Precision Plus All Blue pre-stained molecular weight marker; Lane 2: 150 
mM NaCl elution fraction; Lane 3: 200 mM NaCl. Panel C - Lane 1: Bio-Rad Precision Plus All Blue 
pre-stained molecular weight marker; Lane 2: Flow-through; Lanes 3, 4 & 5: 150, 200 & 250 mM 
NaCl in buffer A respectively. 
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3.3.4 Western blot for recombinant TVlig 
 
Sequence analysis had confirmed the identity of the ORF cloned into pET-16b as that 
encoding the putative TVlig.  In silico analysis gives this polypeptide a mass of 76.4 
kDa which with the additional amino acids of the histidine tag results in a protein of 
mass 78.5 kDa. Whilst the recovery of an abundant protein species of similar 
molecular weight is strongly supportive of this being the recombinant TVlig, to 
confirm the identity of the ~76-78 kDa species as the TVlig a western blot procedure 
was employed (as described in Chapter 2; section 2.2.4). An aliquot of the peak 
fraction eluted from the S-sepharose ion-exchange column was electrophoresed and 
transferred to nitrocellulose membrane. The extent of transfer was determined by 
staining the membrane with Ponceau S followed by washing and blocking the 
membrane for non-specific binding. The membrane was probed with biotinylated 
anti-His antibody (primary antibody) followed by horse radish peroxide (HRP) 
conjugated streptavidin. A single polypeptide corresponding to the abundant ~76-78 
kDa polypeptide species was detected on addition of the peroxidase substrate 
diaminobenzidine (DAB; Figure 3.11). The exact size of the species is impossible to 
discern from this blot because of the overloading of the recombinant protein on the 
gel. This provided good supporting evidence that polypeptide, eluting from the S-
sepharose was the product of the cloned of TVlig gene. 
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Figure 3.11: Western blot of the purified TVlig with anti-his antibody 
A 15 µg aliquot of the purified protein eluted from S-sepharose was separated by 12% SDS-PAGE 
along with pre-stained broad range molecular weight markers (BioRad) and transferred to a 
nitrocellulose membrane in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol). After 
determining the transfer efficiency, by staining of the membrane with Ponceau red stain (0.5% Ponceau 
S, 1% acetic acid), the membrane was blocked with 2% BSA. Proteins blotted onto the nitrocellulose 
membrane were probed with anti-his antibody (Sigma) followed by HRP-conjugated streptavidin 
(Pierce). The detection of his–tagged protein was performed by adding diaminobenzidine in TBS/H2O2 
and photographing the gel.  Lane 1: Prestained broad range molecular weight markers; Lane 2: Purified 
TVlig.  
  
 
3.3.5. Preliminary ligation assays with TVlig 
 
The catalytic activity of the putative TVlig was first examined on Hind III digested  
DNA. It was observed that the activity of the enzyme requires addition of 
macromolecular crowding agents such as polyethylene glycol (PEG 8000) to facilitate 
DNA ligation. When PEG is present at 5% (w/v) with the TVlig, ligation products 
(higher molecular weight species, >23 kb in size) are observed migrating in the 
agarose gel (Figure 3.12).  
 
Addition of PEG stimulates blunt end ligation by Vaccinia virus DNA ligase but is 
not normally thought to be required for cohesive end ligation as that of Hind III 
digested  DNA fragments (Odell et al., 1996). The volume-excluding effect of PEG 
stimulates ligation activity of T4 DNA ligase and is known to increase its affinity for 
its DNA substrate (Hayashi et al., 1986). Similar adaptive effects are noticed for DNA 
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polymerases where the presence of macromolecular crowding agents results in an 
overall increase in enzymatic activity and enhances their binding to DNA 
(Zimmerman & Harrison, 1986).  
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Figure 3.12: Preliminary ligation assays for TVlig with Hind III digested  
DNA 
Purified TVlig was used to ligate Hind III digested  DNA in ligation buffer (containing 50 mM Tris-
HCl pH 7.5, 10 mM MgCl2, 10 mM dithiothreitol and 25 mg/ml bovine serum albumin). The buffer 
was supplemented with 5% PEG and 1 mM ATP. The ligation reaction products were analysed on a 
0.8% agarose gel, stained with ethidium bromide and viewed under UV illumination. Lane 1 contains 
Hind III digested λ DNA; Lane 2 contains ligation reaction carried out in the presence of 5% PEG; 
Lane 3 contains the ligation reaction in the absence of PEG. 
 
 
Crude assessment of the ATP-requiring nature of the enzyme preparation was also 
analysed by similar ligation of Hind III digested  DNA fragments (data not shown). 
The enzyme displayed a low but detectable activity as compared to T4 ligase, but it 
gave enough evidence that it is an ATP dependent ligase, which requires stringent 
conditions, like the addition of PEG for the efficient ligation of DNA molecules.  
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3.3.6. Construction of active site mutant (K338A) of TVlig 
 
When this work was initiated our purified TVlig was the first ligase characterised 
from a parasitic protozoan (P. falciparum DNA ligase was published 
contemporaneously with this study). Moreover, TV at this point was the only 
eukaryote known to possess a single DNA ligase apparently capable of both repair 
and replication. To be absolutely certain that the ligase did not differ from other 
ligases we decided to create an active site, alanine substitution mutant of TVlig. The 
ligation of Hind III digested  fragments strongly supports that the purified ~76-78 
kDa polypeptide is a DNA ligase but by purifying an active site mutant it could be 
confirmed that the ligation activity of the preparation is not contributed to or indeed 
solely as a result of co-purification of the his-tagged recombinant protein with E. coli 
host DNA ligase (75 kDa) whose size is comparable to TVlig (Kodama et al., 1991). 
DNA ligases and other members of the covalent nucleotidyl transferase superfamily 
are defined by an essential lysine residue situated within motif I (KxDGxR). Previous 
studies have shown that during the first step of the DNA ligation reaction, the ligase is 
activated through the formation of a phosphoamidate bond between the amino group 
of this lysine residue and AMP (Doherty & Suh, 2000). The contribution of the motif 
I (KYDGER) residue Lys338 to the activity of TVlig was surmised from the effect of 
substituting the residue with an alanine (A) by a PCR-based method in two steps 
(Figure 3.2).  Forward and reverse primers complementary to the motif I region of the 
protein but encoding a base alteration resulting in a substitution of Lys338 to Ala 
were designed. The altered ligase was amplified from the pET-16b plasmid bearing 
wild type TVlig as a template (as described in materials and methods, section 3.2.7). 
The first step PCR reactions amplified two fragments approximately 1 kb in size (1-
1034 bp and 996-2040 bp) bearing the alanine encoding mutation in both the upper 
and lower strands respectively (Figure 3.13; panel A).  
 
The fragments obtained above were gel purified and used as a template in a single 
PCR reaction to amplify the full-length active site mutant using forward and reverse 
primers (see materials and methods, 3.2.7) complementary to the start and terminal 
portions of the full-length wild type TVlig. Figure 3.13, panel B shows the PCR 
93 
 
product obtained from this experiment producing the 2.02 kb DNA fragment, coding 
for the full-length active site mutant Lys338Ala (K338A). 
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Figure 3.13: Producing an active site mutant (Lys338Ala) of TVlig by PCR  
A plasmid bearing full-length wild type TVlig was used as a template in the reaction amplified over 30 
cycles, consisting of 1 minute at 94
o
C, 2 minutes at 55
o
C and 1 minute at 72
o
C. The reaction products 
were analysed on a 0.7% agarose gel, stained with ethidium bromide and viewed under long-
wavelength UV illumination.  Primer sequences for the mutagenising PCR are detailed in table 3.1; 
section 3.2.7. 
Panel A shows two amplified fragments approximately 1 kb in size (1-1034 bp and 996-2040 bp) 
bearing the alanine mutation in both the upper and lower strands respectively. Lane 1: 1kb DNA ladder 
molecular weight markers; Lane 2: PCR product 1-1034; Lane 3: PCR product from 996 – 2040 bp.  
Panel B shows full-length PCR product of the active site mutant of TVlig. The two PCR fragments 
obtained after introducing the point mutation in the active site of TVlig were used as a template to 
amplify the full-length ORF by 30 cycles consisting of 1 minute at 94
o
C, 2 minutes at 55
o
C and 3 
minutes at 72
o
C. Lane 1: 1 kb DNA ladder molecular weight markers (Promega); Lane 2: full-length 
active site mutant of TVlig (2040 bp). 
 
 
 
The full-length product was gel purified, digested with Bam HI restriction enzyme 
and ligated with Bam HI digested and CIP treated pET-16b expression vector DNA. 
The ligation reaction was transformed into electrocompetent E. coli DH5α cells. Some 
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of the transformed colonies were randomly chosen and plasmid DNA was purified 
and sequenced. A positive mutant, confirmed after sequencing the isolated plasmids 
to confirm no other mutations had been introduced by the PCR reaction, was then 
transformed into E. coli BL21(DE3) cells. Expression of the active site mutant was 
induced by addition of IPTG during growth at 37
o
C in LB broth as described for the 
wild type protein (section 3.2.3). After centrifugal separation of the crude lysate, an 
over expressed 76 kDa species the K338A TVlig was recovered in the soluble 
supernatant fraction (Figure 3.14). 
 
The expected 76 kDa polypeptide was purified from the soluble bacterial extract by 
sequential Ni-NTA affinity chromatography and S-sepharose column chromatography 
steps. The recombinant protein eluted from Ni-NTA resin with buffer A containing 
300 mM imidazole (Figure 3.14; panel A). The eluted fraction was dialysed against 
buffer B containing 25 mM NaCl and applied to the ion exchange resin, S-Sepharose 
(Figure 3.14; panel B). The peak fraction of the 76 kDa protein eluted from this 
column with 0.2-0.25 M NaCl.  
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Figure 3.14: Purification of the K338A active site mutant of TVlig over Ni-
NTA and S-Sepharose chromatography 
 Mutant TVlig was expressed in E. coli BL21(DE3) by induction with 0.4 mM IPTG for two hours at 
37
o
C. The lysed E. coli, soluble extract was applied to Ni-NTA resin, washed and then eluted in buffer 
A (50 mM Tris-HCl pH 7.0, 300 mM NaCl, 10 mM imidazole and 10% glycerol) containing increasing 
amounts of imidazole. Aliquots of column fractions were analysed by 12% SDS-PAGE stained with 
Coomassie Brilliant Blue.  
Panel A: Lane 1: Bio-Rad Precision Plus All Blue pre-stained molecular weight marker (molecular 
weight of marker proteins are shown to the left of the gel image); Lane 2: pellet fraction; Lane 3: 
soluble load fraction; Lane 4: flow through; Lane 5: wash fractions (buffer A with 25 mM imidazole); 
Lanes 6 & 7: elution fractions (buffer A with 300 mM imidazole). The 300 mM imidazole protein peak 
eluted from Ni-NTA agarose was diluted to 25 mM NaCl and applied to S-sepharose.  Panel B: 
Proteins that bound to the S-sepharose were then eluted along an NaCl gradient in buffer A (50 mM 
Tris-HCl pH 7.0, 5.0 mM DTT, 10% glycerol). The elution profile analysed by 12% SDS-PAGE 
stained with Coomassie Brilliant Blue. Lane 1: Bio-Rad Precision Plus All Blue pre-stained molecular 
weight marker; Lane 2: 0.2 M NaCl; Lane 3: 0.25 M NaCl. 
 
 
3.3.7. Catalytic properties of K338A and wild type TVlig 
 
Preliminary ligation assays were performed using Hind III digested  DNA fragments 
(Figure 3.12).  However, this method is difficult to quantify. Earlier studies used a 
radioactively labelled oligo-dT oligomer annealed to a poly-dA polymer strand to 
measure extent of ligation. The drawback with this method was that it was difficult to 
know the exact proportion of accurately juxtaposed dT strands on the poly-dA 
backbone, i.e. it can‟t be assessed if the two substrates are really next to each other or 
if ligation is being seen across the gaps (Tomkinson et al., 1991; Odell et al., 1996).  
Shuman and co-workers have pioneered the use of defined oligonucleotides which 
have allowed the construction of synthetic nicks in vitro where the influence of 3‟ and 
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5‟ mismatches can also be assessed (Sekiguchi & Shuman, 1997; Sriskanda & 
Shuman, 1998; Odell & Shuman, 1999). Use of such specific sequences allows exact 
positioning of the substrate nick and by radiolabelling an oligonucleotide at its 5‟ 
phosphate position the extent of ligation can be quantified by using phosphorimagers. 
Phosphorimagers are quantitative imaging devices used to localise and quantify 
radioactive signals and are more sensitive than X-ray films (Robertson et al., 2001). 
 
The ligase activity of the recombinant TVlig was assessed through its ability to seal a 
single-strand nick in a duplex oligonucleotide. A 42 residue oligonucleotide was 
synthesised with internal base complementarity to allow folding back and the creation 
of a hairpin as shown in Figure 3.15, panel A. An 18 residue oligonucleotide (Figure 
3.15; panel B) complementary to the single-stranded region of the hairpin 
oligonucleotide was subjected to 
32
P end labelling (as described in Chapter 2; section 
2.1.10) before being annealled together with the unlabelled 42-mer (ratio 1:4; 18-mer 
: 42-mer) and used as a duplex substrate in the ligation reactions (as described in 
Chapter 2; section 2.1.11).  
 
A TT CCGA TAGTGA C TACATGTCGC C CT T
ACAGCGGGAA --T AAGGCTA TCACT GA TGT
TT
T T
ATTCCGATAGTGACTACA
TGTCGC C CT T
ACAGCGGGAA --TAAGGCTATCACTGATGT
TT
T T
42-mer
18-mer
60-mer nicked DNA
DNA Ligase
A
C
B
 
Figure 3.15: Substrates used for standard DNA ligation assays  
18-mer oligonucleotide (Panel B) was labelled with 
32
P in a 20 µl reaction for 60 min at 37
o
C and gel 
purified to remove unincorporated nucleotide (described in Chapter 2; section 2.1.10). The quantified 
labelled strand was annealed with a complementary 42-mer DNA strand (Panel A) in the ratio 1:4 to 
create the substrate a nicked duplex DNA (60-mer; Panel C). The asterisk indicates the position of the 
32
P labelled group. 
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The purified K338A protein and wild type TVlig were tested for strand joining 
activity on the singly nicked radiolabelled duplex DNA. T4 DNA ligase was used in 
control ligation reactions as shown in figure 3.16.  The reaction products were run on 
a denaturing polyacrylamide gel, resolved by exposure of the wet gel to a radiation-
sensitive screen, and the intensity of the bands was quantified using Imagequant 
software (Figure 3.16).   
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Figure 3.16: Ligation activity of TVlig 
The ligase activity assay was carried out using 1 pmole of annealed DNA (18-mer + 42-mer) substrate 
and 0.1 pmole of the indicated DNA ligase in reaction buffer containing 50 mM Tris-HCl pH 7.5, 5 
mM DTT, 10 mM MgCl2 and 1 mM ATP for 2 minutes at 37
o
C. The reaction products were analysed 
by electrophoresis through a denaturing 20% polyacrylamide gel and scanned using a Typhoon 
phosphorimager (GE Healthcare). Lane 1: Positive control with T4 DNA ligase shows the formation of 
60-mer ligated product; Lane 2: ligated 60-mer product formed with wild type TVlig; Lane 3: No 
ligation is seen with active site mutant of TVlig. 
 
 
 
Incubation of the purified wild type TVlig with the labelled synthetic nick showed 
conversion of the labelled 18-mer to a DNA species of higher molecular weight 
shown by its retardation on a denaturing acrylamide gel (Figure 3.16).  The mobility 
of this higher molecular weight species coincided exactly with that obtained by 
incubating the same substrate with commercially obtained T4 DNA ligase. The active 
site mutant, K338A showed no ligation when compared to wild type TVlig and T4 
DNA ligase. The loss of ligation activity of the K338A mutant was not unexpected as 
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the alanine change at Lys338 altered the conserved lysine within what we believed 
would be the critical, nucleotidyltransferase motif I. This would abolish ligase activity 
presumptively through preventing the chemical linkage of the enzyme to AMP during 
step I of the ligation reaction. Similar mutational effects at the motif I lysine have 
been noted for the NAD
+
-dependent Thermus thermophilus and E. coli DNA ligases, 
the ATP-dependent PBCV-1 DNA ligase and T4 RNA ligase (Luo & Barnay, 1996; 
Sriskanda & Shuman, 1996; Sriskanda et al., 1999). From this experiment it was 
concluded that the ligation activity observed with the TV preparation is as a result of 
the purified recombinant protein and not as a result of contamination with host, E. coli 
ligase and that this confirms the earlier observation made with lambda Hind III 
fragment sealing that the enzyme is a DNA ligase using the same constellation of 
catalytic residues as other polynucleotide ligases.   
 
To understand the biochemical properties of the recombinant TVlig it was decided to 
profile the enzyme. Initially we decided to define an enzyme concentration where 
alterations in the reaction conditions would directly affect the formation of reaction 
products. Previous studies have performed such analyses where the enzyme has been 
in excess thus analysing effects on single turnover kinetics (Sriskanda & Shuman, 
1998). A more accurate reflection of the impact of cofactor changes on ligase activity 
is revealed where the enzyme is undergoing cycles of ligation incorporating all three 
steps of ligase chemistry. To assess this, an experiment was carried out incubating 
TVlig (0.1 pmole) with an excess of DNA substrate (1 pmole).  The time course of 
this reaction is shown in figure 3.17. 
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Figure 3.17: Ligation time course of TVlig sealing a 32P-labelled nicked 
substrate 
The time course of ligation reaction was studied by incubating TVlig (0.1 pmole) with an excess of 
DNA substrate (1 pmole) in reaction buffer containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 5 mM 
DTT and 1 mM ATP and incubated at 37
o
C. At each time-point, 10 µl of the sample was removed and 
the reaction was quenched by adding 20 µl loading buffer [98% (v/v) formamide, 10 mM EDTA, 
0.01% (w/v) bromophenol blue] followed by incubation at 95
o
C for 3 minutes.  Panel A: Ligation 
reaction separated on a 20% acrylamide-8M urea gel. Lanes 1 to 7 represent 0, 30, 60, 90,120, 240 and 
360 seconds of incubation at 37
o
C. The sample at time zero was taken before adding the enzyme. Panel 
B: TVlig activity, measured as the amount of ligated product (60-mer) as a percentage of the total 
radioactivity in each lane. The gel in panel A was scanned using a phosphorimager (GE Healthcare) 
and bands were quantified using Imagequant software (GE Healthcare). 
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The reaction reveals a doubling of the amount of sealed DNA over the first three, 
thirty second intervals. This suggests that the rate of ligation here is directly 
determined by the concentration of enzyme. To confirm this finding we then 
incubated the TVlig at increasing concentrations with a constant amount of ligase 
substrate. The extent of ligation of the nicked substrate increased linearly with the 
concentration of TVlig from 0.1 pmole to 2 pmole (Figure 3.18).  In the experiment it 
can be seen that by 30 seconds 0.1 pmole of enzyme has completed sealing of 10% of 
the substrate - 0.1 pmole. In effect each enzyme molecule completes a single ligation 
cycle.  This is borne out by analysis of the 0.5 pmole enzyme aliquot where 50% of 
the substrate (0.5 pmole) is sealed in 30 seconds.   
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Figure 3.18: Effect of recombinant TVlig concentration on DNA ligation 
The DNA ligation assay was carried out to seal 1 pmole of substrate using a range of enzyme 
concentrations (0.1 – 2 pmoles) in standard reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 5 
mM DTT and 1 mM ATP). A 20 µl of sample was taken from each reaction mixture at the time 
indicated and the reaction was quenched by adding 20 µl loading buffer [98% (v/v) formamide, 10 mM 
EDTA and 0.01% (w/v) bromophenol blue], followed by heating the reaction mixture to 95
o
C. The 
samples were resolved by denaturing 20% PAGE. The gel was scanned using a phosphorimager and 
bands were quantified using Imagequant. The extent of ligation is plotted as a function of time and 
enzyme concentration. 
 
Approximately, 75% of ligation was completed within 30 seconds when the 
concentration of the enzyme used (2 pmole) was double the concentration of the 
substrate (1 pmole) in the reaction mixture. The reaction effectively reached 
completion by the end of 1 minute for both the 0.5 pmole and 2 pmole enzyme 
aliquots, when 75-85% of the substrate was converted into product (Figure 3.18).  
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The time course study of TVlig suggested that the biochemical characterisation of the 
enzyme could be studied using a concentration of substrate and enzyme in the ratio of 
1:10 (enzyme: substrate) when approximately, 50% of ligation is completed in 2 
minutes. Such an enzyme to DNA ratio will allow the reaction to be dissected in 
respect of the effect of changing the reaction conditions, for example temperature or 
pH, over the initial two minutes of the reaction where the rate is directly dependent on 
the enzyme. 
 
3.3.8 Properties of the TVlig 
3.3.8.1. Effect of temperature on ligation activity of TVlig 
 
The activity of the TVlig was expected to be directly influenced by temperature. The 
activity of the TV enzyme was determined at different temperatures ranging from 
5
o
C-60
o
C in the standard ligase assays using the labelled hairpin substrate as 
described above. The recombinant TVlig activity measured in this assay peaked 
between 30 - 40
o
C with optimal activity demonstrated at 35
o
C (Figure 3.19). 
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Figure 3.19: Temperature dependence of strand joining activity of TVlig  
2 pmole of nicked DNA substrate and 0.2 pmole of TVlig were incubated for 2 minutes at indicated 
temperatures (
o
C) in ligation buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 5 mM DTT and 1 mM 
ATP). The extent of ligation in each sample was quantified from densitometric quantification of the 
sample, once electrophoresed on a denaturing 20% polyacrylamide gel.  
 
 
Trichomonas vaginalis grows at 30
o
C - 35
o
C and the optimal enzyme activity at these 
temperatures clearly reflects the physiological growth conditions of the parasite 
serving as source for the ligase. Temperatures higher and lower than the optimal 
physiological growth conditions of the host and the parasite result in lower activity of 
the enzyme. Activity of the enzyme was observed to be half that of the 35
o
C optimal 
temperature when the temperature was reduced by 10
o
C. 
A similar temperature profile has been observed for Plasmodium falciparum DNA 
ligase (hereafter referred to as Pflig; another protozoan DNA ligase; published 
contemporaneously with this report), showing optimal activity at 37°C, which is 
reduced by half when the temperature is lowered to 25°C (Buguliskis et al., 2007).  
Most of the ATP-dependent DNA ligases exhibit temperature optima between 22°C-
37°C, for example, Vaccinia virus DNA ligase works optimally at 32°C (Odell et al., 
1996). The exception for ATP-dependent enzymes are those derived from 
thermophilic archaeons, such as M. thermoautotrophicum and P. horikoshii
 
that show 
optimal in vitro activity at 60°C and 90°C respectively (Sriskanda et al., 2000; 
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Keppetipola & Shuman, 2005). It can be concluded that the temperature requirement 
of these DNA ligases reflects the optimal growth temperature for the source organism. 
 
3.3.6.2 Effect of pH on ligation activity of TVlig 
 
To determine the pH optimum for the TVlig, ligation reactions were carried out over a 
broad pH range at 37°C with the enzyme in modified reaction buffer C (1 mM DTT, 1 
mM ATP and 10 mM MgCl2) with either 50 mM Tris–HCl or 50 mM MOPS or 50 
mM sodium citrate buffers. It was found that activity of the enzyme was essentially 
unchanged over a pH range from 7.0 to 7.5 (Figure 3.20). This pH optima closely 
parallel those for other DNA ligases; pH 7.8–8.2 for Drosophila DNA ligase I (Rabin 
& Chase, 1987), pH 7.2–7.8 for T4 DNA ligase (Weiss et al., 1968), and pH 7.4–8.0 
for mammalian DNA ligase I (Lindahl & Barnes, 1992). A number of ATP-dependent 
ligases show tolerance of higher pH levels, Pflig has maximal activity at pH 8.5 
(Buguliskis et al., 2007) while Vaccinia virus DNA ligase retains >80% of maximal 
activity at pH 9.0 (Odell et al., 1996).  TVlig does not appear tolerant of such high pH 
levels, retaining only 56% of maximal activity at pH 8. 
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Figure 3.20: Effect of pH on ligation activity of TVlig 
TVlig activity profile determined over a broad range of pH (4-8.5) using Tris–HCl (pink line), MOPS 
buffers (yellow line) and sodium citrate (blue line) with 1 pmole of nicked DNA substrate incubated 
with 0.1 pmole of TVlig for 2 minutes at 37
o
C. The reaction products were electrophoresed on a 
denaturing 20% polyacrylamide gel and scanned using a Phosphorimager (GE Healthcare). The band 
intensities were quantified using Imagequant software. The extent of ligation is plotted as a function of 
pH of the buffer used in the assay. 
 
 
The TVlig showed significantly reduced activity in the acidic pH range (5% at pH 6 
compared to 45% percent at pH 7) probably due to instability of the acid labile 
phosphoamide bond formed in step I of the ligation reaction mechanism. The acid 
lability of TVlig is extremely similar to the profile of a number of other ATP-
dependent DNA ligases such as T4 DNA ligase (Rossi et al., 1997). This is contrary 
to the pH profile observed for recently identified acid tolerant DNA ligase from 
archaeon Ferroplasma acidiphilum which shows highest activity at pH 2.5–3.0 
(Ferrer et al., 2008). This 'pH optimum anomaly' observed for F. acidiphilum DNA 
ligase is an adaptation of the organism to inhabit acidic environments (Ferrer et al., 
2008).   
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3.3.6.3 Divalent cation specificity of TVlig 
 
DNA ligases are metal-dependent enzymes and hence, the nick-joining activity was 
also determined in the presence of a variety of cations, using the standard buffer 
conditions for TVlig, but an extended incubation time to reveal all possible divalent 
metals capable of supporting ligation (Figure 3.21, panel A). Efficient nick-joining 
was observed in the presence of 10 mM Mg
2+
 (Figure 3.21, panel A & B). Ligation 
was less efficient with Mn
2+ 
and Ca
2+
 at the same concentrations (Figure 3.21, panel 
A) and other divalent metals, Cu
2+
, Co
2+
 and Ni
2+
 did not support ligation of the 
nicked substrate. The enzyme was consistently more active with Mg
2+
 than with Mn
2+ 
over a range of concentrations from 2 to 20 mM (Figure 3.21, panel B). Mn
2+ 
was 
observed to enable ligation with an optimal efficiency at 12 mM (Figure 3.21, panel 
B). Mg
2+
 is considered as the most common metal associated with enzymes as 
cofactor probably due to its high (millimolar) concentration inside the cell (Andreini 
et al., 2008). Magnesium has a strong association with phosphate-containing 
substrates, including ATP (Andreini et al., 2008). 
 
The ability of ligases to use of Mn
2+
 as a cofactor in the absence of magnesium has 
been reported for a number of enzymes including the T4 DNA ligase, mammalian 
DNA ligase I, PBCV-1 DNA ligase and Vaccinia virus DNA ligase (Weiss et al., 
1968; Lindahl & Barnes, 1992; Odell et al., 1996; Ho et al., 1997). However, the use 
of Ca
2+
 as a divalent cofactor has only been restricted to the ATP-dependent DNA 
ligase from Plasmodium falciparum (Pflig) and an NAD
+
-dependent DNA ligase from 
Thermus thermophilus (Tong et al., 1999; Buguliskis et al., 2007). It has been 
suggested that Ca
2+ 
can compete with Mg
2+ 
for the essential metal binding site located 
in the active site of DNA ligases and results in the accumulation of DNA-adenylate 
intermediates (Sriskanda et al., 2000). This has been observed with M. 
thermoautotrophicum DNA ligase, where Ca
2+
 supported
 
the adenylylation of the 5' 
pDNA strand in step 2 of the ligation reaction but did not suffice for step three of 
phosphodiester
 
bond formation; the ligase catalysed attack of the 3‟-OH on the 
activated 5‟-PO4 (Sriskanda et al., 2000). Such stalled DNA-adenylate intermediates 
were not observed for TVlig and Pflig leading to conclusion that ATP-dependent 
DNA ligases encoded by parasitic protozoans (P. falciparum and T. vaginalis) have a 
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unique ability to utilize calcium as a cofactor for the catalysis of phosphodiester 
bonds. We can be certain that the ligation in the presence of calcium is not due to 
magnesium that is being retained by the enzyme during purification as the enzyme 
shows no discernible activity when in the presence of cobalt, nickel or copper. 
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Figure 3.21: Metal cofactor requirement of TVlig 
The radioactively labelled nicked 60-bp substrate was used to analyse the cation requirement for in 
vitro ligation activity of TVlig. Panel A : A ligation reaction was carried out with 1 pmole of  DNA 
substrate incubated with 0.1 pmole of TVlig for 5 minutes at 37
o
C in the presence of 10 mM of one of 
the following divalent metals, MgCl2, MnCl2, CaCl2, CuCl2, CoCl2 and NiSO4. Ligation products were 
resolved by denaturing PAGE and quantified using a Phosphorimager and Imagequant software. The 
extent of ligation is plotted as a function of divalent cation concentration. Panel B:  A ligation reaction 
was carried out with 1 pmole of DNA incubated with 0.1 pmole of TVlig for 5 min at 37
o
C using 
increasing concentrations (2 mM, 4 mM, 8 mM, 12 mM, 16 mM & 20 mM) of MgCl2 and MnCl2, 
Ligation products were resolved by denaturing PAGE and quantified using a Phosphorimager and 
Imagequant software. Ligation activity is plotted as a function of divalent cation concentration. 
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3.3.6.4 Nucleotide cofactor specificity of TVlig 
In addition to divalent metal ions, DNA ligation reactions also require a nucleotide 
cofactor. Ligases are generally classified by which of the cofactors, ATP or NAD
+
, 
support their activity. The nucleotide specificity of the TVlig was determined by 
examining which of the following nucleotides, ATP, NAD
+
, GTP (the nucleotide 
cofactor of mRNA capping enzymes) and dATP were capable of ligation (Figure 
3.22). It was observed that like many other DNA ligases recombinant TVlig was able 
to perform DNA ligation even in the absence of added cofactor indicating that at least 
part of the purified recombinant enzyme was in the adenylated form (Figure 3.22). 
When enzyme concentration equalled or exceeded the substrate concentration, it was 
not necessary to add additional ATP
 
for efficient ligation. This is a remarkable finding 
that virtually 100% of the enzyme molecules purified from E. coli are in the 
adenylated state and thus one round of nick-sealing is possible without the need for 
additional cofactor (Figure 3.22).  Nick sealing activity in the absence of added ATP 
has similarly been reported for a number of other enzymes for example in PBCV-1 
DNA ligase.  However, the level of adenylation has been more modest, studies have 
indicated that only 11% of enzyme molecules have AMP bound at the active site 
(Sriskanda & Shuman, 1998).  
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Figure 3.22: Nucleotide cofactor specificity of TVlig 
The nucleotide cofactor specificity of TVlig was studied by incubating 0.1 pmole of TVlig with 1 
pmole of DNA substrate in reaction buffer containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 5 mM 
dithiothreitol (DTT) and 1 mM NTP (ATP, NAD
+
, GTP) or dNTP (dATP) and incubated at 37
o
C for 2 
minutes. The extent of ligation in each sample was quantified from analysis of the sample on a 
denaturing polyacrylamide gel using a Phosphorimager and Imagequant software.  
 
 
The ligation activity of TVlig was not stimulated by the addition of 1 mM dATP nor 
the same concentration of NAD
+ 
or GTP, thereby indicating that the enzyme has an 
absolute requirement for ATP in nick sealing reactions (Figure 3.22). The ligase 
fraction used in the above assay was not de-adenylated prior to incubating with 
substrate, hence the activity observed in the presence of NAD
+
 and the other cofactors 
is contributed by the pre-adenylated TVlig and not by the cofactor.  This is evident by 
the same amount of ligation taking place in the absence of any co-factor at all (Figure 
3.22). 
 
Nick-sealing reactions of TVlig were then performed with a range of ATP 
concentrations (0.4-1.2 pmole) in order that the Km value for ATP could be 
determined. At each ATP concentration the formation of ligation products was plotted 
against time and the initial velocities [V] were determined for these graphs (as 
attached in appendix 7.3; Figure 7.3). A Km of 0.458 µM ATP was calculated from 
the double-reciprocal plot of these values (Figure 3.23). 
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Figure 3.23: Determination of the Km for ATP of the TVlig 
Different concentrations of ATP (0.4 pmole to 1.2 pmole) were used to determine the binding affinity 
of the TVlig using 1 pmole of nicked labelled substrate and 0.1 pmole of the ligase. Each ligation 
reaction was performed in a reaction buffer containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2 and 5 
mM DTT and incubated at 37
o
C (Appendix 7.3). At each time-point, 10 µl of the sample was removed 
and the reaction was quenched by adding 20 µl loading buffer [98% (v/v) formamide, 10 mM EDTA, 
0.01% (wt/vol) bromophenol blue] followed by incubation at 95
o
C for 3 minutes. The reaction products 
were electrophoresed on a denaturing 20% polyacrylamide gel and scanned using a Phosphorimager 
(GE Healthcare). The change in the extent of ligation for each concentration of ATP used was 
determined and used as measure of the velocity of reaction [V]. The double-reciprocal plot of these 
values was used to determine Km of TVlig for ATP. 
 
 This Km value is small as compared to 75 µM of PBCV-1 DNA ligase (Ho et al., 
1997) and 95 µM of Vaccinia virus DNA ligase (Odell et al., 1996). The Km value of 
TVlig indicates that its ATP binding affinity is more similar to ligases of multicellular 
organisms, for example mammalian DNA ligase I (1 µM, Lindahl & Barnes, 1992) 
and Pflig (1.36 µM, Buguliskis et al., 2007).    
 
3.3.6.5. Nucleic acid binding specificity 
 
Earlier footprinting studies, based on PBCV-1 DNA ligase and T4 DNA ligase, have 
revealed an asymmetric binding profile of DNA ligases (Odell & Shuman 1999; 
Doherty & Dafforn, 2000). Physical binding analysed by minimal substrate analysis 
have suggested that the ligase needs only 6 nucleotides to seal DNA efficiently (Odell 
et al., 2003). Unpublished observations (Odell & Brooke, 2007) from our laboratory 
suggest that a 21 nucleotide dimer is able to support the binding of two PBCV-1 (34 
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kDa) DNA ligase molecules. Therefore, native gel mobility assay provides a means of 
determining whether the enzyme can in fact bind ends as well as nicks. The nick, in 
the annealed 60-mer DNA substrate, is located 18 nucleotides from the end of the 
molecule (Figure 3.15) a distance that all available data suggests will allow a second 
ligase molecule to bind to the terminus should it be capable. Obviously by virtue of 
having the hairpin only one DNA end will bind DNA. By using a simple gel shift 
analysis we can suggest whether the enzyme can recognise ends. If the enzyme 
recognises both nicks and ends then we will expect two shifted products however only 
a single species might be expected if the ligase is binding centrally.   
 
A native gel mobility shift assay was employed to examine the binding of purified 
recombinant TVlig to the 
32
P-labeled nicked duplex DNA (Odell & Shuman, 1999). 
Binding reactions were performed in the absence of magnesium so as to preclude 
conversion of substrate to product during the incubation (Odell & Shuman, 1999). 
Mixing the wild type TVlig with nicked substrate resulted in the formation of a single 
discrete protein–DNA complex that migrated more slowly than the free DNA during 
electrophoresis through a 10% native polyacrylamide gel (Figure 3.24). The 
abundance of this complex increased in proportion to the amount of input ligase. In 
order to estimate binding affinity, the gel was scanned using a phosphorimager. The 
dependence of protein–DNA complex formation on input ligase is shown in figure 
3.24. 
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Figure 3.24: DNA binding native gel assay  
Binding of TVlig to nicked substrate with a 5‟ phosphate group at the nick is shown. Binding reaction 
mixtures (20µl) containing 50 mM Tris-HCl pH 7.5, 5 mM DTT, 1 pmole of nicked ligand and 0.5, 1, 
2 and 3 pmole of TVlig were incubated for 10 min at 22
o
C. Lane 1: Control reaction contained no 
ligase; Lane 2-5 shows effect of increased ligase concentration from 0.5 – 3 pmole respectively. 
Glycerol was added to 5% and the samples were electrophoresed through a 10% polyacrylamide gel in 
TBE buffer at 100 V for 2.5 hours at 4
o
C. An autoradiogram of the gel scanned using a Typhoon 
Phosphorimager is shown (Figure 7.3; Appendix 7). 
 
 
3.3.6.6 DNA binding by TVlig 
 
Classical analysis of DNA ligases interacting with DNA substrates, including PBCV-
1 DNA ligase, has been undertaken by gel-shift (Ho et al., 1997; Sriskanda & 
Shuman, 1998). The technique has allowed a number of insights into ligase-DNA 
interaction (Odell et al., 2000) however it is limited to study protein-DNA interactions 
that result in stable binding. Alternative methods such as optical biosensor techniques 
like SPR can be employed to analyse real-time biomolecular (dynamic) interactions, 
such as those of proteins with DNA; even if those interactions do not result in the 
formation of stable complexes. Therefore, it was decided to analyse DNA binding by 
TVlig via SPR using Biacore system. The Biacore experiments were performed with 
help from C. Brooke, University of Westminster.  
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The Biacore 2000 instrument was used for all experiments (Biacore AB; Uppsala, 
Sweden). The biotinylated DNA substrates (Nick, Gap and Duplex; Figure 3.25) were 
annealed (as described in Chapter 2, 2.1.11), diluted to 0.5 μM with Biacore buffer 1 
and manually injected at a flow rate of 20 μl/min over individual cells of a Biacore 
SA chip (as described above in section 3.2.8). 
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Figure 3.25: Covalent attachment of biotinylated substrates to strepavidin-
coated SA sensor chip 
Biotinylated dsDNA substrates were immobilised onto a streptavidin-coated SA chip. Panel A shows 
the nicked DNA substrate (Nick; top strand composed of the 10-mer + phosphorylated 11-mer) 
immobilised in cell 2, panel B shows the double-stranded duplex DNA substrate (Duplex; top strand 
21-mer) immobilised in cell 3 and panel C shows the substrate with a 1 nucleotide gap (Gap; top strand 
composed of the 10-mer + phosphorylated 10-mer) immobilised in cell 4. The biotin group is indicated 
by the red circle attached to the 5‟terminus of the bottom strand, the streptavidin groups are indicated 
by the green lines. 
 
 
Following the immobilisation of approximately 200 Resonance Units (RU) of each 
substrate, a buffer wash was carried out and the baseline was monitored to ensure 
substrate stability. The DNA substrates, dsDNA with a centrally placed nick (Nick), 
dsDNA with a 1 nucleotide gap (Gap) and un-nicked duplex DNA (Duplex), utilised 
in this study were chosen as they had been previously applied to analyse DNA 
binding by PBCV-1 DNA ligase via gel shift analysis (Ho et al., 1997; Sriskanda and 
Shuman, 1998).  
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Figure 3.26: Biacore analysis of TVlig binding to duplex and gap DNA 
substrate 
The binding profile of TVlig (0.1 – 3.0 μM) was assessed by 3 minute injections (30 μl/min flow rate) 
over the immobilised DNA substrate (200 RU). Panels A & B show the binding profile of TVlig to 
duplex DNA and the gap DNA substrate respectively. The start and end of the injection are indicated 
by black arrows. The values from the underivatised cell were subtracted and the baseline zeroed. The 
experiment was performed with help of C. Brooke, University of Westminster. 
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Multiple dilutions of TVlig (0.1 – 3 μM protein, in duplicates except 0.5 μM) were 
injected over the derivatised Biacore SA chip and the binding profile of the enzyme 
over each substrate was observed. Analysis of the DNA binding profile of TVlig 
reveals that the enzyme has a fast on-rate, highlighted by a rapid increase in RU 
following the injection of the protein (Figure 3.26). The ligase does not seem to show 
substrate discrimination over gap and duplex DNA as the binding profile and off-rate 
showed over these substrates was quite similar (Figure 3.26; panels A and B). The RU 
values increased with increasing protein concentration. Binding of approximately 150 
RU and 100 RU (for 0.5 µM) was observed for duplex and gap substrate respectively 
(Figure 3.26). This is in contrast with the DNA binding profile observed for PBCV-1 
DNA ligase. The PBCV-1 DNA ligase shows greatest association with the intact, 
duplex DNA substrate (RU480 for 0.5 µM) and the lowest binding was observed with 
the substrate containing the one nucleotide gap (RU of approximately 110 for 0.5 µM; 
Figure 3.27, panel B; Brooke, PhD thesis, 2007).  
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Figure 3.27: Comparison of DNA binding of TVlig and PBCV-1 DNA 
ligase 
Panel A shows the DNA binding curve for TVlig (0.1 – 3.0 μM) assessed by 3 minute injections (30 
μl/min flow rate) over the immobilised nicked DNA substrate (200 RU). In panel B, the binding of the 
PBCV-1 DNA ligase (0.5 μM) was assessed by duplicate 3 minute injections (30 μl/min flow rate) over 
the immobilised substrates. The enzyme was diluted to approximately 50 mM NaCl. The Gap substrate 
is represented by dark blue and magenta, Duplex by yellow and cyan and the Nick by dark purple and 
brown. The start and end of the injection are indicated by black arrows. The values from the 
underivatised cell were subtracted and the baseline zeroed. The figure in panel B is reproduced by kind 
permission of C.Brooke (PhD thesis, 2007), University of Westminster. 
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The binding profile for TVlig to the nicked substrate (Figure 3.27, panel A) is 
significantly different to that observed for PBCV-1 ligase (Figure 3.27, panel B; 
Brooke, PhD thesis, 2007) and HuLigI-Δ232 (Figure 3.28; Brooke, PhD thesis, 2007). 
At lower concentrations, 0.1 and 0.5 μM, it showed a maximum binding of 
approximately 190 and 380 RU respectively (Figure 3.27, panel A) as compared to 
the 10 and 100 RU observed for the HuLigI-Δ232 (Figure 3.28). At the end of the 
injection with PBCV-1 and HuLig1 biphasic dissociation was observed for 0.1 µM – 
an initial rapid dissociation of material that was not stably bound, followed by a 
second phase showing very little decrease in RU; indicative of stable binding to the 
substrate. Unlike the PBCV-1 ligase and the truncated human enzyme, a change in the 
shape of the binding curve was observed at higher concentrations of TVlig (1-3 µM). 
The cause of the change in shape of binding curve at these ligase concentrations is 
unknown although it may have occurred as a result of a conformational change in the 
structure of the enzyme. 
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Figure 3.28: The DNA binding curve observed for HuLigI-Δ232 binding 
on the nick 
HuLigI-∆232 (0.1 – 3.0 μM) was injected for 3 minutes at a flow rate of 30 μl/min over the nicked 
DNA substrate (described in Chapter 3, 3.2.8), averaged duplicate runs are shown: The values from the 
underivatised cell were subtracted and the baseline zeroed. The start and end of the injection are 
indicated by black arrows. The figure is reproduced by kind permission of C.Brooke (PhD thesis, 
2007), University of Westminster. 
 
 
The above experiments confirms that TVlig binds to singly nicked duplex DNA but it 
is not clear how DNA ligase I might bind to double-strand DNA breaks. Double-
strand breaks (DSBs) in DNA are generated when the two complementary stands of 
the
 
DNA double helix are broken simultaneously at sites that are
 
insufficiently close 
to one another, such that base-pairing and chromatin
 
structure are insufficient to keep 
the two DNA ends juxtaposed (Takata et al., 1998). One of the major pathways 
employed by the cells to repair DSBs is non-homologous end joining (NHEJ). The 
main proteins required for NHEJ are the Ku heterodimer (Ku70/80), DNA-PKcs (the 
catalytic subunit of DNA-PK, the DNA-dependent protein kinase), XRCC4 (X-ray-
cross complementation gene 4; LifI in yeast), DNA ligase IV and XLF (an XRCC4-
like factor; also called Cernunnos; Wyman et al., 2004; Hefferin & Tomkinson, 
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2005). The Ku heterodimer binds to ends of DNA at DSBs and initiates the 
recruitment process of additional components of the NHEJ pathway, including ligase 
IV. A type IV ligase is found in all eukaryotic organisms including unicellular species 
such as yeast however there was no evidence of such an enzyme when we analysed 
the TV genome. 
 
As previously stated, our bioinformatics analysis suggests that a homologue of DNA 
ligase IV is absent in the TV genome.  Furthermore, other core members of the NHEJ 
pathway, especially, Ku70/Ku80 also appear absent. BLAST searches of the TV 
genome with human, yeast and drosophila Ku proteins failed to identify any 
homologue. We hypothesised that the TVlig might function in the parasite genome as 
a dimer, which binds to and aligns DNA ends at DSBs, thereby, compensating for the 
loss of Ku heterodimer. Such a protein species would probably only allow one dimer 
to bind to our DNA substrate and as such result in only a single species under gel-shift 
analysis.  
 
To test this hypothesis, an additional step of zonal velocity sedimentation was 
employed. This sedimentation method involves the separation of particles by 
centrifugation through a fluid of increasing density. The protein components in a 
mixture, sediment through the gradient in separate zones based on their sedimentation 
rates which are determined by differences in their size, shape and density (Tanese, 
1997). This analytical approach has been employed in the analysis of various enzymes 
including, DNA ligases and topoisomerases (Cheng & Shuman, 1997; Keppetipola & 
Shuman, 2005). The native size of TVlig was gauged by sedimentation through a 15–
30% glycerol gradient containing 0.5 M NaCl (as described in Chapter 2; section 
2.2.5). Marker proteins - catalase (248 kDa), bovine serum albumin (BSA; 66 kDa) 
and cytochrome c (12 kDa) were included as internal standards during sedimentation. 
Aliquots of the even-numbered gradient fractions were analyzed by SDS-PAGE 
(Figure 3.29).  
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Figure 3.29: Gradient sedimentation profile of TVlig 
An aliquot (70 μg) of the purified, wild type TVlig was mixed with catalase (50 μg), bovine serum 
albumin (BSA; 50 μg), and cytochrome c (50 μg). The mixture was applied to a 5-ml 15–30% glycerol 
gradient containing 50 mM Tris–HCl pH 7.0, 500 mM NaCl, 2 mM DTT, 1 mM EDTA, and 0.01% 
Triton X-100. The gradient was centrifuged at 36,800 x g for 17 hours at 4°C. Aliquots (18 µl) of the 
even-numbered gradient fractions (2-26) were analysed by denaturing 12% SDS-PAGE. The 
Coomassie blue-stained gel is shown. Bio-Rad broad range pre-stained protein standard molecular 
weight marker proteins were resolved in the extreme left lane (M; the position and sizes of the marker 
proteins are indicated to the left of the gel). The positions of the ligase polypeptide and the internal 
standards catalase, BSA, and cytochrome (cyto) c are indicated.   
 
The 76 kDa TVlig polypeptide sedimented as a single component, coincident with the 
BSA peak, in fractions 16–18. It was concluded from the sedimentation 
chromatography that the TVlig, similar to other eukaryotic DNA ligases, exists as a 
monomer. 
 
3.4 Discussion 
3.4.1 Trichomonas vaginalis DNA ligase 
 
This work began as an attempt to establish Ligase enzymes as targets for therapeutic 
intervention. DNA ligases inhibitors have been previously proposed as antibacterial 
agents to selectively target the NAD
+
-dependent replicative ligase enzyme of bacteria. 
DNA ligases from the protozoal family had never been analysed and so their 
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biochemistry and properties had not been explored. We chose this opportunity to 
characterise a DNA ligase from the parasitic protozoan Trichomonas vaginalis. We 
report here the identification, expression and characterisation of the single DNA 
ligase encoded by the Trichomonas vaginalis (TV) genome. 
 
DNA ligases belong to a superfamily of covalent nucleotidyltransferases which 
include the polynucleotide ligases and the mRNA capping enzymes. These proteins 
show a wide variation in size, ranging from for the smallest described 298-amino acid 
PBCV-1 DNA ligase to >900 amino acid for some of the mammalian DNA ligases 
such as 919 amino acid human DNA ligase I (Tomkinson et al., 2006). However, all 
these proteins contain a catalytic domain which includes six motifs that are conserved 
in both sequence and spacing (Odell et al., 2000). The active site contains a reactive 
lysine residue in the sequence -KYDGER- which is common to these enzymes from a 
wide range of organisms including bacteriophages, yeasts and human (Sriskanda & 
Shuman, 2002a). In the ligase proteins, large portions of the regions N terminal and C 
terminal to the catalytic domain can be deleted without a subsequent loss in enzymatic 
activity (Tomkinson et al., 2006). Since the PBCV-1 DNA ligase contains only 26 
amino acid upstream of the lysine motif I at the N-terminus and no amino acids 
downstream of motif VI at the C-terminus, it represents the catalytic core of the 
nucleotidyltransferase supefamily (Figure 1.8, panel A; Odell et al., 2000).  
 
Eukaryotes can have at least three DNA ligase species (I, III and IV), which show 
sequence identity with each other but DNA ligase III has been identified only in 
vertebrates (Timson et al., 2000; Martin & MacNeill, 2002). In other species or lower 
eukaryotes, for example in plants, Drosophila and fungi, only two species of DNA 
ligase (I and IV) are found. In each case a single replicative ligase is present. 
Saccharomyces cerevisiae encodes
 
two different DNA ligases, Cdc9 and ligase IV, 
which play distinct
 
roles in DNA replication, repair and recombination. Cdc9 
catalyses the joining of Okazaki fragments during DNA replication
 
and it functions in 
the base excision and nucleotide excision
 
repair pathways. DNA ligase IV in yeast 
plays a specialized role in the repair
 
of double-strand DNA breaks via the NHEJ 
pathway. The presence of multiple DNA ligases in eukaryotic cells suggest that theses 
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enzymes are assigned different functions and deletion of any of these genes in 
mammalian cell lines have exhibited different phenotype (Tomkinson et al., 2006). 
 
Sequence analysis of the entire Trichomonas vaginalis genome identified a gene 
encoding a protein with significant homology to the replicative DNA ligase. The open 
reading frame for the ligase-like protein was identified through alignment studies of 
TV genome from the TIGR database with the yeast ligase I and IV sequences 
(Schizosaccharomyces pombe), small viral DNA ligase sequences (PBCV-1) and with 
archael ATP-dependent ligases (Sulfolobus solfataricus).  
 
The ORF of the putative DNA ligase bears 54% similarity with Drosophila 
melanogster DNA ligase I, 53% with yeast DNA ligase I and 51% with HuLigI 
(Table 3.3). Alignment studies suggested that identified ORF has the six key 
nucleotidyltransferase motifs (I-V) that constitute the catalytic core of DNA ligases. 
The order and spacing of conserved motifs in the putative ligase is similar, as its 
sequence conservation, to that seen in other ATP-dependent ligase family members 
such as Vaccinia virus DNA ligase, PBCV-1 DNA ligase and HuLigI (Figure 3.5; 
panel A). The domain architecture of TVlig as deduced from the sequence alignment 
studies consists of a N-terminal PCNA interacting domain, DNA binding domain and 
catalytic core - comprising of AdD and OB-fold domains (Figure 3.5, panel B). The 
predicted tertiary structure of TVlig suggests close structural alignment with known 
structure of HuLigI (Figure 3.30).  
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Figure 3.30: Predicted tertiary structure of TVlig 
TVlig structure was predicted using the structural predictive programme from Phyre (Panel A; Kelley 
& Sternberg, 2007). Panel B shows the position of six signature motifs of DNA ligases that form the 
adenylation domain (AdD; I- red; Ia-blue; III-cyan; IIIa-purple; IV-orange; V-black) and moif VI 
(pink) present in OB domain. Panel C: Ribbon diagram showing TVlig structure (grey; as predicted 
from Phyre) aligned to structure of human DNA ligase I enzyme in complex bound to adenylated DNA 
(green; 1X9N; Pascal et al., 2004;). The image in panel A was prepared with Rasmol (Bernstein, 2000) 
and images in panel B and C were prepared PyMol (DeLano, 2002). Abbreviations: AdD - Adenylation 
domain; OB - Oligomer binding domain; DBD - DNA binding domain. 
 
 
The bioinformatic analysis suggests that TVlig, similar to HuLigI, uses DBD to 
encircle and stabilise the nicked DNA substrate in co-ordination with the conserved 
AdD and OB-fold domains (Figure 3.6; Figure 3.30; Pascal et al., 2004). The catalytic 
core of TVlig, comprising of adenylation domain (AdD) and oligomer binding (OB) 
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domain, has conserved amino acid residues; functions of which have been highlighted 
earlier in structural and mutational studies of other DNA ligases (Figure 3.5, panel B). 
For example, motif I (KYDGER) encompass the conserved lysine residue (Lys338) 
that constitutes part of the ATP binding pocket of the enzyme and motif III has 
conserved aspartate (Asp387) and glutamate (Glu389) residues required for step I and 
III of catalysis (Odell et al., 2000). Similarly, motif V has a pair of conserved lysines 
(Lys512 and Lys513) essential to form contacts with the ribose sugar hydroxyl group 
of AMP (Figure 3.5, panel A; Sriskanda & Shuman, 2002). The predicted size of 
TVlig (76 kDa) is closer to yeast DNA ligase I (83 kDa) but smaller than higher 
species such as human DNA ligase I (101 kDa) which could be due to the 
evolutionary complexity of the organism. To better understand the TVlig and to 
confirm its function, the polypeptide was cloned, sequenced and expressed from E. 
coli. as a recombinant His-tagged fusion protein which was purified to near 
homogeneity by a two-step column chromatographic procedure.  
 
Initial characterization of the ligation activity of this enzyme was performed by using 
Hind III digested  DNA. Preliminary results confirmed that the enzyme required 
ATP consistent with the bioinformatic analysis of the sequence of the polypeptide. 
Ligation of the compatible ends of the Hind III digested λ DNA required the addition 
of macromolecular crowding agents such as polyethylene glycol (PEG 8000; Figure 
3.12). PEG is known to function as a volume exclusion factor, increasing the apparent 
concentration of DNA and thereby possibly facilitates the ligation. The surprising 
observation here was that the efficient ligation of cohesive ends should require such a 
crowding agent. Previous studies with T4 DNA ligase have suggested that 
macromolecular crowding is only required for blunt-ended DNA fragments (Hayashi 
et al., 1986). 
 
A more detailed, quantified analysis of TVlig reaction chemistry was performed using 
a synthetic singly nicked duplex DNA consisting of a 42-nucleotide 3'-OH terminated
 
hairpin DNA and a 5' 
32
P-labeled 18-mer strand annealed to the 5'-tail of the hairpin
 
strand (Figure 3.15). The results obtained during biochemical characterisation of 
TVlig suggested that the purified protein was able to catalyse phosphodiester bond 
formation on nicked DNA substrates and observed that the product formation was 
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similar when compared to equimolar T4 DNA ligase (Figure 3.16). The active site 
mutant K338A TVlig, constructed by substituting the lysine (Lys338; K) residue with 
alanine (A) in the active site motif I, failed to show any ligation activity. This lysine 
residue is the active site of AMP transfer by the ligases and GMP transfer by the 
capping enzymes (Odell et al., 2000). Absence of ligation by the active site mutant 
highlights the importance of the residue during the step I of the ligation reaction 
mechanism (Figure 3.16) and confirmed that the ligation activity purified was as a 
result of our recombinant protein expression. 
 
Analysis of the activity of TVlig in the presence of different co-factors identified 
optimal ligation in the presence of ATP with Km of 0.458 µM and a divalent metal. 
The ligation of the nicked DNA substrate was observed in the absence of added ATP 
which suggested (Figure 3.22) that a fraction of purified TVlig I was pre adenylated. 
Adenylated form of DNA ligases in the cell are stable and also enhance their DNA 
nick sensing capability (Odell et al., 2000; Ellenberger & Tomkinson, 2008). The lack 
of ligation in the presence of NAD
+ 
was consistent with our summation that the TV 
genome elaborates an ATP-dependent replicative ligase as is found in all other 
eukaryotic organisms. The essential divalent cation cofactor, was found to be most 
readily satisfied by Mg
2+
; however, Mn
2+ 
and Ca
2+
  were found to sustain 50% and 
40% ligation respectively at the same concentrations. Structural studies of
 
DNA 
ligases suggest that the divalent metals presumably orient the phosphate atoms of 
AMP and the DNA as well as helping to neutralize the charge during phosphoryl 
transfer reactions (Nair et al., 2007). Previous studies have suggested that other 
ligases can use of Mn
2+ 
as their divalent cofactor, including T4 DNA ligase, 
mammalian DNA ligase I, PBCV-1 DNA ligase and Vaccinia virus DNA ligase 
(Weiss et al., 1968; Lindahl & Barnes, 1992; Odell et al., 1996; Ho et al., 1997). 
However the use of Ca
2+
 for efficient nick sealing has only been reported in the 
NAD
+
-dependent DNA ligase from Thermus thermophilus (Tflig) and ATP-
dependent DNA ligase from P. falciparum (Pflig; Tong et al., 1999; Buguliskis et al., 
2007). This behaviour is attributed to the large ionic radius of Ca
2+
 (1.00 Å) than 
Mg
2+
 (0.72 Å) or Mn
2+
 (0.80 Å) requiring more flexibility within the catalytic core of 
DNA ligase (Buguliskis et al., 2007).  
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The location of Ca
2+
 in the active site of T4 RNA ligase I structure suggests that it
 
competes with Mg
2+
 for an essential metal-binding site in these enzymes (RNA 
ligases are a member of the nucleotidyltansferase superfamily and share the same 
catalytic core with DNA ligases; Wang et al., 2006).  DNA ligases are able to use 
Ca
2+
 to catalyse the formation of DNA-adenylate intermediate but are unable to 
convert the nick into a phosphodiester bond (except in the cases of TVlig, Pflig and 
Tflig). We conclude that protozoal DNA ligases (TVlig and Pflig) have evolved to 
catalyse phosphodiester bond synthesis in the presence of Ca
2+
, although at least 50% 
less efficiently than when compared to Mg
2+
, but without the accumulation of DNA-
adenylate intermediates in step 2 of catalysis. 
 
TVlig showed optimal ligation activity on a nicked DNA substrate in the presence of 
ATP
 
and MgCl2 at 30
o
C-38
o
C (Figure 3.19). The temperature optima of TVlig I 
suggests that the enzyme is adapted to functioning in physiological temperature of the 
host similar to that observed in Pflig (Buguliskis et al., 2007). The pH profile of 
TVlig is similar to that observed for T4 DNA ligase. The ligase shows optimal 
activity at pH 7-7.5 and loses its activity by 80% in slightly acidic pH (Figure 3.20). 
Whilst previous authors have commented that this reflects the acid lability of the 
phosphoamidate lys-AMP bond there have not been extensive studies to confirm that 
this is the case.   
 
Alignment of the amino acid sequence of the TVlig to that of HuLigI suggest that this 
is the homologue of the DNA ligase I and as such is likely to be responsible for ligase 
events associated with DNA replication. TVlig shares 32% and 27% identity with 
human DNA ligase III and IV respectively, with highest homology restricted to DNA 
binding domain and common catalytic core shared by all members of 
nucleotidyltransferase family. Detailed alignment studies are attached in appendix 
7.2.1. The presence of additional DNA ligase III and IV specific domains such as 
BRCT domain that target these ligases to sites where their action is required,
 
seem to 
be absent in the TVlig. Instead the amino acid sequence of TVlig revealed a probable 
NLS  in the N-terminal region of the enzyme (Figure 3.4, panel B). NLS are required 
for active transport of enzymes into the nucleus through nuclear pores and are 
characterised by the presence of lysine (K) and/or arginine (R) clusters which in some 
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cases are preceded by a proline (Dingwall & Laskey, 1991). A NLS has been 
identified in HuLigI at residues 119–131, deletion of which abolished nuclear 
trafficking of the protein (Montecucco et al., 1995; Cardoso et al., 1997).  
 
DNA ligase I has a conserved PCNA-interacting polypeptide (PIP) motif.  This is 
essential for proteins that interact with PCNA and is found in DNA polymerase, FEN-
1 (flap endonuclease-1), the clamp loader RFC (replication factor C), CAF1 
(chromatin assembly factor), DNA repair factors such as MutS, XPG (xeroderma 
pigmentosum complementation group G) and UDG (uracil DNA glycosylase) and a 
number of cell-cycle-regulatory proteins such as p21; (Vivona & Kelman, 2003; 
Vijayakumar et al., 2007). The archaeal PCNA binding proteins, e.g. archaeal DNA 
polymerase B, generally interact with their PCNA via a conserved PIP motif located 
in their C-terminal region except for the DNA ligases from Sulfolobus solfataricus 
and Pyrococcus furiosus (PfuLig; Dionne et al., 2003; Kiyonari et al., 2006). The PIP 
motif of PfuLig is instead located in the loop structure connecting α helices in the N-
terminal DNA binding domain (Kiyonari et al., 2006). TVlig, similar to HuLigI (2-9
 
amino acid residues) and yeast DNA ligase I (cdc9; 18-25 amino acid residues), 
apparently has a PIP motif located in the N-terminal portion (3-10 amino acid 
residues) of its DNA binding domain (Figure 3.4, panel A; Warbrick, 2000; 
Vijayakumar et al., 2007).  
 
It is interesting to note that P. falciparum’s genome (another parasitic protozoan) 
encodes for two homologues of PCNA gene but the recently characterised DNA 
ligase I (published contemporaneously with this report) from this organism lacks an 
obvious PIP motif. Instead this polypeptide has an apicoplast targeting signal located 
in its N-terminus (Buguliskis et al., 2007). The apicoplast is a plastid organelle, 
homologous to the chloroplasts of plants, that occurs throughout the Apicomplexa; a 
group of protists characterized by the presence of apicoplast (Foth & McFadden, 
2003). The absence of the PIP motif raises interesting questions about the mode of 
interaction of Pflig with PCNA that is usually required during the process of 
replication and repair in eukaryotes. However, not all PCNA-interacting proteins 
possess a PIP motif, as reported for proteins like the histone acetyl transferase
 
(HAT) 
p300, and histone deacetylase 1 (HDAC1; Stoimenov & Helleday, 2009). It could be 
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hypothesised that P. falciparum DNA ligase I uses some unusual PCNA interacting 
motif similar to that recently reported in the archaeal organism Pyrococcus furiosus 
(Kiyonari et al., 2006). PCNA interacting differences have been reported for P. 
falciparum. The recently identified P. falciparum FEN-1 has a PIP motif located 
internally as opposed to C-terminal location observed in other FEN-1 homologues 
(Casta et al., 2008). 
 
3.4.2. DNA Repair in Trichomonas vaginalis 
 
DNA repair processes are vital to all living organisms; loss of which invariably results 
in accumulation of mutations and/or cell death. Many of the DNA lesions repair 
pathways have been conserved throughout eukaryotes and many eukaryotic enzymes 
have homologues in prokaryotes (Taylor & Lehman, 1998). There are no reports of 
DNA repair proteins or pathways that exist in TV or other related parasitic protozoans 
such as Toxoplasma gondii or Trypanosoma cruzi. We attempted to identify putative 
TV homologues for DNA repair proteins using tBLASTn to shed light on whether we 
would expect that there would be a requirement for additional ligases, such as a type 
III or IV enzyme. Table 3.4 lists some of the putative genes present in TV genome 
that might be involved in DNA repair pathways (when compared to DNA repair 
proteins in S.cerevisiae). Single-strand DNA (ssDNA) breaks are repaired either by 
short-patch base excision repair (BER) or long-patch BER whereas double-strand 
breaks (DSB) are repaired by non-homologous end joining (NHEJ) or homologous 
recombination (HR). Mammalian cells uses short-patch BER for single ssDNA 
repairs and NHEJ for DSB repairs. Short patch BER utilises DNA glycosylases, AP 
endonucleases, XRCC1 and DNA ligase III whereas long patch BER is PCNA 
dependent pathway involving FEN-1, replication protein A (RPA) and DNA ligase I 
(described in depth in Chapter 1; section 1.6.1.3). 
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Table 3.4: Hypothetical TV proteins that may participate in different DNA 
repair pathways 
 
Gene Name Present in TV S.cerevisiae Protein ID T.vaginalis Protein ID
Long patch base excision repair
PCNA Y AAS56041 XP_001329442
Rad1 Y P06777 XP_001329017
Cdc9 (DNA ligase I) Y CAA48158 XP_001581589
Rad27 (FEN-1) Y CAA81953 XP_001294157
Short patch base excision repair
DNA ligase III N - -
XRCC1 N - -
Homologous recombination (HR)
Mre11 (Rad32) Y BAA02017 XP_0013291917
Rad50 Y CAA65494 XP_001311080
Rad51 Y CAA45563 XP_001303202
RPA1 Y NP_009404 XP_009404
Non-homologous end joining (NHEJ)
Ku70 N NP_014011 -
Ku80 N NP_013824 -
DnL4 (DNA ligase IV) N CAA99193 -
Lif I (XRCC4) N NP_011425 -
 
Amino acid sequences of DNA repair proteins from S.cerevisiae were collected from NCBI 
GENBANK, and compared to the TV protein and nucleotide database using BLASTP and tBLASTN 
(significance was defined arbitrarily as an e-value of 10
-5 
or less). Presence (Y) or absence (N) of repair 
proteins in TV is indicated, along with the genbank accession numbers for both S.cerevisiae and TV 
proteins.  Proteins lacking obvious homologues are indicated in bold type. Pathway components were 
largely compiled from the following sources: Base excision repair from Boiteux & Guillet, 2004; HR 
from Filippo et al., 2008; NHEJ from Hefferin & Tomkinson, 2005. 
 
Haltiwanger et al. (2000) observed that cell-free lysates prepared from P. falciparum 
repaired regular and synthetic AP sites in various DNA substrates by long-patch BER. 
This mechanism was different from mammalian cells, yeast, Xenopus and E. coli 
which predominantly repair such AP sites by removal of a single nucleotide or small-
patch BER. This could be because of the absence of proteins involved in short-patch 
BER, specifically XRCC1 and DNA ligase III in the P. falciparum genome 
(Buguliskis et al., 2007). Recent characterisation of FEN-1 and other genes such as 
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DNA ligase I and AP endonucleases from P. falciparum suggests that the malarial 
parasite has the entire core enzymes required for long-patch BER pathway and hence 
uses the above mechanism for repairing damages in single-strands of DNA (Casta et. 
al., 2008). The TV genome also appears to encode for homologues of FEN-1, PCNA 
and DNA ligase I (characterised in this study) the enzymes required for long-patch 
BER but is devoid of DNA ligase III and XRCC1 required for short-patch BER. This 
lead us to speculate that T. vaginalis being related to P.  falciparum and having only 
one DNA ligase in its genome is likely to use long-patch BER for single-strand DNA 
break repair. 
Double-strands breaks (DSB) are the most serious forms of DNA damage and a single 
unrepaired DSB can lead to cell death. These types of damage are repaired 
predominantly by either non-homologous DNA end joining (NHEJ) or homologous 
recombination (Burton et al., 2007). NHEJ pathway relies on DNA ligase IV, XRCC4 
(LifI in yeast) and the Ku70/Ku80 heterodimer (Figure 1.9; panel A). Extensive 
BLAST searches revealed that the TV genome is devoid of the core machinery 
required for DSB repairs by NHEJ. We searched the genomes of three other related 
parasites: Trypanosoma cruzi, Leishmania major and Plasmodium falciparum but 
orthologues for DNA ligase IV and XRCC4/LifI were not detected. However, 
homologues of DNA ligase I were apparent in Trypanosoma cruzi (EAN97122) and 
Leishmania major (CAJ02559) genome (DNA ligase I is already characterised in 
Plasmodium falciparum). The lack of Ku proteins in the TV genome is highly 
interesting. These proteins play a pivotal role in NHEJ; they bind to and align DNA 
DSB sites and recruit other repair factors to the break site and are present in 
Archaebacteria, Prokaryotes and Eukaryotes. The core of Ku proteins is highly 
conserved from prokaryotes to eukaryotes (Hefferin & Tomkinson, 2005).  
A native gel mobility shift was used to demonstrate the formation of stable complex 
between the TVlig and nicked DNA (Figure 3.24). A more sensitive, Biacore SPR 
analysis - a solution study that facilitates the investigation of the dynamics of DNA-
ligase interactions, was used to study TVlig binding to different, immobilised DNA 
substrates (Figure 3.25). It was observed that TVlig binds equally well to the duplex 
as to the gap DNA substrates (Figure 3.26) but its binding affinity was different for 
nicked DNA substrate. This suggests that TVlig can differentiate nicks from duplex 
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DNA. At low concentrations, the enzyme rapidly reached equilibrium over the nicked 
substrate and following the end of the injection, dissociation of some, unbound ligase 
molecules was observed. The shape of the binding and dissociation curve observed at 
higher TVlig concentrations was quite unusual. It was initially thought that this 
behaviour of TVlig bound to nicked DNA substrate is a result of enzyme 
oligomerisation. We hypothesised the existence of TVlig as a dimer which could bind 
to and align DNA ends at DSB sites but velocity sedimentation analysis clearly 
demonstrated that TVlig exists as a monomer, similar to other eukaryotic DNA 
ligases. One additional experiment that might be attempted would be to repeat the 
velocity sedimentation with a blunt-ended DNA duplex.  It may be that the enzyme 
can self-associate when such DNA is present and that by this means the organism can 
seal DSBs. 
Verkaik et al. (2002) demonstrated that the inactivation of the factors involved in the 
NHEJ pathway (Ku80, DNA-PK, DNA ligase IV and XRCC4), in mammalian cells, 
results in increase of micro homology mediated end joining (MHEJ) of the DNA 
substrate. This DNA repair pathway uses short stretches of homology or micro 
homology near the DNA ends (Glover et al., 2008). Although MHEJ had been 
previously reported to help NHEJ-mediated repair of DSBs, the MHEJ pathway is 
distinct from NHEJ because it does not rely on the Ku, DNA ligase IV and XRCC4 
proteins for completion (Decottignies, 2007). It has been suggested that micro 
homology end joining (MHEJ) can act as a back-up pathway where DSBs were not 
repaired by HR or NHEJ (Nussenzweig & Nussenzweig, 2007). MHEJ is dependent 
on Rad1, Mre11 and Rad50 in yeast and FEN-1 in mammalian cells (Glover et al., 
2008). 
 
Trypanosoma brucei‟s (T. brucei) genome, a parasitic protozoan, does not encode 
homologues of DNA ligase IV or XRCC4, suggesting that NHEJ is also absent in 
these protozoans (Conway et al., 2002b). Conway et al. (2002a) created KU null 
mutants of T. brucei by deleting both alleles of Ku70 and Ku80 (components of 
NHEJ). However, no increased sensitivity of this mutant to methyl methane 
sulphonate (MMS; causes both single and double-strand breaks) and
 
to phleomycin 
(causes double-strand breaks)
 
was detected, indicating the existence of a repair 
pathway independent of the Ku proteins (Conway et al., 2002a). Burton et al. (2007) 
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have observed that DSBs in T. brucei cell extracts are repaired by sequence micro 
homology which is distinct from NHEJ and is independent of the Ku –heterodimer. 
These is similar to findings of Glover et al. (2008), who demonstrated that 
chromosomal DSB repairs in T. brucei were predominantly repaired by MHEJ and 
homologous recombination.  
 
Liang et al. (2008) studied the role of DNA ligase I in end joining of DNA double-
strand breaks by micro homology mediated end joining (MHEJ) in mammalian cells 
and demonstrated that human DNA ligase IV is not required in MHEJ. Comparisons 
were made by down regulating DNA ligase I in human HTD114 cells which lead to 
impaired joining of DNA ends mediated by micro homology and treatment of 
HTD114 nuclear extracts with antiserum against DNA ligase I significantly reduced 
MHEJ (Liang et al., 2008).  
 
All the above findings and lack of evidence for the core machinery of NHEJ (to date) 
in the TV genome suggests that double-stranded breaks are most likely repaired by 
micro homology mediated end joining pathway (MHEJ). It is difficult to imagine how 
the organism could exist without any means to mend DSB DNA. TV must, therefore, 
utilize some other form of double-strand break repair, or contain such highly 
divergent copies of most NHEJ and HRR proteins that were impossible to identify in 
this study. A more detailed study of Trichomonas vaginalis DNA repair proteins will 
determine whether controlling the disease caused by these pathogenic parasites can be 
undertaken through inhibiting these components.  
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CHAPTER 4: PRODUCTION OF VARIOUS ATP-DEPENDENT 
DNA LIGASES FOR USE IN DEVELOPING A LIGASE-
INHIBITOR ASSAY 
4.1 Introduction 
 
Research over the past few years has provided ample evidence that genome instability 
caused by germline mutations in DNA repair genes can cause a predisposition to 
carcinogenesis. For example, defects in the BRCA1 and BRCA2 proteins strongly 
predispose individuals to breast and ovarian cancer (Turner et al., 2005). DNA repair 
mechanisms also play a critical role in sensitivity and resistance of tumour cells both 
during and after anti-cancer drug treatment and irradiation. Commonly used 
chemotherapeutics such as, doxorubicin, cisplastin and etoposide induce DNA 
damage, which in turn generates a complex cascade of events leading to cell cycle 
arrest, transcriptional and post-transcriptional activation of a subset of genes including 
those associated with DNA repair and ultimately the triggering of apoptosis 
(Christmann et al., 2003). The cytotoxicity of the majority of these drugs is directly 
related to their ability to cause DNA damage (Madhusudan & Hickson, 2005).  
 
The range of DNA damage induced by chemotherapeutic drugs and clinically 
employed radiation can activate multiple DNA repair pathways such as base excision 
repair (BER), nucleotide excision repair (NER), homologous recombination (HR) and 
non-homologous end joining (NHEJ; Hoeijmakers, 2001). Tumour cells that are 
deficient in one or more DNA repair pathway depend upon the remaining pathways 
for damage repair (Turner et al., 2005). Therefore, therapeutic inhibition of those 
remaining pathways or particular components of these pathways should make a 
crucial impact on the survival of the tumour cells. This cytotoxicity may in fact be at a 
sub-lethal level for normal human cells, where all the DNA repair processes are 
intact. 
 
Although a number of approaches have undergone intensive and close scrutiny as 
potential approaches to treat and kill cancer (targeting signalling pathways and 
components of multi-drug resistance, etc.), much less work has focussed on blocking 
the ability of a cancer cell to recognise and repair the damaged DNA which results 
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primarily from the front line cancer treatments; chemotherapy and radiation. More 
recent studies on a number of DNA repair targets have produced proof-of-concept 
results showing that selective targeting of these DNA repair enzymes has the potential 
to augment the currently used chemotherapeutic agents and radiation as well as 
overcoming drug resistance (Salles et al., 2006). A key protein responsible for the 
terminal step of all DNA repair pathways is DNA ligase. Whilst human DNA ligase 
has been a possible target of the chemotherapeutic doxorubicin (Ciarrocchi et al., 
1999), at the outset of our study no previous experimental data was available where 
human ligase was being deliberately targeted as a means of treating cancer. 
 
DNA ligase I is required for ligation of Okazaki fragments during replication and 
ligases are the last step of almost all DNA repair pathways. DNA ligase deficient cell 
lines exhibit sensitivity to a wide range of DNA damaging agents (Tomkinson et al., 
2006; Vijayakumar et al., 2009). Thus DNA ligase inhibitors would be predicted to 
have pleiotropic effects on cell proliferation and sensitivity to DNA damage. Among 
the three DNA ligases (I, III and IV) found in humans, expression of DNA ligase I is 
elevated in tumour cells as compared to normal cells whereas the expression of DNA 
ligase III and IV does not significantly change in proliferating and resting cells (Sun 
et al., 2001). Cisplastin, an anticancer drug, reacts to link covalently with DNA 
molecules and blocks the replication process by forming inter and intrastrand DNA 
crosslinks (Selvakumaran et al., 2003). This damage is repaired by the NER pathway 
(Sun et al., 2002). Increased NER activity has been observed in cisplastin-resistant 
tumour cell lines, whereas cells defective in NER are more sensitive to cisplastin 
(Selvakumaran et al., 2003; Sun et al., 2002). These studies suggest that combining a 
therapeutic such as cisplatin with ligase inhibitors could possibly augment the lethal 
effect of the initial chemotherapeutic. 
 
The catalytic core structure of DNA ligases is maintained between diverse species. At 
only 298 amino acids, PBCV-1 DNA ligase is the smallest characterised eukaryotic 
ATP-dependent DNA ligase (Ho et al., 1997; Odell & Shuman, 1999). The PBCV-1 
enzyme consists only of the ligase catalytic core without the flanking N and C-
terminal domains found in the larger cellular eukaryotic DNA ligases (Odell et al., 
2000). The structure of the 34 kDa PBCV-1 DNA ligase enzyme-adenylate 
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intermediate shows the same two-domain arrangement (an N-terminal adenylation 
domain and a C-terminal OB-fold domain) as the larger 41 kDa T7 DNA ligase 
(Subramanya et al., 1996; Odell et al., 2000). The critically conserved catalytic 
residues of both the T7 and the PBCV-1 ATP-dependent DNA ligases are 
superimposable when one compares their three dimensional structures (Figure 1.8, 
panel B).  
 
All ATP-dependent DNA ligases retain critical residues that can be shown to be 
involved in ligase reaction chemistry (Shuman, 1996). The linear spacing of these 
residues is very closely conserved and structural studies suggest that their linear 
arrangement reflects their conservation in the three dimensional arrangement of 
residues involved in DNA ligation (Subramanya et al., 1996; Odell et al., 1999; Odell 
et al., 2000).   
 
HuLigI is a 919 amino acid polypeptide (102 kDa) that can only be expressed in a 
recombinant form in very small amounts. Our initial strategy was to clone and express 
this enzyme and by modification of the second amino acid and use of appropriate 
bacterial strains to obtain sufficient material to use in an inhibitor assay. Ultimately 
this approach did not yield sufficient protein material however a truncated version of 
this protein, ∆232 (232-919 amino acid), used by Pascal et al. (2004) to study the 
detailed structure of the catalytic and DNA binding core, is smaller in size and is 
better expressed in E. coli cells. More importantly we know from the crystal structure 
of this truncated form bound to its substrate that it is capable of recognising and 
binding to DNA nicks (Pascal et al., 2004). It was not only shown to be capable of 
stably interacting with DNA furthermore it was catalytically active in DNA sealing 
(Pascal et al., 2004). It is our opinion that the truncated form of the human ligase 
represents a defined version of the human enzyme that can therefore be used to 
identify inhibitors of the human enzyme that block both key catalytic residues and 
moreover those residues critical for DNA recognition. This truncated version, 
containing the DNA binding domain, the adenylation domain and the OB fold 
domain, was therefore purified for use in inhibitor assays (Chapter 5) as a primary 
screen in place of full-length HuLigI.  
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 In this study we also used PBCV-1 DNA ligase as a representative of the catalytic 
site of ATP-dependent DNA ligases and as a representative of a new class of potential 
targets found in the ATP-dependent ligases of eubacteria.  
 
4.2 Materials and methods 
4.2.1 Cloning and expression of full-length human DNA ligase I 
 
Forward and reverse primers were designed for the mRNA sequence of HuLigI 
available at www.ncbi.nlm.nih.gov under accession number NM_000234 to amplify 
the coding region of the gene. Repeated attempts to amplify the full-length ORF of 
DNA ligase I using purified cDNA library obtained from HT-29 or MDA MB-435 
cells (as described in Chapter 2; 2.1.6) yielded no product. New primers, as listed in 
Table 4.1, were designed to amplify the N-terminal and C-terminal portions of the 
gene in two different reactions whose products could later be ligated to yield the full-
length ORF (Teraoka et al., 1993). The reaction samples were prepared as described 
in section 2.1.9, and these underwent an amplification reaction using different set of 
primers as listed in table 4.1. 
 
 The full-length clone (1-3421 bp) of HuLigI in vector pCMV-SPORT6 was 
purchased from Gene Services Ltd, Cambridge (MGC: 117397; IMAGE: 6141535). 
Forward (5‟-GATCCTCGAGATGCAGCGAAGTATCATGTC-3‟) and reverse (5‟-
GATCCTCGAGTTAGTAGGTATCTTCAGGGTCAGAG-3‟) primers were designed 
with Xho I restriction sites; italicised and underlined in the primer sequence; flanking 
the ORF (421-3180 bp) of the full-length clone.   
 
PCR to amplify full-length ORF was performed for 20 cycles (consisting of 1 minute 
at 94
o
C, 1 minute at 55
o
C and 3 minutes at 72
o
C) after initial denaturation at 95
o
C for 
2 minutes. The products were resolved on a 0.7% agarose gel, purified using the 
Qiagen DNA purification kit (as described in Chapter 2, 2.1.4.1) and eluted from the 
DNA affinity resin in 30 µl of sterile distilled water. The purified PCR product was 
digested with Xho I restriction enzyme (New England Biolabs) for 3 hours at 37
o
C 
and then ligated with Xho I digested pET-16b vector for 16 hours at 4
o
C. The ligated 
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mixture was transformed into E. coli (DH5α) cells (Invitrogen) and plated onto LB-
Amp (100 µg/ml ampicillin) plates. Plasmid DNA was extracted using a Qiagen 
plasmid mini-prep kit (Chapter 2, 2.1.2) from overnight cultures, inoculated with a 
single, transformed bacterial colony and digested with Xho I as described earlier to 
check for insert release. The integrity of the constructs was confirmed by sequencing 
purified plasmid at the Advanced Biotechnology Centre (ABC), London. 
 
The pET-16b plasmid containing full-length HuLigI was transformed in E. coli 
BL21(DE3) and E. coli BL21(DE3)RP strains. The E. coli cells harbouring the 
plasmid containing the human DNA ligase gene were grown at 37
o
C either in Luria-
Bertani broth or 2YT media (8 g Bacto tryptone, 5 g Yeast extract, 5 g NaCl per 1 
litre) containing 100 µg/ml ampicillin and/or 34 µg/ml chloramphenicol. The 
expression of HuLigI was induced by the addition of 0.2-1 mM isopropyl β-D-
thiogalactopyranoside (IPTG) when the culture density reached 0.4-0.5 at OD595 and 
incubation was continued either overnight at 18
o
C or for 3 hours at 37
o
C. The cells 
were harvested by centrifugation for 10 minutes at 3,000 g and resuspended in buffer 
A (50 mM Tris-HCl pH 7.5, 10% glycerol and 300 mM NaCl). The cells were lysed, 
centrifuged and the soluble fraction was loaded onto Ni-NTA resin as previously 
described (Chapter 2; 2.2.1; 2.2.2; 2.2.3). The expression of the protein was checked 
by electrophoresis using a 10% sodium dodecyl sulphate (SDS)-polyacrylamide gel 
and a western blot was performed with anti-his antibody as described in Chapter 2; 
2.2.5. 
 
4.2.2 Expression and purification of ∆232 HuLigI 
 
10 ml LB media was inoculated with a single colony of E. coli BL21(DE3)RP 
harbouring plasmid encoded ∆232 HuLigI (obtained from Dr. T. Ellenberger, 
Washington University, USA). The antibiotic concentration was adjusted to 50 µg/µl 
kanamycin and 34 µg/µl chloramphenicol and the culture grown overnight at 37
o
C 
with aeration. This overnight culture was diluted (1 in 100) into 500 ml LB, adjusted 
to 50 µg/µl kanamycin and 34 µg/µl chloramphenicol and grown at 37
o
C with shaking 
until the absorbance measured at A595nm reached 0.4-0.5. The protein expression was 
induced by the addition of IPTG to a final concentration of 0.4 mM and the culture 
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was incubated at 37
o
C for further two hours. The cells were harvested by 
centrifugation and processed as described above for full-length HuLigI. The soluble 
extract was loaded onto Ni-NTA resin as previously described (Chapter 2; 2.2.1) and 
protein was eluted in buffer A (50 mM Tris-HCl pH 7.5, 10% glycerol and 300 mM 
NaCl) containing 300 mM imidazole. The elution profile was monitored via SDS-
PAGE.  
 
The peak fraction eluted from Ni-NTA (judged by SDS-PAGE) was diluted to 25 mM 
NaCl with buffer B (50 mM Tris-HCl pH 7.5, 10% glycerol, 5 mM DTT) and applied 
to Q-Sepharose resin (GE Healthcare), pre-equilibrated with buffer B containing 25 
mM NaCl. The column was washed with buffer B containing 15 mM NaCl and the 
protein was step eluted with buffer B containing 0.075, 0.1, 0.2, 0.3, 0.5 and 1.0 M 
NaCl. The elution profile was monitored via 12% SDS-PAGE. The peak fraction was 
dialysed against buffer B containing 100 mM NaCl. The purified protein was 
aliquoted in small volumes and stored at -80
o
C until required. 
 
4.2.3 Expression and purification of PBCV-1 DNA ligase 
 
LB media containing 100 g/ml ampicillin was inoculated with a single colony of E. 
coli BL21(DE3) cells transformed with pET-16b containing the PBCV-1 ligase gene 
(obtained from Professor S. Shuman, Sloan-Kettering, New York) and grown 
overnight in LB broth at 37
o
C. Fresh, pre-warmed LB was inoculated from this static 
overnight culture (at a 1/100 dilution), adjusted to 100 μg/ml ampicillin and incubated 
at 37
o
C with shaking. When the optical density of the cultures reached 0.4-0.5 
(OD595), cells were induced with IPTG (0.4 mM final) and incubated at 37
o
C for 2 
hours with constant shaking. The cells were processed as described above, the soluble 
fraction was applied to Ni-NTA resin as described previously (Chapter2, 2.2.3) and 
protein was eluted in buffer A (50 mM Tris-HCl pH 7.5, 10% glycerol and 300 mM 
NaCl) containing 300 mM imidazole. The elution profile was monitored via SDS-
PAGE.  
 
The peak protein fractions from the Ni-NTA column were diluted to 50 mM NaCl 
with buffer B (50 mM Tris-HCl pH 7.5, 5.0 mM DTT and 10% glycerol) and applied 
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to an S-sepharose column pre-equilibrated with buffer B. The column was washed 
with buffer B containing 25 mM NaCl and the protein was step eluted with buffer B 
containing 0.1, 0.15, 0.2, 0.3, 0.5 and 1.0 M NaCl. The elution profile was monitored 
via 12% SDS-PAGE. The peak fraction was dialysed against buffer B containing 100 
mM NaCl. The purified protein was aliquoted in small volumes and stored at -80
o
C 
until required. 
 
4.2.4 Hind III DNA ligation assays with ∆232 HuLigI 
 
The purified ∆232 HuLigI was used to ligate Hind III digested  DNA in 50 mM Tris-
HCl pH 7.5, 10 mM MgCl
2
, 10 mM dithiothreitol, 1 mM ATP and 25 μg/ml bovine 
serum albumin at 16
o
C for 5 minutes. The ligated mix was resolved on a 0.8% 
agarose gel, stained with ethidium bromide (0.5 µg/ml) and viewed under UV 
illumination.  
4.3 Results 
 
Our desire to develop inhibitors to the HuLigI enzyme required that we clone and 
express the full-length human protein. Whilst we altered our strategy during the 
cloning of the full-length HuLigI - deciding to use the better expressed, truncated 
232 HuLigI to identify inhibitors - potential inhibitors from our assay that will need 
to be screened against the full-length enzyme to substantiate the idea that can be 
developed for in vivo cell inhibition.  
 
4.3.1 Amplification and cloning of HuLigI 
 
Based on previous findings of Sun et al. (2001) that human DNA ligase I (HuLigI) is 
up-regulated in proliferating cancer cells, we chose HT-29 (a metastatic colorectal 
cancer cell line) and MDA MB-435 (a breast carcinoma cell line) cells to make 
human cDNA libraries from which to isolate a human DNA ligase I clone. Total RNA 
was isolated from these cells lines using SV total RNA isolation kit (Promega) 
followed by mRNA isolation using the Poly A Tract
® 
mRNA Isolation system 
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(Promega; as described in Chapter 2; section 2.1.6). A reverse transcriptase (RT) 
reaction was performed with this mRNA to allow cDNA synthesis using a universal 
riboclone
®
 cDNA synthesis kit (Promega). Random primers, gene specific primers 
and oligo-dT primers were used to prepare separate cDNA libraries from the purified 
mRNA obtained from the above cell lines (as described in Chapter 2; 2.1.6). Use of 
oligo-dT primers is recommended as they can initiate first strand synthesis by 
annealing to the 3‟ end of any polyadenylated RNA molecule whereas the gene 
specific primers (Table 4.1; set1) should only initiate the first strand synthesis by 
annealing to a gene specific region on appropriate RNA molecules.  
 
Initial attempts made to amplify the full-length HuLigI gene by PCR using gene 
specific sets of primers (Table 4.1; set 1 & 2), in independent reactions containing any 
of the cDNA libraries isolated above, were largely unsuccessful. Various attempts 
including varying annealing temperature of the primers and changing DNA 
polymerase used in the amplification reaction failed to yield a PCR product of 
required length. A commercially available human pancreatic cDNA library 
(Invitrogen) was also used as a template in a PCR reaction using primer set 1 and 2 
(Table 4.1) but failed to amplify the gene. Table 4.1 lists various primer sequences 
used in an attempt to amplify full-length HuLigI.   
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Table 4.1: Oligonucleotide primer sequences used for the amplification of 
the HuLigI  
 
Primer Set used Sequence of the primers used (5’-3’) Region 
corresponding  
to mRNA  of 
HuLigI 
Expected 
size of 
amplified 
PCR 
product 
 
Set 1  
Forward GCCTGGCGGATCTGAGTTG 10-29 
 
 
~ 3 kb 
Reverse 
 
TGAAAGAAATGACGGGATGAATC 3040-3062 
 
Set 2 
Forward ATGCAGCGAAGTATCATGTC 
 
121-140 
 
 
~ 2.8 kb 
Reverse 
 
GCGAGGGCTTAGTAGGTATC 2868-2888 
 
Set 3  
Forward 
 
ACCCAGCGAAGTATCATGTCATTT 
 
35-55 
 
 
0.75 kb 
(N- terminal) Reverse 
 
GAAGTGAAGGAAGAGGAGCC 755-774 
 
Set 4  
Forward 
 
AGAGCTCCCAAGACGCTCAG 
 
698-717 
 
 
2.1 kb 
(C-terminal) Reverse 
 
GATACCTACTAAGCCCTCGC 2780-2799 
 
Set 5  
Forward 
 
CAGAGGGCGAGTTTGTCTTC 
 
2186-2205 
 
 
0.2 kb 
Reverse 
 
AGCCAGTTGTGCGATCTCTT 2329-2348 
 
Teraoka et al. (1993) cloned full-length HuLigI into E. coli by separately amplifying 
the N-terminal and C-terminal ends of the gene, followed by their ligation into a 
single expression vector. Based on their experimental design, we designed a new set 
of primers (Table 4.1; set 3) with which DNA ligase I could be amplified separately 
as an N-terminal fragment (0.75 kb) and a C-terminal fragment (2.1 kb). 
 
Only the N-terminal region of the gene (0.75 kb; Figure 4.1) could be successfully 
amplified while the C-terminal region failed to amplify even after trying all available 
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cDNA libraries as the template and varying the primer annealing temperatures using 
gradient PCR over a 20
o
C range.  
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Figure 4.1: Amplification of N-terminal of Human DNA ligase I 
A PCR reaction performed for 30 cycles, consisting of 95
o
C denaturation for 1 minute, 55
o
C annealing 
and 72
o
C extension for 1 minute, using primers (Table 4.1; set 3) designed to amplify from 35-774 bp 
of the N-terminal region of the HuLigI gene. The resultant PCR product was analysed by 0.7% agarose 
gel electrophoresis stained with ethidium bromide and viewed under UV illumination. Lane 1: 1kb 
ladder molecular weight marker; Lanes 2 & 3: 0.75 kb N-terminal PCR product. 
 
Different components of the PCR reaction that can effect the amplification reaction 
were addressed separately. The role of Mg
2+
 in PCR is to promote DNA/DNA 
interactions and form complexes with dNTPs (Eckert & Kunkel, 1991). The total 
Mg
2+
 concentration (usually 1.5 mM) used in the PCR reaction must exceed the total 
dNTP concentration so that after forming complexes with dNTPs, free magnesium 
ions are available to serve as an enzyme cofactor for the DNA polymerase. At the 
same time, too high a concentration of Mg
2+
 results in strong base pairing such that 
very high temperature (≥94oC) is required to denature the double helical structure of 
DNA (Eckert & Kunkel, 1991). The MgCl2 concentration was varied from 0.5-8 mM 
in PCR reactions and different DNA polymerases ranging from the widely used Taq 
DNA polymerase to proof-reading Pfu DNA polymerase and high fidelity Phusion 
DNA polymerase failed to amplify the full-length or C-terminal region of HuLigI. A 
PCR reaction was also tried in the presence of dimethylsulfoxide (DMSO). The use of 
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such solvents helps increase the yield, efficacy, and specificity of PCR amplifications 
by effectively lowering the melting and strand separation temperatures (Eckert & 
Kunkel, 1991). Several independent PCR reactions tried with increased template 
concentration failed to amplify the full-length ORF of HuLigI. 
 
The amplification of a PCR product clearly also depends on the presence of the 
mRNA of the gene in the corresponding cDNA library. We designed new primers 
(Table 4.1; set 5) that would amplify a region from 2186-2348 bp of the HuLigI 
mRNA to check expression of the C-terminal region in the various cDNA libraries 
used as templates. Figure 4.2 shows that a PCR product corresponding to ~200 bp was 
obtained with all the different template reactions, although, the intensity of the 
product formed varied with the source of cDNA. The size of the product (200 bp) was 
bigger compared to expected size (162 bp) and there is no clear rationale for this 
discrepency. 
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Figure 4.2: Amplification of a C-terminal region of HuLigI using various 
cDNA libraries as a template.   
Expression of mRNA corresponding to the C-terminal region of HuLigI in cDNA libraries obtained 
from different sources was checked by performing a PCR reaction for 30 cycles consisting of 1 minute 
denaturation at 95
o
C, 1 minute annealing at 55
o
C and 30 seconds extension at 72
o
C. Reactions were 
performed using a set of primers specific for the 2186-2348 bp region of the full-length HuLigI. Lane 
1: 50 bp step ladder molecular weight marker; Lane 2: cDNA obtained from HT-29 cells used as 
template; Lane 3: commercially obtained pancreatic cDNA library used as template; Lane 4: cDNA 
obtained from MDA MB-435 cells used as a template in amplification reaction.  
 
In order to obtain a full-length polypeptide of the HuLigI a source of the mature, full-
length ligase I gene was required. A shuttle vector containing a cDNA clone of 
HuLigI was obtained from Gene Services Ltd., Cambridge.  The vector contained the 
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genomic region for HuLigI and this allowed the use of better quality DNA in greater 
abundance in the amplification reaction as compared to the cDNA obtained from 
different cell lines.   
 
The primers complementary to the 5‟ and 3‟ ends of the coding region of HuLigI 
incorporating Xho I restriction sites at both ends of the gene allowing cloning into the 
pET-16b expression vector were employed (sequence given above in section 4.2.1). 
PCR was performed for 20 cycles (consisting of 1 minute at 94
o
C, 1 minute at 55
o
C 
and 3 minutes at 72
o
C) after initial denaturation at 95
o
C for 2 minutes. This time the 
PCR was successful. An amplified PCR product of ~3 kb was obtained (Figure 4.3; 
panel A). The PCR product was gel purified, digested with Xho I restriction enzyme 
and ligated into Xho I digested CIP treated pET-16b expression vector. The ligation 
reaction was transformed into electro competent E. coli (DH5α) cells. 
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Figure 4.3: PCR cloning of the full-length ORF encoding HuLigI 
The pCMV-SPORT6 vector harbouring the cDNA of HuLigI was used as a template in a PCR reaction 
to amplify the coding region of the human ligase. The reaction was performed for 20 cycles consisting 
of 1 minute at 94
o
C, 1 minute at 55
o
C and 3 minutes at 72
o
C and products were analysed on a 0.7% 
agarose gel, stained with ethidium bromide and viewed under UV illumination as shown in panel A. 
Lane 1: 1kb DNA ladder molecular weight markers (Promega); Lane 2: Negative control (only 
template); Lane 3: product of amplification reaction. 
Panel B: The gel purified PCR product was digested with Xho I and ligated into Xho I digested and CIP 
treated pET-16b expression vector and the success of the insertion was confirmed by restriction with 
Xho I. Lane 1: 1 kb DNA ladder molecular weight markers (Promega); Lane 2: Insert release 
(corresponding to 2759 bp of HuLigI) & linearised pET-16b vector; Lane 3: Uncut plasmid before 
digestion with Xho I. 
 
 
Some of the transformed colonies were randomly chosen and screened for the 
presence of the appropriate clone. Figure 4.3 (panel B) shows the insert release after 
the restriction digest of one of these plasmids. The clones that were positive for insert 
were sequenced to confirm that no changes had been introduced during the PCR 
procedure. An accurate, fully sequenced clone was then used to study expression of 
full-length human DNA ligase. The initial expression of HuLigI carried out in E. coli 
BL21(DE3) cells, induced for 3 hours with 0.4 mM IPTG at 37
o
 C, failed to give a 
146 
 
visible band at 102 kDa (Figure 4.4). This could be due to poor yield of the protein 
associated with its high molecular weight. The expression conditions were varied by 
changing IPTG concentration from 0.4 mM to 0.8 and 1 mM, and independently 
increasing the induction time period from 3 hours at 37
o 
C to 18 hours at 18
o
C with 
the various IPTG concentrations. The change in the induction conditions failed to 
improve the expression of the protein.  
 
Several attempts were made by varying all the possible parameters to improve the 
expression of the full-length protein including change of growth media from LB to 
richer 2YT media (twice the amount of yeast and tryptone as of LB media). Kane 
(1995) suggests that if the gene of interest contains codons not commonly used in E. 
coli, low expression may result due to depletion of tRNAs for the rare codon. This is 
more concerning when the sequence encodes a protein >60 kDa or when rare codons 
are found at high frequency or multiple rare codons are found over a short distance of 
the coding sequence. We looked at rare codon usage in HuLigI and found that HuLigI 
gene encodes for 12 rare arginine (AGG, AGA and CGA) and 14 rare proline (CCC) 
codons. Moreover, rare codons for arginine (AGG, AGA) were found in tandem at 
different positions (185, 575, 745, 878, 1019, 1765 and 2051 base pairs). Such 
sequences can create a recognition sequence for ribosome binding (such as –
AGGAGG) that closely approximates a Shine-Dalgarno sequence (UAAGGAGG). 
The Shine-Dalgarno sequence helps recruit the ribosome to the mRNA to initiate 
protein synthesis by aligning it with the start codon. This AGGAGG sequence may 
bind ribosomes non-productively and block translation from the functional ribosome 
binding site at the initiator codon (Kane, 1995). One such rare arginine codon is 
present next to the initiation codon (ATG) in HuLigI. Chen & Inouye (1990) have 
shown that the number and the position of the arginine codons in an mRNA play an 
important role in modulating gene expression at the level of translation. The presence 
of rare arginine codons in a close proximity to the initiation codon exhibit severe 
negative effects on the expression of that gene (Chen & Inouye, 1990).  
 
Based on these observations we decided to change the host strain to E. coli 
BL21(DE3)RP, which contains a plasmid that encodes copies of the rare arginine and 
proline tRNA genes and is able to rescue expression of genes restricted by either 
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AGG/AGA codons or CCC codons. Various attempts were made to improve the 
expression of HuLigI in E. coli BL21(DE3)RP cells, including varying inducer 
concentration from 0.2-0.4 mM and opting for longer hours of induction (24 or 48 
hours) at 16
o
C or 20
o
C.  All of these experiments were largely unsuccessful with no 
production of significant amounts of appropriately sized, recombinant protein. A 
typical profile for expression of the full-length HuligI is shown in Figure 4.4. Whilst a 
number of proteins appear to be bound to the column (being released by the 300 mM 
imidazole wash) none compared to the predicted weight of HuligI (101.7 kDa).  These 
may reflect proteolytic breakdown products of the full-length ligase or E. coli proteins 
that have been able to bind in the absence of an over-expressed His-tagged protein 
(Figure 4.4).  
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Figure 4.4: Analysis of recombinant HuLigI using Ni-NTA 
chromatography 
The pET-16b plasmid containing full-length human DNA ligase was transformed into E. coli 
BL21(DE3)RP. Cultures were grown and induced with 0.4 mM IPTG for three hours at 37
o
C. The 
lysed, soluble extract was applied to Ni-NTA resin and eluted with buffer A (50 mM Tris-HCl pH 7.5, 
300 mM NaCl and 10% glycerol) containing 300 mM imidazole. The polypeptide composition was 
analysed by SDS-PAGE (10% resolving gel). Lane 1 contained Bio-Rad precision plus prestained 
molecular weight marker proteins (sizes shown in kilodaltons); Lane 2: cell pellet; Lane 3: Flow 
through collected from column after loading the soluble fraction; Lane 4: wash with buffer A 
containing 25 mM imidazole; Lane 5: elution with buffer A containing 300 mM imidazole. 
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The sensitivity of SDS PAGE (50 ng/band) is much less than the sensitivity of 
Western blotting (1 ng/band). Therefore, it was decided to probe uninduced and 
induced soluble and insoluble fractions with anti-His antibody to check whether we 
were getting even minimal expression (Figure 4.5). We further hoped that if any of 
the polypeptide species that bound to the Ni-NTA resin derived from the N-terminus 
of the expressed full-length human enzyme that these too would be detected by the 
western blot. No detectable signal was observed corresponding to a protein species of 
molecular weight 102 kDa (without taking account of the additional 2kDa as a result 
of the His-tag), the expected size of full-length HuLigI. The presence of lower 
molecular weight species (very faintly staining bands at ~80, 62 and 45 kDa) could be 
due to cross-reaction artefacts from host cell proteins. A number of native E. coli 
proteins have been identified, which are over-expressed in response to cellular stress, 
for example the 29 kDa E. coli protein SlyD is histidine-rich and is a common 
contaminant following over-expression of recombinant proteins in E. coli (Bolanas-
Garcia & Davies, 2006). The presence of the 80, 62 and 45 kDa species in both the 
induced and uninduced samples suggests that these species are not derived from the 
expression of human HuligI. The presence of a unique ~42 kDa species in the induced 
insoluble fraction (Figure 4.5) may represent a degraded product from the expression 
of the full-length HuLigI enzyme.  
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Figure 4.5: Western blot analysis with anti-his antibody of proteins 
expressed in E. coli cells harbouring a plasmid expressing full-length 
HuLigI 
Soluble and insoluble extracts from cells grown in the presence or absence of IPTG were prepared in 
reducing sample buffer and separated by SDS-PAGE. Proteins were then transferred to a nylon 
membrane and incubated with anti-his antibody. Lane 1 shows the position of broad range molecular 
weight markers (kilo Daltons determined by staining the membrane with Ponceau-S), Lane 2 is a 
sample of soluble protein from uninduced E. coli cultures harbouring the HuligI plasmid and lanes 3 & 
4 are the soluble and insoluble sample obtained after 3 hour induction with 0.5 mM IPTG.   
 
 
After varying all the possible parameters, full-length HuligI protein was not expressed 
in detectable levels. This might be due to its size, full-length HuLigI is 102 kDa as 
compared to the well-expressed 34 kDa PBCV-1 DNA ligase. A low yield of pure 
protein production has always been the main obstacle in studying this enzyme 
recombinantly. Similar results with expression of full-length HuLigI have been 
reported by Kodama et al. (1991) and they concluded that this was probably due to 
degradation of the recombinant enzyme by E. coli encoded proteases (Kodama et al., 
1991). Harcum & Bentley (1992) reported enhanced protease activity in E. coli cells 
in a response to over-expression of recombinant proteins, for example, induction of 
recombinant chloramphenicol acetyltransferase (CAT) increased intracellular protease 
activity and triggered stress responses. Kodama et al. (1991) observed that a truncated 
HuLigI (250-919 amino acids) is the optimal size for expression of the HuLigI protein 
in E. coli. This truncated version of HuLigI polypeptide was found to be catalytically 
active in vitro and in vivo, shown by complementation assays (Kodama et al., 1991). 
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4.3.2 Purification of ∆232 HuLigI 
 
Since Kodama et al. (1999) had defined an optimum size for the function of human 
DNA ligase I in E. coli; truncated HuLigI has been studied in place of the full-length 
protein. When this work was in progress, Pascal et al. (2004) solved the structure of a 
similarly truncated HuLigI (232-919 amino acid) bound to adenylated DNA. This 
structure, for the first time, revealed the role of the HuligI N-terminal DNA binding 
domain which stabilises and encircles the nicked DNA substrate in coordination with 
the adenylation and oligomer binding domains (Pascal et al., 2004). 
 
After numerous attempts to express full-length HuLigI, the plasmid pET-28a 
harbouring a truncated HuLigI [232-919 amino acid; used for structural studies by 
Pascal et al. (2004)] was obtained from Professor T. Ellenberger (Washington 
University, USA). The structure of ∆232 HuLigI has been solved in complex with 
DNA and furthermore the authors had shown that the truncated enzyme was active as 
a ligase in in vitro sealing assays (Pascal et al., 2004). We knew therefore that the 
enzyme could function as a model both for enzyme binding inhibition and for 
catalytic inhibition and furthermore the conditions for the expression and purification 
of this construct were well documented. The pET-28a plasmid was transformed into 
E. coli BL21(DE3) cells to over-express the N-terminal His-tagged protein. The 
soluble fraction containing the protein of interest was applied to Ni-NTA resin and the 
protein was eluted with buffer A (50 mM Tris-HCl pH 7.5, 10% glycerol and 300 mM 
NaCl) containing 250 mM imidazole (Figure 4.6, panel A). The electrophoresis made 
estimation of the molecular weight difficult, of the predominant protein species 
retained on the nickel resin. We decided to proceed with the purification and make a 
better estimate of the size when the protein was more pure. The eluted fractions were 
pooled, diluted to 25 mM NaCl with buffer B (50 mM Tris-HCl pH 7.5, 10% 
glycerol, 5 mM DTT and 25 mM NaCl) and applied to Q-sepharose (anion exchange 
resin with a quaternary amine exchange group). A prominent polypeptide of ~80 kDa 
was recovered during step elution from Q-sepharose in a fraction containing 0.2 M 
NaCl (Figure 4.6, panel B), as judged by the SDS gel electrophoresis. The molecular 
weight of the ∆232 HuLigI recombinant truncated protein was estimated to be 78.2 
kDa on the basis of the amino acid sequence with the inclusion of the histidine tag. 
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The 0.2 M NaCl fraction containing purified ∆232 HuLigI was then dialysed 
extensively against buffer B containing 100 mM NaCl and stored at -80
o 
C for use in 
further assays. 
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Figure 4.6: Elution profile and ligation activity of ∆232 HuLigI  
The pET-28a plasmid bearing ∆232 HuLigI was expressed in E. coli BL21(DE3) cells by induction 
with 0.4 mM IPTG for two hours at 37
o
C. The lysed, soluble extract was chromatographed on Ni-NTA 
resin, aliquots were analysed by 12% SDS-PAGE stained with Coomassie Brilliant blue. Panel A - 
Lane 1: Bio-Rad Precision Plus All Blue pre-stained molecular weight marker (size of the molecular 
weight of marker proteins are shown to the left of the gel); Lane 2: flow through; Lane 3: wash fraction 
(50 mM Tris-HCl pH 7.5, 300 mM NaCl, 25 mM imidazole and 10% glycerol); Lane 4: elution 
fraction (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 300 mM imidazole 10% glycerol). 
The protein peaks eluted from Ni-NTA agarose were diluted to 25 mM NaCl and applied to Q-
sepharose and eluted along an NaCl gradient (NaCl in buffer B: 50 mM Tris-HCl pH 7.5, 5.0 mM 
DTT, 10% glycerol). The elution profile is analysed in panel B. Lane 1: Bio-Rad Precision Plus All 
Blue pre-stained molecular weight marker; Lane 2: wash (50 mM NaCl in buffer B), Lanes 3 & 4: 0.1 
M NaCl in buffer B; Lane 5: 0.2 M NaCl in buffer B. 
Purified ∆232 HuLigI was used to ligate Hind III digested  DNA in ligation buffer (containing 50 mM 
Tris-HCl pH 7.5, 10 mM MgCl
2
, 10 mM dithiothreitol, 1 mM ATP and 25 mg/ml bovine serum 
albumin). The ligation reaction products were analysed by 0.8% agarose gel (panel C), stained with 
ethidium bromide and viewed under UV illuminator. Lane 1 contains Hind III digested λ DNA; Lane 2 
contains ligation reaction product when carried out in the presence of ∆232 HuLigI. 
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To verify that the purified human protein had retained activity during the purification 
we incubated the enzyme with  DNA digested with Hind III (as described in section 
4.2.4; Figure 4.6; panel C). From the alteration in the migration of these cohesive 
fragments we determined that the truncated human enzyme retained DNA ligation 
activity.   
 
4.3.3 Purification of PBCV-1 DNA ligase 
 
All ATP-dependent DNA ligases, including the PBCV-1 DNA ligase, that of TV and 
the human DNA ligases, share six motifs that are in large part responsible for the 
enzyme catalytic core (Odell et al., 2000). Using the known 3-dimensional structures 
of these enzymes it is possible to superimpose the key catalytic residues that contact 
the ATP co-factor (Figure 1.8; panel B). PBCV-1 DNA ligase, the smallest 
characterised eukaryotic DNA ligase, is regarded as the minimal catalytic unit present 
in all ligases, such that anything that applies to this enzyme will apply to the larger 
ligases (Odell et al., 2003). This is the only ligase with its structure analysed for both 
DNA bound and unbound adenylated states, providing instructive insights into the  
mechanism of DNA ligation and conformational changes that occur upon DNA 
binding (Odell et al., 2000; Odell et al., 2003; Nair et al., 2007). The fact that the 
recombinant PBCV-1 ligase is expressed and purified easily in high yield from E. coli 
makes it a useful tool to screen for inhibitors of larger DNA ligases that are more 
difficult to express in large quantities and whose behaviour has not been so closely 
studied. Hence it was our initial intention to use this enzyme as a first screen to 
identify ligase catalytic inhibitors. Once a potential candidate compound had been 
identified it could then be tested for its activity against the purified target ligase 
enzymes such as the TV or HuLigI.   
 
The 34 kDa PBCV-1 DNA ligase encoded on a pET-16b vector was obtained from 
Professor Stewart Shuman (Sloan-Kettering, New York), then transformed and 
expressed in E. coli BL21(DE3) under the inducible control of a T7 promoter as 
previously reported (Ho et al., 1997). The PBCV-1 enzyme was purified from a 
soluble bacterial extract via affinity chromatography from Ni-NTA resin. The protein 
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was eluted in buffer A (50 mM Tris-HCl pH 7.5, 10% glycerol and 300 mM NaCl) 
containing 300 mM imidazole. A significantly over-expressed polypeptide species 
with an apparent molecular weight of 40 kDa elutes from the column as analysed by 
SDS-PAGE (Figure 4.7, panel A). Although PBCV-1 DNA ligase is a 34 kDa 
polypeptide, it migrates unusually slowly on SDS-PAGE as has been previously noted 
(Odell et al., 1999). The peak protein fractions eluted from Ni-NTA resin were diluted 
to 50 mM NaCl with buffer B (50 mM Tris-HCl pH 7.5, 5.0 mM DTT and 10% 
glycerol) and applied to an S-sepharose column pre-equilibrated with buffer B. The 
protein was step-eluted along an NaCl gradient (0.1–1.0 M NaCl in 50 mM Tris-HCl 
pH 7.5, 5 mM DTT and 10% glycerol) and the protein elution profile analysed by 
SDS-PAGE (Figure 4.7, panel B). The analysis of the peak fractions from S-
sepharose chromatography showed that apparently homogenous PBCV-1 DNA ligase 
elutes at 0.2 M NaCl (Figure 4.7, panel B).  Approximately 5 mg of wild type PBCV-
1 DNA ligase was obtained per litre of culture as estimated by a Bradford protein 
assay (Sigma) using BSA as a standard (standard curve attached in the appendix 7.4). 
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 Figure 4.7: Chromatography profile of PBCV-1 DNA ligase over Ni-NTA 
and S-sepharose resins    
The pET-16b plasmid bearing PBCV-1 DNA ligase was transformed into E. coli BL21(DE3) cells, 
grown overnight in LB media. The overnight culture was diluted 1 in 100 into fresh LB media and 
grown at 37
o
C until A595 reached 0.4-0.5. The cells were adjusted to a final concentration of 0.4 mM 
IPTG and incubated at 37
o
C for 2 hours. The soluble protein was applied to Ni-NTA resin, aliquots 
were analysed by 12% SDS-PAGE stained with Coomassie Brilliant Blue. Panel A, Lane 1: Bio-Rad 
Precision Plus All Blue pre-stained molecular weight marker (molecular weight of marker proteins are 
shown to the left of the gel); Lane 2: flow through; Lane 3: wash fraction (50 mM Tris-HCl pH 7.5, 
300 mM NaCl, 30 mM imidazole); Lanes 4-6: elution fractions (50 mM Tris-HCl pH 7.5, 300 mM 
NaCl, 300 mM imidazole).  
The protein peaks eluted from Ni-NTA agarose were diluted to 50 mM NaCl and applied to S-
sepharose and eluted along an NaCl gradient (50 mM - 0.2 M NaCl) in buffer B (50 mM Tris-HCl pH 
7.5, 5.0 mM DTT, 10% glycerol). The elution profile is analysed in panel B. Lane 1: Bio-Rad Precision 
Plus All Blue pre-stained molecular weight marker; Lane 2: flow through; Lane 3: wash (50 mM NaCl 
in buffer B); Lane 4: 0.2 M NaCl in buffer B.  
 
4.4 Discussion 
 
An increased repair of drug-induced DNA damage is an important mechanism of 
chemotherapy resistance in many human tumours (Madhusudan & Hickson, 2005). 
Several reports suggest that inhibiting the activity of major components of DNA 
damage repair pathways such as Poly(ADP-ribose)polymerase 1 (PARP 1) and 
replication protein A (RPA) could potentially circumvent resistance to certain 
chemotherapeutic agents (Andrews & Turchi, 2004; Curtin et al., 2004). PARP is a 
zinc-finger DNA binding enzyme that is activated by binding to DNA breaks. DNA 
damage is converted into intracellular signals via poly(ADP)-ribosylation of nuclear 
proteins which activates DNA repair by the base excision repair pathway (BER; 
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Curtin et al., 2004). PARP inhibitors (such as NU1025) have been shown to enhance 
the anti-tumour activity of temozolomide (a DNA methylating agent) and are now 
under clinical evaluation (Madhusudan & Hickson, 2005). The type of DNA damages 
caused by the various drugs used in chemotherapy and the corresponding repair 
mechanism triggered as a part of cell response to fix these damages are summarised in 
figure 4.8. NHEJ, BER and NER are some of the principal repair pathways, which, 
ultimately converge on a common terminal step in restoring the continuity of the 
repaired DNA strand by DNA ligases.   
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Figure 4.8: DNA damage induced by anti-tumour agents and the various 
pathways involved in repairing such lesions 
 
Interferring with human DNA ligase‟s ability to bind DNA, ultimately interfering 
with DNA repair and replication, could potentiate DNA damage induced by other 
agents and also prevent the uncontrolled cell division that characterises cancer 
pathology. 
 
Several lines of evidence suggest that proliferating cells contain a substantially higher 
level of DNA ligase I than other non-dividing or resting cells. Such a correlation does 
not exist for DNA ligases III and IV (Signoret & David 1986, Montecucco et al., 
156 
 
1992; Sun et al., 2001). Sun et al. (2002) suggested that an increase in expression of 
DNA ligase I in a human pancreatic cell line after exposure to cisplastin, an 
anticancer agent, might be required for aiding the cells to recover from DNA damage 
as a result of the cisplatin treatment by facilitating the repair process.  
 
Other work by the same group, Sun et al. (2001) has shown that DNA ligase I in 
human tumours is present at higher levels than in normal tissues and normal 
peripheral lymphocytes. In their studies, using the HT-29 cell line (a metastatic 
colorectal cancer cell line) to investigate the kinetics of DNA ligase I expression, they 
showed that expression appeared constitutive and increased with the size of the 
tumour.  Since, the HT-29 cell line is known to express high levels of DNA ligase I, it 
was used to construct a cDNA library from which we attempted unsuccessfully to 
isolate a HuLigI clone. 
 
The amplification of DNA by PCR is dependent on a number of variables including 
the source of DNA template, primers, annealing temperature and concentration of 
MgCl2 used in the reaction. All these variables were extensively analysed but failed to 
allow the production of a full-length HuLigI clone. HT-29 cell lines are known to 
have high level expression of HuLigI but cDNA obtained from these cell lines failed 
to amplify either the C-terminus or full-length HuLigI. Teraoka et al. (1993) 
constructed a recombinant plasmid, pTD-T7N, for expression of full-length HuLigI 
by separately amplifying the N-terminal region (0.7 kb) and the C-terminal region 
(2.1 kb) of the gene. We attempted to clone the same HuLigI enzyme fragments from 
cDNA obtained from the HT-29 cell line and two other cDNA libraries using the 
same primers (set 3 & 4, table 4.2) as those published by Teraoka et al. (1993), 
however no PCR reaction was successful for the C-terminal PCR product (2.1 kb). 
The N-terminal region of the gene (750 bp) was, however, successfully amplified. 
The cell lines used in this study were available in-house but we considered that the 
expression of the HuLigI gene in this passage of the cell line might have been 
different to that of the previous study. We therefore probed for the presence of mRNA 
showing expression of the HuLigI C-terminus in the cDNA library by performing a 
PCR amplification of a region (Figure 4.3; primer set 5) corresponding to 200 base 
pairs this region of the gene. Two different cDNA libraries; pancreatic cDNA library 
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(Invitrogen) and cDNA obtained from MDA MB-435 (a breast carcinoma cell line), 
were also used as a template in the control reaction. The PCR product was obtained 
with all the three templates, however, none of them yielded the 2.1 kb sized C-
terminal product. Despite trying the PCR under several conditions, amplification of 
full-length or the remaining C-terminal region of the gene was unsuccessful. The 
primers used for the PCR reaction were same as published by Teraoka et al. (1993), 
and furthermore we used the same cell line which suggested to us that an alternate 
splicing of the ligase was not responsible for the PCR failure.  Possible reasons for the 
failure to amplify the gene could be our cDNA template, though the success of the C-
terminal fragment and the N-terminal amplification argue against this. 
 
Because of the PCR difficulties a full-length cDNA clone of the HuLigI, mRNA 
sequence from nucleotide 1 through to the poly (A) tail in a shuttle vector pCMV-
SPORT6 was purchased from Gene Services Ltd, Cambridge. The coding region of 
the gene (421-3180) was amplified using this plasmid. The amplified product was 
ligated into the pET-16b expression vector and the sequence of the clone obtained 
was confirmed by sequencing. 
 
The initial expression studies of full-length HuLigI were performed using the E. coli 
BL21(DE3) strain. The recombinant protein failed to express under these conditions. 
Expression of heterologous proteins depends on various parameters such as induction 
conditions, host strain, growth temperature and media etc.  All these above mentioned 
factors, which could affect the expression of full-length HuLigI, were addressed 
separately to optimise conditions for expression of the protein. Efficient production of 
heterologous proteins in E. coli can also be limited by the use of tRNAs by the human 
protein that are either absent or are less common in E. coli (Kane, 1995). The HuLigI 
nucleotide sequence encodes for 12 rare arginine (AGG, AGA and CGA) codons and 
14 rare proline (CCC) codons. One of the rare arginine (AGG) codon is present in 
close proximity to start codon, methionine (ATG). This codon-bias could be the main 
obstacle in the expression of difficult target proteins as previously described by Cheng 
& Inouye (1990). In order to circumvent this problem the E. coli strain, 
BL21(DE3)RP, was used for expression studies which expresses the rare tRNAs from 
additional plasmid copies of the arginine and the proline tRNA genes. Unfortunately, 
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the use of this different E. coli host strain failed to improve the expression of full-
length HuLigI. It was not possible to demonstrate significant expression of full-length 
HuLigI in these E. coli cells, after varying different growth and induction parameters. 
 
Sequence comparisons of eukaryotic DNA ligases have suggested that a catalytic 
domain, common to all ATP-dependent ligases, is embellished by additional specific 
protein segments situated at their amino or carboxyl termini (Odell & Shuman, 1999). 
These protein segments are not essential for catalysis such as in HuLigI, which 
retained activity after removal of 249 amino acids from the N-terminus and 16 amino 
acids from the C-terminus (Kodama et al., 1991). Further deletions of HuLigI resulted 
in loss of function, so it is understood that the 654 amino acid segment of ligase I 
represents the catalytic core (Kodama et al., 1991). During the progress of this work, 
Pascal et al. (2004) published the crystal structure of truncated version of HuLigI 
(232-919 amino acids) bound to adenylated DNA. This confirmed that the small 
truncated version of HuLigI is stable and functional enzyme with required catalytic 
domains.  
 
We decided to use a truncated version of HuLigI in our screening assays. The ∆232 
HuLigI (232-919 aa) has been well studied and shown to not only catalyse DNA nick-
sealing but also to bind stably to DNA (Pascal et al., 2004). The ∆232 HuLigI has the 
ligase DNA binding domain, required to encircle the substrate in cooperation with the 
catalytic domain consisting of the adenylation and OB-fold domains. This construct 
was used to express a truncated version of HuLigI, which was purified to near 
homogeneity after two chromatography steps. DNA ligation assays confirmed the 
earlier reports that this fragment retained DNA sealing capability. 
 
The 298 amino acid PBCV-1 DNA ligase is the smallest characterised eukaryotic 
DNA ligase containing all six motifs that characterise the nucleotidyltransferase 
superfamily to which DNA ligases belong. It contains no additional amino acid 
sequences downstream of motif VI, which is located at its extreme C-terminus and 
only 26 amino acids N-terminal of the active site (lysine 27) within motif I (Odell & 
Shuman, 1999). Cellular DNA ligases are much larger, for example, human ligases I, 
III and IV are 919, 922 and 844 amino acid polypeptides respectively whereas at 34 
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kDa, PBCV-1 DNA ligase is the smallest and most well researched eukaryotic DNA 
ligase. This size makes it an attractive choice to use as a paradigm for all ATP-
dependent enzymes. Structural comparison of HuligI and PBCV-1 DNA ligase reveal 
that the adenylation (AdD) and oligomer binding (OB) domains adopt similar 
conformations while the DNA binding domain of HuLigI and β-hairpin latch of 
PBCV-1 DNA ligase occupies almost the same angular position when docked on the 
nicked DNA substrate (Shuman, 2009). This suggested that PBCV-1 would be a 
useful representative of ATP-dependent DNA ligases for the large volume, high-
throughput screening step of our in vitro assays. The small size of the PBCV-1 
enzyme and lack of rare codons made it an ideal candidate for high-level expression.   
 
The recombinant PBCV-1 DNA ligase was expressed from the plasmid pET-16b, a 
construct that adds a ten histidine, amino acid tag to the amino terminus of the mature 
recombinant polypeptide. This enabled the use of Ni-NTA resin (that has affinity for 
multiple histidine residues) to purify recombinant His-tagged PBCV-1. Although this 
step helped remove many contaminating polypeptides some low molecular weight 
contaminating polypeptides were still retained in the protein sample. These additional 
protein species may have been due to cleavage of the PBCV-1 ligase by cellular 
proteases during protein synthesis; some of the cleavage products retaining the 
histidine tag would thus co-purify with the full-length ligase during Ni-NTA 
chromatography. For use in an enzyme-based inhibitor assay further processing of the 
enzyme preparation was needed, therefore the protein was further purified, to near 
homogeneity, using S-sepharose ion-exchange resin.  
 
In recent years the essential NAD
+
-dependent DNA ligases of eubacteria have been 
proposed and are under development as potential antibacterial targets on the basis of 
their cofactor requirement and sequence differences between these enzymes and their 
eukaryotic host (Brotz-Oesterhelt et al., 2003; Srivastava et al., 2005). These 
differences include an absence of motif VI in the OB domain of the catalytic core of 
NAD
+
-dependent DNA ligases and different accessory domains extending from the 
catalytic core of these ligases (Wilkinson & Bowater, 2001; Sriskanda & Shuman, 
2002). However, in addition to NAD
+
-dependent DNA ligases, some bacteria also 
encode for ATP-dependent DNA ligases; for instance, Mycobacterium tuberculosis 
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codes for three different such enzymes: LigB, LigC and LigD in addition to an NAD
+
-
dependent ligase, LigA (Gong et al., 2004) whereas Bacillus subtilis harbours two 
ATP-dependent ligases  (YkoU and YoqV) and an essential NAD
+
-dependent ligase 
(YerG). All three ATP-dependent ligases of M. tuberculosis were found to be capable 
of nick-sealing, although their catalytic efficiency was lower than that of LigA (Gong 
et al., 2004). Neither LigB, LigC or LigD are essential for Mycobacterial growth, 
although deletion of LigD renders the bacteria defective in NHEJ (Gong et al., 2004). 
The crystal structure of M. tuberculosis LigD has been solved. The enzyme is 
composed of a basic DNA ligase catalytic core (AdD and OB domain), equivalent to 
that of the PBCV-1 ligase, fused to a polymerase and phosphoesterase module (Akey 
et al., 2006). LigD functions in NHEJ, but unlike PBCV-1 ligase, is inefficient at in 
vitro nick joining and is unable, alone, to sustain cell viability in yeast or M. 
tuberculosis cells (Gong et al., 2004; Akey et al., 2006).  
 
Cheng & Shuman (1997) identified and characterised a 31 kDa (268 amino acids) 
ATP dependent DNA ligase from Haemophilus influenzae. It was referred to as URF1 
before its characterisation as an ATP-dependent ligase, and its deletion had lethal 
effects on the organism; suggesting that the ATP-dependent ligase is critical for H. 
influenzae cell growth (Cheng & Shuman, 1997). The H. influenzae enzyme at 31 kDa 
is markedly smaller than the multi-domain ligase proteins found in Mycobacteria, 
possessing only a nucleotide binding domain and an OB-fold domain.  The PBCV-1 
enzyme also lacks the DNA binding domain of the larger cellular enzymes and has 
been shown to bind to DNA by a different mechanism involving a short nucleotide 
loop (Nair et al., 2007). We searched for other small ATP-dependent DNA ligases, in 
size comparable to PBCV-1 DNA ligase, to identify the type of organisms that have 
such a DNA ligase. BLAST searches of the NCBI database, performed using PBCV-1 
DNA ligase protein as the query sequence, revealed that PBCV-1 shared sequence 
similarity with a number of other small, putative ATP-dependent DNA ligases (all 
between 30 and 40 kDa in size). It was interesting to note that most of the protein 
sequences of the small, ATP-dependent DNA ligases homologous to PBCV-1 DNA 
ligase, were encoded by bacteria including many pathogenic organisms for example 
Vibrio cholerae, Haemophilus influenzae, Burkholderia pseudomallei and Neisseria 
meningitidis (Figure 4.9, panel A). Many of these enzymes are uncharacterised except 
161 
 
those of Haemophilus influenza (31 kDa) and Neisseria meningitides (31.5 kDa) 
which have been studied and confirmed to catalyse DNA end-joining, and are thus 
functional ligases (Cheng & Shuman, 1997; Magnet & Blanchard, 2004). Sequence 
alignment of these proteins suggests that they share the same catalytic core and 
conserved motifs as PBCV-1 ligase. It was noted from the sequence alignment of 
PBCV-1 DNA ligase and other small ATP-dependent ligases that the region 
homologous to the essential DNA binding surface loop („latch‟) motif present in the 
PBCV-1 ligase (Figure 4.9, highlighted in orange) is truncated in most of these 
enzymes except the 306 amino acid DNA ligase from Burkholderia pseudomallei. A 
gram negative bacterium B. pseudomallei is the causative agent of melioidosis; a fatal 
disease causing an acute pneumonia or acute septicaemia. The organism is resistant to 
a number of antibiotics thereby creating a need for the development of other 
therapeutic strategies, including the identification of novel therapeutic targets 
(O'Carroll et al., 2003). The use of the PBCV-1 enzyme in the assay will hopefully 
provide information on compounds that can have inhibitory effects on smaller ligases 
but particularly the B. pseudomallei enzyme where the enzyme retains an almost 
identical DNA binding loop to the PBCV-1 enzyme. 
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Figure 4.9: Sequence and structural comparison of PBCV-1 DNA ligase 
with a selection of small ATP-dependent ligases and structure of the DNA 
binding loop 
Panel A shows a ClustalW alignment analysis (Chenna et al., 2003) of PBCV-1 ligase with a selection 
of ATP-dependent DNA ligases from bacteria, with their accession number indicated in brackets - 
Haemophilus influenzae (Haemophilus; YP_001290961), Aggregatibacter aphrophilus 
(Aggregatibcater; YP_003007537), Neisseria meningitidis (Neisseria; AAQ72358), Vibrio cholerae 
(Vibrio; ZP_04418809) and Burkholderia pseudomallei (Burkholderia; YP_333052). Completely 
conserved residues are shown in green, identical residues in yellow and similar residues are shown in 
cyan. The position of conserved motifs I- VI is shown with a black bar underneath. The residues that 
make up the surface loop „latch‟ in PBCV-1 and Burkholderia pseudomallei ligase are highlighted in 
orange. Panel B shows the ribbon structure of PBCV-1 DNA ligase (PDB: 2QT), highlighting in 
orange the residues in the latch region which are absent from the sequences of the other putative DNA 
ligases except Burkholderia pseudomallei in panel A. The figure was prepared using Pymol (Delano, 
2002).  
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B. pseudomalleus encodes for a 75.6 kDa NAD
+
-dependent DNA ligase, homologous 
to that of E. coli (LigA; accession number: Q3JR23-1). Although the exact function of 
the ATP-dependent DNA ligase in B. pseudomallei is not known, previous studies 
suggest that ATP-dependent DNA ligases in bacteria are not required for DNA 
replication but participate in DNA repair pathways (Gong et al., 2004; Korycka-
Machala et al., 2005). Weller et al. (2002) observed that deletion of the ATP-
dependent DNA ligase (YkoU) in B. subtilis is not lethal, confirming that this 
pathway is non-essential for growth but the mutant strains were sensitive to ionizing 
radiation in stationary phase (Weller et al., 2002).  
 
We propose that such small ATP-dependent DNA ligases in pathogenic bacteria 
especially, B. pseudomallei, might be dispensable for cell growth but their inhibition 
may render the repair mechanism inefficient and could be exploited as potential target 
in combinatorial drug therapy. Our belief is that any small molecule or chemical 
compound inhibiting PBCV-1 DNA ligase would also have inhibitory effect on the 
ATP-dependent DNA ligase of B.  pseudomallei. Furthermore the complementation 
by additional ATP-dependent DNA ligases encoded by eubacteria might complicate 
potential strategies to target NAD
+
-dependent DNA ligases with antibiotics. We 
therefore realised that the inclusion of a small ATP-dependent ligase would extend the 
screening assay to identify inhibitors for DNA ligases encoded by eubacteria. The 
main focus of this study has been to develop an assay to identify inhibitors for 
eukaryotic ligases, exemplified by the TV enzyme and HuLigI, using PBCV-1 as an 
initial catalytic inhibitor screen.  However, it is clear that once potential inhibitors are 
identified their efficacy can also be tested as potential anti-bacterial agents. 
Furthermore, the conditions under which the wild-type PBCV-1 DNA ligase 
crystallises are known, in fact they can be grown from three different conditions, so it 
would hopefully be possible to grow such crystals with the inhibitor or to soak the 
inhibitor into the wild type crystals. Therefore its use can be advanced as a screening 
agent, through the use of the crystal structure of the PBCV-1 in complex with the 
inhibitor to enable modifications to be made to the compounds structure chemically to 
enhance its activity.  Inhibitors identified from this screen with PBCV-1 will then be 
analysed against the ∆232 HuLigI and the TV enzyme in the same in vitro screen to 
confirm (hopefully) the inhibitory potential against these enzymes. 
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CHAPTER 5: DEVELOPMENT OF AN ASSAY TO SCREEN 
FOR INHIBITORS OF DNA LIGASES 
5.1 Introduction  
 
Chemotherapy and radiation during treatment of cancer has the ability to induce DNA 
damage and hence different mechanisms are employed by the cells to detect and 
repair such damage. The modulation of these pathways has a great impact on clinical 
outcome and is frequently responsible for therapeutic resistance to anti-cancer agents 
(Martin, 2001; Damia & D‟Incalci, 2007). Such studies have lead to the identification 
of several potential drug targets and consequently the development of small molecular 
inhibitors of DNA repair (Madhusudan & Middleton, 2005). Given the unique and 
critically important roles of DNA ligases in DNA replication, DNA damage repair 
and maintenance of genomic stability, the efficacy of anti-cancer drug treatments may 
be improved in certain cases by targeting human DNA ligases.  
 
DNA ligases utilize either ATP or NAD
+
 as cofactors to catalyse the formation of 
phosphodiester bonds in nicked DNA. Differences in the cofactor specificity of 
bacterial DNA ligases have made them an attractive target for broad-spectrum 
antibiotics (Korycka-Machala et al., 2007). Recent studies have identified various 
small molecules such as pyridochromanones that inhibit NAD
+
-dependent DNA 
ligases (Gong et al., 2004). Although, the NAD
+
-dependent ligases are restricted to 
eubacteria some bacteria encode for both NAD
+
 and ATP-dependent DNA ligases 
(Doherty & Suh, 2000). Mycobacterium tuberculosis encodes for at least three 
different types of ATP-dependent DNA ligases and an NAD
+
-dependent ligase (Gong 
et al., 2004) whereas Bacillus subtilis harbours two ATP-dependent ligases and an 
essential NAD
+
-dependent ligase (Petit & Ehrlich, 2000). Targeting NAD
+
-dependent 
DNA ligases might not be immediately successful as additional ATP-dependent DNA 
ligases encoded by these organisms will influence the efficacy of the NAD
+
-inhibitory 
compounds. This might lead to drug resistance or the opportunity for some of these 
strains to survive assault on the NAD
+
-dependent DNA ligases. Therefore, there is a 
need to develop a compound or series of compounds that can be used in conjunction 
with NAD
+
-dependent DNA ligase inhibitors to overcome possible drug resistance in 
these organisms. 
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This potential of ligase inhibition in cancer therapeutics or otherwise will only 
become apparent once potent and selective inhibitors become available for 
pharmacological studies over the next few years. DNA ligase inhibitors are likely to 
be anti-proliferative and potentiate the cytotoxicity of DNA damaging agents. Recent 
efforts by various independent research groups have resulted in the identification of 
many classes of ligase inhibitors by screening chemical and natural product libraries 
(Tan et al., 1996; Chen et al., 2008; Dwivedi et al., 2008; Zhong et al., 2008). The 
assays used in these efforts however, have not been well suited to high throughput 
screening of natural product extracts. This prompted us to develop a 96-well plate 
based assay that can be used for high throughput screening to identify inhibitors of 
ATP-dependent DNA ligase enzymes, human, protozoal and bacterial. The key 
feature of the rapid DNA ligation, inhibition assay is the relative binding of affinities 
of the components of the unligated DNA substrate and ligated DNA product to the ion 
exchange resin, Q-sepharose. Knowledge of the smallest size of DNA that ligases can 
efficiently ligate on the 5‟-PO4 side of the DNA nick was utilised to provide 
differential binding affinity between the unligated, labelled 5‟-PO4 strand and the 
sealed ligation product (Odell et al., 2003). 
 
Crude extracts from the culture of white rot fungus, Basidiomycetes - already known 
for anti-tumour and anti- bacterial properties, were used as test extracts in developing 
the screening of the inhibitors (Russell & Patterson, 2006; Silva, 2006). Various ATP-
dependent ligases (produced and purified in-house) were used to set up the assay. 
Various salt conditions and other steps required to optimise the assay are described 
here.  
5.2 Materials and methods 
5.2.1 Optimisation of oligonucleotides binding to Q-sepharose 
 
A 30-mer hairpin strand with a 10-nucleotide 5‟ single-strand tail (Figure 5.1) and 6-
mer oligonucleotide complementary to the tail were designed and then obtained from 
Invitrogen.                                                                                        
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The oligonucleotides were diluted to a final concentration of 0.2 mg/ml with buffer A 
(50 mM Tris-HCl pH 7.5, 5 mM DTT and 10 mM MgCl2) and applied separately to 1 
ml of Q-Sepharose resin (Sigma-Aldrich) pre-equilibrated with buffer A. The bound 
fraction was step eluted with 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8 and 1 M NaCl in buffer A. 
The DNA elution profile was monitored by checking the absorbance of the eluate at 
260 nm. 
 
5.2.2 Ligation inhibition assay methodology 
5.2.2.1 Preparation of the nicked DNA substrate 
 
A 36-mer (30 + 6-mer) nicked duplex was synthesised commercially as two separate 
oligonucleotides by Invitrogen and used as a substrate for the ligase reaction (see 
figure 5.1). 
The 5‟-end of the 6-mer oligonucleotide was labelled with 32P using T4 
polynucleotide kinase (as described in Chapter 2; 2.1.10). The nicked duplex DNA 
substrate (Figure 5.1) was formed by mixing the 6-mer strand labelled with 
32
P at its 
5‟ end with the complementary 30-mer strand at a molar ratio of 1:4 [1 (6-mer) : 4 
(30-mer)] in 0.2 M NaCl as previously described (Chapter 2; 2.1.11).  
 
5.2.2.2 Inhibition assay 
 
The assay was carried out in 96-well microtitre plates. All potential inhibitor extracts 
(~8 µg) were supplied in solvent 30% Dimethylsulfoxide (DMSO): Methanol (1:1; 
v/v). To preclude the action of the solvent being responsible for the inhibition, DNA 
ligase activity of all test ligases (T4, PBCV-1 and HuLigI) was tested in a standard 
ligation assay (Chapter 2; 2.1.12) in the presence of 10%, 5%, 2.5%, 1.25%, 1.0%, 
0.5% and 0.25% solvent and 0-4 µM Doxorubicin (Sigma-Aldrich) as a positive 
control for ligase inhibition in separate reactions. 
  
The final ligation assay reaction mixture (20 µl) included 50 mM Tris pH 7.5, 10 mM 
MgCl2, 1 mM ATP, 5 mM DTT, 1 pmole annealed (30 + 6-mer) nicked duplex DNA, 
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1 pmole DNA ligase and 0.5 µl of potential inhibitor (in 0.5% solvent). The reaction 
was incubated at 22
o
C for 5 minutes and terminated by the addition of 5 µl of 0.1 M 
EDTA.  
 
100 µl of Q-sepharose resin, pre-equilibrated with buffer A (50 mM Tris pH 7.5, 10 
mM MgCl2 and 5 mM DTT) was suspended in each well of a 96 well filterEX filter 
plate (Corning). The filter plate containing Q-sepharose resin was stacked on top of a 
96-well receiver plate and placed into the top chamber of a vacuum manifold (Figure 
5.7). The vacuum manifold unit was connected to a pressure pump via a waste bottle 
covered with an appropriate filter to trap liquid.  
 
The completed ligation reactions were heated at 65
o
C for 5 minutes prior to loading 
onto the resin. The filter plate (Q-sepharose) was washed with either 300 µl or 3 x 100 
µl of pre-warmed (37
o
C) buffer A containing 0.2 M NaCl. Loosely bound annealed 
DNA substrates were eluted with buffer A containing 0.6 M NaCl and ligated DNA 
substrate was eluted with buffer A containing 1 M NaCl. The contents of the 
receiving plates were freeze dried for 8 hours, dissolved in 20 µl water and spotted 
onto nitrocellulose membrane (Hybond NX, GE Healthcare). The membrane was 
exposed to a phosphorimager plate that was subsequently scanned using Typhoon 
imager (GE Healthcare).  
5.3 Results 
5.3.1 Determination of oligonucleotide binding affinity to Q-
sepharose 
 
The oligonucleotides used in this assay were designed based on a previous study that 
defined the minimum DNA length requirement for strand sealing on the 5'-PO4 side of 
the nick by PBCV-1 DNA ligase (Odell et al., 2003). These authors used a 30-mer 
oligonucleotide with internal base complementarity which allowed folding back and 
creation of a hairpin (as shown in figure 5.1; panel A) and annealing of a short 
complementary oligonucleotides (Figure 5.1; panel B) to this hairpin structure creates 
a synthetic double-stranded DNA (dsDNA) substrate with a single-strand nick (Figure 
5.1; panel C). Odell et al. (2003) showed that a 30-mer hairpin strand (Figure 5.1) 
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with a 10 nucleotide (nt) 5‟ single-strand tail when annealed with an excess of 
complementary 10-mer, 8-mer, 6-mer and 4-mer 5'-PO4 strands can be joined in vitro 
to yield a 40-mer, 38-mer, 36-mer and 34-mer product respectively. However the 
ligation
 
of the 4-mer strand was less successful, possibly due to the absence of a 
duplex segment distal to the annealed 4-mer strand at the nick or more likely the 
thermal instability of such a construct. Identical rates and extents of sealing was 
observed for the 10-mer, 8-mer and 6-mer
 
substrates, leading to the conclusion that a 
6 nucleotide 5'-PO4 strand sufficed for efficient ligation (Odell et al., 2003). We 
therefore set out to devise a ligase inhibition assay method using a 30-mer hairpin 
strand with a 10 nt 5‟ single-strand tail and 6-mer oligonucleotide [32P-labelled in 
vitro at its 5‟ terminus; (Figure 5.1)] complementary to the tail as the DNA substrate.  
 
To follow the course of sealing of this nicked dsDNA substrate the 6-mer will be pre-
incubated with T4 polynucleotide kinase and gamma-labelled ATP resulting in the 
attachment of a radioactive phosphate moiety to the 5‟ terminus of the 
oligonucleotide. This radioactive 6-mer then becomes incorporated into the backbone 
of the hairpin on successful DNA ligation creating a 36 nucleotide labelled product. 
 
*T GCGTGCGG
CGCACGCCCGCTGCGATG
T
T
T
GCGACG
*GCGACG
T
GCGTGCGG
CGCACGCCCGCTGCGATG
T
T
T
C
BA
 
Figure 5.1: Structure of the radiolabelled synthetic substrate used in DNA 
ligation assays 
The oligonucleotides were designed as described by Odell et al. (2003). A: Unlabelled 30-mer hairpin 
strand with an unpaired 10 nucleotide 5‟ single-strand tail; B: Radiolabelled 6-mer oligonucleotide 
complementary to the tail of hairpin structure (the asterisk indicates the position of the labelled 
nucleotide); C: Final annealled labelled DNA substrate.  
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The key principle behind the DNA ligation/inhibition assay is the relative binding 
affinities of the DNA substrates (the 6-mer and the 30-mer and the product 36-mer) to 
Q-sepharose (a sepharose resin with attached quaternary ammonium groups 
functioning as an anion exchanger) resin. The negatively charged phosphate groups of 
DNA are fully ionized at a pH above 4 as a result of which DNA binds to positively 
charged groups such as the quaternary amine group (Tseng & Ho, 2003).  
 
To test the assumptions that underpin the assay, solutions of both the 30-mer and the 
6-mer at 0.2 mg/ml were applied independently to a Q-sepharose column in ligation 
buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM ATP and 5 mM DTT). The 
binding affinity of the 30-mer hairpin structure and the 6-mer oligonucleotide to the 
Q-sepharose resin was expected to be different as the 30-mer will have more potential 
sites for attachment to the matrix and will hence show different affinity to the 6-mer 
when eluted with salt. Figure 5.2 shows the salt concentrations where the 30-mer and 
6-mer are released from the Q-sepharose. The 6-mer oligonucleotide eluted at 0.25-
0.3 M NaCl whereas the 30-mer hairpin structure eluted at 0.5 M NaCl. As the final 
product of a successful ligation would be a 36-mer, it was concluded that this would 
demonstrate tighter binding to the Q-sepharose resin than the 30-mer allowing 
differentiation between the unligated 6-mer and the ligation product by affinity to the 
ion exchange resin. 
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Figure 5.2: Elution profile of oligonucleotide DNA substrates, hairpin 30-
mer and linear 6-mer from Q-sepharose under NaCl treatment 
The 30-mer and 6-mer oligonucleotides (0.2 mg/ml) were applied independently to a Q-sepharose 
column in buffer A (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM ATP and 5 mM DTT) and step-
eluted with 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8 and 1 M NaCl in buffer A. The DNA elution profile was 
monitored by checking the absorbance of the eluate at 260 nm.  
 
5.3.2 Inhibitory effect of Doxorubicin 
 
Before the search for inhibitors could be undertaken it was necessary to show that the 
physical manipulations of the assay and the buffer conditions would not affect the 
normal function of a ligase enzyme.  Furthermore it was important to demonstrate that 
a known ligase inhibitor, doxorubicin, could show activity under these conditions.  
 
Doxorubicin is a highly effective anthracycline chemotherapeutic agent known to 
inhibit the ATP-dependent DNA ligase of bacteriophage T4 and NAD
+
-dependent 
DNA ligase of E. coli with a similar potency (Ciarrocchi et al., 1999). The inhibitory 
effect of doxorubicin was studied by titrating doxorubicin against HuLigI (232), 
PBCV-1 and T4 DNA ligases in a standard ligation reaction as described previously 
(Chapter 2, 2.1.12).  
 
172 
 
The 6-mer oligonucleotide was end-labelled with 
32
P in a kinase reaction and 
annealed with the 30-mer hairpin (as described in Chapter 2; 2.1.10, 2.1.11) to create 
a synthetic nicked dsDNA substrate. The annealed product was incubated at 22
o
C for 
5 minutes with the test ligases (T4, PBCV-1 and 232 HuLigI) with and without 
doxorubicin.  The extent of ligation in each sample was quantified from analysis of 
the sample on a denaturing polyacrylamide gel. It was found that 0.5 µM had no 
discernible effect on DNA ligation under the reaction conditions used however 3 µM 
doxorubicin was sufficient to inhibit >90% of the ligation activity of all the above 
enzymes (Figure 5.3). These values closely parallel those reported by Ciarrocchi et al. 
(1999) for the T4 enzyme. 
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Figure 5.3: The effect of Doxorubicin on ATP-dependent DNA ligation 
monitored with a radiolabelled, nicked DNA substrate.  
The activity of T4, PBCV-1 and HuLigI were tested in the presence of different concentrations of 
doxorubicin (0-3 µM). The standard ligation reaction was carried out at 22
o
C for 5 minutes and stopped 
by the addition of 5 µl of 0.1 M EDTA and heating the sample at 95
o
C for 5 minutes. The extent of 
ligation in each sample was quantified from analysis of the sample on a denaturing polyacrylamide gel 
analysed using a Typhoon Phosphorimager (GE Healthcare) and Imagequant software. 
 
5.3.3 Validation of assay conditions 
 
The elution profile of the oligonucleotides (30-mer and 6-mer; Figure 5.2) confirms a 
difference in their binding affinity to Q-sepharose and reveals that a higher salt 
concentration is required to remove bound 30-mer oligonucleotide compared to bound 
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6-mer. The binding affinites of annealed (30+6)-mer substrate and ligated product 
(36-mer; using 
32
P-labelled 6-mer) to Q-sepharose resin were then determined to 
optimise the washing protocol of the assay. A ligation reaction (50 µl) was carried out 
with T4 DNA ligase, PBCV-1 DNA ligase and (232) HuLigI on annealed (30+6 
mer) substrate and loaded independently onto Q-sepharose resin. The resin was step 
eluted with 0.25, 0.6 and 1 M NaCl and the fractions obtained were spotted onto a 
nitrocellulose membrane and exposed to a phosphorimager screen (Figure 5.4; panel 
A).  
A B
FT
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0.6 M
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6-mer
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Figure 5.4: DNA ligation assay products analysed by spotting onto a 
nitrocellulose membrane and by denaturing gel electrophoresis 
Panel A: A 50 µl ligation reaction was carried out with 1 pmole of annealed (30+6 mer) substrate in 
ligation buffer (containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM ATP and 5 mM DTT) in the 
presence of 0.1 pmole of either T4 DNA ligase, PBCV-1 DNA ligase or human (232) DNA ligase I 
and loaded independently onto Q-sepharose resin. The resin was step eluted with 0.25, 0.6 and 1 M 
NaCl and the fractions obtained were spotted onto a nitrocellulose membrane and exposed to a 
phosphorimager screen. Lane1: control reaction with T4 DNA ligase; Lane 2: control reaction without 
ligase; Lanes 3 & 4: NaCl elution fractions obtained from the PBCV-1 and HuLigI reactions 
respectively.  
Panel B: The reaction products from the same reaction shown in panel A were also analyzed using 15% 
denaturing polyacrylamide gel electrophoresis. The gel was exposed to a radioactive detecting screen 
and scanned using a phosphorimager (GE Healthcare). The autoradiogram is shown. Lane 1: DNA 
substrate with no ligase; Lane 2: control reaction with T4 ligase before loading onto the column; Lanes 
3-6: different fractions collected after washing the Q-sepharose column loaded with the ligation 
reaction carried out with the hairpin substrate in the presence of T4 DNA ligase. Lane 3: FT- Flow-
through, Lane 4: 0.25 M NaCl, Lane 5: 0.6 M NaCl, Lane 6: 1 M NaCl. 
The preliminary wash was performed with 0.25 M NaCl to confirm that all the 6-mer 
had annealed to the 30-mer hairpin creating ds DNA, which in turn elutes at 0.6 M 
NaCl. In the absence of any ligase all the radiolabelled DNA species eluted from the 
resin at 0.6 M NaCl confirming that the substrate had formed correctly (Figure 5.4; 
panel A). Incubation with commercial T4 DNA ligase converted the radiolabelled 
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DNA into the final product of a successful ligation, the 36-mer. This demonstrated 
even higher affinity for the Q-sepharose resin than the 30-mer alone and hence eluted 
at 1 M NaCl. The absence of any radioactive signal in the resin flow through, 0.25 M 
and 0.6 M NaCl wash fractions indicates that all the available DNA substrate has been 
ligated. In reactions performed with PBCV-1 and the truncated HuLig I a very faint 
signal in the 0.6 M salt fraction suggests the presence of a very small amount of 
unligated DNA substrate (Figure 5.4; panel A). This may have occurred if the DNA 
ligase disengaged from the substrate after second step of the reaction i.e. after 
transferring the AMP moiety to the end of the DNA before completing the ligation 
reaction. This fraction would then be resistant to DNA ligation, but would remain 
annealled to the hairpin. This error occurs in vivo in human DNA metabolism as the 
cells produce a protein, aprataxin, which can reverse such stalled ligation 
intermediates (Ahel et al., 2006). Aprataxin repairs such lesions by catalyzing the 
release of 5′-adenylate groups from the single-strand breaks, resulting in the 
restoration of 5′ phosphate termini that can be efficiently rejoined (Ahel et al., 2006).  
 
The results from the dot blot analysis were confirmed by electrophoresing, on a 
denaturing polyacrylamide gel, the various fractions obtained from the NaCl step-
gradient elution of a ligation reaction. T4 DNA ligase was incubated with the 
radiolabelled substrate and the products were applied to Q-sepharose before washing 
with NaCl (Figure 5.4; panel B). The input size of the DNA in the absence of ligase 
represents the migration of the labelled 6-mer. Upon ligation the 6-mer converts to a 
slower migrating product whose size increase we take to indicate as conversion to a 
36 nucleotide product. The larger, ligated product elutes from the Q-sepharose resin 
only upon washing with 1 M NaCl (Figure 5.4; panel B; lane 6). 
 
To confirm that 0.6 M NaCl wash distinguishes between ligated and unligated DNA, 
T4 DNA ligase was used to seal the nick in the preformed DNA duplex in the 
presence of an inhibitory concentration of doxorubicin. The ligation reaction mixture 
was loaded onto Q-sepharose resin and step eluted with 0.25, 0.6 and 1 M NaCl. The 
eluted fractions were run on a 15% denaturing polyacrylamide gel (Figure 5.5). The 
reaction performed in the presence of doxorubicin, gave an intense signal at 0.6 M, 
indicating that unligated substrate elutes at this salt concentration.  
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Figure 5.5: T4 DNA ligase sealing in the presence of doxorubicin analysed 
by conventional electrophoresis 
A ligation reaction performed with 0.1 pmole T4 DNA ligase, 1 pmole DNA substrate in buffer A 
(containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM ATP and 5 mM DTT) in the presence of 3 
µM doxorubicin, loaded onto Q-sepharose resin. The resin was then washed with 0.25, 0.6 and 1 M 
NaCl in buffer A and the different fractions were collected and run on 15% denaturing gel. Lane 1: 
control reaction with no ligase; Lane 2: control reaction with 1 pmole T4 DNA ligase in the absence of 
doxorubicin; Lanes 3-6: different elution fractions collected after washing the column loaded with the 
ligation reaction carried out in the presence of doxorubicin. Lane 3: FT- Flow-through, Lane 4: 0.25 M 
NaCl, Lane 5: 0.6 M NaCl, Lane 6: 1 M NaCl. 
 
This experiment validated that the assay scheme that we wanted to employ would 
identify inhibitors of ATP-dependent DNA ligases in a manner comparable to 
electrophoretic analysis. In order that the assay could be automated and carried out 
rapidly we designed a procedure that would use 96-well microtitre plates. The 
sequence of steps involved in the inhibitor screening assay is shown in figure 5.6. 
The standard ligation reaction, in the presence of potential inhibitors, is carried out in 
a 96-well microtitre plate (reaction volume 25 µl) and stopped by the addition of 5 µl 
of 0.1 M EDTA to each well and by incubating at 65
o
C for 5 minutes. Each reaction 
sample is then pipetted (using a multi-channel pipette) into a second microtitre plate 
containing Q-sepharose resin, pre-equilibrated with ligation buffer (50 mM Tris-HCl 
pH 7.5, 10 mM MgCl2, 1 mM ATP and 5 mM DTT). The samples and sepharose in 
the filtration plate lined with 0.25 mm glass fibre filter are placed onto 96-well 
collection plates. The resin was washed with warm 0.2 M NaCl to remove enzyme 
and inhbitors that might affect the elution of the DNA. The unligated DNA bound to 
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Q-sepharose elutes with the 0.6 M NaCl wash whereas ligated DNA duplex, binds 
more tightly to the resin and elutes at 1 M NaCl.  
Since, the 0.6 M elution fraction contains only unligated species, the extent of 
inhibition by different compounds could be measured by measuring the intensity of 
radioactive signal in this fraction as a fraction of the total radioactivity contained in 
both the 0.6 and 1 M fractions.   
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Figure 5.6:  A schematic illustration of the various steps involved in the 
DNA ligase assay 
The annealed double-stranded DNA duplex formed with a single-stranded nick is used as a substrate in 
DNA ligation reaction that can be performed in the presence of potential inhibitors. The ligation 
reaction is stopped by the addition of 0.1 M EDTA and incubating at 65
o
C for 5 minutes and mixed 
with Q-sepharose resin in the filter plate. The resin is washed with 0.25 M NaCl in buffer A (50 mM 
Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM ATP and 5 mM DTT), followed by a 0.6 M NaCl wash in 
buffer A. A further 1 M NaCl wash in buffer A is performed to release ligated DNA. Differences in the 
radioactive signal intensity in 0.6 M and 1 M wash is calculated to determine the percentage inhibition 
of the ligation reactions. 
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Due to our desire to create a high-throughput assay, the lower collection plate was 
replaced with nitrocellulose in intimate contact with the base of the Q-sepharose resin 
microtitre plate. This assembly was then put onto a vacuum manifold designed to 
draw the various elution fractions through onto the nitrocellulose. At each step a new 
nitrocellulose membrane was inserted so that each part of the wash and elution could 
be quantified. By this means it was hoped that the degree of ligation inhibition could 
be monitored, by quantifying the total radioactivity eluted from the column in the 
0.25, 0.6 and 1 M NaCl fractions. The proportion present in the 1 M fraction would 
represent the percentage of successful ligation achieved. Various efforts were made to 
place the nitrocellulose membrane in intimate contact with the filtration plate to avoid 
any loss of signal. Despite many attempts, a sufficiently tight seal could not be 
obtained between the vacuum and the nitrocellulose membrane. It was found that the 
volume of elution fraction (300 µl) obtained from each well was more than the 
vacuum pump could extract before cross-contamination occurred between samples. In 
order to prevent sample overflow, the volume of the buffer used to elute DNA was 
reduced but it resulted in inefficient washing of the resin. Figure 5.7 shows the signal 
overlap due to sample diffusion when the nitrocellulose membrane was placed in 
contact with filtration plate and we had adjusted all possible physical factors to 
increase the vacuum and reduce cross-contamination of the samples. 
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Figure 5.7: DNA ligation assay processed through Q-sepharose onto 
nitrocellulose using a vacuum manifold 
Various panels showing diffusion of signal across the nitrocellulose membrane, when placed in 
intimate contact with filtration plate during elution. Arrow indicates the overlapping zone between 
samples. Panels 1-3 represents overlapping of  radioactive signal observed after washing the resin with 
300 µl of elution buffer whereas panels 4-6 represents overlapping of  radioactive signal observed after 
reducing the volume of elution buffer (3 x 100 µl). 
 
Therefore, we decided to allow the various washes of the Q-sepharose to pass by 
gravity flow into separate receiving plates and then to freeze dry these elutions. The 
samples were then dissolved in 20 µl of distilled water and spotted onto nitrocellulose 
membranes and exposed to a phosphorimager plate without mixing of the samples 
taking place (see figure 5.8). 
 
Once we had established that the assay was as reliable as the standard electrophoretic 
assay used to measure DNA ligase activity, potential inhibitors were screened from 
the Mycodiverse
TM
 library of Hypha Discovery, London. The Hypha Discovery 
chemical library contains dried whole cell mass and extracts derived from cultures of 
Ganoderma species. Ganoderma is a basidiomycete white rot fungus whose extracts 
contain many bioactive compounds, including polysaccharides and terpenoids, some 
of which are known for their biomedical importance including anti-tumour and anti-
bacterial activities (Russel & Patterson, 2006; Silva, 2006).  
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The dried extracts of white rot fungal cultures present in a specially selected bioactive 
subset, EC10B were dissolved in solvent (Dimethylsulphoxide: Methanol in a 1:1 
ratio). The activity of HuLigI, PBCV-1 and T4 DNA ligase were tested in the 
presence of 0.25-10% v/v solvent in a standard ligation assay. 1% of solvent had no 
effect on the ligation activity of any of these enzymes (data not shown). In order to be 
certain that the solvent would not have a significant impact on ligation reaction, its 
concentration was further halved (0.5%) in screening assays. 
 
After performing the ligation reaction in the presence of potential inhibitors from the 
EC10B collection (Hypha Discovery), the assay procedure was followed, as detailed 
in Figure 5.7. The control reactions (data not shown) were performed with T4 DNA 
ligase and PBCV-1 DNA ligase (with and without Doxorubicin). The different wash 
fractions, 0.6 M (Figure 5.8; panel A) and 1.0 M NaCl (Figure 5.8; panel B), of the Q-
sepharose resin were collected and spotted onto nitrocellulose membranes. The extent 
of inhibition by different compounds was measured by measuring the intensity of 
radioactive signal in 0.6 M fraction as a fraction of the total radioactivity contained in 
both the 0.6 and 1 M fractions. It was observed that almost all the potential inhibitors 
pools from the EC10B collection were able to inhibit the activity of PBCV-1 DNA 
ligase (Figure 5.8) but the extent of inhibition varied in each reaction.           
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Figure 5.8: PBCV-1 ligase inhibition by EC10B Ganoderma extracts 
revealed in the wash fractions of the ligase assay 
The ligation reaction using PBCV-1 DNA ligase performed in the presence of Ganoderma extracts was 
applied to Q-sepharose resin. The resin was washed with 0.25 M, 0.6 M and 1 M NaCl in buffer A (50 
mM Tris-HCl pH 7.5, 10 mM MgCl2, 1 mM ATP and 5 mM DTT).  
Panel A: The 0.6 M wash fraction collected in collection plates, after vacuum manifold, was freeze-
dried and spotted onto a nitrocellulose membrane. The membrane was exposed to a Phosphorimager 
radioactive detection screen and read using a Typhoon scanner (GE Healthcare).  
Panel B: The membrane was washed with 1 M NaCl in buffer A to elute the 36-mer ligated product 
from the resin. The 1 M wash fraction was collected, freeze-dried and spotted onto a nitrocellulose 
membrane. The membrane was exposed to a Phosphorimager radioactive detection screen and read 
using a Typhoon scanner (GE Healthcare).  
 
 
The EC10B collection contains dried cell mass extracts where each pool contains 
several chemical elements. As such many of these may have a toxic effect on the 
action of an enzyme. The only way to be certain of the presence of specific ligase 
inhibitor is to titrate the amount of toxic component. This could be achieved by 
setting an arbitrary lower limit of inhibition, for example 90%, and then decreasing 
the percentage of Ganoderma extract being added by a sequential series of two-fold 
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dilutions. If inhibition continues at a level of 90% over more than three such diltuions 
then the presence of a specific inhibitor may be inferred.    
The rapid assay could be adapted to give more reliable results by using pure chemical 
or purified natural product libraries which would reduce the background signal and 
provide more precise information in terms of the specificity. Although, the first 
screening with the assay shows almost total inhibition of the reaction, serial dilution 
of the pools, used for screening, would lower the concentration of toxic contaminants 
and give a true measure of their inhibitory potential.  
 
5.4 Discussion 
 
The earliest stages of drug discovery involve identification of an appropriate 
biological target followed by development of an assay capable of rapid high 
throughput screening for effective, novel inhibitors. There is an emerging interest in 
developing small molecule inhibitors that can block the activity of some of the key 
proteins in the DNA repair processes to improve the effectiveness of current cancer 
treatments. Various chemicals that inhibit human DNA ligase I have been reported, 
including some widely used anti-tumour drugs such as doxorubicin, but little work 
has been done to develop a dedicated, rapid, non-electrophoretic assay to screen for 
other, ligase-specific inhibitors. 
 
The widely used in vitro DNA ligase activity assay involves the monitoring of DNA 
ligation using a radiolabelled DNA substrate and analysing the results by gel 
electrophoresis. In this method of analysis, aliquots of the reaction are withdrawn at 
various times and quenched immediately with SDS to denature the enzyme and 
EDTA to chelate the essential metal cofactor, magnesium. The reaction products are 
analysed on a denaturing polyacrylamide gel. This method is time consuming and 
unsuitable for high throughput screening.   
 
After the beginning of this work, Sun & Urrabaz (2004) published a non-
electrophoretic assay for screening of inhibitors for DNA ligases. This assay was 
based on the use of radioactive label in addition to a bulky biotin group. The presence 
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of bulky group might affect the binding of inhibitors to the enzyme or DNA substrate 
used in vitro whereas the use of radioactively labelled phosphate alone rules out such 
a possibility.  
 
The footprinting of PBCV-1 DNA ligase as studied by Odell & Shuman (1999; using 
an alanine substitution mutant of the active site Asp29 to inhibit strand joining) shows 
that the enzyme contacts 19–21 residues when bound to nicked duplex DNA. It 
extends 8–9 nucleotides on the 3'-OH side of the nick and 11–12 nucleotides on the 
5'-PO4 side of the nick. A similar asymmetric footprint was observed for T7 DNA 
ligase extending 9 nucleotides on the 5'-PO4 side of the nick and 3–5 nucleotides on 
the 3'-OH side (Doherty & Dafforn, 2000). However, Odell et al. (2003) reported that 
PBCV-1 DNA ligase requires a minimum of 6 nucleotides at ligatable 3'-OH and 5'-
PO4 strands at the nick for efficient in vitro sealing. The discrepency between the 
footprint and the physical DNA size required for efficient ligation is probably 
explained by stearic hindrance. The PBCV-1 footprint was obtained by binding the 
ligase protein and then digesting with an exonucleolytic enzyme. Collision between 
the external surface of the two enzymes naturally overexaggerates the actual size of 
the ligase footprint on the DNA. These studies formed the basis of the design of the 
DNA substrates used in this assay system. The DNA consisted of a 30-mer strand 
with a stretch of nucleotides that were complementary, folding back on their Watson 
and Crick partner bases to create a hairpin with a 10 nucleotide 5‟ single-strand tail. 
To this tail a complementary 6-mer oligonucleotide (Figure 5.1) can be annealled that 
juxtaposes its 5'-PO4 moiety adjacent to the 3'-OH of the 30-mer. On sealing this 
substrate a continuous 36-mer oligonucleotide is created (Figure 5.1). 
 
The rapid assay method is based on the strength of interaction of the oligonucleotides 
with Q-sepharose, a strong anion exchanger. The binding affinities of the ligated 36-
mer and the unligated substrate to Q-sepharose resin are different and hence have 
shown different elution profiles when the bound oligonucleotides are eluted with the 
salt NaCl. The 36-mer ligated product binds more tightly to the resin eluting with 1 M 
NaCl as compared to 0.6 M NaCl for the unligated 6-mer oligonucleotide when part 
of the annealed DNA substrate. The validity of our conclusions was confirmed by 
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comparing our fractionated ligation reaction on a denaturing gel in direct comparison 
with a complete ligation reaction using the same substrate. 
 
The ligation assay we designed to be carried out in volumes that could be 
accommodated in a 96-well format to allow development of the technology as a rapid, 
robotic-based high throughput assay. After completion of the ligation step the DNA 
was added to a 96-well filtration plate containing Q-sepharose resin. The reaction 
mixture contained a mixture of ligated 36-mer product, unligated 6-mer substrate and 
annealed (30 + 6)-mer DNA substrate, all of which have different binding affinity for 
the resin. The resin was washed with warm NaCl buffer and the eluate collected in 
microtitre plates. With the vacuum apparatus available to us nitrocellulose membrane 
could not be kept in intimate contact with the filtration plate, causing a measure of 
cross contamination between the wells. Since the volume of wash buffer used was 
more than the retaining capacity of the membrane, the eluates were freeze-dried and 
later spotted onto individual nitrocellulose membranes. 
 
A test ligation reaction was performed with T4 DNA ligase followed by PBCV-1 
DNA ligase and HuLigI with our synthetic oligonucleotides as a substrate in the 
presence of doxorubicin, an anti-cancer drug and a known inhibitor of ATP-dependent 
ligases. Our data supported the findings (Ciarrocchi et al., 1999) that doxorubicin 
inhibits ATP-dependent ligases. Significantly the sensitivity to doxorubicin 
determined by our assay was comparable to that determined by the previous study. 
Thus our assay has been demonstrated to be as reliable as conventional 
electrophoresis-based methods in identifying DNA ligase inhibitors. The method has 
been adapted to analyse multiple reactions in a 96-well plate format. This will allow 
for a high throughput version of this assay to be used that will be faster than the 
conventional gel-based analysis and suitable for high volume screens.  
 
The assay procedure was tested using a collection of whole cell extracts obtained as 
part of a natural product library from Ganoderma species. Several Ganoderma species 
have been described having antibacterial activities for example; basidiocarp extracts 
of G. lucidum and G. recinaceum inhibit the growth of Bacillus subtilis and show 
additive effects on the activity of other antibiotics (Russel & Patterson, 2006). Culture 
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extracts of G. recinaceum can also inhibit Staphylococcus aureus (Russel & 
Patterson, 2006). Some of the biologically active compounds isolated from 
Ganoderma species have anti-tumour properties such as the triterpenes from G 
.lucidum that suppress growth and invasive behaviour of cancer cells (Silva, 2006). 
Aqueous extracts from G. tsugae inhibit cell proliferation in human breast cancer cell 
lines MCF-7 and MDA MB-231 without exerting any significant cytotoxic effects on 
normal human mammary epithelial cells (Yue et al., 2006). 
 
Recently, Lee et al. (2009) reported on the anti-tumour effect of another white rot 
fungus, Inonotus obliquus, which inhibited the growth of HT-29, human colon cancer 
cells, by inducing apoptosis. It is believed that this apoptosis was as a result of the 
inactivation of the DNA repair protein, poly(ADP-ribose) polymerase (PARP; Lee et 
al., 2009). Mizushina et al. (1998) isolated cerebrosides such as glycosphingolipids 
from the fruiting body of G. lucidum which inhibited eukaryotic DNA polymerase in 
a dose dependent manner, suggesting a possible chemotherapeutic role through the 
inhibition of DNA replication. 
 
Screening with the crude Ganoderma extracts revealed inhibitory compounds present 
in many of the natural product pools. Further dilution analysis of these pools would 
have to be used to confirm whether the inhibition is due to ligase specific inhibitors 
rather than protein denaturants or toxic elements present in the crude extracts. This 
was not possible to undertake in this study because of recurrent and then long-term 
loss of the departmental phosphorimager.  
 
Once a hit/lead compound pool has been identified from the natural product library 
the individual components of the pool can be separated by chromatography and their 
structures determined using gas chromatography/mass spectroscopy (GC/MS). The 
compounds may then be screened, using a computer-aided drug design (CADD) 
method to identify those with a high probability of binding to the target site in the 
chosen ligase. 
 
The exact nature of the target in the case of the ligase is multifactorial. The assay can 
be used to identify inhibitors that inhibit both substrate recognition and the second 
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and third steps of ligase catalysis. But will in its current format have limited use in 
identifying inhibitors of the first, adenylation step of the DNA ligation reaction. This 
is because a mixed preparation of DNA ligase is used in the assay; a portion of the 
ligase enzyme is already adenylated in the cell, i.e. AMP had bound to the enzyme 
before purification and this form of the enzyme will be resistant to inhibition affecting 
this step (Odell et al., 2000). One means of circumventing this problem would be 
through the employment of a deadenylation step. Incubation of adenylated ligase 
enzymes with sonicated salmon sperm DNA in the presence of a divalent metal 
provides numerous substrate molecules that exhaust the adenylated enzyme molecules 
that can then be purified using an affinity/ion exchange resin. In order that inhibition 
of catalysis can be separated from substrate recognition we propose that a surface 
plasmon resonance (SPR) step should be incorporated. Work in this laboratory 
(Figure 3.27; Brooke, PhD thesis, 2007) has shown that ligase binding to DNA can be 
directly monitored using SPR. Once inhibition is identified the pool/component can 
be added into the binding step of purified enzyme under SPR analysis. 
 
The interest in DNA ligase inhibitors has increased since the beginning of our study 
particularly in those compounds that perturb normal DNA substrate recognition.  It is 
at this step that the behaviour of the enzymes appears to be most different and thus 
where a selective inhibitor may be best targetted. The catalytic core of ligases is very 
strongly conserved but their substrate recognition is clearly different (Odell et al., 
2000; Pascal et al., 2004 and this study - Figure 3.27). From the structure of HuLigI in 
complex with DNA, Chen et al. (2008) used a computer-aided drug design (CADD) 
method to screen small molecules as potential inhibitors of human DNA ligases. 
Using this ligand-based in silico screening technique they identified three inhibitors, 
L67, L82 and L189 (Figure 5.10), specific to human DNA ligases. These inhibitors 
inhibit cell proliferation and at sub-toxic concentrations, specifically potentiate the 
killing of cancer cells by DNA-damaging agents.  
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Figure 5.9: Chemical structure of HuLigI inhibitors identified by CADD  
Chen et al. (2008) used CADD to identify human DNA ligase I inhibitors based on the structure of 
HuLigI complexed with nicked DNA and identified three inhibitors that could complex with the DNA 
binding domain of HuLigI and inhibit the DNA ligation reaction. L189 inhibits step 2 whereas L67 and 
L82 inhibits step 3 of the ligation reaction (adapted from Chen et al., 2008). 
 
The limitation of the CADD approach is that it can only screen libraries of known 
chemicals, where the structure of all the compounds to be tested has been established, 
and not natural product pools. It is our belief that the CADD will be more efficient if 
used in conjunction with our rapid assay system. Once the hit/lead compounds are 
identified after screening of natural product libraries CADD could help in studying 
interactions of the identified lead compounds with DNA ligases to suggest synthetic 
modifications to increase their potency.  
 
This rapid assay method once combined with efficient vacuum methodologies will be 
able to analyse multiple reactions in a 96-well plate much faster than conventional gel 
based analysis. Since this method does not include additional steps, involving other 
enzymatic treatments or signal amplification using other enzymatic methods, it 
eliminates some of the indirect assay errors obtained from false positive or negative 
data resulting from. Due to time constraints, further studies could not be carried to 
improve washing protocols which would make the assay more efficient than the 
current method in quantitatively analysing DNA ligase activity. Use of pure chemical 
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or natural product libraries, instead of crude extracts, will help in the rapid 
identification of inhibitor molecules. Further optimisation of resin quantity, wash 
buffer volumes and retention capacity of DNA affinity membranes to be used will 
help in screening larger numbers of compounds. Undoubtedly, the utility of the 
compounds identified will have to ultimately be judged against whole cells and tissues 
rather than the isolated enzyme to determine their specificity in treating cancers and 
their effectiveness in combinational therapies. 
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CHAPTER 6: CONCLUSIONS, GENRAL DISCUSSION AND 
FUTURE WORK 
 
6.1 MAIN CONCLUSIONS 
6.1.1. Identification and characterisation of a DNA ligase from 
Trichomonas vaginalis 
 
DNA ligases have been studied in depth from various eukaryotic and prokaryotic 
organisms except protozoans. This study has identified, cloned, expressed and 
characterised the single DNA ligase from Trichomonas vaginalis (T. vaginalis), a 
pathogenic protozoan parasite.  
 
Prior to beginning of the characterisation of T. vaginalis DNA ligase (TVlig), there 
were no reports of DNA ligases from protozoan protists. The sequence analysis of the 
T. vaginalis genome revealed an open reading frame (ORF) encoding a protein with a 
51% and 53% homology to human DNA ligase I and Cdc9 of Saccharomyces 
cerevisiae respectively. Amino acid sequence alignment studies of TVlig with ATP-
dependent DNA ligases from human, yeast and Plasmodium falciparum suggest the 
presence of a number of features in common with replicative DNA ligases: A PIP 
motif (PCNA interacting polypeptide); a nuclear localisation signal; a DNA binding 
domain N-terminal to the catalytic core, of adenylation and oligomer binding 
domains. The adenylation domain of TVlig, as with other members of 
nucleotidyltransferase superfamily members including DNA and RNA ligases, 
consists of six conserved motifs (I, Ia, III, IIIa, IV and V). The oligomer binding 
domain in TVlig possesses a seventh conserved amino acid motif VI as present in 
other ATP-dependent DNA ligases – for example those encoded by PBCV-1, T7 
bacteriophage, Vaccinia virus, yeast and human. The spacing of the conserved motifs 
in TVlig is consistent with other previously reported DNA ligases. Further 
bioinformatic analyses were carried on the sequence of TVlig and its tertiary structure 
was predicted which superimposes well on the known structure of human DNA ligase 
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I bound to adenylated DNA, hence leading to the conclusion that identified gene is 
indeed a DNA ligase I. 
  
The TVlig was successfully amplified and cloned from genomic DNA extracted from 
a T. vaginalis culture. The recombinant gene was expressed and the encoded protein 
was purified to near homogeneity from Escherichia coli cells. The purified 
polypeptide was used to study the biochemical properties of the TVlig.  
 
 In vitro nick-sealing experiments demonstrated that TVlig showed optimal ligation 
activity on a nicked DNA substrate in the presence of 1 mM ATP and (8- 20) mM 
MgCl2 at 30-38
o
C. The ligase showed optimal activity at pH 7-8 which is similar to 
that observed for DNA ligase from T4 bacteriophage (pH 7.2–7.8; Weiss et al., 1968). 
Further, a mutant of TVlig (K338A) was prepared by replacing the putative active site 
lysine residue, located within a stretch of amino acids consistent with the ligase motif 
I (KYDGER), with alanine. The K338A mutant version of the TVlig lacked catalytic 
activity. This result strongly suggests that the lysine at position 338 is the catalytic 
nucleophile in TVlig and is involved in the formation of covalent ligase-adenylate 
intermediate during step 1 of reaction mechanism. The TVlig activity was shown to 
be dependent on a divalent cation. Significantly, in addition to magnesium and 
manganese, divalent calcium was also found to support ligation. The ligase also 
functions as a monomer which raises questions about how the T. vaginalis is able to 
seal double-strand breaks in DNA.  
 
In summary, characterisation of the single DNA ligase encoded by the genome of T. 
vaginalis represents an important step towards understanding replication and repair 
mechanisms for maintaining genomic integrity in the pathogen, T. vaginalis.    
6.1.2 Development of a high throughput assay to screen inhibitors for 
DNA ligases 
 
DNA ligases have an essential role in DNA repair and the substantially higher level of 
DNA ligase I in proliferating cells makes this replicative ligase an attractive 
therapeutic target for the treatment of unregulated cell growth as in a cancerous state. 
Three classes of chemicals (pyridochromanones, glycosyl derivatives and aryl-amino 
192 
 
compounds) that inhibit DNA ligases of either bacteria or humans have been reported 
(Ciarrocchi et al., 1999; Brotz-Oesterhelt et al., 2003; Srivastva et al., 2005) however 
a rapid, non-electrophoretic assay is not routinely used to isolate such chemicals. This 
study sought to develop a high throughput assay that could be used to screen 
inhibitors against various ATP dependent DNA ligases. 
 
The rapid, non-electrophoretic assay method, based on the strength of interaction of 
the oligonucleotides with Q-sepharose (a strong anion exchanger), was developed to 
screen inhibitors from natural product pools as well as chemical libraries. The binding 
affinities to Q-sepharose resin of a nicked DNA substrate (created from a 30-mer 
hairpin oligonucleotide and complementary 
32
P-labelled 6-mer oligonucleotide) and 
its sealed, ligated product (36-mer) were determined. It was concluded that the 36-mer 
ligated product binds more tightly to the resin as compared to unligated 6-mer 
oligonucleotide and annealed DNA substrate. Initial optimisation studies were 
performed with T4 DNA ligase, PBCV-1 DNA ligase and a catalytically active form 
of human DNA ligase I in the presence of doxorubicin, an anti-cancer drug and a 
known inhibitor of ATP-dependent ligases. Doxorubicin inhibition of ligation was 
analysed in parallel between a conventional electrophoretic assay and our labelled 
nick-sealing assay. This showed that the newly developed assay is as reliable as 
conventional electrophoresis-based methods in identifying potent DNA ligase 
inhibitors. The feasibility of the assay was tested in screening a collection of whole 
cell mass extracts, obtained from a natural product library from basidiomycetes, in 96-
well format. 
 
We conclude that our new non-electrophoretic assay method greatly improves the 
efficiency of the DNA ligase assay and can be employed in research aimed at 
identifying DNA ligase inhibitors for new therapeutic intervention against diseases.  
 
193 
 
6.2. GENERAL DISCUSSION AND FUTURE WORK 
 
DNA ligases play an essential enzymatic role in the survival of cells by taking part in 
DNA transactions such as DNA replication, recombination and repair. The enzymes 
are divided into groups depending on their energy co-factor specificity - either NAD
+
-
dependent (eubacterial ligases and certain eukaryotic viruses and mimiviruses) or 
ATP-dependent (eukaryotic, viral and archaebacterial; Timson et al., 2000; 
Ellenberger & Tomkinson, 2008). There is a structural and mechanistic commonality 
between the different groups of DNA ligases. The ligase basic catalytic core contains 
areas with conserved amino acid sequence and spacing (motifs I – V) and is 
composed of an N-terminal adenylation/nucleotide binding domain (AdD) and a C-
terminal domain that adopts an oligonucleotide binding fold (OB-fold; Subramanya et 
al., 1996). The smallest ATP-dependent enzymes (eubacterial and viral) are 
composed of only the basic catalytic core however the larger cellular enzymes have 
the catalytic core adorned with additional functional domains. The overall objectives 
of this work were to develop a high throughput assay that could be used to screen for 
inhibitors against ATP dependent DNA ligases from different origins and to 
characterise various target ligase polypeptides that might then be included in such an 
assay.   
  
Many current non-surgical cancer treatments target the integrity of cellular DNA by 
directly (caused by ionising radiations) and/or indirectly damaging DNA (caused by 
chemotherapeutic drugs; Damia & D‟Incalci, 2007). However, the anti-cancer 
effectiveness of these agents is limited by the activation of DNA-repair machineries in 
the target cell. Indeed, the enhancement of DNA repair is one of the crucial 
mechanisms governing intrinsic or acquired cellular resistance to DNA-damaging 
agents and defects in DNA-repair pathways result in hypersensitivity to these agents 
(Madhusudan & Hickson, 2005; Lord et al., 2006). Thus, there is growing interest in 
the development of DNA-repair interference as an adjuvant to current therapies and 
approaches in the treatment of cancer.  
 
DNA ligases represent an attractive therapeutic target because DNA ligation is the
 
last 
step of almost all DNA repair pathways; except for direct repair pathways, for 
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example the repair of O6-alkyl-guanine occurs without generating DNA breakage 
(Martin, 2001). DNA ligase–deficient cell lines exhibit sensitivity to a wide range of 
DNA-damaging
 
agents
 
due to the inefficient repair of DNA damage in these cell lines 
(Vijayakumar et al., 2009). Moreover, most proliferating cells including human 
cancer cells express high levels of DNA ligase I (HuLigI) when compared to normal 
forms of the same cells in resting and differentiated states (Montecucco et al., 1992; 
Sun et al., 2001). Chen et al. (2008) have recently used in silico docking of 
compounds into the HuLigI structure and identified three inhibitors that show 
differential inhibition of the three human DNA ligases; one compound in particular 
inhibits HuLigI alone. The inhibitors were also found to increase the sensitivity of 
cancerous cells to DNA damage (Chen et al., 2008).  
 
The initial approach undertaken in this study was to clone, express and purify full-
length HuLigI enzyme that could be used in the inhibitor screen to identify lead 
compounds that might have applications in cancer treatment. Previous reports 
identified an elevated expression of HuLigI in proliferating cells (Sun et al., 2001 & 
2002), thus cDNA was isolated from both HT-29 cells (metastatic colorectal cancer 
cell line) and MDA MB-435 cells (a breast carcinoma cell line) and used to isolate a 
HuLigI clone. HuLigI is 2757 base pairs in length making it a relatively difficult 
target to amplify by polymerase chain reaction (PCR). Attempts to amplify full-length 
HuLigI from a single PCR reaction were unsuccessful. Thus, different sets of forward 
and reverse primers (Table 4.1) were designed to amplify the gene in separate N- and 
C- terminal specific reactions that could be later ligated together to form a full-length 
clone. Although this strategy failed to produce a full-length clone the successful 
amplification of the N-terminal portion of the gene suggested the cDNA libraries were 
viable (Figure 4.1). Finally, a full-length of the gene was successfully amplified from 
the pCMV-SPORT6 vector, harbouring a full-length cDNA clone of HuLigI (Figure 
4.3, panel A). This ORF was then cloned into an expression vector pET-16b to allow 
us to produce recombinant polypeptide that could be used in the in vitro assay (Figure 
4.4, panel B). The presence of a rare (for E. coli) arginine (AGG) codon at the second 
position to the start codon, methionine (ATG), we believe may have ultimately 
influenced the expression of the relatively large full-length polypeptide (102 kDa) in 
E. coli cells.  Other authors have also reported difficulties in expressing full-length 
195 
 
HuLigI. For example, Brotz-Oesterhelt et al. (2003), in their study to identify 
inhibitors of the NAD
+
-dependent DNA ligase from E.
 
coli cells used a truncated 
version of HuLigI (250–919 amino acid). Similarly, due to the difficulty of isolating 
large quantities of active HuLigI, Ciarrocchi et al. (1999) used T4 DNA ligase to 
study the inhibition of ATP-dependent ligases. Kodama et al. (1991) suggested that 
the recombinant full-length HuLigI is susceptible to degradation by E. coli encoded 
proteases, which may be an additional problem with such a large polypeptide. We 
believe that the presence of low molecular weight species during our western blot 
analysis of full-length HuLigI may represent such of protein degradation (Figure 4.5). 
Teraoka et al. (1999) suggested the presence of an extra ACC (threonine) codon 
adjacent to the ATG (methionine) initiation codon prevents nonrestricted proteolysis 
and results in high levels of expression of
 
full-length HuLigI in E. coli cells. We have 
successfully amplified the full-length HuLigI gene with an extra ACC codon (data not 
shown) which could be cloned into an expression vector and expressed for further 
analysis of the inhibitors identified with ∆232 HuLigI. 
 
During the course of this work, the crystal structure of a truncated version of HuLigI 
(232-919; ∆232) was reported (Pascal et al., 2004); with conditions for the expression 
and purification of this construct being fully understood. This protein was shown to be 
active in the ligation of DNA and furthermore was sufficiently stable in its interaction 
with DNA substrate to allow protein:DNA crystals to form. A plasmid bearing ∆232 
HuLigI was obtained from Dr. T. Ellenberger‟s group and used to purify the truncated 
version of the protein to near homogeneity, after a two column purification over 
Nickel (affinity) and Q-sepharose (ion exchange) resins (Figure 4.6, panels A & B). 
Kodama et al. (1991) had previously demonstrated that truncated HuLigI (250-919 
amino acids) represents the catalytic domain of the enzyme. They showed this 
polypeptide was capable of forming enzyme adenylate complex and joining nicked 
DNA substrate in their in vitro assays with same ability as the full-length polypeptide. 
This construct was also able to complement a DNA ligase mutant of S. cerevisiae 
indicating that the truncated HuLigI (250-919 amino acids) is sufficient for biological 
activity in yeast and is thus able to fold into a functional protein without the presence 
of the amino-terminal region of the intact protein (Kodama et al., 1991). The 
availability of the crystal structure of HuLigI (232-919 amino acids) bound to 
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adenylated DNA further confirmed that the small truncated version of HuLigI is 
stable and a functional enzyme with sufficient catalytic domains (Pascal et al., 2004). 
The catalytic fragment of HuLigI is thus composed of a DNA binding domain (232-
532 amino acids) and catalytic core (533-919 amino acids) comprising adenylation 
domain and oligomer binding domain. Therefore, we decided to use this catalytically 
active, easily expressed and stable form of HuLigI to identify inhibitors in our rapid 
high throughput assay. Using this form of ligase allows the identification of inhibitors 
that bind either to the DNA-binding domain of HuLigI, thereby inhibiting DNA 
joining and also the catalytic pocket of the enzyme. Chen et al. (2008) showed that 
compounds inhibiting DNA recognition can be selective for individual human ligase 
enzymes. This may well be a more productive area to identify anti-human ligase 
inhibitors as the structure of the catalytic core in ligase enzymes is very highly 
conserved in respect of the three-dimensional location of conserved residues (Odell et 
al., 1999). 
 
The conventional method of screening for inhibitors of DNA ligases involves 
analysing reaction products by gel electrophoresis and is highly unsuitable for rapid 
processing of samples in a 96-well format. When this work was begun there were no 
reports of use of non-electrophoretic approaches for high throughput screening of 
DNA ligase inhibitors. This work aimed to develop a high throughput assay, based on 
the binding affinities of DNA oligonucleotides to Q-sepharose (an anion exchange 
resin), to screen chemical and natural product libraries for small molecule inhibitors 
against ATP-dependent DNA ligases from different origins. 
 
Odell et al. (2003) showed that a 30-mer hairpin strand with a 10 nucleotide 5‟ single 
strand tail when annealed with an excess of a 6-mer oligonucleotide (Figure 5.1) 
complementary to the tail can be efficiently joined in vitro to yield a 36-mer product 
where the 
32
P-label is incorporated into the backbone of the DNA strand. The assay 
method we have designed for DNA ligases incorporates this idea as a central part of a 
high-throughput screen for inhibitors. The different binding affinities of a 30-mer, 6-
mer and 36-mer to Q-sepharose were thus determined by their elution profile with 
different salt concentrations. Initial optimisation studies, performed with T4 DNA 
ligase, PBCV-1 DNA ligase and the truncated, catalytically active form of HuLigI, 
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demonstrated that the newly developed assay is as reliable as conventional 
electrophoresis-based methods in identifying potent DNA ligase inhibitors.  
 
The in silico docking approach, as adopted by Chen et al. (2008), to screen inhibitors 
for human DNA ligases, seems quite promising but it can only be used to screen 
synthetic libraries where the structure of the chemicals is already known. The rapid 
assay developed in this study can be used to screen natural product libraries, which 
provide greater structural diversity and will offer significant opportunities for finding 
novel low molecular weight lead compounds. 
 
Our preliminary screen was performed with crude cell mass extracts derived from 
Ganoderma - a white rot fungus rich in bioactive compounds with potential to 
develop anti tumour and anti bacterial compounds (Russell & Patterson, 2006; Silva, 
2006). We showed that the screen can be adapted for rapid processing of samples in a 
96-well format. The source library used in this study, being crude in nature, contains a 
mixture of peptides, organic compounds, denaturants and toxic host (Ganoderma) 
proteins. Further refinement in washing protocols and serial dilutions of the crude 
sample used for screening will be required to lower the background signal to identify 
accurate hit or lead compounds. Once potentially anti-ligase compound pools have 
been identified, mass spectrometry can be employed to characterise the molecules 
contained therein. These can then be further dissected by appropriate chromatography 
to identify the bioactive component. In order that compounds affecting the catalytic 
and DNA binding steps can be separated Biacore can be used to show whether the 
component affects DNA binding. Thus far the anti-cancer compounds identified by 
Chen et al. (2008) have been molecules that interfere with DNA binding by the 
human ligases. Future work will then include co-crystallisation of identified lead 
compounds with DNA ligases to determine modes of binding and to facilitate 
medicinal chemistry lead optimization. 
 
We also developed the inhibitor assay such that the screen can be used to identify 
potential anti-bacterial agents. There are reports of inhibitors being developed to 
target the essential bacterial NAD
+
-dependent ligases, such as those encoded by E. 
coli, S. aureus, M. tuberculosis and S.  pneumoniae (Ciarrocchi et al., 1999; Brotz-
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Oesterhelt et al., 2003; Srivastava et al., 2005; Meier et al., 2008). The potential for 
antibiotics to target these ligases relies on the fact that these enzymes are vital for all 
bacteria due to their participation in DNA replication. Genetic studies of NAD
+
-
dependent DNA ligases from B. subtilis, M. tuberculosis, S. typhimurium, E. coli, 
S. pneumoniae and S. aureus have established the essential nature of these enzymes 
for the growth of the organisms (Park et al., 1989; Petit & Ehrlich, 2000; Wilkinson & 
Bowater, 2001; Gong et al., 2004; Meier et al., 2008). Moreover, the differential 
cofactor requirement and structural differences between prokaryotic and eukaryotic 
representatives make them an attractive choice to be exploited as a potential 
antibacterial target (Ciarrocchi et al., 1999; Brotz-Oesterhelt et al., 2003; Srivastava 
et al., 2005).  
 
Of the three classes of NAD
+
-ligase inhibitors identified so far; pyridochromanones 
and glycosyl derivatives (ureides and amines) appear to inhibit NAD
+
-dependent 
DNA ligases by competing with NAD
+
 binding, whereas the aryl-amino compounds 
shows non-competitive inhibition for the NAD
+
 binding site
 
(Figure 3.31; Ciarrocchi 
et al., 1999; Brotz-Oesterhelt et al., 2003; Srivastva et al., 2005).  
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NAD+
Pyridochromanone derivatives
A
B
 
Figure 6.1: Chemical structures of inhibitors of NAD
+
-dependent DNA 
ligases 
Panel A shows the chemical structure of the compounds that bind competitively to the NAD
+ 
binding 
site and specifically inhibits the E. coli NAD
+
-dependent DNA ligase. Panel B shows the chemical 
structure of NAD
+ 
(Dwivedi et al., 2007). 
 
Pyridochromanones and glycosyl derivatives specifically inhibit NAD
+
-dependent 
DNA ligases, while not affecting ATP-dependent DNA ligases. The presence of 
additional ATP-dependent ligases in these pathogens however may contribute to the 
survival of cells treated with an NAD
+
-dependent DNA ligase inhibitor and could be 
crucial in the subsequent development of antibacterial drug resistance to such new 
antibiotics. 
 
In order that we could identify lead compounds that inhibit the action of ATP-
dependent DNA ligases we elected to use PBCV-1 DNA ligase. PBCV-1 DNA ligase 
is one of the smallest characterised eukaryotic ATP-dependent DNA ligases. Many 
aspects of its structure and mechanism have been determined and at 34 kDa, 
consisting of only the basic ligase catalytic core, it represents a minimal, functional 
ATP-dependent DNA ligase (Ho et al., 1997; Sriskanda & Shuman 1998, 2002; Odell 
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et al., 1999, 2000 & 2003; Nair et al., 2007; Figure 1.8, panels A & B). In regard to 
this close catalytic resemblance at the structural level it is important to note that the 
DNA binding mode employed by the human and PBCV-1 ligases differs. The HuLigI 
employs a dedicated DNA binding domain (DBD) of nearly 200 amino acids that is 
absent in the smaller ATP-dependent ligases found in bacteria and exemplified by the 
PBCV-1 enzyme. Structural analyses of HuLigI and PBCV-1 ligases in complex with 
DNA show that the DBD and the PBCV-1 ligase latch module function co-operatively 
with the AdD and OB domains and fulfil a similar role, encircling and clamping the 
DNA substrate (Pascal et al. 2004; Nair et al. 2007). The PBCV-1 ligase latch module 
is thus critical for stable DNA binding by this enzyme. Protein sequence alignment of 
other small ATP-dependent DNA ligases encoded by pathogenic bacteria reveals that 
the latch module is not always present in an analogous location within the protein 
(Figure 4.9). In some polypeptides it is not clear if the latch module is present thereby 
raising interesting questions about the ability of these enzymes to stably bind DNA. 
However, the putative ATP-dependent DNA ligase from Burkholderia pseudomallei, 
a human and animal pathogen and causative agent of melioidosis, has a region 
homologous to the essential DNA binding surface loop („latch‟) motif present in the 
PBCV-1 ligase. Although, B. pseudomallei possesses an NAD
+
-dependent DNA 
ligase we believe inhibition of the ATP-dependent DNA ligase will have therapeutic 
value. The role of this loop will need to be studied in more detail to get an insight into 
the properties/DNA binding of these additional small ATP-dependent DNA ligases 
encoded by pathogenic bacteria. We believe that the inhibitors identified from a 
PBCV-1 DNA ligase screen will possess high specificity for the ATP-dependent 
DNA ligase of B. pseudomallei.  
 
Whilst analysing/searching for other organisms where their DNA ligase might 
represent viable targets for therapeutic intervention, we observed that the recently 
annotated parasite Trichomonas vaginalis‟s genome contained only one ligase. The 
identified open reading frame (ORF; XP_001581589), with conserved key 
nucleotidyltransferase motifs (I-VI), bears significant homology to the replicative 
DNA ligases of human, yeast and drosophila (Figure 3.3; Appendix 7.2, Figure 7.1). 
The order and spacing of conserved motifs in the putative ligase is similar, as is its 
sequence conservation, to that seen in other ATP-dependent ligase family members 
201 
 
(Figure 3.4; panel A). The sequence analysis of TVlig revealed an N-terminal NLS, a 
conserved PCNA interacting polypeptide (PIP) motif, DNA binding domain and a C-
terminal catalytic core (Figure 3.4, panel B). The predicted tertiary structure of TVlig 
suggests close alignment with known structure of HuLigI bound to adenylated DNA 
(Figure 3.30; Pascal et al., 2004). Our in-depth bioinformatics analysis of TV genome 
concluded that firstly the TV DNA ligase polypeptide represents a true homologue of 
HuLigI and secondly that its genetic complement is devoid of DNA ligase III and IV 
homologues and the accessory proteins (XRCC1 and XRCC4) required for their 
catalytic function. These findings mirrored those observed from analysis of the 
Plasmodium falciparum genome during the study of DNA ligase I from this organism 
(Buguliskis et al., 2007; published contemporaneously with our study).  
 
The inhibition of such a single replicative, DNA ligase I will profoundly affect the 
repair, replication and recombination of the TV organism. Disruption of such a 
biochemical link might suggest for a rational approach to stop replication and hence 
propagation of the parasite during infection. Moreover, the trichomonads adhere to 
vaginal epithelial cells, thereby raising the possibility of a therapeutic that can be 
administered topically without much effect on the host organism. In this regard it is 
important to note that the single DNA ligase of P. falciparum may in fact not be a 
good target. The parasite resides intra-cellularly within red blood cells of the host and 
disruption of the ligase through inhibition of the catalytic domain may cause 
coincidental inhibition of the human enzymes. It remains to be seen whether the mode 
of DNA binding by the parasite and the human are the same. The initial study 
reported here suggests that the TVlig does not bind to its substrate (nicked DNA) in 
the same manner as the human enzyme (Figures 3.26 & 3.27).   
 
DNA repair mechanisms are aimed at preserving the genomic integrity of an 
organism. Our BLAST analysis suggests that the TV genome lacks core proteins of 
the non-homologous end joining pathway; a principal mechanism to repair double-
strand DNA (dsDNA) breaks in eukaryotes. The apparent absence of DNA repair 
genes involved in double-strand break repairs raises questions about the ability of TV 
and other similar protozoans (P. falciparum) to repair such damages – do they utilise 
a unique, previously uncharacterised method or are they unable to repair dsDNA 
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breaks? Do they instead function in co-ordination with other enzymes, such as 
endonucleases and convert double strands to single strands? And even then how this 
is accurately joined to the other broken end and which enzyme do they use to align the 
DNA ends?  
 
An absence of DNA repair genes has also been reported in Encephalitozoon cuniculi, 
a single celled parasitic eukaryote belonging to the group of microsporidia (Gill & 
Fast, 2007). The E. cuniculi genome has undergone massive genomic reduction 
resulting in a loss of genes from diverse biological pathways, including those that act 
in double strand DNA repair (Gill & Fast, 2007). This is clearly not the case in TV. 
The protein-coding complement of the TV genome numbers almost three times as 
many as the human genome and is the largest (approximately 60,000) of any 
eukaryotic genome sequenced to date (Carlton et al., 2007). 
  
Our literature survey suggests that the common feature in successful therapies 
employed against T. vaginalis and P. falciparum involves DNA damage of these 
parasites. For example, quinine (an anti-malarial drug) complexes with double-
stranded DNA to prevent strand separation and blocks DNA replication (Ibezim & 
Odo, 2008). Similarly, the reduced (active) form of metronidazole (a drug used for the 
treatment of trichomoniasis) disrupts the helical structure of the DNA and prevents 
nucleic acid synthesis which eventually leads to cell death (Cudmore et al., 2004; 
Sood & Kapil, 2008). However, these drugs do not seem to affect host (human) cell‟s 
DNA replication. We believe that the sensitivity of these parasites towards DNA 
damaging drugs may be as a result of their inability to repair such damage.  
 
Based on previous reports of DNA damage repair in T. brucei and P. falciparum and 
their phylogenetic relationship with TV, I would speculate that the repair of single-
strand breaks in TV DNA are performed by long-patch base excision repair (BER) 
pathway and double-strand repair is performed by the microhomology end joining 
method (MHEJ). Both of these pathways function with DNA ligase I as the terminal 
DNA sealing enzyme, as observed by in vitro experiments carried on mammalian cell 
lines and T.brucei and P.falciparum extracts (Haltiwanger et al., 2000; Burton et al., 
2007; Casta et al., 2008; Liang et al., 2008).   
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It remains to be seen what enzymes TV can utilise for such repair. One method to 
isolate any interacting partners might be to utilise the recombinant TVlig. Larger 
cellular ATP-dependent DNA ligases such as DNA ligase I, III and IV do not function 
in isolation, but interact with other proteins that target them to lesions requiring 
sealing (Tomkinson et al., 2006; Ellenberger & Tomkinson, 2008). Surface Plasmon 
Resonance (SPR), using Biacore, could be applied to assess the effect of protein 
interactions by analysing TVlig DNA binding in the presence of TV protein extracts. 
SPR is a solution study which facilitates the direct measurement of real-time 
interactions, even if these interactions do not result in the formation of stable 
complexes. SPR further allows the investigation of the dynamic nature of the ligase 
DNA interaction making it possible to examine the importance of the contribution of 
individual residues and different modules implicated in DNA binding. Leppard et al. 
(2003) used Biacore to assess the binding of Human DNA ligase III on nicked DNA 
duplex. However the concentration of DNA ligase that they used to analyse binding 
(20,000 RU) was far in excess of the 200 RU that is recommended for such studies. 
This may have led to mass transfer effects that may have represented non-specific 
binding. Certainly their ligase disengaged from DNA as soon as the enzyme was no 
longer being passed over the substrate. This is in stark contrast to the more stable 
forms of binding that we have observed using Biacore analysis (Figures 3.26 & 3.27). 
This technique has also been used to study DNA binding by PBCV-1 DNA ligase 
(Brooke, PhD Thesis, 2007).  
 
The presence of a PIP motif in the TVlig made us search for a PCNA homologue in 
the TV genome. PCNA is a well conserved protein found in all eukaryotic species 
from yeast to humans (Stoimenov & Helleday, 2009). It belongs to the family of DNA 
sliding clamps (β clamps of E. coli) and is a toroidal molecule essential for processive 
DNA synthesis in Archaea and Eukaryotes. A BLAST search of the TV genome using 
PCNA gene sequences from human, yeast and drosophila identified an ORF encoding 
a putative PCNA polypeptide (XP_001329442). The ORF of TvPCNA when aligned 
with human PCNA shows 42% identity and 62% similarity (Figure 3.32). 
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HuPCNA :     1 MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTY    
TvPCNA :     1 MVECRLTNPGNLKKILDALRDLVEEANIECSETGLSLQAMDTAHVALVSMNLNANGFEKY  
 
HuPCNA :    61 RCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMD  
TvPCNA :    61 NCAQNTSLGVNLGAIQKILKCGDNNDVLTLETNEDQSCLKFKFENSSSDRYFEFQMNLMD  
 
HuPCNA :   121 LDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNI  
TvPCNA :   121 ISSEHLSIPDAEPEATITLGCSEFQKICRDLAQFGDTVKITVEKSRVSFAVAGTNTNCCL  
 
HuPCNA :   181 KLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLSMSADVPLVVEYK  
TvPCNA :   181 NYSNFESAGKDGSQVTIQCEDKIELSFALRYLNLFTKAAPLSENVKLCLSNDRPFLVQFD  
 
HuPCNA :   241 IAD-MGHLKYYLAPKIEDEE 259 
TvPCNA :   241 LEDEAGDIKYYLAPKVDDNE 260 
 
 
 
 
 
      Figure 6.2: Sequence alignment of putative TvPCNA and HuPCNA 
A BLAST search of TV genome using amino acid sequence of human PCNA gene (HuPCNA; 
NP_002583.1) revealed the presence of a putative TvPCNA (XP_001329442). Conserved residues are 
shown in green and identical residues are shown in yellow. The alignment was performed with 
ClustalW (Chenna et al., 2003). 
 
The putative TvPCNA could be characterised and its binding with TVlig could then 
be assessed using Biacore. Such an analysis may help to unravel the strange DNA 
binding we have observed by Biacore of the TVlig (Figures 3.26 & 3.27). Unlike the 
PBCV-1 enzyme the TVlig shows little discrimination for the gapped versus duplex 
DNA in its binding step (Figure 3.26). It bound very rapidly to all types of DNA 
substrate, nick, gap and duplex (the on-rate was too fast to measure accurately) 
however it showed rapid dissociation from both the duplex „product‟ and the gapped 
„non-productive substrate‟ DNA‟s. The binding to the true ligase substrate – nicked 
DNA – was unusual. At all concentrations the amount of enzyme bound (reflected by 
the total response units; RU) was half that of the duplex DNA substrate, the product 
of the ligation reaction. Previously this discrimination has been observed for the 
PBCV-1 enzyme where the conclusion was drawn that if the nick is centrally placed 
then specific nick recognition would restrict further enzyme binding (Figure 3.27, 
panel B).   
 
At the lower enzyme concentrations (0.1 - 0.5 µM) studied we observed a 
concentration dependent binding and subsequent slow release from the DNA. At 
higher concentrations the enzyme showed a biphasic binding; the initial binding was 
weaker than at lower enzyme concentrations but this altered when the ligase enzyme 
was no longer passed over the surface of the chip. A mechanism has yet to be 
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developed to explain the observations. We initially wondered if the enzyme was 
oligomerising at higher concentrations (1-3 µM) in a manner that might restrict DNA 
binding. When the enzyme was no longer being added to the chip surface the 
concentration would drop rapidly potentially allowing the enzyme to bind to the 
DNA.When we analysed the behaviour of the TVlig at similar concentrations by 
sucrose density gradient it behaved as a monomer (Figure 3.29). This suggests that the 
altered nick binding profile does not reflect a simple oligomerisation of the protein at 
higher concentrations. In the future it will be desirable to extend the assay with TV 
extracts or recombinant proteins to study the interaction of DNA ligase I with PCNA 
during long-patch DNA repair, thereby providing valuable information about the 
DNA repair processes of the parasite. It would also be informative to compare the 
DNA damage repair mechanism of TV with that of Trypanosoma brucei using cell 
free extracts as described by Conway et al. (2000a & 2000b). Future work will also 
include determining the 3-D structure of TVlig alone or in complex with a DNA 
ligand by X-ray crystallography. The determination of the structure of this enzyme 
either bound to its partner proteins or ligand could help in understanding how the 
ligase functions. It will also provide a means whereby computer aided drug design 
(CADD) can be utilised to identify molecules that will specifically inhibit TVlig and 
not the host cellular ligases. 
 
This work has developed a novel assay to screen for inhibitors of ATP-dependent 
DNA ligases which can be adapted for commercial usage in screening libraries of 
small molecules. This study has also enhanced the understanding of DNA ligase and 
repair mechanisms in parasitic protozoa, particularly the Trichomonad T. vaginalis. 
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CHAPTER 7: APPENDICES 
7.1 STRAINS OF E. coli AND PLASMIDS USED 
 
Table 7.1: Genotypes of E. coli used in this thesis 
 
E.coli strains Genotype
DH5α 
(Invitrogen)
F- ф80dlacZ Δ M15 Δ (lacZYA-argF) U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 - λthi-1 gyrA96 relA1
BL21 (DE3)
(Novagen)
F– ompT hsdSB(rB– mB–) gal dcm (DE3
JM109
(Promega)
endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB+ Δ(lac-proAB) 
e14- [F' traD36 proAB+ lacIq lacZΔM15] hsdR17(rK-mK+)
 
 
Table 7.2: Plasmids used in this thesis 
 
Plasmid Function Gene encoded Other 
pET-16b T7 promoter-based expression 
vector. N-terminal 6xHis tag, 
Factor Xa site, 3 cloning sites 
(Nde I, Xho I and Bam HI), lacI 
coding sequence, pBR322 origin, 
bla coding sequence 
PBCV-1 DNA ligase; 
TV DNA ligase and 
K338A mutant; 
HuLigI (full-length) 
Original plasmid – 
Novagen 
pET-16b-latch  
Kind gift from Prof. S. 
Shuman (Sloan Kettering 
Institute, New York, 
USA).  
pET-28a T7 promoter-based expression 
vector. N-terminal 6xHis tag, C-
terminal 6xHis tag, thrombin tag, 
T7 tag, multiple cloning sites (11: 
Bam HI – Xho I), lacI coding 
sequence, pBR322 origin, f1 
origin, Kan coding sequence. 
HuLigI-Δ232 Original plasmid 
(Novagen)  
 
pET28a- HuLigI-Δ232, 
Kind gift from Prof. T. 
Ellenberger (Washinton 
University, Washington, 
USA) 
pGEM-T   Cloning of PCR 
products 
Promega (USA) 
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7.2 SEQUENCE ALIGNMENTS GENERATED DURING THE COURSE 
OF THE THESIS 
 
7.2.1 Sequence alignment of ATP-dependent DNA ligase I from T. vaginalis and 
its orthologues from other organism. 
                                                                    I     
S.pombe             EHG-LGTLRETCKLTPGIPTKPMLAKPTKQISEVLNTFDQAAFTCEYKYDGERAQVHFTE 428 
S.cerevisae         EHG-IMNLDKYCTLRPGIPLKPMLAKPTKAINEVLDRFQGETFTSEYKYDGERAQVHLLN 431 
D.melanogaster      KYD-IKELQERCPMHPGMPLRPMLAQPTKGVHEVFERFGGMQITCEWKYDGERAQIHRNE 407 
A.gambiae           EHG-VQRLSEHCPMEPGTPLKPMLAHPTKGVQEVLQRFDGIDFTCEWKYDGERAQIHLLA 322 
H.Sapiens           EHG-LERLPEHCKLSPGIPLKPMLAHPTRGISEVLKRFEEAAFTCEYKYDGQRAQIHALE 580 
A.thaliana          SGG-VWNLPKTCNFTLGVPIGPMLAKPTKGVAEILNKFQDIVFTCEYKYDGERAQIHFME 456 
P.knowlesi          NGDDMNTLSKKCTVKAGLPVQPMLAKPTKGIQEVLDRFNNVTFTCEYKYDGERAQIHYID 587 
P.falciparum        NGDDMNTLSKKCTVKTGIPVQPMLAKPTKGVQEVLDRFNNVTFTCEYKYDGERAQIHYID 574 
T.vag               RGS-FKGAEKNINIKVGIPAMPMLAKPAKKLDEIKRRLGDGRITGEYKYDGERAQIHKNK 351 
P.furiosus          LEG--NEGLAKVQVQLGKPIKPMLAQQAASIRDALLEMGG-EAEFEIKYDGARVQVHK-D 260 
                                          :       : :                            
                           Ia                   III 
S.pombe             DGKFYVFSRNSENMSVRYPDISVSVSKWKKPDARSFILDCEAVGWDRDENKILPFQKLAT 488 
S.cerevisae         DGTMRIYSRNGENMTERYPEINITDFIQDLDTTKNLILDCEAVAWDKDQGKILPFQVLST 491 
D.melanogaster      KGEISIFSRNSENNTAKYPDLIARSTALLKGDVKSYIIDSEIVAWDVERKQILPFQVLST 467 
A.gambiae           DGSVQIFSRNQENNTSKYPDVIARLEFTRTEPVASAILDCEAVAWDTDKRQILPFQVLST 382 
H.Sapiens           GGEVKIFSRNQEDNTGKYPDIISRIPKIKLPSVTSFILDTEAVAWDREKKQIQPFQVLTT 640 
A.thaliana          DGTFEIYSRNAERNTGKYPDVALALSRLKKPSVKSFILDCEVVAFDREKKKILPFQILST 516 
P.knowlesi          KDNIKIFSRNLETMTEKYPDVIQIVRDQIISGATECIIDSEVVAYDIENKKILPFQVLTT 647 
P.falciparum        KDNIKIFSRNLETMTEKYPDVIQIIKDQIGENVKECIIDSEVVAYDIVNNKILPFQVLTT 634 
T.vag               EGKVRIFSRSAEDSTAKFADVADIITDNVKG--EQYILDSEIVAYDPEKHVILPFQTLMN 409 
P.furiosus          GSKIIVYSRRLENVTRAIPEIVEALKEAIIP--EKAIVEGELVAIG-ENGRPLPFQYVLR 317 
                           .:          :                            .      : .   
                          IIIa 
S.pombe             --RKRKDVKIGDIKVRACLFAFDILYLNGQPLLETPLNERRKLLYSMFQPSTGDFTFAKH 546 
S.cerevisae         --RKRKDVELNDVKVKVCLFAFDILCYNDERLINKSLKERREYLTKVTKVVPGEFQYATQ 549 
D.melanogaster      --RKRKNVDIEEIKVQVCVYIFDLLYINGTALVTKNLSERRKLLLEHFQEVEGEWKFATA 525 
A.gambiae           --RKRKDANEADIKVQVCVFMFDLLYLNGEPLVERPFVERRELLYRHFREIEGQWQYATR 440 
H.Sapiens           --RKRKEVDASEIQVQVCLYAFDLIYLNGESLVREPLSRRRQLLRENFVETEGEFVFATS 698 
A.thaliana          --RARKNVNVNDIKVGVCIFAFDMLYLNGQQLIQENLKIRREKLYESFEEDPGYFQFATA 574 
P.knowlesi          --RKRKDVDIENIKVKICLFPFDLICCNGVPVIKEPLEIRRKLLYSLLKCKEGVLCYATH 705 
P.falciparum        --RKRKDVDIENIKVKVCLFPFDLICCNGIPVIKEPLAVRRKLLYSLLKSKDGVLSYATH 692 
T.vag               --RPKKGTDTP-SAIHVCVCAFDLLSYNGVSMLDEPLEKRRDKLHEIVTVVPTKLQLATY 466 
P.furiosus          RFRRKHNIEEMMEKIPLELNLFDVLYVDGQSLIDTKFIDRRRTLEEIIKQNE-KIKVAEN 376 
                                      :  :  :  .        :                        
                                         IV               V                 
S.pombe             SDQKSIESIEEFLEESVKDSCEGLMVKMLEGPDSHYEPSKRSRHWLKVKKDYLSGVG--- 603 
S.cerevisae         ITTNNLDELQKFLDESVNHSCEGLMVKMLEGPESHYEPSKRSRNWLKLKKDYLEGVG--- 606 
D.melanogaster      LDTNDIDEVQQFLEESIKGNCEGLMVKTLD-EEATYEIAKRSRNWLKLKKDYLSNVG--- 581 
A.gambiae           LDTGDLDELQRFLDEAVRGNCEGLMVKTLA-REATYEIAKRSRNWLKLKKDYLTGVG--- 496 
H.Sapiens           LDTKDIEQIAEFLEQSVKDSCEGLMVKTLD-VDATYEIAKRSHNWLKLKKDYLDGVG--- 754 
A.thaliana          VTSNDIDEIQKFLDASVDVGCEGLIIKTLD-SDATYEPAKRSNNWLKLKKDYMDSIG--- 630 
P.knowlesi          SEMNNVEDMDIFLQDAIENNCEGLMVKTLL-DNASYEPSRRSLNWLKVKKDYIEGLS--- 761 
P.falciparum        SEMNNIEDIDMFLQDAIENNCEGLMVKTLV-ENASYEPSRRSLNWLKVKKDYVEGLS--- 748 
T.vag               KNASKIEDLGDFFEEAVSNRTEGLMVKTLN---GRYECGKRAMSWAKLKKDYISKEVFKG 523 
P.furiosus          LITKKVEEAEAFYKRALEMGHEGLMAKRLD---AVYEPGNRGKKWLKIKPT--------- 424 
                           .       :                                             
S.pombe             --------DSLDLIVIGAYYGKGKRTSVYGAFLLGCYDPDTETVQSICKLGTGFSEEHLE 655 
S.cerevisae         --------DSLDLCVLGAYYGRGKRTGTYGGFLLGCYNQDTGEFETCCKIGTGFSDEMLQ 658 
D.melanogaster      --------DSLDLVVIGGYKGKGRRTGTYGGFLLACYDTENEEYQSICKIGTGFTDEDLQ 633 
A.gambiae           --------DSLDLVVIGGYRGRGKRTGTYGGFLLACYDEENEEYQTICKIGTGFSDDDLQ 548 
H.Sapiens           --------DTLDLVVIGAYLGRGKRAGRYGGFLLASYDEDSEELQAICKLGTGFSDEELE 806 
A.thaliana          --------DSVDLVPIAAFHGRGKRTGVYGAFLLACYDVDKEEFQSICKIGTGFSDAMLD 682 
P.knowlesi          --------DSVDLVPIAGYYGKGKRSGVYGAFVLATYNSETENFQTVCKAGTGFSDEILG 813 
P.falciparum        --------DSVDLVPIAGYYGKGKRSGVYGAFVLAAYNSETENFQTVCKAGTGFSDEILS 800 
T.vag               GVAEEIPPDTIDVVVIGATYGKGKRTSVYGAFLVGVYNNVTGKVESLCFVGTGFKEDDLK 583 
P.furiosus          -------MENLDLVIIGAEWGEGRRAHLFGSFILGAYDPETGEFLEVGKVGSGFTDDDLV 477 
                                                                      * *        
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S.pombe             TFYNQLKDIVISKKKDFYAHSDVPAHQPDVWFEPKYLWEVLAADLSLSPVYKAAIGYVQE 715 
S.cerevisae         LLHDRLTPTIIDGPKATFVFDSS--AEPDVWFEPTTLFEVLTADLSLSPIYKAGS--ATF 714 
D.melanogaster      THSEFLGKHVTSAAKSYYRYDPS--LEPDHWFEPVQVWEVKCADLSLSPIHRAAIGIVDG 691 
A.gambiae           RHTEFFRSHVIAAAKPYYRHEAN--VVPDDWFEPVQVWEVLCADLSLSPVHRAGIGIIDP 606 
H.Sapiens           EHHQSLKALVLPSPRPYVRIDGA--VIPDHWLDPSAVWEVKCADLSLSPIYPAARGLVDS 864 
A.thaliana          ERSSSLRSQVIATPKQYYRVGDS--LNPDVWFEPTEVWEVKAADLTISPVHRAATGIVDP 740 
P.knowlesi          SLYDTLSDKIIPSKKSYYEVSDK--LNPDVWFDAHYVWEVKAADLSLSPVHTAAIGVYSD 871 
P.falciparum        TLYETLSEKIIPNKKSYYEVSDK--LNPDVWFDAHYVWEVKAADLSLSPVHTAAIGIYAD 858 
T.vag               EFYEKLHPLEMEKCPDNVDCRPLD--QDPVFFKPELVWEIQVADIQTTPTYSACWG-ELG 640 
P.furiosus          EFTKMLKPLIIKEE------------GKRVWLQPKVVIEVTYQEIQKSPKY--------- 516 
                               VI 
S.pombe             DKGISLRFPRFIRIREDKSWEDATTSEQVSEFYRSQVAYSQKEKEGSPAAEDY--- 768 
S.cerevisae         DKGVSLRFPRFLRIREDKGVEDATSSDQIVELYENQSHMQN--------------- 755 
D.melanogaster      ERGISLRFPRFIRIRDDKNSENATDANQVAHMYQSQDQVKNNQKSSTQMEMEDEFY 747 
A.gambiae           EKGISLRFPRFIRVREDKGVTDATSARQVSEMYLNQDQIKN-QTGSNARDVEEDFY 661 
H.Sapiens           DKGISLRFPRFIRVREDKQPEQATTSAQVACLYRKQSQIQNQQGEDSGSDPEDTY- 919 
A.thaliana          DKGISLRFPRLLRVREDKKPEEATSSEQIADLYQAQKHNHP----SNEVKGDDD-- 790 
P.knowlesi          DKGIGLRFPRFLRLREDKNAEQATTSQQIVDLYEAQFTYNKNKN-DFNEESESE-- 924 
P.falciparum        DKGIGLRFPRFLRLREDKNAEQATTTQQIVDFYEAQFSSNKNKNIDYNDDTESE-- 912 
T.vag               EKGLTIRFGRYYRTRTDKTWEQSTSTEQLLELYHQQFEK----------------- 679 
P.furiosus          RSGFALRFPRFVALRDDKGPEDADTIERIAQLYELQEKMKGKVES----------- 561 
                          *.      *  :                                       
Figure 7.1: Amino acid sequence alignment of TVlig with other ATP-
dependent DNA ligases. 
Sequence alignment (from motif I) of a selection of ATP-dependent DNA ligases with amino acid 
sequence of TVlig (Tvag; obtained from TIGR database; 85859.m00330. The accession number of the 
DNA ligases used to generate above alignment are as follows:  
Saccharomyces pombe (S.pombe; NP_593318.1), Saccharomyces cerevisiae (S. cerevisae; 
NP_010117.1), Drosophila melanogster (D.melanogster; NP_611843.2), Anopheles gambiae 
(A.gambiae; NP_319999.1), Homo sapiens (H. sapiens; NP_000225.1), Arabidopsis thaliana 
(A.thaliana; NP_175351.1), Plasmodium knowlesi (P.knowlesi; XP_00226193), Plasmodium 
falciparum (P. falciparum; AAL59668), Pyrococcus furiosus (P.furiosus; NP_579364). The alignment 
was performed with ClustalW (Chenna et al., 2003). 
7.2.2 Alignment of TVlig with DNA ligases III & IV 
 
HuLigIV            ----MAASQTSQTVASHVPFADLCSTLER-IQKSKGRAEKIRHFREFLDSWRKFHDALHK 55 
DnL4               MISALDSIPEPQNFAPSPDFKWLCEELFVKIHEVQINGTAGTGKSRSFKYYEIISNFVEM 60 
TVlig              --------MTQQGIAKFFGGKD--------IESTKKNAIVRKQVNVNISDFDNVFKDVEI 44 
HuLigIIIalpha      ----MSLAFKIFFPQTLRALSRKELCLFRKHHWRDVRQFSQWSETDLLHGHPLFLRRKPV 56 
                                                  .  . .          :     .       
 
HuLigIV            NHKDVTDSFYPAMRLILPQLERERMAYGIKETMLAKLYIELLNLPRDGKDALKLLNYR-- 113 
DnL4               WRKTVGNNIYPALVLALPYRDRR--IYNIKDYVLIRTICSYLKLPKNSATEQRLKDWK-- 116 
TVlig              P--------------------------TVEGYNIPRDVVGYVAWNR-------------- 64 
HuLigIIIalpha      LSFQGSHLRSRATYLVFLPGLHVGLCSGPCEMAEQRFCVDYAKRGTAGCKKCKEKIVKGV 116 
                                                      :                         
 
HuLigIV            ---------TPTGTHGDAGDFAMIAYFVLKPRCLQKGSLTIQQVNDLLDSIASNNSAKR- 163 
DnL4               ---------QRVGKGGNLSSLLVEEIAKRRAEPSSK-AITIDNVNHYLDSLSGDRFASGR 166 
TVlig              ---------------GDPIPFTFITKMVDELEPLTGKLEINDLLCKYFLAILMTT----- 104 
HuLigIIIalpha      CRIGKVVPNPFSESGGDMKEWYHIKCMFEKLERARATTKKIEDLTELEGWEELEDNEKEQ 176 
                                  *:            . .         : : .               
 
HuLigIV            --KDLIK-KSLLQLITQSSALEQKWLIRMIIKDLKLG---------VSQQTIFSVFHNDA 211 
DnL4               GFKSLVKSKPFLHCVENMSFVELKYFFDIVLKNRVIG---------GQEHKLLNCWHPDA 217 
TVlig              -PKDIVP--FVFLCLGQLRPNHEGVKINIGQESIISA---------LGDKKVVKEKLKKE 152 
HuLigIIIalpha      ITQHIADLSSKAAGTPKKKAVVQAKLTTTGQVTSPVKGASFVTSTNPRKFSGFSAKPNNS 236 
                     : :           :                               . . ..    .  
 
HuLigIV            AELHNVTTDLEKVCRQLHDPSVGLS-----------DISITLFSAFKPMLAAIADIEHIE 260 
DnL4               QDYLSVISDLKVVTSKLYDPKVRLKDD---------DLSIKVGFAFAPQLAKKVNLSYEK 268 
TVlig              GDLSKVAQQIRSTQKSMTS------------------------------MFGKVNEAYTI 182 
HuLigIIIalpha      GEAPSSPTPKRSLSSSKCDPRHKDCLLREFRKLCAMVADNPSYNTKTQIIQDFLRKGSAG 296 
                    :  .     .    .  .                              :           
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HuLigIV            KD-MKHQSFYIETKLDGERMQMHKD--GDVYKYFSRNGYNYTDQFGASPTEGSLTPFIHN 317 
DnL4               ICRTLHDDFLVEEKMDGERIQVHYMNYGESIKFFSRRGIDYTYLYGASLSSGTISQHLR- 327 
TVlig              TG--VYKEFLKMAGFQG--------------ANSDRNRTQTIQKLLTNCKPEEVKCIVR- 225 
HuLigIIIalpha      DGFHGDVYLTVKLLLPGVIKTVYNLNDKQIVKLFSRIFNCNPDDMARDLEQGDVSETIRV 356 
                           :     : *                 .*           .     :.  ::  
 
HuLigIV            AFKADIQICILDGEMMAYNPNTQTFMQKGTKFD----IK-RMVE------DSDLQTCYCV 366 
DnL4               -FTDSVKECVLDGEMVTFDAKRRVILPFGLVKG----SA-KEALSFNSINNVDFHPLYMV 381 
TVlig              ---------MLECKLRVGAAHESFLFALGMAFRRREYIMG-------------------- 256 
HuLigIIIalpha      FFEQSKSFPPAAKSLLTIQEVDEFLLRLSKLTK--EDEQQQALQDIASRCTANDLKCIIR 414 
                                .: .       ::  .                                
 
HuLigIV            FDVLMVNNKKLGHETLRKRYEILSSIFTPIPGRIEIVQKTQAHTKNEVIDALNEAIDKRE 426 
DnL4               FDLLYLNGTSLTPLPLHQRKQYLNSILSPLKNIVEIVRSSRCYGVESIKKSLEVAISLGS 441 
TVlig              -----MIKNNPDEEDLKDHGHLFREIYYRYPIIDEILVEFLRGSFKGAEKNINIKVGIPA 311 
HuLigIIIalpha      LIKHDLKMNSGAKHVLDALDPNAYEAFKASRNLQDVVERVLHNAQEVEKEPGQRRALSVQ 474 
                        :  ..     *        .         :::        :   .  :        
 
HuLigIV            EGIMVKQPLSIYKPDKRGEGWLKIKPEYVSGLMDELDILIVGGYWGKGSRGGMMSHFLCA 486 
DnL4               EGVVLKYYNSSYNVASRNNNWIKVKPEYLEEFGENLDLIVIGRDSGKKDSFMLGLLVLDE 501 
TVlig              MPMLAKPAKKLDEIKRRLG---------DGRITGEYKYDGERAQIHKNKEGKVRIFSRSA 362 
HuLigIIIalpha      ASLMTPVQPMLAEACKSVEYAMKKCP---NGMFSEIKYDGERVQVHKNGDHFSYFSRSLK 531 
                     ::        :                  :  : .         *              
 
HuLigIV            VAEKPPPGEKPSVFHTLSR-------------------VGSGCTMKELYDLGLKLAKYWK 527 
DnL4               EEYKKHQGDSSEIVDHSSQEKHIQNSRRRVKKILSFCSIANGISQEEFKEIDRKTRGHWK 561 
TVlig              EDSTAKFADVADIITDNVK--------------------------GEQYILDSEIVAYDP 396 
HuLigIIIalpha      PVLPHKVAHFKDYIPQAFPG-------------------------GHSMILDSEVLLIDN 566 
                          ..  . .                                .   :. :       
 
HuLigIV            PFHRKAPPSSILCG-TEKPEVYIEPCNSVIVQIKAAEIVPSD-------MYKTGCTLRFP 579 
DnL4               RTSEVAPPASILEFGSKIPAEWIDPSESIVLEIKSRSLDNTETNMQ---KYATNCTLYGG 618 
TVlig              EKHVILPFQTLMNR----PKKGTDTPSAIHVCVCAFDLLSYN------------------ 434 
HuLigIIIalpha      KTGKPLPFGTLGVH-KKAAFQDANVCLFVFDCIYFNDVSLMDRPLCERRKFLHDNMVEIP 625 
                         *  ::       .    :    :   :   .:   :                   
 
HuLigIV            RIEKIRDDKEWHECMTLDDLEQLRGKASGKLASKHLYIGGDDEPQEKKRKAAPKMKKVIG 639 
DnL4               YCKRIRYDKEWTDCYTLNDLYESRTVKS------NPSYQAERSQLGLIRKKRKRVLISDS 672 
TVlig              ------------GVSMLDEPLEKR-----------------RDKLHEIVTVVPTKLQLAT 465 
HuLigIIIalpha      NRIMFSEMKRVTKALDLADMITRVIQEGLEGLVLKDVKGTYEPGKRHWLKVKKDYLNEGA 685 
                                   * :                              .           
 
 
HuLigIV            IIEHLKAPNLTNVNKISNIFEDVEFCVMSGT--------------DSQPKPDLENRIAEF 685 
DnL4               FHQNRKQLPISNIFAGLLFYVLSDYVTEDTG--------------IRITRAELEKTIVEH 718 
TVlig              YKNASKIEDLGDFFEEAVSNRTEGLMVKTLN--------------GRYECGKRAMSWAKL 511 
HuLigIIIalpha      MADTADLVVLGAFYGQGSKGGMMSIFLMGCYDPGSQKWCTVTKCAGGHDDATLARLQNEL 745 
                     :  .   :  .                                             :  
 
HuLigIV            GGYIVQNPGPDTYCV----IAGSENIRVKNIILSNKHDVVKPAWLLECFKTKSFVPWQPR 741 
DnL4               GGKLIYNVILKRHSIGDVRLISCKTTTECKALIDRGYDILHPNWVLDCIAYKRLILIEPN 778 
TVlig              KKDYIS-----------------KEVFKGGVAEEIPPDTIDVVVIGATYGKGKRTSVYGA 554 
HuLigIIIalpha      DMVKISKDPSKIPSWLKVNKIYYPDFIVPDPKKAAVWEITGAEFSKSEAHTADGISIRFP 805 
                       :                                :                       
 
HuLigIV            FMIHMCPSTKEHFAREYDCYGDSYFIDTDLNQLKEVFSGIKNSNEQTPEEMASLIADLEY 801 
DnL4               YCFNVSQKMRAVAEKRVDCLGDSFENDISETKLSSLYK-----SQLSLPPMGELEIDSEV 833 
TVlig              FLVGVYNNVTGKVES--LCFVGTGFKEDDLKEFYEKLH---------PLEMEKCPDNVDC 603 
HuLigIIIalpha      RCTRIRDDKDWKSATNLPQLKELYQLSKEKADFTVVAGDEGSSTTGGSSEENKGPSGSAV 865 
                       :  .                  . .  .:                   .   .    
 
HuLigIV            RYSWDCSPLSMFRRHT---------------VYLDSYAVINDLSTKNEGTRLAIKALELR 846 
DnL4               RR----FPLFLFSNRI---------------AYVPRRKISTEDDIIEMKIKLFGGKITDQ 874 
TVlig              RP---------LDQDP---------------VFFKP------------------------ 615 
HuLigIIIalpha      SRKAPSKPSASTKKAEGKLSNSNSKDGNMQTAKPSAMKVGEKLATKSSPVKVGEKRKAAD 925 
                                .                 .                             
 
 
 
 
HuLigIV            --FHGAKVVSCLAEGVSHVIIGEDHSRVADFKAFRRTFKRKFKILKESWVTDSIDK-CEL 903 
DnL4               QSLCNLIIIPYTDPILRKDCMNEVHEKIKEQIKASDTIPKIARVVAPEWVDHSINENCQV 934 
TVlig              ELVWEIQVADIQTTPTYSACWGELGEKGLTIRFGRYYRTRTDKTWEQSTSTEQLLELYHQ 675 
HuLigIIIalpha      ETLCQTKVLLDIFTGVRLYLPPSTPDFSRLRRYFVAFDGDLVQEFDMTSATHVLGSRDKN 985 
                     .    :              .  .                :        . : .  .  
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HuLigIV            QEENQYLI---------------- 911 
DnL4               PEEDFPVVNY-------------- 944 
TVlig              QFEK-------------------- 679 
HuLigIIIalpha      PAAQQVSPEWIWACIRKRRLVAPC 1009 
 
 
Figure 7.2: Sequence alignment of TVlig, Human DNA ligase III & IV and 
DnL4 
Amino acid sequence alignment of Trichomonas vaginalis DNA ligase (TVlig) with Human DNA 
ligase IIIα (HuLigIII alpha; NP_039269.2), Human DNA ligase IV (HuLig4; NP_001091738.1) and 
DnL4 (orthologue of HuligIV in Saccharomyces cerevisiae; NP_014647.1) using ClustalW (Chenna et 
al., 2003). 
 
7.3 DETERMINATION OF KM FOR TV DNA LIGASE  
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Figure 7.3: Effect of varying ATP concentration on strand joining activity 
of TVlig 
Graph showig extent of ligation as a function of time when different concentrations of ATP (0.4 pmole 
to 1.2 pmole) were used to determine the binding affinity of the TVlig using 1 pmole of nicked labelled 
substrate and 0.1 pmole of the ligase. Each ligation reaction was performed in a reaction buffer 
containing 50 mM Tris-HCl pH 7.5, 10 mM MgCl2 and 5 mM DTT and incubated at 37
o
C. At each 
time-point, 10 µl of the sample was removed and the reaction was quenched by adding 20 µl loading 
buffer [98% (v/v) formamide, 10 mM EDTA, 0.01% (wt/vol) bromophenol blue] followed by 
incubation at 95
o
C for 3 minutes. The reaction products were electrophoresed on a denaturing 20% 
polyacrylamide gel and scanned using a Phosphorimager (GE Healthcare). 
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7.4 BRADFORD STANDARD CURVE TO ESTIMATE PROTEIN               
CONCENTERATION 
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Figure 7.4: Sample standard curve for Bradford protein concentration 
assay 
The protein used to determine this standard curve was 0 – 10 µg/µl BSA.  
Bradford analysis provides a reasonable estimation of protein concentration within the linear portion of 
the curve. Spectrophotometric analysis of absolutely pure ligase and the employment of the PBCV-1 
DNA ligase extinction co-efficient would be the ideal solution to this problem. In all instances the 
concentration of protein used in the DNA ligation assays was estimated in the Bradford linear range. 
As such all ligase preparations were referenced to these (or similar) values, thus the relative amounts of 
ligase are internally the same though they may not be accurately defined in molarity.  
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7.6 CONFERENCE PRESENTATIONS 
7.6.1 Abstract and poster presented at Annual Biochemical Society 
Meeting held at Glasgow, Scotland, UK (July, 2006) 
 
Characterisation of an ATP dependent DNA ligase from Trichomonas 
vaginalis 
                            L.Kaur and M. Odell 
 
Trichomonas vaginalis, a parasitic protozoan, is the etiological agent of 
trichomoniasis, a sexually transmitted disease (STD) of global concern leading 
to an estimated 180 million cases per annum. The 5-nitroimidazoles, 
especially metronidazole, are the most widely used antimicrobial agents for 
the treatment of trichomoniasis. The mechanism of the protozooicidal effect of 
the 5-nitroimidazoles is thought to involve generation of nitro radicals, which 
leads to subsequent DNA damage and cell death. However metronidazole 
resistant strains of T. vaginalis are on the rise, emphasising the need for 
research into alternative antibiotics and drug targets.  
This laboratory is interested in the maintenance and metabolism of 
DNA in protozoa, particularly in T. vaginalis.  DNA ligases are enzymes 
required to seal single-strand breaks in double-stranded DNA and maintain 
the integrity of an organisms’ genome during various aspects of DNA 
metabolism, such as replication, excision repair and recombination. Most 
organisms’ express at least one DNA ligase enzyme. In yeast two are 
elaborated, one responsible for replication the other intimately involved in 
DNA repair. Human cells encode at least three separate DNA ligase ORFs 
that are responsible for at least four distinct activities.  These cellular DNA 
ligases utilise ATP as an energy co-factor. The analyses of DNA ligase 3-
dimensional structures and their sequences have shown that these enzymes 
are built around a common catalytic core.   
We have identified a single, hypothetical gene from T. vaginalis that 
shows similarity in sequence to cellular ATP-dependent DNA ligases, with the 
highest homology being to the replicative, DNA ligase I enzyme. Using PCR 
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we have successfully cloned, expressed and purified this enzyme from E. coli 
using Nickel-affinity and Ion exchange (S-sepharose) resins. The 78 kDa 
enzyme has been characterised confirming that it is indeed an ATP-
dependent DNA ligase. We will present our detailed analysis of the 
biochemical and enzymatic capabilities of this enzyme that represents the first 
analysis of a protozoan DNA ligase. 
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Cloning, Expression and Characterisation of an ATP dependent DNA ligase from Trichomonas vaginalis
L.Kaur and M.Odell
Department of Molecular and Applied Biosciences
University of Westminster, London (W1W 6UW)
Trichomonas vaginalis (TV) is a parasitic protozoan organism that is the etiological agent of
trichomoniasis; a sexually transmitted disease of global concern leading to an estimated 180 million cases
per annum. This disease is linked to a predisposition to cervical cancer, atypical pelvic inflammatory
disease, infertility and furthermore sufferers have been shown to have an increased susceptibility to
human immunodeficiency virus (HIV) infection (Petrin et al 1998).
Figure 1:Trichomonas vaginalis trophozoite. Images taken from Petrin et al 1998.
The 5-nitroimidazoles, especially metronidazole, are the most widely used antimicrobial agents for the
treatment of trichomoniasis. The mechanism of the protozooicidal effect of the 5-nitroimidazoles is
thought to involve generation of nitro radicals, which leads to subsequent DNA damage and cell death.
However metronidazole resistant strains of T.vaginalis are on the rise, emphasising the need for research
into alternative antibiotics and drug targets.
DNA Ligase enzymes
DNA ligase enzymes are required to seal breaks in double-stranded DNA to maintain the integrity of an
organisms‟ genome during various aspects of DNA metabolism, such as replication, excision repair and
recombination. Most eukaryotic organisms express at least one DNA ligase; the human genome
elaborates three such enzymes (types I, III and IV), Yeasts and Drosophila two (types I and IV). DNA
ligase crystal structures and their sequences have shown that these enzymes are built around a common
catalytic core of two polypeptide domains containing six conserved, co-linearly arranged motifs
numbered I, III, IIIa, IV, V and VI, illustrated below by the structure of the PBCV-1 DNA ligase, the
smallest characterized ATP-dependent ligase. Subsidiary domains are appended to this catalytic core
facilitating the incorporation of the enzyme into cellular machines responsible for DNA replication and
repair
TV Lig  -150-KEGDLSKVAQQIRSTQK-337-EYKYDGER-487-EGLMVKTLN-506-WAKLKKDYIS-532-DTIDVVVIGA
Hu LigI -374-EKGDVGLVAENSRSTQR-565-EYKYDGQR–719-EGLMVKTLD-743-WLKLKKDYLD-755-DTLDLVVIGA
::**:. **:: ****:     ******:* ********:     * ******:.     **:*:*****
Expression and purification of TV DNA Ligase
The open reading frame of the TV ligase was amplified and cloned into the expression vector pET-16b
between the Nde I and Bam HI restriction enzyme sites. The sequence of the final clone completely
matched that of the open reading frame published by TIGR. The soluble protein with a predicted
molecular weight of 78kD and pI of 7.8 was purified by nickel affinity and ion exchange
chromatography (S-sepharose). The elution profiles, monitored via SDS-PAGE are shown in Figure 4.
Figure 3: A.  An alignment of the six conserved motifs of various ATP-dependent DNA ligases incorporating the 
putative TV DNA ligase.B. The sequence alignment of the DNA binding regions of human DNA ligase I with the 
putative TV DNA ligase (predicted expect value of 1e-23).
Figure 5: A. TV ligase purified from S-sepharose. MWM; molecular weight marker proteins. 1 and 2; 0.2 M NaCl 
elution fraction.  B. Western blotting of the purified TV DNA ligase with anti-his antibody. MWM; molecular weight 
marker proteins. 1 0.2 M NaCl fraction.
The purified recombinant protein was used to ligate HindIII digested  DNA with T4 DNA ligase as a
positive control. Figure 6, panel A, reveals a stringent requirement for the presence of polyethylene glycol
(8000) to facilitate DNA ligation. When PEG is present at 5% with the TV DNA ligase ligation products
(higher molecular weight species, >23 kb in size) are observed.migrating in the agarose gel, Figure 6 panel
A. Crude assessment of the ATP-requiring nature of the enzyme preparation has also been analysed by
similar ligation of lambda fragments. Figure 6 panel B.
Figure 6: Preliminary ligation assays for TV DNA ligase with HindIII digested  DNA. Briefly,  DNA in 50 mM 
Tris-HCl (pH 7.5), 10 mM MgCl2, 10 mM dithiothreitol and 25 g/ml bovine serum albumin buffer was 
supplemented with 5% PEG (experiment A) and 5% PEG with 0-4 mM ATP (experiment B).   
Conclusions and Future Work 
We report here the cloning, expression and initial characterisation of the first protozoal DNA ligase.
The ligase requires ATP and PEG for efficient DNA ligation. Analysis of the amino acid sequence of
the enzyme suggests that this is the homolog of the human type I ligase and as such is likely to be
responsible for ligase events associated with DNA replication. Our further analysis of the TV genome
has not revealed the presence of any further ORFs that have homology with DNA ligases. This raises
interesting questions about the nature of double-strand break repair in this organism, an event
normally associated with a type IV DNA ligase.
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This clearly indicates that the putative ORF from TV to function as an ATP dependent DNA ligase.
Higher concentrations of ATP apparently inhibit the ligation which we deduce to be due to the chelation
of the essential, divalent metal magnesium. The enzyme was active only in the presence of PEG which is
believed to act as a macro-molecular crowding agent and hence, enhance the frequency of DNA ligation.
The recombinant  protein carried an N-terminal His-tag and the purified  protein was confirmed by 
western blotting with anti-his antibody. 
Ligation assays
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Recently the Trichomonas vaginalis genome sequence has been made available by The Institute for
Genomic Research (TIGR). Our analysis of this organism has determined the presence of only a single
ORF from T. vaginalis that shows similarity in sequence to cellular ATP dependent DNA ligases. The
homology of 51 and 53% with the human and yeast replicative, DNA ligase I enzymes respectively
suggests that this is the parasite replicative DNA ligase. We have cloned, over expressed and purified
recombinant protein encoded by this ORF that we demonstrate to be an ATP-dependent DNA ligase.
Abstract
Results:
Figure 4: (A) Restriction digest confirmation of TV DNA ligase clone in pET -16b. MWM; molecular weight marker DNA.  
1; NdeI/BamHI restriction digest of TV clone. (B) Elution profile for TV ligase from Ni-NTA agarose: MWM; molecular 
weight marker proteins. 1; Cell pellet. 2; Column flow through. 3; 25mM immidazole wash. 4; 300mM immidazole elution.
A
Figure 2: The structure of the PBCV-1 DNA
ligase enzyme covalently linked to AMP. The
essential catalytic ligase motifs are revealed by
coloured ribbons with their appropriate
numerical numbering illustrated (Odell et al
2000).
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A BLAST search of the newly annotated TV genome revealed a putative polypeptide with 51% and
45% homology to human DNA ligase I and DNA ligase IV respectively. Further sequence analyses
revealed the absence of any further conserved domains consistent with the polypeptide being either a
type III or type IV DNA ligase but suggesting the putative enzyme to be the TV homolog of the type I,
replicative DNA ligase, see Figure 3 below.
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Further experiments with -32ATP labelled substrates are now being used to further characterise the Km
and Vmax of the enzyme. The substrates to be used in the ligation assays are an oligonucleotide 30-mer
(unlabelled) and a radioactively-labelled 10-mer oligonucleotide, as shown in Figure 7. Initial
crystallisation screens of the purified enzyme are also underway.
Figure 7: A: Unlabelled 30-mer hairpin  B: Radiolabelled 10-mer  C: Expected 40-mer product after ligation
GCGACGCTAC
A B
GCGACGCTAC
C
KYDGER
KIDGIR
KYDGQR
KYDGER
DSEIV
DGEIS
DTEAV
DGELM
CVCAFDLL
SYYWFDYV
CLYAFDLI
KLYAILPL
EGLM
EGVM
EGLM
EGLI
WAKLK
LLKMK
WLKLK
WWKMK
FGRYYRTR
FPVFIGIR
FPRFIRVR
FVMFRGTE
I              III           IIIa           IV         V             VI
Trichomonas vaginalis DNA ligase
PBCV-1 DNA ligase
Human DNA ligase I
Bacteriophage T7 DNA ligase
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7.6.2 Abstract submitted for Gordon Research Conference on DNA 
Damage, Mutation & Cancer held in March 2008 at Ventura, USA. 
 
Developing an assay to screen for inhibitors of ATP-dependent DNA ligases 
 
                                        L.Kaur and M.Odell 
 
DNA ligases are enzymes required for the repair, replication and recombination of 
DNA. Most organisms express DNA ligases that utilise ATP as an energy cofactor; 
however eubacteria appear to be unique in having ligases driven by NAD
+
. Sequence 
and structural analyses of DNA ligases have shown that these enzymes are built 
around a common catalytic core, which contains six conserved motifs. DNA ligases 
represent a novel therapeutic target for intervention in cancerous cells through the 
requirement of actively dividing cells to seal the discontinuous strand during semi-
conservative DNA replication. 
 
Our goal is to develop a high-throughput assay that can be used to screen natural 
product libraries to identify inhibitors of ATP-dependent DNA ligase enzymes. 
The key feature of our rapid DNA ligation, inhibition assay is the relative binding 
affinities of the components of the unligated DNA substrate and ligated DNA product 
to the ion exchange resin, Q-sepharose.  
 
The Paramecium bursari Chlorella virus, PBCV-1, DNA ligase is the smallest fully 
functional eukaryotic DNA ligase. This enzyme retains the catalytic core structure 
present in all DNA ligases. We used this enzyme as the primary screen for inhibitors 
in our in vitro assay. When suitable candidate inhibitors are identified their action will 
be evaluated on target ligases including human and protozoal enzymes. A 
hypothetical gene from a parasitic protozoan, Trichomonas vaginalis, showing 
similarity in sequence to other ATP-dependent DNA ligases, has been successfully 
cloned, expressed and purified from E. coli using Nickel-affinity and Ion exchange 
(S-sepharose) resins. This enzyme is biochemically characterised and to be used in 
assays to get an insight into the previously least studied protozoan DNA ligases. 
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Developing an assay to screen for inhibitors of ATP-dependent DNA ligases
L.Kaur, and M.Odell
Department of Molecular and Applied Biosciences
University of Westminster
Introduction
DNA ligases are the enzymes required to seal single-strand breaks in double stranded DNA and
maintain the integrity of an organism's genome during various aspects of DNA metabolism such
as replication, excision repair and recombination. Most organism express DNA ligases that
utilise ATP as an energy co-factor, however eubacteria appear to be unique in having ligases
driven by NAD+. The general DNA ligase catalytic mechanism involves 3 steps (figure 1):
Human DNA Ligase I
Human encode for three different DNA ligases (I, III and IV) which are different from each
other in their catalytic ,physical and serological properties.
DNA ligase I is responsible for majority of DNA ligase activity in proliferating cells. It is been
reported that levels of DNA ligase I are up-regulated in cells from a human tumour versus
normal tissues and the presence of DNA ligase I is essential for the survival of tumour cells
(Sun et al. 2001).
Trichomonas vaginalis DNA Ligase A single, hypothetical gene from Trichomonas vaginalis
(TV) has been identified that shows similarity in sequence to cellular ATP-dependent DNA
ligases, with the highest homology being to the replicative, DNA ligase I enzyme (figure 2b) .
The biochemical and enzymatic capabilities of this enzyme will be the first protozoal DNA
ligase to be so characterised.
Structural and Mechanistic Conservation in DNA ligases Sequence and structural
analyses of DNA ligases have shown that these enzymes are built around a common catalytic
core. The Paramecium bursaria Chlorella virus 1 (PBCV1) ligase represents the most attractive
eukaryotic enzyme to study as it contains the six key catalytic motifs found in all ATP-
dependent DNA ligases with no extraneous protein sequences.
It is regarded by some as the catalytic core present in all ligases such that anything that applies
to this enzyme will apply to the larger, cellular ligases (Odell et al. 2003). Figure 2
demonstrates the validity of this assumption by overlaying the key structural residues of motif I
and III in the active sites of the PBCV1 (34 kD) and much larger 66kDa T7 ligases. The
recently published structure of human DNA ligase I complexed with DNA validates this
presumption (Pascal et al, 2004).
Aims
The project aims to assess the potential of the essential enzymes DNA ligases as targets for
chemotherapeutic intervention. A high-throughput assay is being developed for screening
natural product libraries to identify inhibitors of ATP-dependent DNA ligase enzymes. The key
feature of the assay is the relative binding affinities of the components of the unligated DNA
substrate and the ligated DNA product to the ion exchange resin, Q-sepharose. The inhibition of
a number of DNA ligase enzymes will be assessed as targets for intervention; those of human
cells as a treatment for cancer and a novel DNA ligase from the parasitic protozoan organism
Trichomonas vaginalis.
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Figure 1: Mechanism of DNA ligation
i-ii)Formation of a covalent enzyme-AMP intermediate linked to a lysine
side-chain in the enzyme;
iii-iv)Transfer of the AMP nucleotide to the 5' phosphate of the nicked DNA
strand;
v-vi)Attack on the AMP-DNA bond by the 3'-OH of the nicked DNA sealing
the phosphate backbone and releasing AMP (adapted from Subramanya et
al.1996)
Materials and Methods
Expression and purification of PBCV-1 DNA ligase:
Wild type PBCV1 was over-expressed in E.coli BL21(DE3) cells. Protein expression was induced at 37oC for
3 hours.
The protein was purified by S-sepharose(ion exchange) resin and Nickel affinity chromatography.
Oligonucleotides binding to Q-sepharose
The 30-mer and 6-mer oligonucleotides was applied to Q-sepharose (ion exchange resin) and step eluted with
0-2M NaCl.
The elution profile was monitored by checking the absorbance at 260nm.
Cloning and over expression of TV ligase
Two oligonucleotide primers that flanked the open reading frame of the TV ligase were designed with Bam HI
restriction enzyme sites
5'-GATCGGATCCGATGACTCAACAGGGAATTGC-3‟
5‟-GATCGGATCCTTATTTCTCAAATTGTTGATGATAGAG-3‟.
The oligonucleotides were used in a PCR and the amplified DNA fragment was cloned in the BamHI sites of
the pet-16b plasmid vector..The plasmid was transformed into the E. coli strain BL21(DE3).A transformed
colony was inoculated in to LB medium supplemented with 100 µg·mL-1 ampicillin. Protein expression was
induced at OD595 = 0.5 with 0.5 mM isopropyl thio -D-galactoside (IPTG) for 3 h at 37  C.
Purification of TV ligase
The over expressed protein was applied to Nickel-NTA resin and eluted with 300mM Imidazole. The eluted
fraction was applied to S-sepharose and step eluted with 0.07-1.5M NaCl.
Ligation assays
The purified recombinant protein was used to ligate Hind III digested  DNA in 50 mM Tris-HCl (pH 7.5), 10
mM MgCl2, 10 mM dithiothreitol, 1 mM ATP, 25 μg/ml bovine serum albumin with T4 and PBCV1 DNA
ligases as positive controls.
Results and Discussion
Oligonucleotides binding to Q-sepharose
The non radiolabelled 30-mer and radiolabelled 6-mer oligonucleotides will be used as
substrate in DNA ligation assays after annealing to form the DNA ligation substrate shown
in Figure 4, panel A. After the completion of the reaction, the reaction mixture will be
applied to Q-sepharose ion exchange resin. Figure 4, panel A shows the salt concentrations
whereby 30-mer and 6-mer is unable to bind to the Q-sepharose
Washing of the resin with 180mM NaCl elutes the unligated 6-mer oligonucleotide whereas 6-mer
that has become incorporated into the 30-mer hairpin DNA through DNA ligation will be retained on
the resin. By monitoring the labelled 6-mer passing through the column the percentage of DNA
ligation can be determined.
Cloning and over expression of TV ligase
Genomic DNA was used to amplify the putative TV ligase gene. The insert in pET-16b was sequenced
and the plasmid then transformed into the E. coli strain BL21(DE3) to study expression of the protein.
The soluble protein with molecular weight of 78kD and pI 7.8 was partially purified by nickel affinity
chromatography (figure 7a). The eluate was further applied to S-sepharose resin and the putative ligase
fraction was eluted with 0.2M NaCl (figure 7b).
Further attempts would be made to get pure protein to study detailed analysis of the biochemical and
enzymatic capabilities of this enzyme which represents the first protozoal DNA ligase.
Ligation assays
Some preliminary ligation assays were conducted to ligate Hind III digested  DNA to characterise
the recombinant protein. Figure 8 shows some signs of higher molecular weight species formed
when compared to–ve and +ve control reactions.
Future Work
•The enzymatic and biochemical properties of the TV DNA ligase enzyme will be characterised. The
first such enzyme to be researched from the family of protozoan parasites.
•The Human DNA ligase I enzyme will be expressed and purified. Once this full battery of DNA ligases
is available they will be screened in our in vitro assay to identify potentially useful inhibitory
compounds.
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This clearly indicates that the putative ORF from TV can 
function as an ATP dependent DNA ligase
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Expression and purification of PBCV-1 DNA ligase 
The ligase fraction was eluted using 0.2-0.3M NaCl from S-sepharose with some contaminating proteins 
(see figure 5a). The eluate from Nickel resin gave efficient purification of recombinant enzyme from all 
contaminants (figure 5b). This fraction was used in ligation assays (see figure8) which shows that protein 
is functional.
Figure5: a)S-sepharose Purification of Chlorella Virus Ligase b)  Elution of PBCV1 ligase from Nickel resin
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